Teva Pharmaceutical Industries Limited (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Teva Pharmaceutical Industries Limited (TEVA) - Pharmaceuticals &
Healthcare - Deals and Alliances Profile

Reference Code: GDPH33504D
Publication Date: MAY 2015
Company Overview
Key Facts
Teva Pharmaceutical Industries Limited (Teva) is a fully integrated global

pharmaceutical company. It undertakes the development, manufacture and
marketing of a wide range of generic and branded pharmaceuticals and active
pharmaceutical ingredients (APIs). The company offers chemical and therapeutic
equivalents of originator pharmaceuticals in a wide range of dosage forms, including
capsules, tablets, ointments, liquids, creams, injectables and inhalants. Teva also
provides an array of over the counter (OTC) products through a joint venture with
P&G.
Teva Pharmaceutical Industries Limited,

Pharmaceuticals & Healthcare, Key Facts, 2014
Web Address
www.tevapharm.com
Revenue (US$ million)
20,272
Number of Employees
43,009
GlobalData
Financial Deals Landscape

Teva Pharmaceutical Industries Limited, Pharmaceuticals &
Healthcare, Deals by Type, 2009 to YTD 2015

Healthcare, Deals By Year, 2009 to YTD 2015
Note: Deals include all announced pharmaceuticals & healthcare deals from
2009 onwards, GlobalData
Note: Deals include all announced pharmaceuticals & healthcare deals

from 2009 onwards, GlobalData

Healthcare, Deals By Region, 2009 to YTD 2015

Healthcare, Deals By Therapy Area, 2009 to YTD 2015


Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Source : www.globalcompanyintelligence.com
GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form

Page 1
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables .................................................................................................................................................................................. 7
List of Figures ............................................................................................................................................................................... 12
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 ................................. 13
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015.................................. 14
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 ............................. 15
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 ................... 16
Teva Pharmaceutical Industries Limited, Medical Devices Deals, 2009 to YTD 2015 ...................................................................... 18
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 .............................. 19
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deal Details ................................................................... 34
Asset Purchase ............................................................................................................................................................................. 34
Glenmark Pharma Rumored To Sell Its Oral Contraceptives Division....................................................................................... 34
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million ....................... 36
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics ............................................................ 38
Teva Plans To Acquire Three Women's Health Divisions ......................................................................................................... 39
Cephalon Acquires VOGALENE And VOGALIB From UCB Pharma ........................................................................................ 40
MicroDose Therapeutx Acquires Portfolio Of Compounds From Epix Pharma ......................................................................... 41
MicroDose Therapeutx Acquires Investigational Compounds From ViroPharma ...................................................................... 42
Taiyo Yakuhin Acquires Kasukabe Plant From Schering-Plough .............................................................................................. 43
Neose Technologies Completes Sale Of Its Assets To BioGeneriX .......................................................................................... 44
Venture Financing ......................................................................................................................................................................... 45
Auspex Pharma Raises US$20 Million In Series E Financing ................................................................................................... 45
Labrys Biologics Raises US$31 Million In Series A Financing .................................................................................................. 47
Auspex Pharma Raises US$25 Million In Series D Financing ................................................................................................... 49
Auspex Pharma Raises US$1.5 Million In Venture Financing ................................................................................................... 51
Ceptaris Therapeutics Raises US$10 Million In Series D-1 Financing ...................................................................................... 52
Gamida Cell Raises US$10 Million In Series E Financing......................................................................................................... 54
Ceptaris Therapeutics Raises US$8.3 Million In Venture Financing ......................................................................................... 56
Teva Pharma Industries Invests In MultiGene Vascular Systems ............................................................................................. 58
Yaupon Therapeutics Secures US$14.4 Million In Series D Financing ..................................................................................... 59
SymBio Pharma Secures US$24.5 Million In Series E Financing Round .................................................................................. 61
Yaupon Therapeutics Secures US$2 Million In Venture Financing ........................................................................................... 63
VBL Biogenics Secures US$40 Million In Venture Financing .................................................................................................... 65
Gemin X Pharma Secures US$8 Million In Series E Venture Financing ................................................................................... 67
Auspex Pharma Raises US$12 Million In Series C Financing ................................................................................................... 68
Gemin X Pharma Raises US$3.92 Million In Venture Financing ............................................................................................... 69
Celator Pharma Secures US$2.5 Million In Venture Financing ................................................................................................. 70
Gemin X Pharma Raises US$16 Million In Series D Financing ................................................................................................. 72
Auspex Pharma Raises US$2 Million In Venture Financing ...................................................................................................... 73
SymBio Pharma Secures US$8 Million In Second Tranche Of Series D Financing .................................................................. 74
MultiGene Vascular Systems Secures US$8.5 Million In Venture Financing ............................................................................ 75
Cell Cure Neurosciences Raises US$0.81 Million In Venture Financing ................................................................................... 77
Auspex Pharma Secures US$3 million In Venture Financing .................................................................................................... 79
Yaupon Therapeutics Secures US$3.1 Million In Venture Financing ........................................................................................ 80
Gemin X Pharma Secures US$9.3 Million In Venture Financing ............................................................................................... 81

Page 2
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables .................................................................................................................................................................................. 7
List of Figures ............................................................................................................................................................................... 12
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deal Details ................................................................... 34
Asset Purchase ............................................................................................................................................................................. 34
Glenmark Pharma Rumored To Sell Its Oral Contraceptives Division....................................................................................... 34
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million ....................... 36
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics ............................................................ 38
Teva Plans To Acquire Three Women's Health Divisions ......................................................................................................... 39
Cephalon Acquires VOGALENE And VOGALIB From UCB Pharma ........................................................................................ 40
MicroDose Therapeutx Acquires Portfolio Of Compounds From Epix Pharma ......................................................................... 41
MicroDose Therapeutx Acquires Investigational Compounds From ViroPharma ...................................................................... 42
Taiyo Yakuhin Acquires Kasukabe Plant From Schering-Plough .............................................................................................. 43
Neose Technologies Completes Sale Of Its Assets To BioGeneriX .......................................................................................... 44
Venture Financing ......................................................................................................................................................................... 45
Auspex Pharma Raises US$20 Million In Series E Financing ................................................................................................... 45
Labrys Biologics Raises US$31 Million In Series A Financing .................................................................................................. 47
Auspex Pharma Raises US$25 Million In Series D Financing ................................................................................................... 49
Auspex Pharma Raises US$1.5 Million In Venture Financing ................................................................................................... 51
Ceptaris Therapeutics Raises US$10 Million In Series D-1 Financing ...................................................................................... 52
Gamida Cell Raises US$10 Million In Series E Financing......................................................................................................... 54
Teva Pharma Industries Invests In MultiGene Vascular Systems ............................................................................................. 58
Yaupon Therapeutics Secures US$14.4 Million In Series D Financing ..................................................................................... 59
SymBio Pharma Secures US$24.5 Million In Series E Financing Round .................................................................................. 61
Yaupon Therapeutics Secures US$2 Million In Venture Financing ........................................................................................... 63
VBL Biogenics Secures US$40 Million In Venture Financing .................................................................................................... 65
Gemin X Pharma Secures US$8 Million In Series E Venture Financing ................................................................................... 67
Auspex Pharma Raises US$12 Million In Series C Financing ................................................................................................... 68
Gemin X Pharma Raises US$3.92 Million In Venture Financing ............................................................................................... 69
Celator Pharma Secures US$2.5 Million In Venture Financing ................................................................................................. 70
Gemin X Pharma Raises US$16 Million In Series D Financing ................................................................................................. 72
Auspex Pharma Raises US$2 Million In Venture Financing ...................................................................................................... 73
SymBio Pharma Secures US$8 Million In Second Tranche Of Series D Financing .................................................................. 74
MultiGene Vascular Systems Secures US$8.5 Million In Venture Financing ............................................................................ 75
Cell Cure Neurosciences Raises US$0.81 Million In Venture Financing ................................................................................... 77
Auspex Pharma Secures US$3 million In Venture Financing .................................................................................................... 79
Yaupon Therapeutics Secures US$3.1 Million In Venture Financing ........................................................................................ 80
Gemin X Pharma Secures US$9.3 Million In Venture Financing ............................................................................................... 81

Page 2
SymBio Pharma Receives Investment In Second Tranche Of Series C Financing ................................................................... 82

Dynamix Pharma Secures US$10 Million In Series A Financing ............................................................................................... 83
Partnerships .................................................................................................................................................................................. 84
Teva Pharma Enters Into Licensing Agreement With Alexza Pharma For Adasuve Inhalation Powder .................................... 84
Teva Pharma Industries Amends Licensing Agreement With Active Biotech ............................................................................ 86
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma ................................................................................. 88
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug ................................................................... 89
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems .......................................................................... 90
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan ....................................... 91
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs ............................................. 93
Champions Enters Into Drug Discovery And Development Agreement With Teva ................................................................... 95
Teva Pharma Plans To Enter Into Partnerships ........................................................................................................................ 96
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide ....................................................................... 97
Teva Pharma And Lonza Terminate Joint Venture For Biosimilars ........................................................................................... 99
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test ...................................................... 100
Teva Pharma Terminates Co-Development Agreement With CureTech For CT-011 ............................................................. 102
Teva Pharma To Form Joint Venture With Handok Pharma ................................................................................................... 103
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil ................................................................... 104
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax ............................................. 105
Teva Pharma And Proctor & Gamble Finalize Joint Venture ................................................................................................... 107
Teva Pharma Forms Joint Venture With Procter & Gamble .................................................................................................... 109
Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery ................................................................. 111
ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa ......................................................................... 113
Champions Biotech Enters Into An Agreement With Cephalon ............................................................................................... 114
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra .................................................................... 116
Celator Pharma Extends Research Agreement With Cephalon .............................................................................................. 117
Auspex Pharma Enters Into Co-Development Agreement With Teva Pharma Industries ....................................................... 119
Teva Pharma Enters Into Co-Development Agreement With MediWound And Polyheal ........................................................ 120
MicroDose Therapeutx Enters Into Co-Marketing Agreement With Nexus6 ............................................................................ 122
Celator Pharma Expands Research Agreement With Cephalon ............................................................................................. 123
Cancer Research Technology Enters Into Co-Development Agreement With Cephalon ........................................................ 124
H. Lundbeck Expands Marketing Agreement With Teva Pharma Industries ........................................................................... 125
UCB Terminates Co-Marketing Agreement With Teva Pharma .............................................................................................. 126
Celator Pharma Enters Into Research Agreement With Cephalon .......................................................................................... 127
Teva Pharma Industries Forms Joint Venture With Lonza Group ........................................................................................... 128
Debiopharm Enters Into Distribution Agreement With Mepha Pharma ................................................................................... 129
Dynamix Pharma Enters Into Co-Development Agreement With Teva Pharma ...................................................................... 130
Licensing Agreements ................................................................................................................................................................ 131
Teva Pharma Enters into Licensing Agreement with Eagle Pharma for EP-3102 ................................................................... 131
Cell Cure Neurosciences Terminates Licensing Option Agreement with Teva Pharma Industries for OpRegen .................... 132
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma .............................................................................. 134
Andromeda Terminates Licensing Agreement With Teva Pharma For DiaPep277 Rights...................................................... 135
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate .............................................. 137
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo ..................................................................... 139
Rexahn Pharma Terminates Licensing Agreement With Teva Pharma For RX-3117 ............................................................. 141
Labrys Biologics Enters Into Licensing Agreement With Pfizer For RN-307 ........................................................................... 143
Teva Pharma Terminates Licensing Agreement With Proteologics ........................................................................................ 144

Page 3
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402 ................................................................ 145
Teva Pharma Terminates Licensing Agreement With MediWound For NexoBrid ................................................................... 147
Hospira Terminates Licensing Agreement With Ivax International For Omacetaxine Mepesuccinate ..................................... 148
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig ........................................................... 149
Teva Animal Health Exercises Option For Licensing Agreement With Eden Research .......................................................... 150
Immupharma Regains Lupuzor Rights From Cephalon .......................................................................................................... 151
Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil ................................................................ 153
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine............................................................................. 154
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637 .................................... 156
Lundbeck Enters Into Licensing Agreement With Cephalon ................................................................................................... 158
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI...................................................... 160
ImmunGene Enters Into Licensing Agreement With Cephalon ............................................................................................... 161
Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine ....................................................... 163
SymBio Pharma Enters Into Licensing Agreement With Cephalon ......................................................................................... 165
AstraZeneca Enters Into Licensing Agreement With Teva Pharma For Entocort EC .............................................................. 166
Watson Pharma Enters Into Licensing Agreement With Teva Pharma ................................................................................... 167
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Barr Labs ........................................................... 168
Mersana Therapeutics Enters Into Licensing Agreement With Teva Pharma Industries ......................................................... 170
Sanofi, Debiopharm Enters Into Licensing Agreement With Sandoz, Fresenius & Teva......................................................... 172
Antisense Therapeutics Terminates Licensing Agreement With Teva Pharma ....................................................................... 174
Innate Immune Enters Into Licensing Agreement With Cephalon Australia ............................................................................ 175
MediGene Enters Into Licensing Agreement With Teva Pharma ............................................................................................ 176
ChemGenex Pharma Enters Into Licensing Agreement With Hospira .................................................................................... 177
Codexis Extends Collaboration Agreement With Teva Pharma Industries .............................................................................. 179
Ambrilia Terminates License, Distribution And Supply Agreements With Teva ....................................................................... 180
Rexahn Pharma Enters Into Licensing Agreement With Teva Pharma ................................................................................... 181
Barr Labs Enters Into Licensing Agreement With Bayer ......................................................................................................... 183
Vical Enters Into Licensing Agreement With Teva Pharma ..................................................................................................... 185
Merck Extends Collaboration Agreement With MicroDose Therapeutx .................................................................................. 186
Acusphere Amends Licensing Agreement With Cephalon ...................................................................................................... 187
Cephalon Enters Into Licensing Agreement With SymBio Pharma ......................................................................................... 189
Shire Amends Its Agreement With Duramed Pharma ............................................................................................................. 191
Cephalon Enters Into Licensing Agreement With ImmuPharma For Lupuzor ......................................................................... 192
Codexis Enters Into Licensing Agreement With Teva Pharma ................................................................................................ 194
Equity Offering ............................................................................................................................................................................ 195
Ignyta Raises USD42 Million in Private Placement of Shares ................................................................................................. 195
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares .................................................................................. 197
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares .................................................................................... 199
Auspex Pharma Completes IPO For US$96.6 Million ............................................................................................................. 201
NuPathe Files Registration Statement For Public Offering Of Securities For US$100 Million ................................................. 203
NuPathe Completes Private Placement Of Units For US$28 Million ....................................................................................... 204
NuPathe Completes Second Tranche Of Private Placement Of Common Stock For US$0.6 Million ...................................... 206
NuPathe Completes IPO Of US$50 Million ............................................................................................................................. 208
ChemGenex Completes Rights Issue Of US$5.76 Million....................................................................................................... 210
Cephalon Completes Public Offering Of US$300 Million......................................................................................................... 212
ChemGenex Completes Private Placement Of US$7 Million .................................................................................................. 214
Debt Offering .............................................................................................................................................................................. 216

Page 4
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023 ..................................................... 216
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027 .................................................. 217
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million ................................................................. 218
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion ................................................................... 220
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million ...................................................... 222
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion........................................................ 224
Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For US$875 Million ........................................... 226
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$200 Million ................................ 228
Teva Pharma Completes Public Offering Of Notes Due 2021 For US$875 Million ................................................................. 230
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$1.1 Billion ................................. 232
Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For US$1 Billion ................................................. 234
Teva Pharma Completes Public Offering Of 2.4% Senior Notes Due 2016 For US$950 Million ............................................. 236
ChemGenex Completes Private Placement Of Convertible Notes For US$15 Million ............................................................ 242
Teva Pharma Completes Private Placement Of 1.5% Senior Notes For US$1,000 Million ..................................................... 243
Teva Pharma Completes Private Placement Of Senior Notes For US$500 Million ................................................................. 245
Teva Pharma Completes Private Placement Of 3% Fixed Rate Senior Notes For US$1,000 Million ..................................... 247
Cephalon Completes Public Offering Of Convertible Senior Subordinated Notes For US$500 Million ................................... 249
Asset Transactions ..................................................................................................................................................................... 251
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma.............................................................................. 251
Teva Pharma Plans to Divest Some Operations ..................................................................................................................... 252
Ignyta Acquires Four Oncology R&D Assets from Cephalon .................................................................................................. 253
ANI Pharma Acquires ANDA from Teva Pharma .................................................................................................................... 255
ANI Pharma Acquires 31 Generic Drug Products from Teva Pharma ..................................................................................... 256
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California .................................................................................. 258
CleveXel Pharma Acquires Development Center From Teva Pharma .................................................................................... 259
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma.......................................................... 260
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada .................................................. 261
Acino Pharma Completes Acquisition Of Asia, Latin America, Middle East And Africa Businesses From Mepha For US$123
Million ...................................................................................................................................................................................... 262
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma .................................................................. 264
Partners In Life Sciences Completes Acquisition Of Manufacturing Facility In Mitry-Mory From Cephalon ............................ 265
Perrigo Acquires Rights For Allegra From Teva Pharma ........................................................................................................ 266
Hospira Acquires Worldwide Rights To Filgrastim From PLIVA .............................................................................................. 267
Acquisition .................................................................................................................................................................................. 268
Teva Pharma Acquires Auspex Pharma ................................................................................................................................. 268
Teva Pharma May Increase Bid to Acquire Mylan .................................................................................................................. 270
Ind-Swift Lab May Sell Stake in Company .............................................................................................................................. 272
Teva Pharma Completes Acquisition of Labrys Biologics ....................................................................................................... 273
Novartis Terminates Planned Acquisition Of Gamida Cell For US$600 Million ....................................................................... 274
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer .......................................................... 276
NuPathe Terminates Its Acquisition By Endo Health Solutions For US$105 Million In Tender Offer ...................................... 279
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million ....................................................................... 281
Teva Pharma Completes Acquisition of MicroDose Therapeutx ............................................................................................. 284
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company ............................................................... 286
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million ..................................................................... 288
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million ................................................................ 290

Page 5
Teva Pharma Rumored To Acquire Amarin ............................................................................................................................ 292

Teva Completes Acquisition Of Cephalon For US$6,800 Million ............................................................................................ 294
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For US$150 Million.................................................... 297
Teva Pharma Invests Additional US$19 Million In CureTech .................................................................................................. 299
Teva Pharma Industries Acquires Taiyo Pharma Industry ...................................................................................................... 300
Cephalon Acquires 91.73% Stake In ChemGenex .................................................................................................................. 302
Cephalon Acquires Gemin X Pharma...................................................................................................................................... 304
Cephalon Rejects Unsolicited Bid For Its Acquisition By Valeant Pharma .............................................................................. 307
Clal Biotech Acquires Stake In TransPharma Medical From Teva .......................................................................................... 310
Cephalon Completes Acquisition Of 20% Stake In Mesoblast ................................................................................................ 312
Teva Pharma Industries Acquires Corporacion Infarmasa ...................................................................................................... 314
Teva Pharma Industries Acquires THERAMEX From Merck Serono ...................................................................................... 316
Cephalon Acquires BioAssets Development ........................................................................................................................... 318
Teva Pharma Industries Completes Acquisition Of ratiopharm For Approximately US$4.9 Billion .......................................... 320
Cephalon Acquires Mepha Pharma For US$616 Million ......................................................................................................... 323
Cephalon Acquires Ception Therapeutics ............................................................................................................................... 325
Cephalon Acquires Arana Therapeutics .................................................................................................................................. 328
Teva Pharmaceutical Industries Limited - Key Competitors ........................................................................................................... 330
Key Employees .............................................................................................................................................................................. 331
Locations And Subsidiaries ............................................................................................................................................................ 333
Head Office ................................................................................................................................................................................. 333
Other Locations & Subsidiaries ................................................................................................................................................... 333
Appendix ........................................................................................................................................................................................ 342
Methodology ............................................................................................................................................................................... 342
About GlobalData ....................................................................................................................................................................... 342
Contact Us .................................................................................................................................................................................. 342
Disclaimer ................................................................................................................................................................................... 342


Page 6
List of Tables
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Key Facts, 2014 ............................................................... 1
Teva Pharmaceutical Industries Limited, Deals By Therapy Area, 2009 to YTD 2015 ..................................................................... 16
Glenmark Pharma Rumored To Sell Its Oral Contraceptives Division .............................................................................................. 34
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million .............................. 36
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics .................................................................... 38
Teva Plans To Acquire Three Women's Health Divisions ................................................................................................................ 39
Cephalon Acquires VOGALENE And VOGALIB From UCB Pharma ............................................................................................... 40
MicroDose Therapeutx Acquires Portfolio Of Compounds From Epix Pharma ................................................................................ 41
MicroDose Therapeutx Acquires Investigational Compounds From ViroPharma ............................................................................. 42
Taiyo Yakuhin Acquires Kasukabe Plant From Schering-Plough ..................................................................................................... 43
Neose Technologies Completes Sale Of Its Assets To BioGeneriX ................................................................................................. 44
Auspex Pharma Raises US$20 Million In Series E Financing .......................................................................................................... 45
Labrys Biologics Raises US$31 Million In Series A Financing ......................................................................................................... 47
Auspex Pharma Raises US$25 Million In Series D Financing .......................................................................................................... 49
Auspex Pharma Raises US$1.5 Million In Venture Financing .......................................................................................................... 51
Ceptaris Therapeutics Raises US$10 Million In Series D-1 Financing ............................................................................................. 52
Gamida Cell Raises US$10 Million In Series E Financing ................................................................................................................ 54
Ceptaris Therapeutics Raises US$8.3 Million In Venture Financing ................................................................................................ 56
Ceptaris Therapeutics Raises US$7.5 Million In Venture Financing ................................................................................................ 57
Teva Pharma Industries Invests In MultiGene Vascular Systems .................................................................................................... 58
Yaupon Therapeutics Secures US$14.4 Million In Series D Financing ............................................................................................ 59
SymBio Pharma Secures US$24.5 Million In Series E Financing Round ......................................................................................... 61
Yaupon Therapeutics Secures US$2 Million In Venture Financing .................................................................................................. 63
VBL Biogenics Secures US$40 Million In Venture Financing ........................................................................................................... 65
Gemin X Pharma Secures US$8 Million In Series E Venture Financing .......................................................................................... 67
Auspex Pharma Raises US$12 Million In Series C Financing .......................................................................................................... 68
Gemin X Pharma Raises US$3.92 Million In Venture Financing ...................................................................................................... 69
Celator Pharma Secures US$2.5 Million In Venture Financing ........................................................................................................ 70
Gemin X Pharma Raises US$16 Million In Series D Financing ........................................................................................................ 72
Auspex Pharma Raises US$2 Million In Venture Financing ............................................................................................................. 73
SymBio Pharma Secures US$8 Million In Second Tranche Of Series D Financing ......................................................................... 74
MultiGene Vascular Systems Secures US$8.5 Million In Venture Financing ................................................................................... 75
Cell Cure Neurosciences Raises US$0.81 Million In Venture Financing .......................................................................................... 77
Auspex Pharma Secures US$3 million In Venture Financing ........................................................................................................... 79
Yaupon Therapeutics Secures US$3.1 Million In Venture Financing ............................................................................................... 80
Gemin X Pharma Secures US$9.3 Million In Venture Financing ...................................................................................................... 81
SymBio Pharma Receives Investment In Second Tranche Of Series C Financing .......................................................................... 82
Dynamix Pharma Secures US$10 Million In Series A Financing ...................................................................................................... 83
Teva Pharma Enters Into Licensing Agreement With Alexza Pharma For Adasuve Inhalation Powder ........................................... 84
Teva Pharma Industries Amends Licensing Agreement With Active Biotech ................................................................................... 86

Page 7
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma ........................................................................................ 88
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug .......................................................................... 89
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems ................................................................................. 90
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan .............................................. 91
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs .................................................... 93
Champions Enters Into Drug Discovery And Development Agreement With Teva........................................................................... 95
Teva Pharma Plans To Enter Into Partnerships ............................................................................................................................... 96
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide .............................................................................. 97
Teva Pharma And Lonza Terminate Joint Venture For Biosimilars .................................................................................................. 99
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test ............................................................. 100
Teva Pharma Terminates Co-Development Agreement With CureTech For CT-011 ..................................................................... 102
Teva Pharma To Form Joint Venture With Handok Pharma .......................................................................................................... 103
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil .......................................................................... 104
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax .................................................... 105
Teva Pharma And Proctor & Gamble Finalize Joint Venture .......................................................................................................... 107
Teva Pharma Forms Joint Venture With Procter & Gamble ........................................................................................................... 109
Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery......................................................................... 111
ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa ................................................................................ 113
Champions Biotech Enters Into An Agreement With Cephalon ...................................................................................................... 114
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra............................................................................ 116
Celator Pharma Extends Research Agreement With Cephalon ..................................................................................................... 117
Auspex Pharma Enters Into Co-Development Agreement With Teva Pharma Industries .............................................................. 119
Teva Pharma Enters Into Co-Development Agreement With MediWound And Polyheal ............................................................... 120
MicroDose Therapeutx Enters Into Co-Marketing Agreement With Nexus6 ................................................................................... 122
Celator Pharma Expands Research Agreement With Cephalon .................................................................................................... 123
Cancer Research Technology Enters Into Co-Development Agreement With Cephalon ............................................................... 124
H. Lundbeck Expands Marketing Agreement With Teva Pharma Industries .................................................................................. 125
UCB Terminates Co-Marketing Agreement With Teva Pharma ..................................................................................................... 126
Celator Pharma Enters Into Research Agreement With Cephalon ................................................................................................. 127
Teva Pharma Industries Forms Joint Venture With Lonza Group .................................................................................................. 128
Debiopharm Enters Into Distribution Agreement With Mepha Pharma ........................................................................................... 129
Dynamix Pharma Enters Into Co-Development Agreement With Teva Pharma ............................................................................. 130
Teva Pharma Enters into Licensing Agreement with Eagle Pharma for EP-3102 .......................................................................... 131
Cell Cure Neurosciences Terminates Licensing Option Agreement with Teva Pharma Industries for OpRegen ........................... 132
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma ..................................................................................... 134
Andromeda Terminates Licensing Agreement With Teva Pharma For DiaPep277 Rights ............................................................. 135
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate ..................................................... 137
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo ............................................................................ 139
Rexahn Pharma Terminates Licensing Agreement With Teva Pharma For RX-3117 .................................................................... 141
Labrys Biologics Enters Into Licensing Agreement With Pfizer For RN-307................................................................................... 143
Teva Pharma Terminates Licensing Agreement With Proteologics ................................................................................................ 144
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402 ....................................................................... 145
Teva Pharma Terminates Licensing Agreement With MediWound For NexoBrid .......................................................................... 147
Hospira Terminates Licensing Agreement With Ivax International For Omacetaxine Mepesuccinate ............................................ 148
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig ................................................................... 149
Teva Animal Health Exercises Option For Licensing Agreement With Eden Research ................................................................. 150
Immupharma Regains Lupuzor Rights From Cephalon ................................................................................................................. 151

Page 8
Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil ....................................................................... 153
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine .................................................................................... 154
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637 ........................................... 156
Lundbeck Enters Into Licensing Agreement With Cephalon........................................................................................................... 158
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI ............................................................. 160
ImmunGene Enters Into Licensing Agreement With Cephalon ...................................................................................................... 161
Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine .............................................................. 163
SymBio Pharma Enters Into Licensing Agreement With Cephalon ................................................................................................ 165
AstraZeneca Enters Into Licensing Agreement With Teva Pharma For Entocort EC ..................................................................... 166
Watson Pharma Enters Into Licensing Agreement With Teva Pharma .......................................................................................... 167
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Barr Labs .................................................................. 168
Mersana Therapeutics Enters Into Licensing Agreement With Teva Pharma Industries ................................................................ 170
Sanofi, Debiopharm Enters Into Licensing Agreement With Sandoz, Fresenius & Teva ................................................................ 172
Antisense Therapeutics Terminates Licensing Agreement With Teva Pharma .............................................................................. 174
Innate Immune Enters Into Licensing Agreement With Cephalon Australia ................................................................................... 175
MediGene Enters Into Licensing Agreement With Teva Pharma ................................................................................................... 176
ChemGenex Pharma Enters Into Licensing Agreement With Hospira ........................................................................................... 177
Codexis Extends Collaboration Agreement With Teva Pharma Industries ..................................................................................... 179
Ambrilia Terminates License, Distribution And Supply Agreements With Teva .............................................................................. 180
Rexahn Pharma Enters Into Licensing Agreement With Teva Pharma .......................................................................................... 181
Barr Labs Enters Into Licensing Agreement With Bayer ................................................................................................................ 183
Vical Enters Into Licensing Agreement With Teva Pharma ............................................................................................................ 185
Merck Extends Collaboration Agreement With MicroDose Therapeutx ......................................................................................... 186
Acusphere Amends Licensing Agreement With Cephalon ............................................................................................................. 187
Cephalon Enters Into Licensing Agreement With SymBio Pharma ................................................................................................ 189
Shire Amends Its Agreement With Duramed Pharma .................................................................................................................... 191
Cephalon Enters Into Licensing Agreement With ImmuPharma For Lupuzor ................................................................................ 192
Codexis Enters Into Licensing Agreement With Teva Pharma ....................................................................................................... 194
Ignyta Raises USD42 Million in Private Placement of Shares ........................................................................................................ 195
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares ......................................................................................... 197
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares ........................................................................................... 199
Auspex Pharma Completes IPO For US$96.6 Million .................................................................................................................... 201
NuPathe Files Registration Statement For Public Offering Of Securities For US$100 Million ........................................................ 203
NuPathe Completes Private Placement Of Units For US$28 Million .............................................................................................. 204
NuPathe Completes Second Tranche Of Private Placement Of Common Stock For US$0.6 Million ............................................. 206
NuPathe Completes IPO Of US$50 Million .................................................................................................................................... 208
ChemGenex Completes Rights Issue Of US$5.76 Million .............................................................................................................. 210
Cephalon Completes Public Offering Of US$300 Million ................................................................................................................ 212
ChemGenex Completes Private Placement Of US$7 Million ......................................................................................................... 214
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023 ............................................................ 216
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027 ......................................................... 217
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million ........................................................................ 218
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion .......................................................................... 220
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million ............................................................. 222
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion ............................................................... 224
Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For US$875 Million .................................................. 226
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$200 Million ....................................... 228

Page 9
Teva Pharma Completes Public Offering Of Notes Due 2021 For US$875 Million ........................................................................ 230
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$1.1 Billion ........................................ 232
Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For US$1 Billion......................................................... 234
Teva Pharma Completes Public Offering Of 2.4% Senior Notes Due 2016 For US$950 Million .................................................... 236
ChemGenex Completes Private Placement Of Convertible Notes For US$15 Million .................................................................... 242
Teva Pharma Completes Private Placement Of 1.5% Senior Notes For US$1,000 Million ............................................................ 243
Teva Pharma Completes Private Placement Of Senior Notes For US$500 Million ........................................................................ 245
Teva Pharma Completes Private Placement Of 3% Fixed Rate Senior Notes For US$1,000 Million ............................................. 247
Cephalon Completes Public Offering Of Convertible Senior Subordinated Notes For US$500 Million .......................................... 249
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma ..................................................................................... 251
Teva Pharma Plans to Divest Some Operations ............................................................................................................................ 252
Ignyta Acquires Four Oncology R&D Assets from Cephalon.......................................................................................................... 253
ANI Pharma Acquires ANDA from Teva Pharma ........................................................................................................................... 255
ANI Pharma Acquires 31 Generic Drug Products from Teva Pharma ............................................................................................ 256
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California ......................................................................................... 258
CleveXel Pharma Acquires Development Center From Teva Pharma ........................................................................................... 259
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma ................................................................. 260
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada ......................................................... 261
Acino Pharma Completes Acquisition Of Asia, Latin America, Middle East And Africa Businesses From Mepha For US$123 Million
....................................................................................................................................................................................................... 262
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma ......................................................................... 264
Partners In Life Sciences Completes Acquisition Of Manufacturing Facility In Mitry-Mory From Cephalon ................................... 265
Perrigo Acquires Rights For Allegra From Teva Pharma ............................................................................................................... 266
Hospira Acquires Worldwide Rights To Filgrastim From PLIVA ..................................................................................................... 267
Teva Pharma Acquires Auspex Pharma......................................................................................................................................... 268
Teva Pharma May Increase Bid to Acquire Mylan .......................................................................................................................... 270
Ind-Swift Lab May Sell Stake in Company...................................................................................................................................... 272
Teva Pharma Completes Acquisition of Labrys Biologics .............................................................................................................. 273
Novartis Terminates Planned Acquisition Of Gamida Cell For US$600 Million .............................................................................. 274
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer ................................................................. 276
NuPathe Terminates Its Acquisition By Endo Health Solutions For US$105 Million In Tender Offer ............................................. 279
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million .............................................................................. 281
Teva Pharma Completes Acquisition of MicroDose Therapeutx .................................................................................................... 284
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company ...................................................................... 286
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million ............................................................................ 288
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million ....................................................................... 290
Teva Pharma Rumored To Acquire Amarin.................................................................................................................................... 292
Teva Completes Acquisition Of Cephalon For US$6,800 Million.................................................................................................... 294
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For US$150 Million ........................................................... 297
Teva Pharma Invests Additional US$19 Million In CureTech ......................................................................................................... 299
Teva Pharma Industries Acquires Taiyo Pharma Industry ............................................................................................................. 300
Cephalon Acquires 91.73% Stake In ChemGenex ......................................................................................................................... 302
Cephalon Acquires Gemin X Pharma ............................................................................................................................................. 304
Cephalon Rejects Unsolicited Bid For Its Acquisition By Valeant Pharma ..................................................................................... 307
Clal Biotech Acquires Stake In TransPharma Medical From Teva ................................................................................................. 310

Page 10
Cephalon Completes Acquisition Of 20% Stake In Mesoblast ....................................................................................................... 312

Teva Pharma Industries Acquires Corporacion Infarmasa ............................................................................................................. 314
Teva Pharma Industries Acquires THERAMEX From Merck Serono ............................................................................................. 316
Cephalon Acquires BioAssets Development .................................................................................................................................. 318
Teva Pharma Industries Completes Acquisition Of ratiopharm For Approximately US$4.9 Billion ................................................. 320
Cephalon Acquires Mepha Pharma For US$616 Million ................................................................................................................ 323
Cephalon Acquires Ception Therapeutics ...................................................................................................................................... 325
Cephalon Acquires Arana Therapeutics ......................................................................................................................................... 328
Teva Pharmaceutical Industries Limited, Key Competitors ............................................................................................................ 330
Teva Pharmaceutical Industries Limited, Key Employees .............................................................................................................. 331
Teva Pharmaceutical Industries Limited, Other Locations.............................................................................................................. 333
Teva Pharmaceutical Industries Limited, Subsidiaries ................................................................................................................... 334


Page 11
List of Figures
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 ................................... 1
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 ................................... 1
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 ............................... 1
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 ..................... 1
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 ................................. 14


Page 12
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Year,

2009 to YTD 2015
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Note: Deals include all announced pharmaceuticals & healthcare deals from 2009 onwards, deal values included wherever disclosed.
GlobalData
Teva Pharmaceutical Industries Limited reported 13 pharmaceuticals & healthcare deals worth $49,049.16 million in YTD 2015.
The companys deal volume decreased from 21 pharmaceuticals & healthcare deals in 2013 to 13 pharmaceuticals & healthcare
deals in 2014.
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Year
No. of Deals
Deal Value (US$ million)
2009
34
1,840.74
2010
38
11,005.31
2011
38
20,933.31
2012
29
4,539.56
2013
21
778.93
2014
13
1,884.48
YTD 2015
13
49,049.16
Note: Deals include all announced pharmaceuticals & healthcare deals from 2009 onwards, deal values included wherever disclosed, GlobalData


Page 13
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare Deals By Type,

2009 to YTD 2015
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015
Note: Deals include all announced pharmaceuticals & healthcare deals from 2009 onwards
GlobalData
Teva Pharmaceutical Industries Limiteds deals activity has been reportedly focusing on licensing agreement with 43
pharmaceuticals & healthcare deals during the period 2009 to YTD 2015.
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015
Deal Type
No. of Deals
Licensing Agreement
43
3,370.82
Partnerships
34
573.89
Venture Financing
27
306.94
Acquisition
25
69,256.74
Debt Offerings
19
14,759.07
Divestiture - Assets
14
146.20
Equity Offerings
11
894.06
Asset Purchases
116.11
Divestiture - Company
607.66
GlobalData


Page 14
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Region,

2009 to YTD 2015
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015
GlobalData
Teva Pharmaceutical Industries Limiteds, pharmaceuticals & healthcare, deals activity has been reportedly focusing on North
America with 96 deals worth $66,598.97 million during the period 2009 to YTD 2015.
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015
Region
No. of Deals
North America
96
66,598.97
Middle East and Africa
75
18,441.95
Asia-Pacific
39
5,041.95
Europe
37
9,367.24
South and Central America
18
3,163.60
GlobalData


Page 15
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Therapy

Area, 2009 to YTD 2015
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015
Note: Deals include all announced pharmaceuticals & healthcare deals from 2009 onwards, GlobalData
Teva Pharmaceutical Industries Limited's pharmaceuticals & healthcare deals activity has been reportedly focusing on oncology
therapy area with 75 deals followed by central nervous system with 66 deals during the period 2009 to YTD 2015.
Teva Pharmaceutical Industries Limited, Deals By Therapy Area, 2009 to YTD 2015
Therapy Area
No. of Deals
Oncology
75
81,255.42
Central Nervous System
66
84,126.25
Immunology
42
80,287.76
Respiratory
38
79,633.16
Cardiovascular
33
77,986.66
Musculoskeletal
30
59,643.26
Women's Health
27
57,644.18
Infectious Disease
22
54,864.16
Gastrointestinal
21
59,869.96
Metabolic Disorders
21
59,233.64


Page 16
Toxicology
21
54,951.74
Dermatology
19
59,290.64
Hematological Disorders
19
59,668.95
Mouth And Dental Disorders
17
58,944.36
Ear Nose Throat Disorders
16
53,994.36
Male Health
16
53,999.36
Ophthalmology
16
54,935.46
Hormonal Disorders
15
53,996.86
14
53,994.36
14
53,994.36
Other Diseases
45,395.46
Genetic Disorders
2,172.06
Over-the-Counter Healthcare
303.00
Pharmaceuticals and Healthcare
43,000.00
Genito Urinary
Hormones
System
And
Sex
Nutritional Disorders
GlobalData


Page 17
Teva Pharmaceutical Industries Limited, Medical Devices Deals, 2009 to YTD 2015
Note: Deals include all announced pharmaceuticals & healthcare deals from 2009 onwards, GlobalData
Teva Pharmaceutical Industries Limited's medical devices deals activity has been reportedly focusing on drug delivery devices
with 11 deals during the period 2009 to YTD 2015.
Device Type
No. of Deals
Wound Care Management
NA
Cardiovascular Devices
8.50
In Vitro Diagnostics
300.00
11
676.60
Drug Delivery Devices
GlobalData


Page 18
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals Summary,

2009 to YTD 2015
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015
Deal Date
Deal Status
Acquirer /
Investor /
Licensor
Deal Type
Target / Issuer /
Partners /
Licensee
Vendor
Deal Value
(US$ m)
Teva
Pharmaceutical
Industries Limited
5.00
13-May-2015
Completed
Divestiture
Assets
- ANI
Pharmaceuticals,
Inc.
Testosterone Gel
1%
05-May-2015
Completed
Acquisition
Teva
Pharmaceutical
Industries Limited
Auspex
Pharmaceuticals,
Inc
22-Apr-2015
Planned
Divestiture
Assets
17-Apr-2015
Rumor
Acquisition
31-Mar-2015
Completed
31-Mar-2015
- Undisclosed
Company
Teva
Pharmaceutical
Industries Limited
Operations
3,500.00
Teva
Pharmaceutical
Industries Limited
Mylan NV
43,000.00
Debt Offering
Teva
Pharmaceutical
Industries Limited
1,411.84
Completed
Debt Offering
Teva
Pharmaceutical
Industries Limited
760.22
17-Mar-2015
Completed
Divestiture
Assets
17-Mar-2015
Completed
Equity Offering
05-Mar-2015
Completed
Divestiture
Assets
17-Feb-2015
Completed
Licensing
Agreement
Eagle
Pharmaceuticals,
Inc, Teva
Pharmaceutical
Industries Limited
120.00
16-Feb-2015
Terminated
Licensing
Agreement
Cell Cure
Neurosciences,
Ltd, Hadasit BioHoldings Ltd,
Teva
Pharmaceutical
Industries Limited
7.10
02-Feb-2015
Completed
Licensing
Agreement
Intellipharmaceuti
cs International
Inc, Teva
Pharmaceuticals
USA, Inc
28-Jan-2015
Completed
Equity Offering
Auspex
- Ignyta, Inc.
Four Oncology
R&D Assets
Cephalon, Inc.
Teva
Ignyta, Inc
Pharmaceutical
Industries Limited,
Undisclosed
Investor(s)
- ANI
Pharmaceuticals,
Inc.
41.60
ANDA for
Teva
Flecainide Acetate Pharmaceuticals
USA, Inc.

203.40
Page 19
Pharmaceuticals,
Inc
09-Oct-2014
Announced
Partnership
MedPro
Pharmaceutica
(Pty) Ltd, Teva
Pharmaceuticals
(Pty) Ltd
26-Aug-2014
Completed
Partnership
Teva
Pharmaceutical
Industries Limited,
Venus Remedies
Limited
30-Jul-2014
Rumor
Acquisition
Perrigo
Ind-Swift
International
Laboratories
Holdings
Inc., Limited
Teva
Pharmaceuticals
USA, Inc.
33.28
21-Jul-2014
Completed
Acquisition
Teva
Pharmaceutical
Industries Limited
Labrys Biologics,
Inc
825.00
16-Jul-2014
Completed
Equity Offering
Auspex
Pharmaceuticals,
Inc
60.60
05-Jun-2014
Announced
Partnership
Philips
Healthcare, Teva
Pharmaceutical
Industries Limited
01-May-2014
Terminated
Divestiture
Company
27-Apr-2014
Completed
Partnership
Takeda
Pharmaceutical
Company Limited,
Teva
Pharmaceutical
Industries Limited
24-Feb-2014
Terminated
Licensing
Agreement
Andromeda
Biotech Ltd, Teva
Pharmaceutical
Industries Limited
20-Feb-2014
Completed
Acquisition
10-Feb-2014
Completed
Equity Offering
- Novartis AG
Teva
Pharmaceutical
Industries Limited
Gamida Cell Ltd
Amgen
Inc.,
Auriga Partners,
Clal
Biotechnology
Industries
Ltd.,
Denali Ventures,
Elbit
Medical
Technologies Ltd.,
Israel HealthCare
Ventures,
Teva
Pharmaceutical
Industries Limited
600.00
NuPathe Inc
144.00
Auspex
Pharmaceuticals,
Inc
96.60


Page 20
21-Jan-2014
Terminated
Acquisition
Endo International NuPathe Inc

plc
105.00
08-Jan-2014
Completed
Venture
Financing
BioMed Ventures, Auspex

CMEA
Capital, Pharmaceuticals,
Costa
Verde Inc
Capital, Deerfield
Management
Company,
L.P.,
Panorama
Capital,
LLC,
Thomas,
McNerney
&
Partners, LLC
20.00
26-Dec-2013
Completed
Divestiture
Assets
04-Dec-2013
Completed
Licensing
Agreement
Takeda
Pharmaceutical
Company Limited,
Teva
Pharmaceutical
Industries Limited
27-Nov-2013
Completed
Licensing
Agreement
QRxPharma
Limited, Teva
Pharmaceutical
Industries Limited
03-Oct-2013
Rumor
Asset Purchase Actavis plc, Lupin Oral

Limited, Sandoz Contraceptives
Inc.,
Sun Division
Pharmaceutical
Industries Limited,
Teva
Pharmaceutical
Industries Limited
19-Sep-2013
Completed
Acquisition
16-Sep-2013
Completed
Partnership
Cancer Research
Technology
Limited, Teva
Pharmaceutical
Industries Limited
12-Sep-2013
Completed
Partnership
Champions
Oncology, Inc,
Teva
Pharmaceutical
Industries Limited
- ANI
Pharmaceuticals,
Inc.
Actelion Ltd
Generic Drug
Products
Ception
Therapeutics, Inc

Teva
Pharmaceutical
Industries Limited
12.50
Glenmark
Pharmaceuticals
Ltd.
Aperture Venture
Partners,
LLC,
BioAdvance,
Burrill
&
Company, Osage
Partners LLC ,
Oxford
Finance
LLC, Palo Alto
Investors,
LLC,
Silicon
Valley
Bank, Third Point
LLC,
Vivo
Ventures, LLC
250.00

Page 21
28-Aug-2013
Terminated
Licensing
Agreement
Rexahn
Pharmaceuticals,
Inc, Teva
Pharmaceutical
Industries Limited
15-Aug-2013
Planned
Partnership
Teva
Pharmaceutical
Industries Limited,
Undisclosed
Company
12-Aug-2013
Completed
Partnership
Perrigo Company
plc, Teva
Pharmaceutical
Industries Limited
25-Jul-2013
Terminated
Partnership
Lonza Group Ltd,

Teva
Pharmaceutical
Industries Limited
08-Jul-2013
Completed
Acquisition
01-Jul-2013
Completed
Partnership
Teva
Pharmaceutical
Industries Limited,
Verinata Health,
Inc
08-May-2013
Completed
Partnership
Alexza
Pharmaceuticals,
Inc, Teva
Pharmaceuticals
USA, Inc
16-Apr-2013
Planned
Acquisition
07-Feb-2013
Planned
Divestiture
Assets
- Undisclosed
Company
04-Feb-2013
Completed
Divestiture
Assets
- Clevexel Pharma Teva's

SAS
Development
Center
Teva
Pharmaceutical
Industries Limited
31-Jan-2013
Completed
Divestiture
Company
- BioTime, Inc.
Hadasit
BioHoldings
Ltd.,
Teva
Pharmaceutical
Industries Limited
31-Jan-2013
Terminated
Partnership
03-Jan-2013
Completed
Venture
Financing
Teva
Pharmaceutical
Industries Limited
0.93
MicroDose
Therapeutx, Inc
AstraZeneca PLC, Celltrion, Inc

F.
Hoffmann-La
Roche Ltd., Teva
Pharmaceutical
Industries Limited
Manufacturing
Facility
Cell Cure
Neurosciences,
Ltd
246.00
235.00
Seo Jung-jin
Teva
Pharmaceutical
Industries Limited
3.50
CureTech Ltd,
Teva
Pharmaceutical
Industries Limited
Canaan Partners, Labrys Biologics,
InterWest
Inc
Partners,
LLC,
Sofinnova

31.00

Page 22
Ventures,
Inc.,
Undisclosed
Investor(s),
venBio
03-Jan-2013
Completed
Licensing
Agreement
Labrys Biologics,
Inc, Pfizer Inc
27-Dec-2012
Terminated
Licensing
Agreement
Proteologics Ltd,
Teva
Pharmaceutical
Industries Limited
21-Dec-2012
Filing
Equity Offering
NuPathe Inc
100.00
18-Dec-2012
Completed
Debt Offering
Undisclosed
Investor(s)
Teva
Pharmaceutical
Industries Limited
700.00
18-Dec-2012
Completed
Debt Offering
Undisclosed
Investor(s)
Teva
Pharmaceutical
Industries Limited
1,300.00
16-Dec-2012
Announced
Partnership
Handok Inc, Teva

Pharmaceutical
Industries Limited
11-Dec-2012
Completed
Licensing
Agreement
Teva
Pharmaceutical
Industries Limited,
Xenon
Pharmaceuticals
Inc
11-Dec-2012
Completed
Partnership
Ctcbio Inc, Teva

Pharmaceutical
Industries Limited
10-Dec-2012
Terminated
Licensing
Agreement
MediWound Ltd,
Teva
Pharmaceutical
Industries Limited
04-Dec-2012
Completed
Partnership
Galena
Biopharma, Inc,
Teva
Pharmaceutical
Industries Limited
21-Nov-2012
Completed
Divestiture
Company
15-Nov-2012
Rumor
Acquisition
09-Nov-2012
Announced
Divestiture
Assets
08-Nov-2012
Completed
Venture
Financing
- XTL
Proteologics Ltd
Biopharmaceutical
s Ltd.
Teva
Pharmaceutical
Industries Limited
376.00
Teva
Pharmaceutical
Industries Limited
1.66
Amarin
Corporation plc
- The Procter & OTC Business

Gamble Company
CMEA
Capital, Auspex
Panorama
Pharmaceuticals,
Capital,
LLC, Inc
Sloan
Biotech
Fund,
LLC,
Thomas,
McNerney
&
Partners, LLC

Teva
Pharmaceutical
Industries Limited
25.00

Page 23
25-Oct-2012
Completed
Asset Purchase Teva

Pharmaceutical
Industries Limited
23-Oct-2012
Completed
Equity Offering
31-Jul-2012
Completed
Divestiture
Assets
25-Jul-2012
Announced
Partnership
18-Jul-2012
Completed
Venture
Financing
30-Jun-2012
Terminated
Licensing
Agreement
ChemGenex
Pharmaceuticals
Limited, Hospira,
Inc
13-Jun-2012
Completed
Licensing
Agreement
BioAlliance
Pharma SA
(Inactive), Teva
Pharmaceutical
Industries Limited
05-Jun-2012
Completed
Venture
Financing
Aperture Venture Ception

Partners,
LLC, Therapeutics, Inc
BioAdvance,
Burrill
&
Company, Osage
Partners LLC ,
Palo
Alto
Investors,
LLC,
Third Point LLC,
Vivo
Ventures,
LLC
10.00
15-May-2012
Completed
Venture
Financing
Amgen
Inc., Gamida Cell Ltd
Auriga Partners,
Clal
Biotechnology
Industries
Ltd.,
Denali Ventures,
Elbit Imaging Ltd.,
Israel HealthCare
Ventures,
Teva
Pharmaceutical
Industries Limited
10.00
14-May-2012
Completed
Venture
Financing
Undisclosed
Investor(s)
Ception
Therapeutics, Inc
8.29
25-Apr-2012
Completed
Debt Offering
Teva
Pharmaceutical
Industries Limited
495.30
04-Apr-2012
Completed
Debt Offering
Teva
Pharmaceutical
Industries Limited
1,327.00
Undisclosed
Investor(s)
- Halo
Pharmaceutical,
Inc.
Huntexil
NeuroSearch A/S
NuPathe Inc
Mirabel
Manufacturing
Facility
25.81
28.00
Teva
Limited
Canada
Teva
Pharmaceutical
Industries Limited,
The Procter &
Gamble Company
Undisclosed
Investor(s)
Auspex
Pharmaceuticals,
Inc

1.50

Page 24
21-Feb-2012
Completed
Venture
Financing
17-Feb-2012
Completed
Divestiture
Assets
26-Jan-2012
Completed
Venture
Financing
06-Jan-2012
Completed
Licensing
Agreement
Eden Research
plc, Teva Animal
Health, Inc
0.90
10-Nov-2011
Completed
Debt Offering
Teva
Pharmaceutical
Industries Limited
200.00
10-Nov-2011
Completed
Debt Offering
Teva
Pharmaceutical
Industries Limited
1,100.00
10-Nov-2011
Completed
Debt Offering
Teva
Pharmaceutical
Industries Limited
1,000.00
10-Nov-2011
Completed
Debt Offering
Teva
Pharmaceutical
Industries Limited
950.00
10-Nov-2011
Completed
Debt Offering
Teva
Pharmaceutical
Industries Limited
875.00
10-Nov-2011
Completed
Debt Offering
Teva
Pharmaceutical
Industries Limited
875.00
03-Nov-2011
Completed
Partnership
Teva
Pharmaceutical
Industries Limited,
The Procter &
Gamble Company
21-Oct-2011
Terminated
Licensing
Agreement
Cephalon, Inc,
Immupharma Plc
18-Oct-2011
Completed
Divestiture
Assets
Oxford
Finance Ception
LLC,
Silicon Therapeutics, Inc
Valley Bank
- Acino Holding AG Gasec,
International
Business,
Mesporin,
Spasfon
Teva
Pharmaceutical
Industries Limited
- Par
Pharmaceutical
Holdings, Inc.
7.50
Mepha
AG
Pharma
122.60
MultiGene
Vascular Systems
(MGVS) Ltd
Actiq (Teva
Pharma) ( Teva
Pharmaceutical
Industries Limited
- Marketed ) ,
Cyclobenzaprine
Hydrochloride
(Teva Pharma) (
Teva
Pharmaceutical
Industries Limited
- Marketed ) ,
PROVIGIL
(Cephalon, Inc) (
Cephalon, Inc PipeLine )

Teva
Pharmaceutical
Industries Limited

Page 25
Teva
Pharmaceutical
Industries Limited
14-Oct-2011
Completed
Acquisition
03-Oct-2011
Completed
Divestiture
Assets
26-Sep-2011
Completed
Acquisition
15-Sep-2011
Completed
Partnership
13-Sep-2011
Completed
Acquisition
31-Aug-2011
Completed
Licensing
Agreement
11-Aug-2011
Completed
Venture
Financing
Aperture Venture Ception

Partners,
LLC, Therapeutics, Inc
Burrill
&
Company,
Palo
Alto
Investors,
LLC,
Vivo
Ventures, LLC
14.40
08-Aug-2011
Completed
Equity Offering
Aspire
Capital NuPathe Inc
Fund, LLC
1.10
19-Jul-2011
Completed
Licensing
Agreement
14-Jul-2011
Completed
Acquisition
Teva
Pharmaceutical
Industries Limited
Taiyo
Pharmaceutical
Industry Co, Ltd
934.00
07-Jun-2011
Completed
Acquisition
Cephalon, Inc.
ChemGenex
Pharmaceuticals
Limited
231.00
17-May-2011
Completed
Partnership
30-Apr-2011
Completed
Acquisition
- Partners in
Sciences
Cephalon, Inc
Life Mitry-Mory
Manufacturing
Facility
Teva
Pharmaceutical
Industries Limited
Teva
Pharmaceutical
Industries Limited
Teva-Kowa
Pharma Co, Ltd
6,800.00
Cephalon, Inc.
Kowa
Ltd.
Company,
6.10
150.00
Cocrystal Pharma,
Inc, Teva
Pharmaceutical
Industries Limited
7.50
CureTech Ltd
19.00
Sinclair IS
Pharma Plc, Teva
Pharmaceutical
Industries Limited
CEL-SCI
Corporation, Teva
Pharmaceutical
Industries Limited
Erytech Pharma
SA, Teva
Pharmaceutical
Industries Limited
Cephalon, Inc.
Gemin X
Pharmaceuticals

Business
Development
Bank of Canada,
Caxton Advantage
Life
Sciences
Fund,
L.P,
GrowthWorks
Capital Ltd., H.I.G.
Ventures
LLC,
HBM
Partners
AG, Merlin Nexus,
Ontario Teachers'
525.00

Page 26
Pension
Plan,
Pinnacle
Ventures, L.L.C.,
ProQuest
Investments,
Sanderling
Ventures, SB Life
Science
Equity
Management,
LLC,
Solidarity
Fund
QFL,
Vantage
Point
Partners
20-Apr-2011
Completed
Licensing
Agreement
05-Apr-2011
Terminated
Acquisition
24-Mar-2011
Completed
21-Mar-2011
Gilead Sciences,
Inc, MicroDose
Therapeutx, Inc
Valeant
Pharmaceuticals
International, Inc.
Cephalon, Inc
5,700.00
Partnership
Cephalon, Inc,
Champions
Oncology, Inc
28.39
Completed
Debt Offering
Teva
Pharmaceutical
Industries Limited
500.00
21-Mar-2011
Completed
Debt Offering
Undisclosed
Company
Teva
Pharmaceutical
Industries Limited
250.00
25-Feb-2011
Completed
Venture
Financing
Cephalon,
Inc., SymBio
JAFCO Co., Ltd.
Pharmaceuticals
Limited
23-Feb-2011
Completed
Partnership
22-Feb-2011
Completed
Divestiture
Company
- Clal
Biotechnology
Industries Ltd.
14-Feb-2011
Completed
Acquisition
Cephalon, Inc.
09-Feb-2011
Announced
Asset Purchase Cephalon, Inc.
Larazotide
Acetate
08-Feb-2011
Completed
Licensing
Agreement
Cephalon, Inc, H
Lundbeck A/S
26-Jan-2011
Completed
Acquisition
26-Jan-2011
Completed
Licensing
Agreement
Fresenius Kabi
USA, LLC, Teva
Pharmaceuticals
USA, Inc
10-Jan-2011
Completed
Partnership
Celator
Pharmaceuticals,
Inc, Cephalon, Inc
05-Jan-2011
Completed
Acquisition
24.46
Alcobra Ltd, Teva

Pharmaceutical
Industries Limited
Teva
Pharmaceutical
Industries Limited
Teva
Pharmaceutical
TransPharma
Medical Ltd
Teva
Pharmaceutical
Industries Limited
Mesoblast Limited
Corporacion
Infarmasa SA
THERAMEX SpA

2.50
359.32
Alba Therapeutics
Corporation
15.00
Altra Investments
Inc., The Rohatyn
Group, LLC
Merck
S.A.
Serono
365.54

Page 27
Industries Limited
05-Jan-2011
Completed
Licensing
Agreement
Cephalon, Inc,
ImmunGene, Inc
31-Dec-2010
Completed
Debt Offering
20-Dec-2010
Completed
Partnership
Auspex
Pharmaceuticals,
Inc, Teva
Pharmaceutical
Industries Limited
07-Dec-2010
Completed
Licensing
Agreement
Cephalon, Inc,
Mesoblast Limited
22-Nov-2010
Completed
Venture
Financing
Ben
Franklin Ception
Technology
Therapeutics, Inc
Partners,
BioAdvance,
Burrill
&
Company,
MidCoast Capital,
Osage
Partners
LLC , Palo Alto
Investors,
LLC,
Vivo
Ventures,
LLC
19-Nov-2010
Completed
Acquisition
Cephalon, Inc.
09-Nov-2010
Completed
Partnership
MicroDose
Therapeutx, Inc,
Nexus6 Limited
09-Nov-2010
Completed
Partnership
MediWound Ltd,
Polyheal Ltd,
Teva
Pharmaceutical
Industries Limited
05-Oct-2010
Completed
Venture
Financing
11-Aug-2010
Completed
Equity Offering
10-Aug-2010
Completed
Acquisition
Teva
Pharmaceutical
Industries Limited
04-Aug-2010
Completed
Venture
Financing
Caxton Advantage Gemin X

Life
Sciences Pharmaceuticals
Fund,
L.P,
Sanderling
Ventures
8.00
20-Jul-2010
Completed
Venture
Financing
CMEA
Capital, Auspex
Sloan
Biotech Pharmaceuticals,
Fund,
LLC, Inc
Thomas,
12.00
Cephalon, Inc.
ChemGenex
Pharmaceuticals
Limited
14.71
1,830.00
2.00
BioAssets
Development
Corporation
46.30
303.00
Aurum Ventures Vascular

MKI,
Pitango Biogenics Ltd
Venture Capital,
Teva
Pharmaceutical
Industries Limited
40.00
NuPathe Inc
50.00
ratiopharm GmbH VEM

Vermoegensverw
altung GmbH

4,950.00

Page 28
McNerney
Partners, LLC
&
29-Jun-2010
Completed
Divestiture
Assets
- Perrigo Company Allegra, Allegra D- Teva

plc
12
Pharmaceutical
Industries Limited
21-Jun-2010
Completed
Partnership
18-Jun-2010
Completed
Debt Offering
Undisclosed
Investor(s)
Teva
Pharmaceutical
Industries Limited
1,000.00
18-Jun-2010
Completed
Debt Offering
Undisclosed
Investor(s)
Teva
Pharmaceutical
Industries Limited
500.00
18-Jun-2010
Completed
Debt Offering
Undisclosed
Investor(s)
Teva
Pharmaceutical
Industries Limited
1,000.00
14-Jun-2010
Completed
Licensing
Agreement
Cephalon, Inc,
SymBio
Pharmaceuticals
Limited
18-May-2010
Completed
Licensing
Agreement
AstraZeneca PLC,
Teva
Pharmaceutical
Industries Limited
14-May-2010
Completed
Venture
Financing
Undisclosed Firm
Gemin X
Pharmaceuticals
3.92
10-May-2010
Completed
Venture
Financing
Cephalon,
Inc., Celator
Domain
Pharmaceuticals,
Associates,
Inc
L.L.C.,
GrowthWorks
Capital
Ltd.,
Quaker
BioVentures,
Undisclosed
Investor(s),
Ventures
West
Capital Ltd.
2.50
07-May-2010
Completed
Licensing
Agreement
20-Apr-2010
Completed
Venture
Financing
15-Apr-2010
Planned
Asset Purchase Teva

Pharmaceutical
Industries Limited
Three Women's
Health Divisions
13-Apr-2010
Completed
Licensing
Agreement
Mersana
Therapeutics, Inc,
Teva
Pharmaceutical
Industries Limited
Celator
Pharmaceuticals,
Inc, Cephalon, Inc
Actavis plc, Teva

Pharmaceutical
Industries Limited
Caxton Advantage Gemin X
Life
Sciences Pharmaceuticals
Fund,
L.P,
Sanderling
Ventures

16.00
Undisclosed
Company
334.00

Page 29
13-Apr-2010
Completed
Licensing
Agreement
Barr Laboratories,
Inc, Endo
International plc,
Penwest
Pharmaceuticals
Co (Inactive)
09-Apr-2010
Completed
Acquisition
Cephalon, Inc.
Mepha Pharma
AG
Mepha
AG
Holding
616.30
05-Apr-2010
Completed
Acquisition
Cephalon, Inc.
Ception
Therapeutics, Inc
Aperture Venture
Partners,
LLC,
Astellas Venture
Management LLC,
Essex Woodlands
Health Ventures,
Greenlight
Capital,
Inc.,
Investor Growth
Capital,
Inc.,
Lumira
Capital
Corp.,
MDS
Capital
Corp.,
New
Science
Ventures,
Third
Point Ventures
250.00
01-Apr-2010
Completed
Licensing
Agreement
Debiopharm
International SA,
Fresenius Kabi
Oncology Limited,
Sandoz Inc,
Sanofi, Teva
Pharmaceuticals
USA, Inc
24-Mar-2010
Terminated
Licensing
Agreement
Antisense
Therapeutics
Limited, Teva
Pharmaceutical
Industries Limited
19-Mar-2010
Completed
Partnership
Cancer Research
Technology
Limited,
Cephalon, Inc
15-Mar-2010
Completed
Licensing
Agreement
Cephalon, Inc,
Innate Immune,
Inc
26-Feb-2010
Completed
Venture
Financing
24-Feb-2010
Completed
Partnership
H Lundbeck A/S,
Teva
Pharmaceutical
Industries Limited
22-Feb-2010
Completed
Licensing
Agreement
MediGene AG,
Teva
Pharmaceutical
Industries Limited
08-Feb-2010
Completed
Partnership
Active Biotech AB,
Undisclosed Firm
Auspex
Pharmaceuticals,
Inc

2.00

Page 30
Teva
Pharmaceutical
Industries Limited
Teva
Pharmaceutical
Industries Limited,
UCB SA
29-Jan-2010
Terminated
Partnership
28-Jan-2010
Completed
Venture
Financing
31-Dec-2009
Completed
Asset Purchase Cephalon, Inc.
VOGALENE,
VOGALIB
14-Dec-2009
Completed
Licensing
Agreement
ChemGenex
Pharmaceuticals
Limited, Hospira,
Inc
01-Dec-2009
Completed
Licensing
Agreement
Codexis, Inc,
Teva
Pharmaceutical
Industries Limited
01-Dec-2009
Completed
Asset Purchase MicroDose

Therapeutx, Inc.
MDT-006, MDT006
EPIX
Pharmaceuticals,
Inc. (Inactive)
09-Nov-2009
Completed
Asset Purchase MicroDose

Therapeutx, Inc.
Investigational
Compounds,
MDT-637
ViroPharma
Incorporated
27-Oct-2009
Completed
Venture
Financing
19-Oct-2009
Terminated
Licensing
Agreement
14-Oct-2009
Completed
Venture
Financing
30-Sep-2009
Completed
Divestiture
Assets
21-Sep-2009
Completed
Licensing
Agreement
Cephalon,
Inc., SymBio
Undisclosed Firm, Pharmaceuticals
Weru Investment Limited
Co., Ltd.
24.58
UCB Pharma S.A.
53.30
124.59
Aviv
Venture MultiGene
Capital,
DFJ Vascular Systems
Tamir
Fishman (MGVS) Ltd
Ventures, Ofer HiTech Ltd., Teva
Pharmaceutical
Industries Limited,
Undisclosed
Investor(s)
8.50
Ambrilia
Biopharma Inc,
Teva
Pharmaceuticals
Europe BV
ES
Cell Cell Cure
International Pte Neurosciences,
Ltd, Hadasit Bio- Ltd
Holdings
Ltd.,
Teva
Pharmaceutical
Industries Limited
- Hospira, Inc.
Filgrastim
Rexahn
Pharmaceuticals,
Inc, Teva
Pharmaceutical
Industries Limited

0.81
Pliva
doo
Hrvatska
3.50

Page 31
19-Aug-2009
Completed
Venture
Financing
CMEA
Capital, Auspex
Costa
Verde Pharmaceuticals,
Capital, Thomas, Inc
McNerney
&
Partners, LLC
3.00
13-Aug-2009
Completed
Venture
Financing
Undisclosed Firm
Ception
Therapeutics, Inc
3.14
10-Aug-2009
Completed
Acquisition
Cephalon, Inc.
Arana
Therapeutics
Limited (Inactive)
05-Aug-2009
Completed
Licensing
Agreement
Barr Laboratories,
Inc, Bayer AG
03-Aug-2009
Completed
Licensing
Agreement
Abic Marketing
Limited, Vical
Incorporated
22-Jul-2009
Completed
Licensing
Agreement
Merck & Co, Inc,

MicroDose
Therapeutx, Inc
32.00
24-Jun-2009
Completed
Licensing
Agreement
Acusphere, Inc,
Cephalon, Inc
1.00
27-May-2009
Completed
Equity Offering
Cephalon, Inc
300.00
27-May-2009
Completed
Debt Offering
Cephalon, Inc
500.00
27-May-2009
Completed
Equity Offering
ChemGenex
Pharmaceuticals
Limited
21-May-2009
Completed
Partnership
Celator
Pharmaceuticals,
Inc, Cephalon, Inc
14-May-2009
Completed
Partnership
Lonza Group Ltd,

Teva
Pharmaceutical
Industries Limited
11-May-2009
Completed
Partnership
Debiopharm
International SA,
Mepha Pharma
AG
01-May-2009
Completed
Venture
Financing
30-Apr-2009
Completed
Asset Purchase Taiyo

Pharmaceutical
Industry Co., Ltd.
15-Apr-2009
Completed
Venture
Financing
Cephalon,
Inc., SymBio
Mitsubishi
UFJ Pharmaceuticals
Capital Co., Ltd.
Limited
9.04
09-Apr-2009
Completed
Equity Offering
GBS
7.00
Undisclosed
Investor(s)
Rockwell
Securities Limited,
Start-up Australia
Ventures
Pty.,
Ltd., Undisclosed
Investor(s)
5.76
Business
Gemin X
Development
Pharmaceuticals
Bank of Canada,
Sanderling
Ventures,
Solidarity
Fund
QFL
Kasukabe Plant
Venture ChemGenex

207.00
9.30
Schering-Plough
Corporation
(Inactive)

Page 32
Partners Limited, Pharmaceuticals

Merck
Serono Limited
Australia Pty Ltd.,
Orbis
Funds
Management,
Undisclosed
Investor(s)
27-Mar-2009
Completed
Venture
Financing
09-Mar-2009
Completed
24-Feb-2009
Batsheva Elran, Dynamix

Teva
Pharmaceuticals
Pharmaceutical
Ltd
Industries Limited
10.00
Licensing
Agreement
Cephalon, Inc,
SymBio
Pharmaceuticals
Limited
0.80
Completed
Licensing
Agreement
Shire Plc, Teva

Women's Health
40.00
16-Feb-2009
Completed
Partnership
Dynamix
Pharmaceuticals
Ltd, Teva
Pharmaceutical
Industries Limited
02-Feb-2009
Completed
Licensing
Agreement
Cephalon, Inc,
Immupharma Plc
27-Jan-2009
Completed
Asset Purchase BioGeneriX AG
Intellectual
Property Assets
07-Jan-2009
Completed
Licensing
Agreement
Codexis, Inc,
Teva
Pharmaceutical
Industries Limited
500.00
Neose
Technologies, Inc.
(Inactive)
22.00
Note: Deals include all pharmaceuticals & healthcare deals from 2009 onwards, deal values included wherever disclosed.
GlobalData


Page 33
Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deal Details

Asset Purchase
Glenmark Pharma Rumored To Sell Its Oral Contraceptives Division
Glenmark Pharma Rumored To Sell Its Oral Contraceptives Division
Deal Type
Asset Purchase
Deal in Brief
Glenmark Pharmaceuticals Ltd., an integrated pharmaceutical company, rumored to sell its oral contraceptives division, which
manufactures generic anti-pregnancy medicine, reported by The Economic Times citing two persons familiar with this matter.
Glenmark Pharma has almost the entire range of about 19 variants of the oral contraceptive, which includes its existing product
line and abbreviated new drug applications (ANDAs) pending approvals. The niche hormonal product is manufactured at the
company's factory in Goa and has a market size of more than US$2.5 billion in the US. Reportedly, Sun Pharmaceutical
Industries Limited and Lupin Limited along with global companies, Actavis Inc., Teva Pharmaceutical Industries Limited and
Sandoz Inc. are interested to acquire the entire product range including the ANDA filing to consolidate their position in the US
market.Currently, Glenmark Pharma's portfolio consists of 90 products authorized for distribution in the US marketplace and 53
ANDAs pending approval with the USFDA.
Deal Information
Deal Status
Rumor
RumorDate
Oct 03, 2013
Companies Information
Acquirer Company Information
Company Name
Sun
Pharmaceutical
Industries Limited
Business Description
Sun Pharmaceutical Industries Limited (Sun Pharma) is an integrated specialty pharmaceutical company. It manufactures and
markets a wide range of pharmaceutical formulations such as branded generics and generic pharmaceuticals for various
conditions related to psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics and ophthalmology. The
company carries out product development, process chemistry, and manufacture of complex active pharmaceutical ingredients
(APIs), and dosage forms. The company broadly classifies its products into two categories, namely, Formulations and Active
Pharmaceutical Ingredients (APIs). It sells its products under the brand names of Alcoliv, Adfovir, Benfomet, Betavert, Cansoft,
Dazolic, Ocepred, and Silbostin, among others. It has research centers and manufacturing plants in India, Israel, the US,
Canada, Hungary, Brazil, Mexico and Bangladesh. Sun Pharma is headquartered in Mumbai, Maharashtra, India.
Company Name
Lupin Limited
Lupin Limited (Lupin) is transnational pharmaceutical company. It is one of the largest generic pharmaceutical companies
across the world.The company focuses on the manufacture of generic and branded drugs, formulations and active
pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics,
GI, CNS, anti-infectives, NSAIDs, anti-TB and cephalosporins. The company undertakes extensive research and development
of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis,
diabetes and inflammation. The company operates in India, the US, UK, Europe, Germany, Japan, South Africa, Philippines,
and Australia. It operates subsidiaries in various countries across the world, some of which include Lupin Pharma Canada
Limited; Lupin Pharmaceuticals Inc.; and Pharma Dynamics. Lupin is headquartered in Mumbai, Maharashtra, India.
Company Name
Sandoz Inc.
Parent
Sandoz International GmbH
Sandoz Inc. (Sandoz), is a specialty generic pharmaceutical company. It undertakes the development, manufacturing and
distribution of high-quality pharmaceuticals, delivery systems and follow-on biologics. The company offers a wide range of
products in the therapeutic areas of cardiovascular system, central nervous system (CNS), alimentary tract and metabolism,
respiratory system, blood and blood forming organs, and anti-infectives, among others. Some of the companys key products
include Altavera and Loryna, Lovenox , amoxicillin-clavulanic acid, gemcitabine, Flomax, Cozaar and others. It markets more
than 200 generic medicines in the US. Sandoz distributes its products to retailers, wholesalers, hospitals, prescription benefit
managers and public agencies. It operates two manufacturing facilities located in Broomfiled, Colorado and Wilson, North

Page 34
Carolina; and product development facilities located in East Hanover, New Jersey and Durham, North Carolina. It is a
subsidiary of Sandoz International GmbH. Sandoz is headquartered in Princeton, New Jersey, the US.
Company Name
Actavis plc
Actavis plc (Actavis) is a specialty pharmaceutical company. It focuses on the development, manufacturing, marketing and
distribution of specialized branded, generic, bio-similar and over-the-counter (OTC) products. The company offers products in
the areas of central nervous system, urology, women's health, hormones and synthetic substitutes, cancer, cardiovascular,
nephrology and gastrointestinal, among others. It markets over 250 generic pharmaceuticals and approximately 80 branded
pharmaceuticals. The company develops and out-licenses generic pharmaceutical products through its Medis third-party
business. It has operations in over 60 countries across North America and rest of the world. The company company distributes
approximately 12,650 stock-keeping units (SKUs) through its ANDA Distribution business. It is formed by the merger of Actavis,
Inc. and Warner Chilcott Limited. Actavis is headquartered in Dublin, Ireland.
Company Name
Teva
Pharmaceutical
Industries Limited
Teva Pharmaceutical Industries Limited (Teva) is a fully integrated global pharmaceutical company. It undertakes the
development, manufacture and marketing of a wide range of generic and branded pharmaceuticals and active pharmaceutical
ingredients (APIs). The company offers chemical and therapeutic equivalents of originator pharmaceuticals in a wide range of
dosage forms, including capsules, tablets, ointments, liquids, creams, injectables and inhalants. Teva also provides an array of
over the counter (OTC) products through a joint venture with P&G. The company is also a specialty pharmaceuticals innovator
focusing on various disease areas including multiple sclerosis, Parkinson's disease, autoimmune diseases, cancer, women's
health and respiratory products. Teva operates in more than 60 countries and distributes its products across the world. Teva is
headquartered in Tikva, Israel.
Vendor Company Information
Company Name
Glenmark
Ltd.
Pharmaceuticals
Glenmark Pharmaceuticals Ltd. (Glenmark Pharmaceuticals) is an integrated pharmaceutical company. The company
manufactures and markets formulations and active pharmaceutical ingredients (APIs). It also undertakes the discovery of NCEs
(new chemical entities) and NBEs (new biological entities). The company operates through three business divisions, namely,
drug discovery, formulations business and Glenmark Generics Ltd. The pipeline portfolio of the company includes seven
molecules, which includes four NCEs and three NBEs in various stages of preclinical & clinical development. Glenmark
Pharmaceuticals focuses on therapeutic areas such as dermatology, anti-invectives, respiratory, cardiac, diabetes,
gynaecology, CNS, and oncology. It has 14 manufacturing facilities in four countries and six R&D centers. Geographically, the
company has presence in various countries across Asia-Pacific, Central Eastern Europe, CIS, Latin America and Africa.
Glenmark Pharmaceuticals is headquartered in Mumbai, India.
GlobalData


Page 35
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million
Deal Type
Asset Purchase
Deal in Brief
Teva Pharmaceutical Industries Ltd. completed the acquisition of all rights, assets and obligations relating to Huntexil
(pridopidine/ACR16), a drug candidate being developed for the symptomatic treatment of hand movement, balance and gait
disturbances in Huntington disease (HD), from NeuroSearch A/S, a biopharmaceutical company, for a purchase consideration
of approximately DKK149.5m ($25.81m). As part of the consideration, Teva paid DKK120.8m ($20.85m) in cash, and placed
DKK28.7m ($4.95m) in escrow which will be released upon satisfactory transfer of the Huntexil project, not earlier than six
months. In addition, NeuroSearch may receive regulatory and commercialization milestone payments.
This acquisition enables Teva to expand central nervous system (CNS) development pipeline through design and completion of
new clinical studies of Huntexil to assess its potential for symptomatic relief of Huntington disease.
Huntexil (pridopidine / ACR16) is an oral small molecule dopamine D2 stabilizer being developed for the symptomatic treatment
of non-choreic motor disorders, including HD. Following the acquisition, Teva intends to design and complete new clinical
studies of Huntexil to assess its potential for symptomatic relief of HD. Advanced-stage clinical studies of Huntexil conducted in
the US, EU and Canada in patients with HD demonstrated a significant treatment effect on total motor score (TMS), but failed to
meet the primary endpoint (modified total motor score (mTMS). Data from the clinical studies were presented to the FDA and
EMA in the first half of 2011, but were found insufficient to file for marketing approval.
Michael R. Hayden, president of global R&D and chief scientific officer of Teva Pharmaceutical Industries Ltd., said, "Based on
the clinical trial evidence to date, we believe Huntexil holds promise for symptomatic relief for HD and merits additional study in
late-stage clinical development. Teva has a broad commitment to find new approaches to managing devastating CNS diseases,
such as Huntington disease. This promising development for Teva is just one example of our covenant with patients to develop
medicines to improve their quality of life all around the world.
Deal history
Completed: On October 25, 2012, Teva Pharmaceutical Industries completed the acquisition of all rights, assets and obligations
relating to Huntexil (pridopidine/ACR16) from NeuroSearch, for a purchase consideration of approximately DKK149.5m
($25.81m).
Update: On October 23, NeuroSearch received shareholders' approval for the sale of
Industries.
Huntexil to Teva Pharmaceutical
Announced: On September 27, 2012, Teva Pharmaceutical Industries agreed to acquire all rights, assets and obligations
relating to Huntexil (pridopidine/ACR16) from NeuroSearch, for approximately DKK150m ($26m).
Deal Rationale
This acquisition enables Teva to expand central nervous system (CNS) development pipeline through design and completion of
new clinical studies of Huntexil to assess its potential for symptomatic relief of Huntington disease.
Deal Information
Deal Status
Completed
Announced Date
27-Sep-2012
Completed Date
25-Oct-2012
Deal Financials
Deal Value (DKK million)
149.50
Deal Value (US$ m)
25.81
Deal Payment
Cash (US$ m)
149.50
Company Name
Teva
Pharmaceutical
Industries Limited

Page 36
Company Name
NeuroSearch A/S
NeuroSearch A/S (NeuroSearch) is a biopharmaceutical company that develops novel pharmaceutical agents for the treatment
of various life threatening diseases. It focuses on developing drugs for central nervous system (CNS) disorders such as
Huntingtons, Parkinsons and Alzheimers diseases, tourette syndrome, pain, epilepsy; and psychiatric disorders such as
depression, anxiety and schizophrenia; and metabolic disorders such as obesity. The companys pipeline products include
ordopidine, for the treatment of parkinsons disease and dyskinesia; tesofensine, for the treatment of obesity; and seridopidine,
for the treatment of parkinsons disease and tourette syndrome. Ordopidine and seridopidine have completed Phase I and
tesofensine is in Phase II clinical trial stage of development. It operates through three wholly-owned subsidiaries, namely,
NeuroSearch Sweden AB, Poseidon Pharmaceuticals A/S and NsExplorer A/S; and two associate companies, namely,
Atonomics A/S and NsGene A/S. NeuroSearch is headquartered in Ballerup, Denmark.
GlobalData


Page 37
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics

Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics
Deal Type
Asset Purchase
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, entered into an option agreement to acquire all the assets related to larazotide
acetate, from Alba Therapeutics Corporation, a biopharmaceutical company, for a purchase consideration of $15m.
Under the agreement, Cephalon has an option to purchase all of Alba's assets relating to larazotide acetate, a tight junction
modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease. In return, Cephalon is entitled to pay
Alba $7m upfront option payment and will provide a credit facility to fund Alba's Phase IIb clinical trial expenses for larazotide
acetate. Alba is also entitled to receive additional payments related to regulatory and sales milestones.
Cephalon may exercise its option at any time prior to the expiration of a specified period after receipt of the final study report for
the Phase IIb clinical trial.
Kevin Buchi, CEO of Cephalon, said, We are encouraged by the data that we have evaluated. Alba will now initiate a Phase IIb
trial utilizing a more disease specific primary endpoint. If successful, larazotide acetate will add to our pipeline in immunology
and has the potential to be the first pharmacologic therapy available to treat patients who endure this often serious condition.
Wendy Perrow, president and COO of Alba Therapeutics, said, Celiac disease affects approximately three million people in the
US and 15 million worldwide. For the past six years Alba has been working diligently to research and develop larazotide
acetate, a new oral peptide that has been tested in approximately 450 patients with celiac disease. We are excited to work with
our partner Cephalon. Their passion and experience goes hand in hand with bringing new medicines to the market for patients
who suffer from this disease.
This acquisition enables Cephalon and Alba to bring new medicines to the market for patients who suffer from Celiac disease.
Deal Rationale
This acquisition enables Cephalon and Alba to bring new medicines to the market for patients suffering from Celiac disease.
Deal Information
Deal Status
Announced
Announced Date
09-Feb-2011
Deal Financials
Deal Value - Estimated
Minimum Value (US$ m)
Maximum Value (US$ m)
15
Company Name
Parent
Cephalon, Inc.
Teva
Pharmaceutical
Industries Limited
Cephalon, Inc. (Cephalon) is a biopharmaceutical company recently acquired by Teva Pharmaceutical Industries Ltd. focuses
on the research, development and marketing of innovative therapeutic products. The company through its product portfolio
focuses on the treatment of oncology, pain, central nervous system (CNS) disorders and inflammatory diseases which include
NUVIGIL, TREANDA, AMRIX, FENTORA, TRISENOX, GABITRIL, PROVIGIL and ACTIQ. Cephalon's various products in the
pipeline include small molecules, protein peptides and biologics in various stages of discovery and development. The company
markets its products in Europe, the Middle East and Africa through its sales and marketing organization. The company operates
through its subsidiaries and affiliates in France, Germany, Spain, Italy, UK, Poland and Benelux. Cephalon is headquartered in
Frazer (Pennsylvania), the US.
Company Name
Alba
Corporation
Therapeutics
Alba Therapeutics Corporation (Alba Therapeutics) is a biopharmaceutical company. The company discovers, develops and
commercializes pharmaceutical products to treat autoimmune and inflammatory diseases. Its technology platform is used to
treat and modify autoimmune and inflammatory diseases. Alba Therapeutics offers products for the therapeutic areas of
immune-based disorders, gastrointestinal disorders, metabolic, pulmonary disorders, and renal disease, among others. The
company also offers clinical trial services. It partners with The University of Maryland, and Peptisyntha Inc. Alba Therapeutics is
headquartered in Baltimore, Maryland, the US.
GlobalData


Page 38
Teva Plans To Acquire Three Women's Health Divisions

Teva Plans To Acquire Three Women's Health Divisions
Deal Type
Asset Purchase
Deal in Brief
Teva Pharmaceutical Industries Limited, a pharmaceutical company, plans to acquire three divisions of women's health. The
acquisition may include Merck's women's health division and Abbott's women's health business.
The company will acquire contraceptive products from other drugmakers.
Shlomo Yanai, CEO of Teva, said: his company is eyeing several buyout opportunities, although he hasn't named names.
This acquisition will enable Teva to build its women's health business.
Deal Rationale
This acquisition will enable Teva to build its women's health business.
Deal Information
Deal Status
Planned
Announced Date
Apr 15, 2010
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 39
Cephalon Acquires VOGALENE And VOGALIB From UCB Pharma

Cephalon Acquires VOGALENE And VOGALIB From UCB Pharma
Deal Type
Asset Purchase
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, has acquired VOGALENE And VOGALIB, from UCB Pharma S.A., a
biopharmaceutical company, for a purchase consideration of $53.3 million.
Under the agreement, Cephalon acquired all assets related to the development, manufacturing, marketing and sale of
VOGALENE (metopimazine) and VOGALIB (metopimazine) in France and French overseas territories.
VOGALENE And VOGALIB are approved for the prevention of nausea and vomiting in patients under chemotherapy.
Deal Information
Deal Status
Completed
Completed Date
31-Dec-2009
Deal Financials
Deal Value (US$ m)
53.30
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
UCB Pharma S.A.
Parent
UCB S.A.
UCB Pharma S.A. is a pharmaceutical company and it is a France based subsidiary of UCB Group.The company is engaged in
research and development.The company is also into immunological research of chemical compounds and the company has
got more than 30 Research and Development partnerships. It is a global biopharmaceutical company focused on serious
diseases, the company is present in over 40 countries.The company is headquartered in Colombes,France.
GlobalData


Page 40
MicroDose Therapeutx Acquires Portfolio Of Compounds From Epix Pharma

MicroDose Therapeutx Acquires Portfolio Of Compounds From Epix Pharma
Deal Type
Asset Purchase
Deal in Brief
MicroDose Therapeutx Inc., a pharmaceutical company, acquired a portfolio of compounds from Epix Pharmaceuticals Inc., a
biopharmaceutical company, for the potential treatment of chronic constipation, irritable bowel syndrome with constipation (IBSC) and other diseases.
The lead compound in the portfolio, known as MDT-006 (formerly known as EPX-16006), is a novel oral small molecule. The
compound is potent, possibly allowing for once-a-day dosing, and has demonstrated efficacy and safety in preclinical studies.
The acquisition includes rights to MDT-006, its chemical analogues, supporting patents and development data, including
toxicology studies and related materials.
This acquisition will broaden MicroDoses portfolio in PolyCap oral delivery platform.
Deal Rationale
This acquisition will broaden MicroDoses portfolio in PolyCap oral delivery platform.
Deal Information
Deal Status
Completed
Completed Date
01-Dec-2009
Deal Product
Product Description
MDT-006
<p>MDT-006 (EPX-16006) was under development for the treatment of chronic constipation
and constipation related to irritable bowel syndrome (IBS-C). MDT-006 is a selective, nonabsorbed, oral, small molecule. The drug candidate is a P2Y2 agonist. It is developed based
on PolyCap delivery platform. The PolyCap system is a approach that enables the rapid
development of fixed-dose-combination therapies in a single capsule, but separated by a
physical barrier.</p>
Company Name
MicroDose Therapeutx, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
MicroDose Therapeutx, Inc. (MicroDose) is a pharmaceutical company. The company provides next-generation products by
using drug delivery technologies. Its proprietary products include MDT-637/antiviral, MDT-010/atropine, MDT-006, MDT-011
and MDT-012. MicroDose also offers partner products, such as NCE/novartis and MMI-0100/moerae matrix. The companys
products are used in the treatment of respiratory syncytial virus, nerve agent antidote, IBC-C and constipation, COPD, autoimmune, diabetes and hypertension. Its delivery platforms include dry powder inhalation, fixed-dose-combination oral dosage in
PolyCap and needlefree transdermal systems. The company also carries out business operations through MicroDose Defense
Products, LLC and MicroDose Military Group, LLC. The company was formerly known as MicroDose Technologies, Inc.
MicroDose is headquartered in Monmouth Junction, New Jersey, the US.
Company Name
EPIX Pharmaceuticals, Inc.

(Inactive)
Epix Pharmaceuticals, Inc. (Epix) is a biopharmaceutical company, engaged in discovery, development and commercialization
of novel medicines through its proprietary and highly efficient in silico drug discovery platform, for the treatment of various
chronic diseases including cardiovascular disease, central nervous system, Alzheimers disease, depression and cognitive
impairment. The company is headquartered at Lexington, Massachusetts, the US.
GlobalData


Page 41
MicroDose Therapeutx Acquires Investigational Compounds From ViroPharma

MicroDose Therapeutx Acquires Investigational Compounds From ViroPharma
Deal Type
Asset Purchase
Deal in Brief
MicroDose Therapeutx Inc. (formerly known as MicroDose Technologies, Inc.), a biopharmaceutical company, has completed
the acquisition of portfolio of compounds, used for the treatment of respiratory syncytial virus (RSV) from ViroPharma
Incorporated, a biopharmaceutical company.
The acquired portfolio of compounds include small molecule fusion inhibitor, MDT-637. It is used in antiviral activity in
preclinical studies in both prophylaxis and treatment.
Following the acquisition, MicroDose will develop the compound in dry powder format for inhalation through its novel dry
powder inhaler (DPI).
This acquisition enables MicroDose to leverage its respiratory product development for addressing a large unmet need in RSV
disease.
Deal Rationale
This acquisition enables MicroDose to leverage its respiratory product development for addressing a large unmet need in RSV
disease.
Deal Information
Deal Status
Completed
Completed Date
09-Nov-2009
Deal Product
Product Description
MDT-637
MDT-637 was under development for the treatment of respiratory syncytial virus (RSV)
infections and asthma. The drug candidate is an inhalable small molecule anti-viral fusion
inhibitor. It is based on MicroDose dry powder inhaler platform.
Company Name
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
ViroPharma Incorporated
Parent
Shire Plc
ViroPharma Incorporated (ViroPharma) is a biopharmaceutical company. It develops and commercializes products for the
treatment of various serious life threatening ailments. The companys marketed products include Cinryze, for the treatment of
Hereditary Angioedema (HAE); Vancocin, for the treatment of antibiotic associated pseudomembranous colitis caused by
Clostridium difficile and enterocolitis caused by Staphylococcus aureus; Buccolam, for the treatment of Pediatric Epilepsy; and
Plenadren for treatment of adrenal insufficiency in adults. The product pipeline of Viropharma comprises Cinryze (C1 esterase
inhibitor [human]) for management of HEA; VP 20621 for the management of C. difficile infection (CDAD); and VP20629, for the
treatment of Friedreichs Ataxia. The company operates in the US, Belgium, France, Switzerland, Germany and the UK.
ViroPharma is headquartered in Pennsylvania, the US.
GlobalData


Page 42
Taiyo Yakuhin Acquires Kasukabe Plant From Schering-Plough

Taiyo Yakuhin Acquires Kasukabe Plant From Schering-Plough
Deal Type
Asset Purchase
Deal in Brief
Taiyo Yakuhin Co., Ltd., a bio-pharmaceutical company, completed the acquisition of Kasukabe Plant from Schering-Plough
Corporation, a pharmaceutical company.
Kasukabe Plant is engaged in the manufacture of pharmaceutical drugs.
Deal Information
Deal Status
Completed
Announced Date
14-Apr-2009
Completed Date
30-Apr-2009
Company Name
Taiyo
Pharmaceutical
Industry Co., Ltd.
Parent
Teva
Pharmaceutical
Industries Limited
Taiyo Pharmaceutical Industry Co., Ltd. (Taiyo) is a bio-pharmaceutical company. The company manufactures generic
pharmaceutical products. Its products include generic medicines. Taiyo provides services such as research and development
and contract manufacturing. The company utilizes technology and equipment. It develops products for cancer and ophthalmic
solutions. The company also manufactures glass syringes and pre-filled syringes. It also offers contract manufacturing service
to domestic and international innovators. The company research and development department provides generic drugs in the
form of tablets, injectables and formulations for external use. It is a subsidiary of Teva Pharmaceutical Industries Limited and is
headquartered in Nagoya-city, Japan.
Company Name
Schering-Plough Corporation
(Inactive)
Schering-Plough Corporation (Schering-Plough) is a pharmaceutical company focused on discovery, development,
manufacturing and marketing of medical therapies and treatments. The company has operations across more than 140
countries worldwide. The key therapeutics areas of the company include cardiovascular, respiratory, inflammatory disorders,
womens health and infectious diseases. Schering-Plough commercializes consumer brands in the over-the-counter (OTC), foot
care and sun care areas. It also sells live stock, companion animal and poultry products for animal health worldwide. The
company is headquartered in New Jersey, the US. In November 2009, Merck & Co., Inc. and Schering-Plough Corporation
completed their merger and Schering-Plough changed its name to Merck and its common stock trade under the ticker symbol
MRK on the New York Stock Exchange. The new Merck is a global health care leader aimed at providing innovative,
distinctive products and services that save and improve lives, while satisfying customer needs and creating long term
shareholder value.
GlobalData


Page 43
Neose Technologies Completes Sale Of Its Assets To BioGeneriX

Neose Technologies Completes Sale Of Its Assets To BioGeneriX
Deal Type
Asset Purchase
Deal in Brief
Neose Technologies, Inc., a clinical-stage biopharmaceutical company, completed sale of its intellectual properties assets to
BioGeneriX AG, a pharmaceutical company, for a consideration of $22 million in cash.
Assets include intellectual property relating to discovery, research, development and commercialization of any product
developed relating to G-CSF and intellectual property assets used to modify peptides and proteins for all indications and books,
records, files and documents related to such assets.
Morgan Lewis & Bockius LLP acted as special transaction counsel and RBC Capital Markets, Inc. acted as exclusive financial
advisor to Neose on the transaction.
Deal Information
Deal Status
Completed
Announced Date
17-Sep-2008
Completed Date
27-Jan-2009
Deal Financials
Deal Value (US$ m)
22
Deal Payment
Cash
100
Company Name
Parent
BioGeneriX AG
ratiopharm GmbH
BioGeneriX AG (BioGeneriX) is a pharmaceutical company. It develops and markets therapeutic proteins using bio-engineering
techniques. The company develops bio-engineered drugs in therapeutic areas of anemia, multiple sclerosis, neutropenia,
cancer and renal diseases. The companys products include acimethin 500 mg tablets, aneurin as-100 mg tablets, anti
phosphate 600 mg film-coated tablets, ASA 100 mg elac tablets, ASA 100 mg elac TAH tablets, ASA 500 mg elac tablets, ASA
Teva 100 mg tablets and ASA Teva 500 mg tablets. The company operates as a wholly owned subsidiary of ratiopharm GmbH,
Europe's premier generic drug company.. BioGeneriX is headquartered in Mannheim, Germany.
Company Name
Neose Technologies,
(Inactive)
Inc.
Neose Technologies, Inc. (Neose) is a biopharmaceutical company engaged in the development of therapeutic proteins. The
company uses its enzymatic pegylation technology, GlycoPEGylation to improve the drug properties of therapeutic proteins by
attaching polyethylene glycol (PEG) to, carbohydrate structures on the proteins. Neose has two compounds: GlycoPEG-GCSF
and Factor VIIa, which are at clinical trials and two compounds Factor VIII and Factor IX in research stage for hemophilia
indications. The companys headquarters is based in Horsham, Pennsylvania, the US. On March 2, 2009, the company filed a
Certificate of Dissolution with the Secretary of State of the State of Delaware and no longer engaged in any business activities.
Advisor Information
Company Being Advised
Financial Advisor
Neose Technologies,
(Inactive)
RBC Capital Markets Inc.
Inc.
GlobalData


Page 44
Venture Financing
Auspex Pharma Raises US$20 Million In Series E Financing
Auspex Pharma Raises US$20 Million In Series E Financing
Deal Type
Deal Sub Type
Venture Financing
Later Stage
Deal in Brief
Auspex Pharmaceuticals, Inc., a biopharmaceutical company, raised US$20m in series E financing round. The financing was
led by Deerfield Management Company, along with the existing investors Thomas, McNerney & Partners, LLC, CMEA Capital,
Panorama Capital, LLC, BioMed Ventures and Costa Verde Capital. In parallel, the company received US$15m four-year
venture loan from Oxford Finance LLC.
The company intends to use the proceeds to advance SD-809, its lead program, in Phase III clinical development for the
treatment of chorea associated with Huntingtons disease.
Pratik Shah, president and CEO of Auspex, said, These financings strengthen the balance sheet as we advance SD-809, our
lead program, in Phase III clinical development for the treatment of chorea associated with Huntingtons disease. We believe
Auspex is in a strong financial and strategic position to continue developing and seeking to commercialize novel medicines for
the treatment of orphan diseases.
Jonathan Leff, partner at Deerfield Management and chairman of the Deerfield Institute, said, We have been impressed by the
quality of the management team, the potential of the SD-809 program for the treatment of hyperkinetic movement disorders and
the promise of the deuterium chemistry platform.
William Slattery, partner at Deerfield Management, said, We are pleased to be supporting Auspex as it advances development
of SD-809 and other compounds in its pipeline of deuterium-substituted analogues of clinically validated drugs.
Deal Rationale
The company intends to use the proceeds to advance SD-809, its lead program, in Phase III clinical development for the
treatment of chorea associated with Huntingtons disease.
Deal Information
Deal Status
Completed
Deal Finance
Series E
Completed Date
08-Jan-2014
Deal Financials
Deal Value (US$ m)
20
Deal Product
Product Description
dutetrabenazine ER
Dutetrabenazine (SD-809 ER) is under development for the treatment of hyperkinetic

movement disorders including chorea associated with Huntington's disease, Tourette
syndrome and Tardive dyskinesia. The drug candidate is administered orally. SD-809 is a
synthetic deuterium substituted analogue of tetrabenazine. It is a new chemical entity. It is a
reversible depletor of monoamines and reversible inhibitor of the vesicular monoamine
transporter 2 (VMAT-2). SD-809 is being developed by using deuterium-substituted drug
technology.
Target Company Information
Company Name
Auspex
Inc.
Pharmaceuticals,
Parent
Teva
Pharmaceutical
Industries Limited
Auspex Pharmaceuticals, Inc. (Auspex) is a biopharmaceutical company. The company develops and commercializes novel
medicines for the treatment of orphan diseases. Its pipeline products include candidates to address unmet medical needs in
hyperkinetic movement disorders such as tardive dyskinesia, chorea associated with Huntingtons disease, and Tourette
syndrome, and other orphan indications. Auspexs lead product candidate, SD-809, is used for the treatment of chorea. The
companys SD-560 is used for the treatment of idiopathic pulmonary fibrosis. Its SD-970 is used for the treatment of acute
coronary syndrome, and SD-900 is used for the treatment of rheumatoid arthritis (RA). Auspex is headquartered in San Diego,
California, the US.

Page 45
Investor Firm Information

Firm Name
Thomas,
McNerney
Partners, LLC
&
Thomas, McNerney & Partners, LLC, (Thomas, McNerney & Partners) is a health care venture capital firm. It invests in the
pharmaceutical, medical device, biotechnology and diagnostic sectors as well as in other areas that utilize medical technology
innovation. The firm invests in companies at all stages of their development. It is involved in providing growth capital to
emerging companies and undertaking restructuring transactions such as spin-outs, roll-ups and recapitalizations. The firms
portfolio companies include Apptec Laboratory Services, Coley Pharmaceutical Group, Invitae Corporation, Virdante
Pharmaceuticals, Arkal Medical, Axiomed Spine Corporation, Galil Medical, Osteobiologics and Clarus Therapeutics among
others. It has offices in Minnesota and California. Thomas, McNerney & Partners is headquartered in Stamford, Connecticut,
the US.
Firm Name
Costa Verde Capital
Costa Verde Capital is a venture capital firm with focus on investing in pharmaceutical companies.
Firm Name
CMEA Capital
CMEA Capital is a venture capital firm with $1,000 million of capital under management. The firm invests in both early and later
stage across life sciences, high technology, energy, clean technology and materials investments.
Firm Name
BioMed Ventures
Firm Name
Deerfield
Management
Company, L.P.
Deerfield Management Company, L.P. (Deerfield) is an investment management firm. Deerfield provides capital financing as
well as offers advanced, innovative, and tailored investment solutions. It invests mainly in the healthcare sector including
pharmaceuticals, medical devices, and biotechnology. The firm holds expertise in clinical development evaluation, Healthcare
policies, market assessment, product potential, Regulatory affairs, Pricing and reimbursement and Product and services
performance. It works with Healthcare associations and institutes, Academic thought leaders, Healthcare providers and
administrators, Regulatory, commercialization and reimbursement experts. It has partnered with Childrens Health Fund,
Childrens Health Fund, Covenant House, GOAL, Health Builders, and many others. The firm operates in the United States,
China and Europe. Deerfield is headquartered in New York, the US.
Firm Name
Panorama Capital, LLC
Panorama Capital, LLC is a venture capital arm of JPMorgan Chase & Co. The firm invests at all stages of development of a
company in the range between $6 million to $18 million primarily focusing in life sciences and technology companies. The firm
also invests in energy and clean technology sectors.
GlobalData


Page 46
Labrys Biologics Raises US$31 Million In Series A Financing

Labrys Biologics Raises US$31 Million In Series A Financing
Deal Type
Deal Sub Type
Venture Financing
Start-up
Deal in Brief
Labrys Biologics, Inc., a development stage biotechnology company, raised additional $16.41m in series A financing round,
bringing the total proceeds to $31m. The financing was led by venBio, along with Canaan Partners, InterWest Partners, LLC,
Sofinnova Ventures, Inc. and other investors. In conjunction with the financing, Nina Kjellson of InterWest Partners and Mike
Powell of Sofinnova Ventures, will join Labrys Biologicss board of directors.
Earlier, on December 21, 2012, Labrys Biologics raised $14.59m of its planned $31m series A financing round. Following the
closing of the financing, the company acquired worldwide rights to RN-307, a Phase II ready anti-calcitonin gene-related
peptide (CGRP) humanized monoclonal antibody for the treatment of chronic migraine, from Pfizer.
Corey Goodman, managing director at venBio, said, RN-307 is an ideal candidate for a prophylactic drug for chronic migraine
that is capable of reducing both frequency and severity of migraines without debilitating side effects. There is significant interest
in new treatments that can improve upon the limited efficacy of current pharmaceuticals.
The company intends to use the proceeds for working capital purposes, and to initiate Phase II clinical trials for RN-307 in
2013.
Deal Rationale
The company intends to use the proceeds for working capital purposes, and to initiate Phase II clinical trials for RN-307 in
2013.
Deal Information
Deal Status
Completed
Deal Finance
Series A
Announced Date
21-Dec-2012
Completed Date
03-Jan-2013
Deal Financials
Deal Value (US$ m)
31
Deal Product
Product Description
TEV-48125
TEV-48125 (LBR-101, PF-04427429) is under development for the treatment of chronic and
episodic migraine. The drug candidate is administered through intravenous and subcutaneous
routes. It is an anti-CGRP humanized monoclonal antibody. It is derived from a murine
precursor antibody. Neuropeptide calcitonin gene-related peptide (CGRP) has an integral role
in the pathophysiology of migraine. Calcitonin gene-related peptide (CGRP) is a 37 amino-acid
sensory-nerve derived neuropeptide. It was also under development for the treatment of
vasomotor symptoms of menopause (menopausal hot flashes).
Investor Company Information
Company Name
venBio

Company Name
Labrys Biologics, Inc.
Parent
Teva
Pharmaceutical
Industries Limited

Firm Name
InterWest Partners, LLC
InterWest Partners, LLC (InterWest) is a financial service provider. The company offers venture capital service to developmentstage information technology and life sciences companies. It invests in early-stage companies, including preclinical and clinical
stage firms and companies with commercial-stage assets. InterWest invests in information technology companies such as
Aryaka, Badgeville, Biba, C3 Energy, GOJEE, Joyus, mobee, Optimizely, Spredfast, Swell, The RealReal and Vidora. The
companys portfolio of healthcare companies include alt12apps, Autonomic Technologies, CEBIX, doximity, Indi, Invuity, Labrys

Page 47
Biologics, Obalon, Sera Prognostics, Tesaro, USDS and wellotok. It manages more than 100 active investments. InterWest is
headquartered in Menlo Park, California, the US.
Firm Name
Sofinnova Ventures, Inc.
Sofinnova Ventures, Inc. (Sofinnova) is a venture capital firm. It is involved in providing financing such as seed, startup, early
stage, series A, first venture round, and corporate spinouts. The firm offers its services in the areas of life sciences and
technology sectors. It invests in life sciences sector through active investments and selected realized investments. The
companys active investments portfolio includes Aclaris Therapeutics, Aerie Pharmaceuticals, Alimera Sciences, Alvine,
Ascendis Pharma and Auris Medical among others. Its selected realized investments portfolio spans Actelion, Cellective
Therapeutics, and NextWave Pharmaceuticals among others which majorly focus on therapeutic drug development, small
molecule oncology drugs and related areas. The companys technology investment portfolio comprises ConteXtream, Atomz,
Cyrano and other companies.
Sofinnova is headquartered in Menlo Park, California, the US.
Firm Name
Canaan Partners
Canaan Partners (Canaan) is a venture capital firm. The company provides networks, insights and operational guidance
required to visionary entrepreneurs in the fields of technology and healthcare. It invests in technology and healthcare sector.
Canaans technology sector concentrates on digital media, communications and mobility, software developers and cleantech
companies. The company's healthcare sector concentrates on medical devices, diagnostics, biopharmaceuticals, and
healthcare infrastructure firms. It provides services to technology companies including Acme Packet, CommerceOne,
DoubleClick, healthcare giants Cerexa, Dexcom and Peninsula Pharmaceuticals. The company partners with Poptech, the
Cornell Entrepreneur Network, and the National Venture Capital Association. It has its presence in India, and Israel. Canaan is
headquartered in Menlo Park, California, the US.
GlobalData


Page 48
Auspex Pharma Raises US$25 Million In Series D Financing

Auspex Pharma Raises US$25 Million In Series D Financing
Deal Type
Deal Sub Type
Venture Financing
Later Stage
Deal in Brief
Auspex Pharmaceuticals, Inc., a biopharmaceutical company, raised $25m in series D financing round. The financing was led
by Panorama Capital, LLC, along with the existing investors Thomas, McNerney & Partners, LLC, CMEA Capital and Sloan
Biotech Fund, LLC. In conjunction with this financing, Gaurav Aggarwal, partner at Panorama Capital, joined the Auspex.The
company intends to use the proceeds to advance the development of its portfolio of drug molecules and for the phase III
development of its lead molecule, SD-809, a treatment for hyperkinetic movement disorders including Huntingtons disease,
Tourette syndrome and tardive dyskinesia. Lawrence C. Fritz, president and CEO of Auspex, said, This new financing provides
resources for the pivotal trial of SD-809 in Huntingtons Disease and for the acceleration of this compounds development in
additional movement disorders. We are very pleased that Panorama Capital, with its depth of experience and outstanding track
record in the biopharmaceutical industry, has decided to join us in this important work. Gaurav Aggarwal, partner at Panorama
Capital, said, We are pleased to back Auspexs experienced development team and to work with the company to bring a
promising and much needed therapy to market for Huntington's disease and other severe movement disorders.
Deal Rationale
The company intends to use the proceeds to advance the development of its portfolio of drug molecules and for the phase III
development of its lead molecule, SD-809.
Deal Information
Deal Status
Completed
Deal Finance
Series D
Completed Date
08-Nov-2012
Deal Financials
Deal Value (US$ m)
25
Deal Product
Product Description
dutetrabenazine ER

technology.
Company Name
Auspex
Inc.
Pharmaceuticals,
Parent
Teva
Pharmaceutical
Industries Limited
California, the US.
Firm Name
CMEA Capital

Page 49
Firm Name
Thomas,
McNerney
Partners, LLC
&
the US.
Firm Name
Sloan Biotech Fund, LLC
Firm Name
Panorama Capital, LLC
Panorama Capital, LLC is a venture capital arm of JPMorgan Chase & Co. The firm invests at all stages of development of a
company in the range between $6 million to $18 million primarily focusing in life sciences and technology companies. The firm
also invests in energy and clean technology sectors.
GlobalData


Page 50
Auspex Pharma Raises US$1.5 Million In Venture Financing

Auspex Pharma Raises US$1.5 Million In Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Growth Capital/Expansion
Deal in Brief
Auspex Pharmaceuticals, Inc., a biopharmaceutical company, raised $1.5m in a venture financing round. To raise this
financing, the company issued debt, warrant and option or other right to acquire another security to five investors. The company
may raise an additional $1.5m from this financing.
The company intends to use the proceeds for general corporate purposes.
Deal Rationale
Deal Information
Deal Status
Completed
Completed Date
18-Jul-2012
Deal Financials
Deal Value (US$ m)
1.50
Company Name
Auspex
Inc.
Pharmaceuticals,
Parent
Teva
Pharmaceutical
Industries Limited
California, the US.
GlobalData


Page 51
Ceptaris Therapeutics Raises US$10 Million In Series D-1 Financing

Ceptaris Therapeutics Raises US$10 Million In Series D-1 Financing
Deal Type
Deal Sub Type
Venture Financing
Later Stage
Deal in Brief
Ceptaris Therapeutics, Inc. (formerly Yaupon Therapeutics, Inc.), a specialty pharmaceutical company, raised $10m in a series
D-1 financing round. The financing was provided by existing investors Vivo Ventures, LLC, Palo Alto Investors, LLC, Burrill &
Company, Aperture Venture Partners, LLC, Osage Partners and BioAdvance Ventures LP along with new investor Third Point
LLC.The company intends to use the proceeds for operational expenses, including activities related to addressing the US Food
and Drug Administration (FDA) requests. Stephen Tullman, president and CEO of Ceptaris Therapeutics, said, "We believe that
our proprietary mechlorethamine gel will be an important new treatment option and this latest round of financing provides
Ceptaris additional capital for ongoing activities. We appreciate the commitment of all of our investors and welcome Third Point,
a valued investor familiar with the management team from an earlier investment in Ception Therapeutics."
Deal Rationale
The company intends to use the proceeds for operational expenses, including activities related to addressing the US Food and
Drug Administration (FDA) requests.
Deal Information
Deal Status
Completed
Deal Finance
Series D
Completed Date
05-Jun-2012
Deal Financials
Deal Value (US$ m)
10
Company Name
Ception Therapeutics, Inc.
Parent
Cephalon, Inc.

Firm Name
BioAdvance
BioAdvance is a life science venture capital firm. The company invests in life sciences technologies, which has potential to
improve human health and with better commercialization prospects. Its key areas of life science investments include
therapeutics, medical devices, diagnostics, research tools and healthcare IT. BioAdvance has invested in companies to develop
drugs used in the treatment of diseases such as Alzheimers, obesity, diabetes, macular degeneration and cancer. The
companys investment portfolio companies include Acuity Pharmaceuticals, Inc., Alteris Therapeutics, Inc., Avid
Radiopharmaceuticals, Inc., SansRosa Pharmaceutical Development, Inc., Gelifex, RMH Sciences, Treventis Corporation and
Relmada Therapeutics, Inc., among others. BioAdvance is headquartered in Philadelphia, Pennsylvania, the US.
Firm Name
Aperture Venture Partners,

LLC
Aperture Venture Partners, LLC (Aperture) is a venture capitalist firm, engaged in executing the investment needs of the
company at the initial stages. The company primarily invests in the healthcare industry which includes biopharmaceutical,
biotechnology, healthcare services, information technology, diagnostics, healthcare tools and devices. Aperture is in
partnership with several firms such as Altea Therapeutics for drug delivery system, Cameron Health for development of
implantable cardioverter defibrillator, Cardiocore Lab, Inc. for providing cardiac testing services, CardioMEMS for wireless
medical pressure sensors, Ception Therapeutics, Inc., Redpoint Bio, Mako Surgical and other firms. So far, the company has
invested more than 1 billion dollar in healthcare industry. Aperture is headquartered in New York, the US.
Firm Name
Burrill & Company
Burrill & Company (Burrill) is a financial advisory service provider. The company provides mergers and acquisitions, divestiture,
buy and sell side, reverse mergers, spin off, private placement, and due diligence advisory services. It offers equity and venture
capital investments for devices, human healthcare and related medical technologies, biotechnology, diagnostics,

Page 52
pharmaceuticals, agricultural biotechnology, and industrial biotechnology companies. Burrill provides an extensive and
complementary range of services to address the needs of its clients at various stages in their growth. The company has an
active portfolio of stakes in public and late-stage private life sciences companies. Burrill is headquartered in San Francisco,
California, the US.
Firm Name
Palo Alto Investors, LLC
Palo Alto Investors, LLC is an SEC-registered investment advisor providing money management services to institutional clients
and high net worth individuals.
Firm Name
Vivo Ventures, LLC
Vivo Ventures, LLC (formerly BioAsia Investments) is a venture capital firm with over $650 million of capital under
management. It invests in all stages of development of a company. It focuses on various sectors like: biopharmaceuticals,
specialty pharmaceuticals, cleantech and medical devices companies across U.S.
Firm Name
Third Point LLC
Third Point LLC is an employee owned hedge fund sponsor. The firm provides its services to pooled investment vehicles.
Firm Name
Osage Partners LLC
Osage Partners, LLC is a venture capital firm. The firm invests in technology and manufacturing industries. It manages three
venture capital and private equity funds, Osage Ventures, Osage University Partners and Osage Industries.
GlobalData


Page 53
Gamida Cell Raises US$10 Million In Series E Financing

Gamida Cell Raises US$10 Million In Series E Financing
Deal Type
Deal Sub Type
Venture Financing
Later Stage
Deal in Brief
Gamida Cell Ltd., a biotechnology company, raised $10m in series E financing round. The financing was provided by major
shareholders including Elbit Medical Technologies Ltd (also Elbit Medical Imaging Ltd.), Clal Biotechnology Industries Ltd., and
Israel Healthcare Ventures Ltd., Teva Pharmaceutical Industries Limited, Amgen, Inc., Denali Ventures LLC and Auriga
Ventures (also Auriga Partners).
The company intends to use the proceeds to support the global commercialization of its cell therapy product, StemEx; and for
the continued development of pipeline products.
Mr. Reuven Krupik, chairman of the board of Gamida Cell, said, The investors were unanimous in their decision to reinvest,
understanding the importance of bringing StemEx to market as well as maintaining the companys leadership role in the stem
cell industry. Gamida Cell is a game changer.
Dr. Yael Margolin, president and CEO of Gamida Cell, said, With the continued support of our shareholders and the analysis of
the clinical results of the StemEx trial just around the corner, we are now focused on submitting the BLA.
Deal Rationale
The company intends to use the proceeds to support the global commercialization of its cell therapy product, StemEx; and for
the continued development of pipeline products.
Deal Information
Deal Status
Completed
Deal Finance
Series E
Announced Date
04-Mar-2012
Completed Date
15-May-2012
Deal Financials
Deal Value (US$ m)
10
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Amgen Inc.
Amgen Inc. (Amgen) is a biotechnology company. It undertakes the discovery, development, manufacture and
commercialization of innovative human therapeutics. The company pioneered the development of new products based on
advances in recombinant DNA and molecular biology. It offers medicines for the treatment of cancer, rheumatoid arthritis,
kidney disease, bone disease and many other serious illnesses. Amgens R&D organization has expertise in multiple treatment
modalities, antibodies, large-molecule proteins and small molecules. The companys key products include Neulasta
(pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis;
Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidney disease
and in cancer; and Prolia (denosumab) used in the treatment of osteoporosis in postmenopausal women among others. Its
product pipeline focuses on treating conditions such as ovarian cancer, heart disease, migraine and schizophrenia. The
company has research and development (R&D) facilities in the US, Canada, the UK, Germany and Iceland. Amgen is

Page 54
headquartered in Thousand Oaks, California, the US.

Company Name
Elbit Imaging Ltd.
Elbit Imaging Ltd. (Elbit) is a holding company. The company has business activities in shopping malls and entertainment,
centers, hotels, Elbit medical, Elbit India, and Elbit trade and retail, and others. It specializes in identifying, initiating, developing
and exiting of large scale real estate projects in the retail sector, located in Central and Eastern Europe and India. Elbit provides
hotels services, residential real estate services, bio and medical device services and retail and other services. The company
owns, operates and develops retail properties. It undertakes projects such as kragujevac Plaza, Torun Plaza, Koregaon Park
and Kharadi Pune. The company has its presence in Hungary, Israel, the US, India, the Czech Republic, Poland, the
Netherlands, Romania, Bulgaria, Latvia, Greece and Serbia. Elbit is headquartered in Bnei Brak, Israel.
Company Name
Gamida Cell Ltd.
Gamida Cell Ltd. (Gamida) is a health care company. The company is into development of therapeutic products. It offers
products such as StemEx, NiCord, CordBridge, and NK Cell product. Gamidas product StemEx is used for the treatment of
leukemia, lymphoma, krabbe disease, metachromatic leukodystrophy and hurler syndrome. The companys cell therapy
products provide the treatment for blood cancer, peripheral vascular diseases and neurological disorders. It markets its
products through brands such as NiCord, and StemEx. Gamida operates with copper Chelator based technology and NAM
based technology towards developing an impressive pipeline of cell therapy products for a wide range of clinical applications.
Gamida is headquartered in Jerusalem, Israel.
Firm Name
Denali Ventures
Denali Ventures is a venture capital fund.
Firm Name
Auriga Partners
Auriga Partners is a venture capital firm that invests in life sciences and information technology companies. The firm manages
funds focusing mainly in startups, early and growth companies. The firms AURIGA IV Bioseeds, is a seed fund focusing on
projects in the areas of infectiology and microbiology. It also invests in businesses such as digital economy that are in the
commercial expansion phases, especially on an international basis. Since its incorporation, the firm has accumulated around
EUR350 M through several investment vehicles such as AURIGA Ventures I, AURIGA Ventures II, AURIGA Ventures III,
AURIGA IV Bioseeds and European Medical Ventures. Auriga Partners is headquartered in Paris, France.
Firm Name
Clal Biotechnology Industries

Ltd.
Parent
Clal
Industries
Investments Ltd.
and
Clal Biotechnology Industries is an investment company with $300 million of capital under management. The firm invests at all
stages of development of a comapny focusing on biopharmaceutical sector.
Firm Name
Israel HealthCare Ventures
Israel HealthCare Ventures is a venture capital fund that offers investment to Israeli and Israeli related companies functioning in
the areas of medical devices, biotechnology, pharmaceuticals, nanotechnology and medical-related IT.
GlobalData


Page 55
Ceptaris Therapeutics Raises US$8.3 Million In Venture Financing

Deal Type
Deal Sub Type
Venture Financing
Later Stage
Deal in Brief
Ceptaris Therapeutics, Inc. (formerly Yaupon Therapeutics, Inc.), a specialty pharmaceutical company, raised $8.29m of its
planned $10m venture financing round. The financing was provided by Vivo Ventures Fund VI, L.P., Osage Ventures Partners
II, LP and Palo Alto Investors, along with other investors. The company intends to use the proceeds for general corporate
purposes.
Deal Rationale
Deal Information
Deal Status
Completed
Completed Date
14-May-2012
Deal Financials
Deal Value (US$ m)
8.29
Company Name
Parent
Cephalon, Inc.
GlobalData


Page 56

Deal Type
Deal Sub Type
Venture Financing
Later Stage
Deal in Brief
Ceptaris Therapeutics, Inc. (formerly Yaupon Therapeutics, Inc.), a specialty pharmaceutical company, raised $7.5m in venture
debt financing round. The financing was provided by Silicon Valley Bank and Oxford Finance Corporation. The company will
raise an additional $7.5m, following the approval of New Drug Application (NDA) for its drug candidate mechlorethamine gel, by
the US Food and Drug Administration (FDA).Stephen Tullman, president and CEO of Ceptaris, said, "We are very pleased with
our venture debt relationships with both SVB and Oxford and the additional capital it provides Ceptaris for pre- and post-launch
activities. Management has worked with both lending institutions in prior companies, including Ception Therapeutics and Vicept
Therapeutics, and we look forward to continuing these relationships." The company intends to use the proceeds for ongoing
operational expenses and for the commercialization of its lead compound, a proprietary gel formulation of mechlorethamine
hydrochloride for the treatment of early-stage mycosis fungoides.
Deal Rationale
The company intends to use the proceeds for ongoing operational expenses and for the commercialization of its lead
compound, a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early-stage mycosis fungoides.
Deal Information
Deal Status
Completed
Completed Date
21-Feb-2012
Deal Financials
Deal Value (US$ m)
7.50
Company Name
Parent
Cephalon, Inc.

Firm Name
Oxford Finance LLC
Oxford Finance LLC (Oxford Finance) is a financial service provider. The company provides financial services to public and
private life science and health care services companies. It offers financial services such as senior secured term loans, cash
flow loans, revolving lines of credit, real estate term loans and equipment loans. Oxford Finance offers its services to life
sciences sectors such as pharmaceuticals and biopharmaceuticals, and healthcare services, among others. The company
provides its services to acute care and specialty hospitals sectors such as LTACH, psychiatric, rehabilitation and sub-acute
facilities, medical laboratories and large physician groups, among others. Oxford Finance is headquartered in Alexandria,
Virginia, the US.
Firm Name
Silicon Valley Bank
Parent
SVB Financial Group
Silicon Valley Bank (SVB), a subsidiary of SVB Financial Group, is a bank. The companys product portfolio includes business
checking, in-country accounts, multi-currency accounts, money market accounts, and sweep accounts. Its services comprise
treasury management, digital solutions, credit solutions, and strategic advisory services. SVB also provides investments
solutions, asset management, finance management, conventional construction financing, and wealth management services.
The company caters to software and internet, hardware and infrastructure, life science and healthcare, energy and resource
innovation, venture capital and private equity, community development finance, and premium wine bank industries, among
others. It operates across the US, the UK, Israel, China, and India. SVB is headquartered in Santa Clara, California, the US.
GlobalData


Page 57
Teva Pharma Industries Invests In MultiGene Vascular Systems

Teva Pharma Industries Invests In MultiGene Vascular Systems
Deal Type
Venture Financing
Deal Sub Type
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, invested an additional amount in MultiGene Vascular
Systems (MGVS) Ltd., a biotech and medical device company, at the company value of $135m. Teva exercised the option to
make the investment upon completion of MGVS's Phase I/IIa clinical trial of MultiGeneAngio cell therapy-based treatment of
chronic critical limb ischemia.
In October 2009, Teva Pharma invested $4m in MGVS as a part of an $8.5m financing round at the company value of $20m,
with an option to continue funding the clinical development program of MGVSs MultiGene Angio and MultiGene Graft products
up to regulatory approval.
Deal Information
Deal Status
Completed
Deal Finance
None
Completed Date
26-Jan-2012
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
MultiGene Vascular Systems

(MGVS) Ltd.
MultiGene Vascular Systems (MGVS) Ltd. (MultiGene) is a medical device company. The company develops vascular products
for the cardiovascular market. It offers products such as MultiGeneAngio and MultiGeneGraft. MultiGenes product
MultiGeneAngio is a cell therapy product for alleviating symptoms and signs of ischemia in patients with peripheral arterial
disease and coronary artery disease. The companys product MultiGeneGraft is a biosynthetic vascular graft, which is lined with
the patients own endothelial cells. It conducted clinical research in seven leading medical centers in Israel, and included twenty
three patients with chronic critical limb ischemia. MultiGene is headquartered in Nesher, Israel.
GlobalData


Page 58
Yaupon Therapeutics Secures US$14.4 Million In Series D Financing

Yaupon Therapeutics Secures US$14.4 Million In Series D Financing
Deal Type
Deal Sub Type
Venture Financing
Later Stage
Deal in Brief
Yaupon Therapeutics, Inc., a privately-held specialty pharmaceutical company, secured $14.4m in series D preferred stock
financing. The financing was provided by Vivo Ventures, LLC, Palo Alto Investors, LLC, Burrill & Company and Aperture
Venture Partners, LLC.
Steve Tullman, chairman and CEO of Yaupon Therapeutics, said, This financing provides us with the necessary capital to take
us through the NDA regulatory review process, while preparing for commercialization either alone or with an industry partner.
We appreciate the strong support of existing and new investors and their ongoing confidence in the potential of our product for
the treatment of this common type of CTCL.
The company intends to use the proceeds to support new drug application (NDA) regulatory review and for the
commercialization of its lead compound, a proprietary gel formulation of mechlorethamine hydrochloride, for the treatment of
early-stage mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL).
Deal Rationale
The company intends to use the proceeds to support new drug application (NDA) regulatory review and for the
commercialization of its lead compound, a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of
early-stage mycosis fungoides.
Deal Information
Deal Status
Completed
Deal Finance
Series D
Completed Date
11-Aug-2011
Deal Financials
Deal Value (US$ m)
14.40
Company Name
Parent
Cephalon, Inc.

Firm Name
Burrill & Company
California, the US.
Firm Name
Vivo Ventures, LLC
Firm Name

LLC

Page 59
Firm Name
GlobalData


Page 60
SymBio Pharma Secures US$24.5 Million In Series E Financing Round

SymBio Pharma Secures US$24.5 Million In Series E Financing Round
Deal Type
Venture Financing
Deal Sub Type
Later Stage
Deal in Brief
SymBio Pharmaceuticals Limited, secured JPY2,000m ($24.46m) in series E financing round. The financing was led by its
existing investors Cephalon Inc. and JAFCO Co., Ltd.
Mr. Fuminori Yoshida, president and CEO, said, "I am extremely pleased that our two major shareholders continue to support
our business at this juncture where SymBio needs capital to more aggressively expand into other Asia Pacific markets. In 2011,
SymBio is being transformed into a biopharmaceutical company with top-line revenue, multiple drug candidates in all stages of
development, and growing licensing opportunities. We will use proceeds from this round to maximize the value for patients as
well as shareholders."
The company intends to use the proceeds to accelerate the development of other hematological indications for bendamustine,
including aggressive non-Hodgkin's lymphoma and multiple myeloma, to advance development of its granisetron transdermal
patch for RINV/CINV, and to in-license other new drug candidates as it continues its geographical expansion in key Asian
countries.
Deal Rationale
The company intends to use the proceeds to accelerate the development of other hematological indications for bendamustine,
including aggressive non-Hodgkin's lymphoma and multiple myeloma, to advance development of its granisetron transdermal
patch for RINV/CINV, and to in-license other new drug candidates as it continues its geographical expansion in key Asian
countries.
Deal Information
Deal Status
Completed
Deal Finance
Series E
Completed Date
25-Feb-2011
Deal Financials
Deal Value (JPY million)
2,000
Deal Value (US$ m)
24.46
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
SymBio
Limited
Pharmaceuticals
SymBio Pharmaceuticals Limited (SymBio) is a biopharmaceutical company. The company conducts research and
development and manufactures new drug candidates. It develops drug delivery products such as transdermal patch containing
granisetron for the treatment of chemotherapy induced nausea or vomiting. SymBios products under clinical development
include SyB L-0501, SyB D-0701, SyB-0702, PEG-ZnPP and SyB L-1101. The companys SyB L-1101 drug candidate is used
for the treatment of hematologic malignancies and solid tumors; and SyB D-0701 is used as an antiemetic transdermal patch. It
offers products for use in the therapeutic areas of autoimmune, oncology and hematology diseases. SymBio is headquartered
in Tokyo, Japan.


Page 61

Firm Name
JAFCO Co., Ltd.
JAFCO Co., Ltd. (JAFCO) is an investment management company. The company invests in unlisted companies on a global
basis through JAFCO-operated funds. Its fund investors include financial institutions, business corporations, and pension funds.
JAFCO forms venture capital groups to invest in domestic and foreign private companies. The company provides business
development support for overseas portfolio companies invested by JAFCO America and JAFCO Asia. It has operations in
Singapore, Taiwan, China, the US, and South Korea. The company operates through its subsidiaries, such as JAFCO America
Ventures Inc., JAFCO Investment (Asia Pacific) Ltd, JAFCO Investment (Hong Kong) Ltd, and JAFCO Investment (Korea) Co.,
Ltd., among others. JAFCO is headquartered in Chiyoda-ku, Japan.
GlobalData


Page 62
Yaupon Therapeutics Secures US$2 Million In Venture Financing

Yaupon Therapeutics Secures US$2 Million In Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Later Stage
Deal in Brief
Yaupon Therapeutics, Inc., a specialty pharmaceutical company, secured $2m in venture financing round. The company
intends to raise an additional of $4m in the same round. The financing was led by the investors including Osage Partners, Palo
Alto Investors, LLC, Vivo Ventures, LLC, Burrill & Company, BioAdvance Ventures LP, Ben Franklin Technology Partners and
Midcoast Capital.
Deal Information
Deal Status
Completed
Completed Date
22-Nov-2010
Deal Financials
Deal Value (US$ m)
Company Name
Parent
Cephalon, Inc.

Firm Name
Ben Franklin
Partners
Technology
Ben Franklin Technology Partners (BFTP) is a venture capital firm. It manages various funds and provides seed and growth
capital. It focuses on various sectors which include information technology, life sciences, medical devices, communications,
advanced manufacturing, advanced materials and environmental technology.
Firm Name
Osage Partners LLC
Firm Name
MidCoast Capital
Firm Name
Vivo Ventures, LLC
Firm Name
Firm Name
Burrill & Company
California, the US.
Firm Name
BioAdvance


Page 63
GlobalData


Page 64
VBL Biogenics Secures US$40 Million In Venture Financing

VBL Biogenics Secures US$40 Million In Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
Vascular Biogenics Ltd., a drug development company, secured $40 million in venture financing round. The round was led by a
US venture capital fund with participation of existing investors including Teva Pharmaceutical Industries Ltd., Pitango Venture
Capital, Max Herzberg and Aurum Ventures MKI Ltd.
Deal Information
Deal Status
Completed
Completed Date
05-Oct-2010
Deal Financials
Deal Value (US$ m)
40
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Vascular Biogenics Ltd.
Vascular Biogenics Ltd. (VBL) is a clinical stage biotechnology company that develops treatments for immuno-inflammatory
diseases and cancer. The companys product portfolio includes products such as VB-201 and VB-111. Its product VB-201 is
developed based on the lecinoxoid class of oral anti-inflammatory agents. VB-201 is an oral disease modifying medicine for the
treatment of chronic immuno-inflammatory diseases such as psoriasis, inflammatory bowel disease, multiple sclerosis
rheumatoid arthritis, and atherosclerosis. The companys product VB-111, is developed based on the proprietary Vascular
Targeting System (VTS) technology platform. VB-111, is an anti-angiogenic agent for the treatment of various cancers such as
differentiated thyroid cancer, renal cell carcinoma, neuroendocrine tumors, glioblastoma multiforme and ovarian cancer. VBL is
headquartered in Or Yehuda, Tel Aviv, Israel.
Firm Name
Pitango Venture Capital
Pitango Venture Capital (Pitango) is a venture capital firm. It seeks to invest in information technology and life sciences
companies in seed, expansion and late stages. The firms key areas of investments include communications and wireless
technologies, networking and storage, enterprise software, internet and media, semiconductors, life sciences, clean technology,
public and acquisition sectors. Some of the firms key investment portfolio companies include 3DV Systems, AeroScout,
BioLineRx, Carambola, Discretix, Check, MobileAccess, ClearForest, Disc-O-Tech, LifeBond, Kilopass, Medinol and Phonetic
Systems, among others. It also has its operational presence with its office located in the US. Pitango is headquartered in
Herzliya, Israel.
Firm Name
Aurum Ventures MKI

Page 65
Aurum Ventures MKI (Aurum) is a financial service provider that invests in life science and clean tech companies. Its life
science investment provides finances and managerial resources to life science companies. The company concentrates on
investing into novel therapeutics including pharmaceuticals and non-therapeutics such as agricultural biotechnology and bio
energy. Aurums clean tech investment provides finances and managerial resources to cleantech companies related to
alternative and renewable energy, fuels, waste water treatment, water disinfection and others segments. The firms investment
portfolio includes various biotechnology and research companies. Aurum is headquartered in Ramat Gan, Israel.
GlobalData


Page 66
Gemin X Pharma Secures US$8 Million In Series E Venture Financing

Gemin X Pharma Secures US$8 Million In Series E Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Later Stage
Deal in Brief
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company, secured $8 million in series E venture financing round.
The financing was led by the company's preferred stockholders, Caxton Advantage Life Sciences Fund, L.P. and Sanderling
Venture Partners.
Eric Roberts, co-founder and managing director at Caxton Advantage and member of the Gemin X board, said: Since our initial
investment in Gemin X in June 2008, the company has made tremendous progress with its portfolio of cancer therapeutics,
particularly obatoclax, which is making strides in small cell lung cancer, an area where there has been no change in standardof-care for over 25 years and where new and improved therapies are desperately needed. As a product candidate for the firstline treatment of patients with SCLC, we believe that obatoclax represents a significant market opportunity and an important
addition to the treatment regimen. We remain enthusiastic supporters of the company and its novel scientific approaches to
cancer management that are now gaining clinical validation.
Peter R. Dolan, chairman and chief executive officer of Gemin X, said: We are pleased that our committed group of investors
continue to support Gemin X and the future of our lead product candidate, obatoclax, as we explore strategic opportunities for
this novel pan Bcl-2 inhibitor. The series E funding follows on a growing body of positive clinical data from our randomized,
controlled Phase 2b study of obatoclax for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC), and we
look forward to submitting this data for presentation at an upcoming medical conference. A positive outcome in ES-SCLC
provides proof-of-principle that we expect could translate to multiple other cancer indications.
Deal Information
Deal Status
Completed
Deal Finance
Series E
Completed Date
04-Aug-2010
Deal Financials
Deal Value (US$ m)
Company Name
Gemin X Pharmaceuticals
Parent
Cephalon, Inc.
Gemin X Pharmaceuticals (Gemin) is a pharmaceutical company that is engaged in the discovery, development and
commercialization of novel, targeted cancer therapeutics for the treatment of diseases such as small cell lung cancer, multiple
hematological, solid tumor cancer, melanoma and glioblastoma. Its major pipeline products include GX15-070 (obatoclax) for
the treatment of small cell lung cancer, and GMX1777 for the treatment of tumor efficacy or toxicity problems. Its other products
include telomere capping. The company has collaborations with Leo Pharma. The company has research oriented group in
Montreal, Canada and clinical, regulatory and drug development group in Malvern, Pennsylvania. Recently, the company has
completed the patient enrollment in phase 2 clinical study of obatoclax for the treatment of small cell lung cancer. Gemin X
Pharmaceuticals is headquartered at Malvern in Pennsylvania, the US.
Firm Name
Caxton
Advantage
Sciences Fund, L.P
Life
Caxton Advantage Life Sciences Fund, L.P is a venture capital firm which invests in early and growth stage companies focusing
on life-science sector.
Firm Name
Sanderling Ventures
Sanderling Ventures is a venture capital investment firm. It invests in seed, early and later stage companies across
biotechnology, therapeutics and pharmaceuticals, drug delivery, medical devices and instrumentation, imaging and diagnostics,
medical informatics and health care services.
GlobalData


Page 67
Auspex Pharma Raises US$12 Million In Series C Financing

Auspex Pharma Raises US$12 Million In Series C Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
Auspex Pharmaceuticals, a privately held pharmaceutical company, secured $12m in series C financing round. The financing
wasprovided by Thomas, McNerney & Partners, LLC, CMEA Ventures and Sloan Biotech Fund, LLC.
The company will use the funds for working capital and general corporate purposes.
Deal Rationale
Deal Information
Deal Status
Completed
Deal Finance
Series C
Completed Date
20-Jul-2010
Deal Financials
Deal Value (US$ m)
12
Company Name
Auspex
Inc.
Pharmaceuticals,
Parent
Teva
Pharmaceutical
Industries Limited
California, the US.
Firm Name
CMEA Capital
Firm Name
Thomas,
McNerney
Partners, LLC
&
the US.
Firm Name
Sloan Biotech Fund, LLC
GlobalData


Page 68
Gemin X Pharma Raises US$3.92 Million In Venture Financing

Gemin X Pharma Raises US$3.92 Million In Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
Gemin X Pharmaceuticals, a biopharmaceutical company, has secured $3.92 million in venture financing round led by
accredited investors. The company has an option to raise additional $4.58 million from this round of financing.
Deal Rationale
Deal Information
Deal Status
Completed
Completed Date
14-May-2010
Deal Financials
Deal Value (US$ m)
3.92
Company Name
Parent
Cephalon, Inc.
GlobalData


Page 69
Celator Pharma Secures US$2.5 Million In Venture Financing

Celator Pharma Secures US$2.5 Million In Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
Celator Pharmaceuticals, Inc., a biopharmaceutical company, secured $2.5 million in a venture financing round led by
GrowthWorks Capital Ltd., Cephalon, Inc., Ventures West Capital Ltd., Quaker Bioventures, Domain Associates, LLC and other
investors. To raise this financing, the company issued debt and option securities to its investors.
Celator is a research focused biopharmaceutical company engaged in development of innovative therapeutics for the treatment
of cancer. It currently focuses on development of treatments for acute myeloid leukemia, colorectal cancer, small cell lung
cancer and several other types of cancers.
Deal Information
Deal Status
Completed
Deal Finance
None
Completed Date
10-May-2010
Deal Financials
Deal Value (US$ m)
2.50
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Celator
Inc.
Pharmaceuticals,
Celator Pharmaceuticals, Inc. (Celator) is a pharmaceutical company. The company develops and distributes therapies for the
treatment of cancer. Its products include CPX-351 Liposome injection, which is a liposomal formulation of a synergistic 5:1
molar ratio of cytarabine and daunorubicin, two agents used to treat hematologic malignancies and CPX-1 Liposome Injection
is a liposomal formulation of a synergistic 1:1 molar ratio of irinotecan HCI and floxuridine a drug regimen used in the treatment
of cancer. Celators combiplex technology is used in identifying, delivering and maintaining synergistic ratios of
chemotherapeutic drugs resulting in new drug product candidates. The companys products in clinical development and
preclinical programs include therapies targeting acute myeloid leukemia, colorectal cancer, and small cell lung cancer. Celator
is headquartered in Princeton, New Jersey, the US.
Firm Name
Quaker BioVentures
Quaker BioVentures is a venture capital and private equity firm with $700 million of assets under management. It invests at all
stages of development of a company focusing on life science industry, including biopharmaceuticals, medical devices, human
diagnostics, specialty pharmaceuticals and healthcare services. Its investment size ranges between $2.5 million to $25 million.
Firm Name
Domain Associates, L.L.C.

Page 70
Domain Associates, L.L.C. (Domain) is a venture capital firm that invests in the life sciences sector. The companys investment
areas include pharmaceuticals, diagnostics, and medical devices companies. It also evaluates the investment opportunities in
sectors of the life sciences industry such as healthcare IT, healthcare technologies and healthcare economics. The company
has its presence in various parts of the US, such as Princeton, and San Diego. It operates as a member of the National Venture
Capital Association. Domain is headquartered in Princeton, New Jersey, the US.
Firm Name
GrowthWorks Capital Ltd.
GrowthWorks Capital Ltd. is a venture capital firm with more than CAD685 million ($560.05 million) capital under management.
The firm invests in growth-oriented companies within the range of CAD0.1 million ($0.8 million) to CAD5 million ($4.08 million)
across information technology, life sciences, advanced manufacturing, clean technology and alternative energy sectors.
Firm Name
Ventures West Capital Ltd.
Ventures West Capital Ltd., is a venture capital investment group with $700 million of capital under management. The firm
invests in early stage in biotechnology, clean technology, alternative energy and communications across Canada.
GlobalData


Page 71
Gemin X Pharma Raises US$16 Million In Series D Financing

Gemin X Pharma Raises US$16 Million In Series D Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
Gemin X Pharmaceuticals, Inc., a biopharmaceutical company, has secured $16 million in series D financing round. The
investment was led by Caxton Advantage Life Sciences Fund LP and Sanderling Venture Partners. The company also has an
option to raise an additional $4 million from this round of financing.
Michael Dixon, Chief Financial Officer of Gemin X, said: "We appreciate the broad and ongoing investor commitment to Gemin
X and this series D financing. The financing is occurring on the heels of positive Phase 1b data for our lead product candidate,
obatoclax, in patients with small cell lung cancer. This continued support has enabled Gemin X to recently complete enrollment
in our randomized controlled Phase 2b study of obatoclax in the first-line treatment of patients with extensive-stage small cell
lung cancer, and we look forward to announcing data from this trial later this quarter".
The company intends to use the proceeds for Phase 1b data for a lead product, obatoclax which will treat small cell lung
cancer.
Deal Rationale
The company intends to use the proceeds for Phase 1b data for a lead product, obatoclax which will treat small cell lung
cancer.
Deal Information
Deal Status
Completed
Deal Finance
Series D
Completed Date
20-Apr-2010
Deal Financials
Deal Value (US$ m)
16
Company Name
Parent
Cephalon, Inc.
Firm Name
Sanderling Ventures
Firm Name
Caxton
Advantage
Sciences Fund, L.P
Life
GlobalData


Page 72
Auspex Pharma Raises US$2 Million In Venture Financing

Auspex Pharma Raises US$2 Million In Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
Auspex Pharmaceuticals, a privately held pharmaceutical company, secured $2 million from venture financing round. The
company is engaged in the development of next-generation medicines with improved safety and performance with the targeted
application of deuterium chemistry to clinically validated drugs.
Deal Rationale
The company intends to use the funds for working capital and general corporate purposes.
Deal Information
Deal Status
Completed
Completed Date
26-Feb-2010
Deal Financials
Deal Value (US$ m)
Company Name
Auspex
Inc.
Pharmaceuticals,
Parent
Teva
Pharmaceutical
Industries Limited
California, the US.
GlobalData


Page 73
SymBio Pharma Secures US$8 Million In Second Tranche Of Series D Financing

SymBio Pharma Secures US$8 Million In Second Tranche Of Series D Financing
Deal Type
Venture Financing
Deal Sub Type
Later Stage
Deal in Brief
SymBio Pharmaceuticals Limited, a biotechnology company, secured additional JPY700m ($7.82m) in second tranche of series
D financing round, by issuing 11,467 shares. In total, the company secured JPY2,200m ($24.58m) through the issue of 36,467
shares in series D financing round.
Earlier on December 11, 2009, the company raised JPY1,500m ($16.76m) in first tranche of series D financing and issued
25,000 shares. The financing was provided by Weru Investment Co., Ltd., Cephalon, Inc. and other four companies. Cephalon
invested $2.2m in the company related to this offering.
The company intends to use the proceeds for the launch of its key driver, bendamustine hydrochloride (SyB L-0501), provided
the impetus for fund raising.
Deal Rationale
The company intends to use the proceeds for the launch of its key driver, bendamustine hydrochloride (SyB L-0501), provided
the impetus for fund raising.
Deal Information
Deal Status
Completed
Deal Finance
Series D
Announced Date
11-Dec-2009
Completed Date
28-Jan-2010
Deal Financials
Deal Value (JPY million)
2,200
Deal Value (US$ m)
24.58
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
SymBio
Limited
Pharmaceuticals
in Tokyo, Japan.
Firm Name
Weru Investment Co., Ltd.
Weru Investment Co., Ltd. is an Financial Investment Company. The company is headquartered at Japan
GlobalData


Page 74
MultiGene Vascular Systems Secures US$8.5 Million In Venture Financing

MultiGene Vascular Systems Secures US$8.5 Million In Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
MultiGene Vascular Systems (MGVS) Ltd., a biotechnology company, secured $8.5 million in a venture financing round. The
financing was led by Teva Pharmaceutical Industries Limited in participation with existing investors DFJ Tamir Fishman
Ventures, Ofer Hi-Tech Ltd., Aviv Venture Capital along with private investors. Teva has invested $4 million and the existing
and new investors have invested $4.5 million.The company intends to use the proceeds from financing to complete its
MultiGene Angio dosing study (Phase I\IIa) and to advance its MultiGene Graft product into clinical study.
Deal Rationale
The company intends to use the proceeds from financing to complete its MultiGene Angio dosing study (Phase I\IIa) and to
advance its MultiGene Graft product into clinical study.
Deal Information
Deal Status
Completed
Completed Date
27-Oct-2009
Deal Financials
Deal Value (US$ m)
8.50
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
MultiGene Vascular Systems

(MGVS) Ltd.
MultiGene Vascular Systems (MGVS) Ltd. (MultiGene) is a medical device company. The company develops vascular products
for the cardiovascular market. It offers products such as MultiGeneAngio and MultiGeneGraft. MultiGenes product
MultiGeneAngio is a cell therapy product for alleviating symptoms and signs of ischemia in patients with peripheral arterial
disease and coronary artery disease. The companys product MultiGeneGraft is a biosynthetic vascular graft, which is lined with
the patients own endothelial cells. It conducted clinical research in seven leading medical centers in Israel, and included twenty
three patients with chronic critical limb ischemia. MultiGene is headquartered in Nesher, Israel.
Firm Name
Aviv Venture Capital
Aviv Venture Capital is a venture capital firm which invests in seed, early and growth stage companies focusing on technology,
healthcare and medical devices sectors across Israel.
Firm Name
DFJ
Tamir
Ventures
Fishman


Page 75
DFJ Tamir Fishman Ventures is a venture capital group with $200 million of capital under management. The firm invests in
early stage companies focusing on communications, cleantech, IT and life sciences sectors across Israel. Its investment size
ranges between $3 million to $10 million.
Firm Name
Ofer Hi-Tech Ltd.
Ofer Hi-Tech is a private equity firm which invests in seed, early stage to publicly-traded companies focusing on various sectors
which include, communications, software, medical devices, bio-technology and microelectronics.
GlobalData


Page 76
Cell Cure Neurosciences Raises US$0.81 Million In Venture Financing

Cell Cure Neurosciences Raises US$0.81 Million In Venture Financing
Deal Type
Venture Financing
Deal Sub Type
Start-up
Deal in Brief
Cell Cure Neurosciences Ltd., a biotechnology company, has secured NIS3 million ($0.81 million) in venture financing. The
investment was provided by Hadasit Bio Holdings Ltd which has invested NIS2.2 million ($0.59 million) and owned 38% of the
company investment. In addition the other investors include Teva Pharmaceutical Industries Ltd., ES Cell International and
Israeli ALS Association.
Cell Cure Neurosciences Ltd. is focused on the development of cell therapy cures for neural degenerative diseases
(Parkinsons, ALS, and multiple sclerosis) based on a platform of neural cells derived from human embryonic stem cells
(hESCs). The companys first product is dopaminergic neural progenitor cells for Parkinsons disease.
Deal Information
Deal Status
Completed
Completed Date
14-Oct-2009
Deal Financials
Deal Value (ILS million)
Deal Value (US$ m)
0.81
Company Name
ES Cell International Pte Ltd
Parent
BioTime, Inc.
ES Cell International Pte Ltd (ESI) is a pharmaceutical company. The company provides regenerative medicines. Its products
include antibodies, cell lines, cell culture media, differentiation kits, ECM substrates and components, hydrogel kits, progenitor
cells and small molecules. The company develops human embryonic stem cell technologies for research and commercial
applications. ESI has intellectual property in the areas of drug discovery, diagnostics and therapeutics. ESI markets products
under the brand names, such as ES Cell International, Extralink, Gelin-S, Glycosil, Heprasil, HyStem and PureStem. The
company operates as a subsidiary of BioTime, Inc. ESI is headquartered in Singapore.
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Hadasit Bio-Holdings Ltd.
Hadasit Bio-Holdings Ltd. (Hadasit) is a biotechnology company. It provides biotech financing, research and development,
promoting and commercializing the intellectual property services in the biotechnology field. The company funds the preparation
and execution of phase I and preparation for phase II of the portfolio companies. Hadasits preparations include pre-clinical
trials, manufacturing, regulatory and business development tasks. The companys portfolio of companies includes ProtAb,
Enlivex Therapeutics, Cell Cure, KAHR Medical, BioMarCare Technologies and D-Pharm. It provides services in the field of
oncology, regenerative medicine and inflammatory disease. Hadasit is a subsidiary of Hadassah Medical Organization (HMO).
Hadasit is headquartered in Jerusalem, Israel.
Company Name
Cell
Ltd.
Cure
Neurosciences,
Parent
BioTime, Inc.

Page 77
Cell Cure Neurosciences, Ltd. (Cell Cure Neurosciences) is a developer of therapeutic cells. It specializes in the development
and supply of cell therapies for retinal and neural degenerative diseases. The companys therapeutic cells include retinal
pigmented epithelial (RPE) cells and neural progenitor cells. The company is a subsidiary of BioTime, Inc. Cell Cure
Neurosciences is headquartered in Jerusalem, Israel.
GlobalData


Page 78
Auspex Pharma Secures US$3 million In Venture Financing

Auspex Pharma Secures US$3 million In Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
Auspex Pharmaceuticals, Inc., has raised $3 million in new venture financing round. The financing was led by Thomas,
McNerney & Partners in participation from CMEA Ventures and Costa Verde Capital.
Deal Information
Deal Status
Completed
Completed Date
19-Aug-2009
Deal Financials
Deal Value (US$ m)
Company Name
Auspex
Inc.
Pharmaceuticals,
Parent
Teva
Pharmaceutical
Industries Limited
California, the US.
Firm Name
Thomas,
McNerney
Partners, LLC
&
the US.
Firm Name
Costa Verde Capital
Costa Verde Capital is a venture capital firm with focus on investing in pharmaceutical companies.
Firm Name
CMEA Capital
GlobalData


Page 79
Yaupon Therapeutics Secures US$3.1 Million In Venture Financing

Yaupon Therapeutics Secures US$3.1 Million In Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
Yaupon Therapeutics, Inc., a specialty pharmaceutical company, secured $3.14m in venture financing round. The company
intends to raise an additional of $0.36m in the same round.
Deal Information
Deal Status
Completed
Completed Date
13-Aug-2009
Deal Financials
Deal Value (US$ m)
3.14
Company Name
Parent
Cephalon, Inc.
GlobalData


Page 80
Gemin X Pharma Secures US$9.3 Million In Venture Financing

Gemin X Pharma Secures US$9.3 Million In Venture Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
Gemin X Pharmaceuticals, Inc., a pharmaceutical company, secured $9.3 million in venture financing round in the form of debt.
The financing was led by 24 investors, including Caxton Associates, Business Development Bank of Canada, Sanderling
Ventures, and Solidarity Fund QFL.
The company intends to use the proceeds for Phase IIb trial of Gemin X's obatoclax.
Deal Rationale
The company intends to use the proceeds for Phase IIb trial of Gemin X's obatoclax.
Deal Information
Deal Status
Completed
Completed Date
01-May-2009
Deal Financials
Deal Value (US$ m)
9.30
Company Name
Parent
Cephalon, Inc.
Firm Name
Business Development Bank

of Canada
Business Development Bank of Canada (BDC) is a financial services company. The company provides financing, consulting,
and venture capital services to small and medium-sized businesses. It provides financing solutions for the purchase of land and
buildings, construction of new premises, and expansion or improvement of existing or rented premises. BDC also provides debt
and equity financing. In addition, the company offers consulting services to manage, develop, enhance efficiency and sale
businesses. Further, it provides venture capital services to various sectors including energy or cleantech, health, information
technology, and communications. It operates through a network of branches in Canada. BDC is owned by the Government of
Canada. The company is headquartered in Montreal, Canada.
Firm Name
Sanderling Ventures
Firm Name
Solidarity Fund QFL
Solidarity Fund QFL is a labor-backed development capital fund that helps to create and maintain jobs in Quebec by investing
in small and medium-sized businesses in Quebec province, Canada.
GlobalData


Page 81
SymBio Pharma Receives Investment In Second Tranche Of Series C Financing

SymBio Pharma Receives Investment In Second Tranche Of Series C Financing
Deal Type
Deal Sub Type
Venture Financing
Deal in Brief
SymBio Pharmaceuticals Limited, a biotechnology company, received investment in the second tranche of series C financing
round. The financing was provided by Mitsubishi UFJ Capital Co., Ltd., a venture capital firm.
Earlier on March 17, 2009, SymBio Pharmaceuticals secured JPY888.48m ($9.04m) in the first tranche of series C financing
round. The financing was provided by Cephalon, Inc., a biopharmaceutical company.
Deal Information
Deal Status
Completed
Deal Finance
Series C
Announced Date
17-Mar-2009
Completed Date
15-Apr-2009
Deal Financials
9.04
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
SymBio
Limited
Pharmaceuticals
in Tokyo, Japan.
Firm Name
Mitsubishi UFJ Capital Co.,

Ltd.
Parent
Mitsubishi UFJ
Group, Inc.
Financial
Mitsubishi UFJ Capital Co., Ltd. is a venture capital firm. The company invests in all stages of development of a company
focusing on IT, Medical Devices, consulting and biotech sectors.
GlobalData


Page 82
Dynamix Pharma Secures US$10 Million In Series A Financing

Dynamix Pharma Secures US$10 Million In Series A Financing
Deal Type
Deal Sub Type
Venture Financing
Start-up
Deal in Brief
Dynamix Pharmaceuticals Ltd., a pharmaceutical company, secured $10 million in series A financing. The financing was led by
Batsheva Elran, founder and managing partner of Opal Ventures, as a Medica3 fund investment, together with Teva
Pharmaceutical Industries Limited.
Dynamix Pharmaceuticals Ltd. is a pharmaceutical company engaged in discovery and development of novel small-molecule
drugs for the treatment of metabolic disorders and inflammatory diseases.
Deal Information
Deal Status
Completed
Deal Finance
Series A
Completed Date
27-Mar-2009
Deal Financials
Deal Value (US$ m)
10
Company Name
Batsheva Elran
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Dynamix
Ltd.
Pharmaceuticals
Dynamix Pharmaceuticals (Dynamix Pharma) is a pharmaceutical company. The company discovers and develops small
molecule drugs for treating patients with cancer and autoimmune disorders. Its products under clinical development include
PKM2, SYK, JAK3, FAK/PYK2 and PLK1. Dynamix Pharmas JAK3 is an intracellular tyrosine kinase, which is involved in
cytokine and antibody receptor signaling. The companys FAK/PYK2 is a cytoplasmic protein tyrosine kinase that resides at the
sites of integrin clustering. It also develops type II kinase inhibitor for SYK and DNX-2000. The company partners with Teva
Pharmaceutical Industries Ltd. Dynamix Pharma is headquartered in Rehovot, Israel.
GlobalData


Page 83
Partnerships
Teva Pharma Enters Into Licensing Agreement With Alexza Pharma For Adasuve Inhalation Powder
Teva Pharma Enters Into Licensing Agreement With Alexza Pharma For Adasuve Inhalation Powder
Deal Type
Deal Sub Type
Partnerships
Licensing Agreement
Deal in Brief
Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., entered into an agreement with Alexza
Pharmaceuticals, Inc., a specialty pharmaceutical company, for licensing and supplying Adasuve (loxapine) inhalation 10 mg
powder exclusively in US. Adasuve is used for the acute treatment of agitation associated with schizophrenia or bipolar I
disorder in adults.
Under the agreement, Teva will be responsible for all US commercial and clinical activities for Adasuve, including US postapproval clinical studies, and has gained rights to conduct additional clinical trials of Adasuve for potential new indications in
neurological disorders. Alexza will be responsible for manufacturing and supplying Adasuve to Teva for commercial sales and
clinical trials.
Alexza will receive an upfront cash payment of US$40m and is eligible to receive up to US$195m in additional milestone
payments, based upon successful completion of the Adasuve post-approval studies in the US and achieving net sales targets.
In addition, Teva will make tiered royalty payments based on net commercial sales of Adasuve. Teva will also make available
up to US$25m to Alexza through a five-year convertible note and agreement to lend, which Alexza may access to support its
Adasuve activities. Alexza may prepay up to 50% of the outstanding amount at any time prior to maturity. Teva may convert, at
maturity, all or a portion of the then outstanding amount under the note into equity of Alexza.
The agreement enables Teva to enhance its treatment options for patients.
Larry Downey, president, North America Specialty Medicines, Teva, said, Approximately four to five million patients with
bipolar I disorder or schizophrenia in the US experience and seek treatment for agitation episodes. This agreement reflects our
business development strategy to pursue opportunities in our core therapeutic areas where we can apply our expertise and
experience to enhance treatment options for patients. Adasuve is a compelling addition to our US Specialty Medicines portfolio,
and we look forward to working with Alexza as we commercialize this important treatment option.
Thomas B. King, president and CEO of Alexza, said, Teva brings an established commercial presence in hospital and
psychiatric markets. Adasuve is approved to address agitation episodes in the hospital-setting, providing a fast-acting, noncoercive treatment option to patients with schizophrenia and bipolar I disorder. Teva has considerable strength and market
presence with the Teva Select Brands group, and we are confident of their ability to deliver commercial success for this
important new product.
Deal Rationale
The agreement enables Teva to enhance its treatment options for patients.
Deal Information
Deal Status
Completed
Completed Date
08-May-2013
Deal Financials
Deal Value (US$ m)
235
Deal Product
Product Description
loxapine
Loxapine (Adasuve, AZ 004), is a tranquilizing agent. It is formulated as powder for Inhalation

route of administration. It is indicated for the treatment of agitation associated with
schizophrenia or bipolar disorder. It was under development for the treatment of Migraine.
Partner Company Information
Company Name
Teva Pharmaceuticals USA,

Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Teva Pharmaceuticals USA, Inc. (Teva) is a generic pharmaceutical company. The company manufactures and markets
pharmaceutical products. Its products include analgesics, anti-glaucoma agents, antiulcer agents and acid suppressants,
antiviral capsules, antibacterial injection, corticosteroids, contraceptives, antacid tablets, laxatives, anti-inflammatory drugs,

Page 84
tamsulosin hydrochloride, losartan potassium, hydrochlorothiazide, dorzolamide hydrochloride ophthalmic solutions and
pramipexole dihydrochloride. The company manufactures generic drugs and over-the-counter healthcare products. Teva
markets products through brand such as Tylenol, Diamox, Zovirax, Proventil, Amikin, Cordarone, Lotrel, Amoxil and Accutane.
It commercializes products through retail chains, wholesalers, distributors and government agencies. The company was
formerly known as Lemmon Pharmacal Company. Teva is headquartered in North Wales, Pennsylvania, the US.
Company Name
Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals, Inc. (Alexza), formerly Alexza Molecular Delivery Corp., is a specialty pharmaceutical company. The
company carries out the research and development and commercializes novel proprietary products used for the acute
treatment of central nervous system diseases. The company develops all its products based on its own proprietary technology,
Staccato system. The companys only lead product Adasuve (Staccato loxapine) is indicated for the treatment of agitation
associated with schizophrenia or bipolar disorder. Its only product candidate AZ-002 (Staccato alprazolam) is being developed
for the treatment of acute repetitive seizures, which are called as cluster seizures or ARS. Alexza is headquartered at Mountain
View in California, the US.
GlobalData


Page 85
Teva Pharma Industries Amends Licensing Agreement With Active Biotech

Teva Pharma Industries Amends Licensing Agreement With Active Biotech
Deal Type
Partnerships
Deal Sub Type
Licensing Agreement
Deal in Brief
Teva Pharmaceutical Industries Ltd., an international pharmaceutical company, amended its licensing agreement with Active
Biotech AB, a biotechnology company, for marketing and distributing oral laquinimod, an investigational treatment for relapsingremitting multiple sclerosis (RRMS).
Under the agreement, Teva obtained extended rights for marketing and distributing oral laquinimod in Nordic and Baltic regions.
Laquinimod is an orally administered immunomodulatory compound under phase III clinical trials for the treatment of RRMS.
Earlier on June 14, 2004, both the companies entered into a licensing agreement to develop and commercialize laquinimod.
Under this agreement, Teva received exclusive rights to develop, register, manufacture and commercialize laquinimod
worldwide, excluding the Nordic and Baltic countries.
This agreement will enable Teva to execute its branded strategy and expand its innovative pipeline.
Deal Rationale
This agreement will enable Teva to execute its branded strategy and expand its innovative pipeline.
Deal Information
Deal Status
Completed
Completed Date
08-Feb-2010
Deal Product
Product Description
laquinimod sodium
<div>
<div>
<p>Laquinimod sodium (ABR-215062) is under development for the treatment of primary
progressive multiple sclerosis, relapsing remitting multiple sclerosis, Crohn's
disease, systemic lupus erythematosus and lupus nephritis. It is an orally administered
immunomodulatory compound. Laquinimod exerts its therapeutic effect by modulating the
immune system from a pro-inflammatory to an anti-inflammatory response and by preventing
the immune system cells that cause the damage in MS from entering the central nervous
system (CNS). It was under development for systemic lupus erythematosus patients with lupus
arthritis.</p>
</div>
</div>
Company Name
Active Biotech AB
Active Biotech AB (Active Biotech) is a biotechnology company. It undertakes the development and commercialization of
pharmaceuticals in the field of autoimmune/inflammatory diseases and cancer. The company has five projects in clinical
development of which three have been licensed out. Its key products in development include Nerventra (laquinimod), for the
treatment of multiple sclerosis, Nerventra is also in Phase II development for the treatment of Crohn's disease and Lupus;
tasquinimod for the treatment of prostate cancer; Anyara for the treatment of renal cell cancer. The other two orally
administered compounds include paquinimod, a quinoline compound in development for the treatment of systemic sclerosis
and RhuDex, which is in development for the treatment of rheumatoid arthritis. Active Biotech has licensing agreements with
Teva, Ipsen and MediGene AG. Active Biotech is headquartered in Lund, Sweden.
Company Name
Teva
Pharmaceutical
Industries Limited

Page 86
GlobalData


Page 87
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma

Medpro Pharma to Enter into Distribution Agreement with Teva Pharma
Deal Type
Partnerships
Deal Sub Type
Co-Marketing
Deal in Brief
Medpro Pharmaceutica (Pty) Ltd, a pharmaceutical company and a subsidiary company of Cipla Medpro, agreed to enter into a
distribution agreement with Teva Pharmaceuticals (Pty) Ltd, a pharmaceutical company and a subsidiary of Teva
Pharmaceutical Industries Ltd, to market Teva Pharma's broad pharmaceutical product portfolio in South Africa.Under the
agreement, Medpro Pharma will receive distribution rights from Teva Pharma to sell and distribute its product portfolio in South
Africa. This agreement will allow Medpro Pharma to strengthen its product portfolio and focus on the therapeutic areas of
oncology, central nervous system, women's health, cardiovascular, ophthalmology and other specialty products; while it will
allow Teva Pharma to market its products in South Africa. The agreement is subject to approval by the Competition
Commission of South Africa and it is restricted to the territory of South Africa.
Deal Rationale
This agreement will allow Medpro Pharma to strengthen its product portfolio and focus on the therapeutic areas of oncology,
central nervous system, women's health, cardiovascular, ophthalmology and other specialty products; while it will allow Teva
Pharma to market its products in South Africa.
Deal Information
Deal Status
Announced
Announced Date
09-Oct-2014
Company Name
MedPro Pharmaceutica (Pty)

Ltd
Company Name
Teva Pharmaceuticals (Pty)

Ltd
Parent
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 88
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug
Deal Type
Partnerships
Deal Sub Type
Co-Marketing
Deal in Brief
Venus Remedies Limited, a pharmaceutical company, has entered into an agreement with Teva Pharmaceutical Industries Ltd.,
a developer of generic drugs, to develop and distribute an anti- cancer drug in the Canadian market.Under the agreement,
Venus Remedies will be initially develop the drug in its research unit 'Venus Medicine Research Center' for assisting Teva
Pharma in registrations. Thereafter, Venus Remedies will also use its manufacturing capability to support its valuable partner in
enhancing the business in Canada market. The GMP granted to Venus Remedies for EU is also valid for Canada, based on
which, Venus Remedies infrastructure and regulatory competence will be used for commercialization of anti- cancer drug in
Canadian market. Teva Pharma will use Venus Remedies infrastructure and regulatory competence for commercialization of
anticancer product in Canadian market.This agreement enables Venus Remedies and Teva Pharma to develop and
commercialize anticancer product in Canada.
Deal Rationale
This agreement enables Venus Remedies and Teva Pharma to develop and commercialize anticancer product in Canada.
Deal Information
Deal Status
Completed
Completed Date
26-Aug-2014
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Venus Remedies Limited
Venus Remedies Limited (Venus) is a pharmaceutical company. It develops, manufactures and commercializes pharmaceutical
products. The company, through its research centre Venus Medicine Research Centre, provides novel solutions for unmet
medical needs in the fields of field of oncology, anti-microbial resistance, wound care and pain management. Its products
include Elores, Vancoplus, Potentox, Tobracef, Supime, Zydotum, and Pirotum, among others. Venus's products are used in
various therapeutic areas such as anti cancer, anti infective, neurology, skin & wound care, and pain management, neurology
and OTC. The company has three injectable manufacturing units in Panchkula, Baddi (both India) and Werne (Germany). It has
operational presence in Germany and India through its 11 overseas marketing offices. Venus is headquartered in Panchkula,
Haryana, India.
GlobalData


Page 89
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems
Deal Type
Partnerships
Deal Sub Type
Joint Venture
Deal in Brief
Teva Pharmaceutical Industries Ltd., a developer and manufacturer of generic and branded pharmaceuticals and APIs, has
agreed to enter into a joint venture agreement with Philips Medical Systems Ltd. (Philips Healthcare), a healthcare division of
Royal Philips Electronics. Under the agreement, the partners will form a medical device and drug development incubator, in
Israel. This agreement enables Teva Pharmaceutical Industries and Philips Medical Systems to provide personalized medicine
in Israel.
Deal Rationale
This agreement enables Teva Pharmaceutical Industries and Philips Medical Systems to provide personalized medicine in
Israel.
Deal Information
Deal Status
Announced
Announced Date
05-Jun-2014
Company Name
Philips Healthcare
Parent
Koninklijke Philips N.V.
Philips Healthcare, formerly Philips Medical Systems, undertakes the manufacture and distribution of diagnostic imaging
systems, healthcare information technology solutions, patient monitoring and cardiac devices. Philips Healthcare is a division of
Royal Philips Electronics of the Netherlands, which is a global company in healthcare, lighting and consumer lifestyle, delivering
innovative products, services and solutions. The company classifies its business activities into four areas, namely, imaging
systems, healthcare informatics, solutions and services, patient care and monitoring solutions and customer services. It has
manufacturing facilities in the Netherlands, Germany, the US, Finland, Israel, China and Brazil. Philips Healthcare is
headquartered in Massachusetts, the US.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 90
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan
Deal Type
Deal Sub Type
Partnerships
Co-Marketing
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, entered into an agreement with Takeda Pharmaceutical
Company Limited, a manufacturer of ethical drugs and consumer healthcare, to commercialize Teva Pharmas Rasagiline
(Azilect) for the treatment of Parkinsons disease in Japan. Rasagiline is a monoamine oxidase B (MAO-B) inhibitor which is
presumed to act by increasing available synaptic dopamine in the brain which may improve the motor symptoms characteristic
of Parkinsons disease.
Under the terms of the agreement, Takeda Pharma will develop Rasagiline tablets for the Japanese market and submit a New
Drug Application for registration of the product in Japan.
This agreement enables Teva Pharma and Takeda Pharma to commercialize Rasagiline for the treatment of Parkinsons
disease in Japan.
Michael Hayden, president of global R&D and chief scientific officer of Teva Pharma, said, This agreement represents Tevas
continued commitment to introducing our innovative medicines to patients in Japan. Rasagiline has an established safety and
efficacy profile and is currently approved for use in over 40 countries, and will be an important product for Japan, where the
number of available treatment options for Parkinsons disease remains limited.
Nancy Joseph-Ridge, general manager of the Pharmaceutical Development Division, of Takeda, said, It is estimated there are
about 150,000-180,000 people diagnosed with Parkinson's disease in Japan, many of whom are waiting for a new treatment
option of Takedas pharm Development Division. We will continue working on the development in cooperation with Teva so that
we can bring this medicine to Japanese patients as quickly as possible.
Deal Rationale
This agreement enables Teva and Takeda to commercialize Teva's innovative treatment for Parkinsons disease, rasagiline
(Azilect) in Japan.
Deal Information
Deal Status
Completed
Completed Date
27-Apr-2014
Deal Product
Product Description
rasagiline mesylate
<div>
<p>Rasagiline mesylate (Azilect, TVP-1012) is an indanes derivative drug belongs to antiparkinson and central nervous system agent. It is formulated as tablets for oral route of
administration. It is indicated for the treatment of idiopathic Parkinson's disease (PD) as
monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of
dose fluctuations. The drug candidate is under development for the treatment of
Parkinson's disease in Japan and for amyotrophic lateral sclerosis.</p>
</div>
Company Name
Takeda
Pharmaceutical
Company Limited
Takeda Pharmaceutical Company Limited (Takeda) is a research-based global pharmaceutical company. It focuses on the
research & development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and
consumer health care products. The company manufactures and markets photographic chemicals, inorganic chemicals, vitamin
bulks, test reagents and clinical diagnostics. Takeda markets its ethical drugs worldwide through its subsidiaries in North
America, Europe and Asia. It operates production facilities in Osaka, Hikari, Italy, Ireland, China and Indonesia. The company
also manages research and development facilities in Palo Alto, San Diego, San Francisco, Deerfield, Osaka, Tsukuba, London,
Cambridge and Singapore. Takeda is the largest pharmaceutical company in Japan and is headquartered in Chuo-ku, Osaka,
Japan.
Company Name
Teva
Pharmaceutical


Page 91
Industries Limited
GlobalData


Page 92
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs
Deal Type
Partnerships
Deal Sub Type
Co-Development
Deal in Brief
Cancer Research Technology Limited (CRT), an oncology-focused development and commercialization company, entered into
a R&D agreement with Teva Pharmaceutical Industries Ltd. (Teva), a pharmaceutical company, to research and develop firstin-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.Under the agreement,
Cancer Research UK and CRT have established a new hub of expertise in DDR-related basic, translational, and clinical
research which will provide the foundations for CRT's and Teva's work towards developing novel therapies based on DDRrelated targets for the treatment of cancer. As per the terms of the agreement, CRT will receive research funding and be eligible
to receive milestone payments, and royalties on projects advancing through Tevas drug pipeline.This agreement provides Teva
with the opportunity to research and develop selected and differentiated novel treatments targeting DDR processes. With a
focus on mechanisms and molecular targets related to the emergence of therapeutic resistance in cancer cells, the partnership
also opens up the potential to expand the clinical utility and therapeutic effectiveness of Tevas current portfolio of oncology
chemotherapeutic agents.Michael Hayden, president, global R&D and chief scientific officer of Teva, said, For cancer patients,
it is important that we maintain the momentum of progress that has been made in oncology in recent years. Cancer Research
UK, CRT, and their outstanding academic partners, are a driving force in the improved understanding of cancer and its
treatment. This research collaboration will build on our understanding of how cells repair DNA damage, help us identify possible
points of therapeutic intervention, and lead us onto a pathway to improve clinical outcomes for cancer patients."Dr Hamish
Ryder, director of drug discovery at CRTs Discovery Laboratories, said, "Cancer Research UK scientists are carrying out
exciting research in the area of DNA damage repair. Some cancer therapies work by targeting DNA damage response
pathways in cancer cells, and finding new ways to block repair in tumours can boost the effectiveness of existing therapies.
This exciting alliance with Teva brings together the cutting-edge research funded by Cancer Research UK, CRTs expertise in
progressing new drug targets and Tevas drug research and development capabilities in a compelling partnership."Harpal
Kumar, CEO of Cancer Research UK, said, Our scientists are leading the world in understanding the machinery that causes
and subsequently repairs damage to DNA in our cells. We believe this machinery offers many opportunities for new treatments.
Cancer Research UK has been at the heart of research that has seen survival from cancer double in the last forty years. By
working alongside international partners from industry to discover and develop new targeted cancer drugs we hope to be able
to accelerate this progress. This innovative alliance provides a vital new route to turn our research excellence into new drugs to
treat cancer patients, hopefully saving more lives, more quickly."
Deal Rationale
This agreement enables CRT and Teva to develop cancer drugs which modulate DNA damage and repair response (DDR)
processes in cancer cells.
Deal Information
Deal Status
Completed
Completed Date
16-Sep-2013
Company Name
Cancer
Research
Technology Limited
Parent
Cancer Research UK
Cancer Research Technology Limited (CRT), a subsidiary of Cancer Research UK is a cancer research organization that
develops and commercializes new discoveries for treatment in the areas of cancer. The organization offers services which
include project development, commercialization, drug discovery, clinical development, imaging and funding. It provides
commercialization services to Cancer Research UK and oncology institutes worldwide, and also operates drug discovery
laboratories. The organization collaborates with clinical and academic institutions, pharmaceutical companies and
biotechnology companies in the UK and worldwide. It operates in the US and the UK. CRT is headquartered in London, the UK.
Company Name
Teva
Pharmaceutical
Industries Limited

Page 93
GlobalData


Page 94
Champions Enters Into Drug Discovery And Development Agreement With Teva
Champions Enters Into Drug Discovery And Development Agreement With Teva
Deal Type
Partnerships
Deal Sub Type
Co-Development
Deal in Brief
Champions Oncology Inc. (Champions), a biotechnology company, entered into a new discovery and drug development
agreement with Teva Pharmaceutical Industries Ltd. (Teva), a global pharmaceutical company. Under the agreement, the
partners will utilize Champions TumorGraft technology. The development process will include initial screening studies on large
numbers of TumorGraft models to develop response hypotheses for different tumor types and sub-populations. These
hypotheses will be further refined and validated with more in depth studies.
As part of the collaboration, Teva will pay Champions an upfront fee and Champions may also receive milestone payments and
royalties for the compounds being studied if the response hypotheses are successfully utilized for clinical trial design and
resulting commercial success of the compounds.
This agreement enables Champions to identify highly responsive cancer subtypes, and their corresponding molecular and
biochemical biomarkers of responsiveness to Teva's novel therapeutic agents, resulting in new and personalized therapeutic
options for cancer patients.
Joel Ackerman, CEO of Champions, said, "We are excited to announce this opportunity for us to work with the team at Teva to
identify and validate sub-populations that are best suited for these compounds. This represents an exciting opportunity for us to
align our success with the value our technology provides our customers."
Deal Rationale
This agreement enables Champions to identify new and personalized therapeutic options for cancer patients.
Deal Information
Deal Status
Completed
Completed Date
12-Sep-2013
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Champions Oncology, Inc.
Champions Oncology, Inc. (Champions), formerly known as Champions Biotechnology, Inc., is a biotechnology company. It
develops advanced technology solutions and services to personalize the development and use of oncology drugs. The
companys TumorGraft Platform is developed on the basis of implantation of primary human tumors in immune-deficient mice.
Champions uses TumorGraft platform for identifying different tumor cancers and their response to drugs to predict clinical
outcomes in cancer patients. . It provides a wide range of personalized oncology solutions (POS) to oncologists,
pharmaceutical and biotechnology companies. The company offers personalized TumorGraft development, drug studies and
genome sequencing as part of POS. It also offers translational oncology solutions for faster drug approval, helping the
technology to evaluate tumor sensitivity/resistance. Champions is headquartered in Hackensack, New Jersey, the US.
GlobalData


Page 95
Teva Pharma Plans To Enter Into Partnerships

Teva Pharma Plans To Enter Into Partnerships
Deal Type
Partnerships
Deal Sub Type
Co-Development
Deal in Brief
Teva Pharmaceutical Industries Limited is planning to form strategic partnerships to enter into China and Brazil markets, and
expand its global presence.
Jeremy Levin, CEO of Teva, said, "We look to expand our geographic footprint where we feel that there are markets that we're
not present in. And you should know we're not present in places like Brazil in any meaningful way. We're not present yet in the
large expanding markets of China in any meaningful way."
Deal Rationale
These agreements will enable Teva to enter into China and Brazil markets, and expand its global presence.
Deal Information
Deal Status
Planned
Announced Date
Aug 15, 2013
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 96
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide
Deal Type
Partnerships
Deal Sub Type
Co-Marketing
Deal in Brief
Teva Pharmaceutical Industries Ltd. entered into an agreement with Perrigo Company, a pharmaceutical company, to market
the generic equivalent to Temodar (temozolomide). Under the agreement, Teva will manufacture, market and distribute the
product in the US and both companies will equally share in the cost and profitability of the product in the US. Teva was first to
file, making the product eligible for 180 days of marketing exclusivity.
This product is the generic equivalent to Temodar (temozolomide), indicated for the treatment of adult patients with newly
diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory
anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and
procarbazine.
This agreement enables the partners to provide more cost effective alternative to Temodar for cancer therapy.
Joseph C. Papa, chairman, president and CEO of Perrigo, said, This first-to-file launch with our partner Teva is another
example of our focus to manufacture complex APIs. We are pleased to offer this important product to patients in the US.
Allan Oberman, president and CEO of Teva Americas Generics, said, We are pleased to partner with Perrigo to offer patients
a high-quality, less expensive alternative of this important medicine. This launch demonstrates Tevas commitment to continue
to pursue first-to-market opportunities and enhance the value of our portfolio by concentrating on high-margin, low competition
markets.
Deal Rationale
This agreement enables the partners to provide more cost effective alternative to Temodar for cancer therapy.
Deal Information
Deal Status
Completed
Completed Date
12-Aug-2013
Deal Product
Product Description
temozolomide
<p>Temozolomide (Temodar, Temodal, Astromide, Temozolomida) is an alkylating agent acts

as antineoplastic agent. It is a triazene analog of dacarbazine activity. It is formulated as
capsule for oral administration and powder for solution for intravenous administration. It is
indicated for the treatment of glioblastoma multiforme concomitantly with radiotherapy (RT)
and subsequently as monotherapy treatment. It is also used for the treatment of malignant
glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or
progression after standard therapy. Temozolomide is under development for the treatment of
relapsed and refractory acute myeloid leukemia (AML), small cell lung cancer and
myelodysplastic syndrome (MDS). It was also under development for the treatment of
aerodigestive tract cancers including esophageal cancer, colorectal cancer, head and neck
cancer and non-small cell lung cancer.</p>
Company Name
Perrigo Company plc
Perrigo Company plc (Perrigo) is one of the leading pharmaceutical companies. It develops, manufactures and distributes overthe-counter products, generic and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (APIs),
infant formulas, and consumer products. The company operates its business through six reportable segments, namely,
Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, APIs, Specialty Sciences and Others. It also provides consumer
products such as cosmetics, toiletries, bar soaps, and detergents. Perrigo operates in the US, the UK, Mexico, Israel, Australia,
Canada and China, besides Latin America. Perrigo is headquartered in Dublin, Ireland.
Company Name
Teva
Pharmaceutical
Industries Limited

Page 97
GlobalData


Page 98
Teva Pharma And Lonza Terminate Joint Venture For Biosimilars

Teva Pharma And Lonza Terminate Joint Venture For Biosimilars
Deal Type
Partnerships
Deal Sub Type
Joint Venture
Deal in Brief
Teva Pharmaceutical Industries Limited and Lonza Group Ltd, a chemical and biotechnology company, terminated their joint
venture (JV) to better advance their own strategies and efforts. According to Lonza, the companies will require more capital
than initially planned and will also take more time until the products reach the market.
In 2009, Teva Pharmaceutical entered into JV with Lonza, to develop, manufacture and market a portfolio of biosimilars.
Michael Hayden, president, global R&D and CSO of Teva, said, Teva has a track record of success in the biologics arena and
we plan to continue and build on that success. This decision supports our ability to maintain a highly selective approach in our
efforts to create a balanced portfolio of biosimilars, biobetters and innovative biologics that align with our overall portfolio and
areas of disease focus, and by doing so better support our patients in these areas.
Stephan Kutzer, COO of Lonza Pharma & Biotech Market Segment, said, With the discontinuation of the joint venture we will
cease investing in areas that are not strategic to Lonza such as clinical developments and end product commercialization. In
our assessment those investments in biosimilar will require more capital than initially planned and will also take more time until
they reach the market. This is why we intend in the future to limit our role by focusing on our core expertise in the areas of
contract manufacturing and cell line development.
Deal Rationale
The termination of JV enables the companies to better advance their own strategies and efforts; and allows Lonza to focus on
its core business of contract manufacturing and cell line development.
Deal Information
Deal Status
Terminated
Terminated Date
Jul 25, 2013
Company Name
Lonza Group Ltd
Lonza Group Ltd (Lonza) is a biopharmaceutical company. It manufactures and develops chemical and biological active
pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell
therapies, drinking water sanitizers, vitamin B compounds, industrial preservatives, microbial control solutions and organic
personal care ingerdients. It also provides custom development and custom manufacturing services to its clients. Lonzas client
base ranges from professionals in the biotechnology, pharmaceutical, academic, and government research industries to
manufacturers of health and consumer products, distributors, formulators and service companies. The companys key markets
include bioresearch, nutrition, pharma and biotech, microbial control, agriculture, materials science and personal care
industries. It operates several manufacturing and research and development (R&D) facilities across the world. The company
has presence in Asia, Europe, Americas and other countries. Lonza is headquartered in Basel, Switzerland.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 99
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test
Deal Type
Deal Sub Type
Partnerships
Co-Marketing
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, entered into an exclusive agreement with Verinata Health,
Inc., an in-vitro diagnostics company, for the commercialization of the verify non-invasive prenatal test in Israel. Under the
terms of the five-year agreement, Teva Pharmaceuticals will be the exclusive distributor of the verify prenatal test in Israel. The
MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi prenatal test to customers of Clalit
Health Services who are at high risk of having a fetus with a chromosomal abnormality. The MOR Institute, a wholly-owned
subsidiary of Clalit Health Services, will also establish a 9,000-patient clinical outcomes registry to collect performance data and
will share the data with Verinata. All tests will be run in Verinata Health's CLIA-certified laboratory in California. Clalit Health
Services will provide reimbursement for the verify prenatal test through supplemental insurance.
The verifi prenatal test is a blood test that analyzes genetic material (or DNA) naturally found in a pregnant woman's blood to
detect the most common fetal chromosome abnormalities. The verifi test can be offered to pregnant women of at least 10
weeks gestation and at high risk of carrying a fetus with a genetic abnormality.
Ron Mayron, CEO of Teva Israel, said, We are extremely pleased to partner with Verinata in Israel, to bring pregnant women
unprecedented access to what we believe is the superior non-invasive prenatal test to detect chromosomal abnormalities. The
verifi prenatal test exemplifies our investment in the women's health segment and our commitment to offer clinically-validated,
innovative new products to Israeli women to improve their health and quality of life.
Orit Jacobson, CEO of MOR Institute, said, We strongly believe that the verifi prenatal test will have a lasting and positive
impact on the Israeli community, and beginning July 1, MOR will provide a special nursing service, allowing pregnant women to
have their sample collected for the test in the convenience of their homes, as well as in MOR clinics in the country. The patient
registry developed through this collaboration will be the largest and most extensive of its kind, demonstrating our commitment
to leadership in women's health.
Vance Vanier, vice president of global commercial operations for Verinata, said, This collaboration brings together the top
healthcare marketing and sales force in Israel with an established reimbursement infrastructure and long-term performance
measurements. The unique collaboration emphasizes the value of the verifi prenatal test. With the test now available in several
international markets, we look forward to expanding our commercial presence by continuing to partner with leading
organizations around the globe.
Deal Rationale
This agreement enables Teva Pharmaceutical and Verinata Health to offer pregnant women with access to non-invasive
prenatal test to detect chromosomal abnormalities.
Deal Information
Deal Status
Completed
Completed Date
01-Jul-2013
Deal Product
Product Description
MAGE-A3 HPV-16 Vaccine
MAGE-A3 HPV-16 vaccine was under investigation for patients with squamous cell carcinoma
of the head and neck. The vaccine is administered subcutaneously. MAGE-A3/HPV 16 peptide
vaccine is a Trojan antigen. MAGE-A3 HPV-16 vaccine consists of human melanoma antigen
A3 (MAGE-A3) and human papillomavirus (HPV) 16 peptide epitopes linked by the furinsensitive linker peptide RVKR (arginine-serine-lysine-arginine) with immunostimulatory and
anti-tumor activities. Trojan Ags contain a CTL epitope localized to intracellular compartments,
where MHC class I-binding peptides are generated in a TAP-independent fashion by the action
of various exopeptidases and the endopeptidase furin. Trojan Ags containing several CTL
epitopes joined via furin-sensitive linkers generate all of the corresponding MHC class Ibinding peptides, which are recognized by CTL. However, Trojan Ags prepared with furinresistant linkers fail to produce the MHC class I-binding peptides. Trojan Ags bearing both CTL
and Th epitopes can generate the corresponding MHC class I- and II-binding peptides, which
are capable of stimulating T cell responses.
Company Name
Teva
Pharmaceutical


Page 100
Industries Limited
Company Name
Verinata Health, Inc.
Parent
Illumina, Inc.
Verinata Health, Inc. (Verinata) is a medical technology company. The company offers in-vitro diagnostic tests for early
identification of fetal chromosomal abnormalities. It develops non-invasive alternatives for maternal and fetal health; and noninvasive verifi prenatal tests to detect turner syndromes. Verinata concentrates on completing the clinical validation of first noninvasive prenatal diagnostic test, which is designed to determine fetal chromosomal abnormalities. The company serves
patients and physicians, as well as managed care organizations. It markets products and technologies in domestic and
international healthcare markets. The company operates as a subsidiary of Illumina, Inc. Verinata is headquartered in San
Carlos, California, the US.
GlobalData


Page 101
Teva Pharma Terminates Co-Development Agreement With CureTech For CT-011

Teva Pharma Terminates Co-Development Agreement With CureTech For CT-011
Deal Type
Partnerships
Deal Sub Type
Co-Development
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, terminated its co-development agreement with CureTech Ltd.,
a biotechnology company, relating to CureTech's product, CT-011, as Teva is in the process of conducting review of its pipeline
and analyzed the most recent clinical and biochemical data of the product. The company intends to invest its resources in other
areas where it can have the impact for patients.
CT-011 is a humanized monoclonal antibody which interacts with PD-1, a B7 family-associated protein and exhibits anti-cancer
immune response against mouse and human tumors. It is being developed as a treatment for hematological malignancies and
solid tumors. CT-011 was assessed in several Phase I and II clinical studies in various cancer indications including diffuse large
B-cell lymphoma, colon cancer, metastatic melanoma and additional investigator initiated studies.
Earlier in May 2006, CureTech entered into an agreement with Teva Industries for the development of CureTech's product, CT011.
Michael Hayden, president and CEO of R&D and chief R&D officer of Teva, said, We are in the process of conducting a
disciplined review of our pipeline. As we looked closely at CT-011 and the most recent clinical and biochemical data, we have
made the strategic decision to invest our resources elsewhere where we can have the most impact for patients.
Deal Information
Deal Status
Terminated
Terminated Date
Jan 31, 2013
Deal Product
Product Description
pidilizumab
<div><p>Pidilizumab (CT-011) is under development for the treatment of relapsed

glioblastoma multiforme, acute myelocytic leukemia (AML), colorectal cancer, follicular
lymphoma, relapsed and refractory multiple myeloma, renal cell carcinoma, metastatic
melanoma, pancreatic cancer, diffuse intrinsic pontine glioma and hormone refractory prostate
cancer. CT-011 is an intravenously administered humanized monoclonal antibody (mAb) that
modulates the immune response and inhibits tumor growth and the spread of metastases. CT011 interacts with PD-1 (Programmed Death-1). It was also under development for
hepatocellular carcinoma, hepatitis C and diffuse large B-cell lymphoma.</p></div>
Company Name
CureTech Ltd.
CureTech Ltd. (CureTech) is a pharmaceutical company that conducts research, develops and commercializes immune
modulating products used in the treatment and control of cancer. The company develops products which include antibodies and
peptide based vaccines. Its product pidilizumab (CT-011) is a humanized monoclonal antibody that interacts with PD-1, a B7
receptor family associated protein, and exhibits anti cancer immune response against tumors. The company undertakes
research studies and clinical trials in other cancer diseases including renal cell carcinoma, multiple myeloma, pancreatic
cancer, and glioblastoma. CureTech is headquartered in Yavne, Israel.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 102
Teva Pharma To Form Joint Venture With Handok Pharma

Teva Pharma To Form Joint Venture With Handok Pharma
Deal Type
Partnerships
Deal Sub Type
Joint Venture
Deal in Brief
Teva Pharmaceutical Industries Ltd. entered into an agreement with Handok Pharmaceuticals Co., Ltd. to establish a joint
venture (JV) in South Korea. Under the terms of the agreement, Teva will contribute its global resources, with responsibilities
for manufacturing and supplying affordable and novel medicines. Handok will be responsible for sales and marketing,
distribution, and regulatory affairs. Teva will have a controlling stake of 51%, while Handok will hold 49% stake.
This agreement will allow Teva to enter into the Korean pharmaceutical market, currently valued at approximately $14 billion. It
will also enable Handok to strengthen its position in South Korea.
Itzhak Krinsky, chairman of Teva Japan, chairman of Teva South Korea and head of business development Asia Pacific, said,
"This is another significant step in our strategy to expand Tevas presence in growing markets and excluding Japan, this is our
first alliance in East Asia. By utilizing Tevas broad portfolio, R&D capabilities and its global infrastructure and know-how
coupled with Handoks expertise and strong reputation in Korea, Teva and Handok plan to assume a prominent position in the
Korean pharmaceutical market. The business venture will enable patients to gain more access to the treatments they need
including innovative therapies, such as our multiple sclerosis treatment Copaxone and branded generics.
Young-jin Kim, CEO of Handok, said, "We are glad to open up new business opportunities through this business venture with
Teva, which has a broad, unparalleled portfolio of innovative specialty therapeutics, generics, biosimilars and innovative
medicines. We expect this business venture to contribute greatly to the Korean pharmaceutical industry by supplying medicines
at more affordable prices and providing innovative treatment solutions for CNS, respiratory and womens health.
The Teva-Handok venture is subject to receipt of applicable regulatory approvals, and is expected to commence activities in the
next few months.
Deal Rationale
This agreement will enable Teva to enter into the Korean pharmaceutical market. It will enable Handok to strengthen its position
in South Korea.
Deal Information
Deal Status
Announced
Announced Date
16-Dec-2012
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Handok Inc.
Handok Inc. (Handok) formerly Handok Pharmaceuticals Co., Ltd. is a pharmaceuticals and healthcare company, based in
South Korea. The company carries out the discovery, development, manufacture and marketing of prescription drugs,
consumer healthcare products, medical devices, in-vitro diagnostics, food supplements and medical nutrition. It provides
prescription medicines for the treatment of diabetes, high blood pressure, ulcers, skin ailments, cancer and allergy among
others. The company supplies personal healthcare drugs, such as over the counter drugs for digestion, calcium, antibiotic pills
and injections, diuretics, skin ointment, and anti-histamines. It operates with a research and development laboratory in Seoul
and a manufacturing plant in Chungcheongbuk-Do, Korea. Handok is headquartered in Seoul, Gyeonggi-do, South Korea.
GlobalData


Page 103
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil
Deal Type
Partnerships
Deal Sub Type
Co-Marketing
Deal in Brief
Teva Pharmaceutical Industries Limited entered into co-marketing agreement with CTC Bio Inc. (formerly Se Chuk Co. Inc.), a
pharmaceutical and healthcare company, for orally-disintegrating films of sildenafil 100mg.
Sildenafil is a generic version of Viagra that is used to treat erectile dysfunction.
Deal Rationale
This agreement enables the partners to commercialize orally-disintegrating films of sildenafil.
Deal Information
Deal Status
Completed
Completed Date
11-Dec-2012
Company Name
Ctcbio Inc.
CTCBIO INC. (CTCBIO) is a pharmaceutical company. The company discovers, develops, and manufactures pharmaceuticals,
veterinary drugs, animal feed supplements, and functional foods. CTCBIO conducts research in the areas of bio food,
biotechnology, functional food, antibiotics, environment, animal health products, pharmaceutical, bioinformatics, proteomics,
and genomics. The company also provides technology platforms, such as gene and protein manipulation, assay technology,
microorganism development and screening, fermentation and purification, and process optimization. It has pharmaceutical,
functional food, and animal health departments. It markets products under the brand name, CTCZYME. The company partners
with BASF, Pfizer, and NOVUS. CTCBIO is headquartered in Songpa-gu, Seoul, Korea.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 104
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax
Deal Type
Partnerships
Deal Sub Type
Co-Marketing
Deal in Brief
Galena Biopharma, Inc., a biotechnology company, entered into an agreement with a subsidiary of Teva Pharmaceutical
Industries Limited (Teva Pharma) for NeuVax (nelipepimut-S or E75). Under the agreement, Teva Pharma will assume
responsibility for regulatory registration in Israel, provide financial support for local development, and will commercialize the
product in the region. Galena is entitled to receive significant royalty payments on future sales.
NeuVax is the immmunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established
target for therapeutic intervention in breast carcinoma. Treatment with NeuVax stimulates cytotoxic (CD8+) T cells in a highly
specific manner to target cells expressing any level of HER2. Based on a successful Phase II trial, which achieved its primary
endpoint of disease-free survival (DFS), the USFDA granted NeuVax, a Special Protocol Assessment (SPA) for its Phase III
study.
Mark Ahn, president and CEO of Galena, said, This agreement is the first piece of our global commercialization strategy. Teva
is a world-class pharmaceutical company and a major pharmaceutical company in Israel. We look forward to their valuable
financial support towards our development goals in Israel, as well as market leadership for NeuVax commercialization in the
region."
Noa Efrat, head department of oncology at Kaplan Medical Center, said, We are embarking on a very exciting and innovative
venue for the adjuvant treatment of early breast cancer. In this study we are boosting the body's natural immune system to deal
with possible residual cancer cells still present. The biological reasoning behind this treatment is sound. We hope that the
results of this large randomized study will confirm the encouraging results seen in earlier studies using this agent.
Deal Rationale
This agreement enables Galena Biopharma to develop and commercialize NeuVax in Israel.
Deal Information
Deal Status
Completed
Completed Date
04-Dec-2012
Deal Product
Product Description
nelipepimut-S
<p>Nelipepimut-s (NeuVax) is under development for the treatment of gastric cancer, breast
cancer and prostate cancer. Nelipepimut-s is administered as intradermal injection. NeuVax
consists of the E75 peptide derived from human epidermal growth factor receptor 2 (HER2)
combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GMCSF). Treatment with NeuVax stimulates cytotoxic (CD8+) T cells in a highly specific manner
to target cells expressing any level of HER2.</p>
Company Name
Galena Biopharma, Inc.
Galena Biopharma, Inc. (Galena) is a biotechnology company. The company discovers, develops and commercializes
therapies for the treatment of unmet medical needs, and advance care. Its products include Abstral, NeuVax, NeuVax
Herceptin, and folate binding protein. The company provides NeuVax and NeuVax Hercepti for the treatment of breast cancer
and folate binding protein for the treatment of endometrial and ovarian cancer. Galenas Abstral is a sublingual tablets for the
management of breakthrough pain in cancer patients of 18 years of age. It partners with academia, small companies, and large
multinationals. Galena is headquartered in Lake Portland, Oregon, the US.
Company Name
Teva
Pharmaceutical
Industries Limited

Page 105
GlobalData


Page 106
Teva Pharma And Proctor & Gamble Finalize Joint Venture

Teva Pharma And Proctor & Gamble Finalize Joint Venture
Deal Type
Deal Sub Type
Partnerships
Joint Venture
Deal in Brief
Teva Pharmaceutical Industries Ltd. and The Procter & Gamble Company (P&G), a consumer goods company, finalized the
joint venture (JV) to establish OTC drug manufacturing facility in India. The joint venture, to be named P&G Teva, will be based
in Gujarat, India.
P&G Teva will set up an over-the-counter (OTC) drug manufacturing facility at Sanand in Gujarat, with an initial investment of
INR2,500m ($44.5m). The facility will have two separate lines, one for manufacturing Ayurvedic drugs and another for allopathic
medicines. The facility will be used to produce liquid, oral solid dosage and inhaler, including P&G's current Vicks range of
cough & cold medicines and throat drops in India, along with other OTC products for India and other markets. The facility will
initially cater domestic and Asia Pacific markets. Teva Pharm India Pvt. Ltd expects completion of construction of the plant in
two years. The new plant will complement the existing network of P&G's Vicks contract manufacturers in India.
Eran Katz, executive vice president, strategy and operation at Teva Global Operations, said, "The multipurpose plant in India
will support the growing demand for our non-prescription health care products across Asia. The Sanand facility will be a critical
component of PGT Healthcare, Teva's international partnership and joint venture with Procter & Gamble."
HG Kohsia, commissioner of Gujarat's Food and Drug Control Administration (FDCA), said, "TPI and P&G joint venture P&G
Teva would set up over the counter (OTC) drug manufacturing facility at Sanand with an initial investment of INR2,500m
($44.5m). The total proposed investment in Gujarat by the JV is around INR5,000m ($89m). They would initially hire 500
people, which could go up to 1,000. Around 15 acres of land for the project has already been acquired. The facility to come up
on 15 acres of land is proposed to have two separate lines, one for manufacturing Ayurvedic drugs and another for allopathic
medicines. A four member delegation led by Karin Baer, vice president corporate quality of Teva, met us and sought details of
setting up a facility to manufacture OTC products like cough syrups, inhalers....amongst others assistant vice president Teva
Rajiv Palliwal, senior director OTC operations Teva Haresh Gill, and Seema Sundereshan, a senior scientist from P&G were
part of the delegation. The proposed facility at Sanand would have state-of-the-art equipment and adhering to good
manufacturing practices (GMP) norms to make products both for Indian and overseas market.
Deal history
Update2: On January 29, 2013, Teva Pharmaceutical Industries and P&G finalized the joint venture (JV) to establish OTC drug
manufacturing facility in India.
Update1: On November 12, 2012, Teva Pharmaceutical Industries and P&G received EU regulatory approval to form JV to
establish OTC drug manufacturing facility in India.
Announced: On July 25, 2012, Teva Pharmaceutical Industries agreed to form joint venture (JV) with P&G, to establish OTC
drug manufacturing facility in India.
Deal Rationale
The JV will support growing demand for Teva Pharmaceutical's non-prescription health care products across Asia. It will also
complement the existing network of P&G's Vicks contract manufacturers in India.
Deal Information
Deal Status
Announced
Announced Date
25-Jul-2012
Company Name
The Procter
Company
&
Gamble
The Procter & Gamble Company (P&G) is a global manufacturer and marketer of branded consumer goods. The company
primarily offers beauty, health, fabric, home, baby, family, and personal care products. These products are marketed under the
brands of Head & Shoulders, Tide, Ariel, Olay, Pantene, Pampers, Gillette, Braun, Fusion, Duracell, Bounty, Vicks and Oral-B,
among others. The companys products are offered in more than 180 countries through mass merchandisers, grocery stores,
membership club stores and drug stores and department stores, among others. It has operations across all the six continents in
the world. P&G is headquartered in Cincinnati, Ohio, the US.
Company Name
Teva
Pharmaceutical
Industries Limited


Page 107
GlobalData


Page 108
Teva Pharma Forms Joint Venture With Procter & Gamble

Teva Pharma Forms Joint Venture With Procter & Gamble
Deal Type
Deal Sub Type
Partnerships
Joint Venture
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, entered into an agreement with The Procter & Gamble
Company (P&G), a consumer goods company, to establish a new partnership and joint venture (JV) in consumer health care.
The joint venture, to be named PGT Healthcare, will be based in Geneva, Switzerland and will operate in markets outside of
North America. The joint venture will also develop new brands for the North American market.
PGT Healthcare will focus on the development and commercialization of branded OTC medicines. Teva will be responsible for
manufacturing, and also provides access to its portfolio, research and development capabilities and manufacturing of drugs and
health care products for both the joint venture markets and P&G's North American business. The JV will bring together each
companys complementary capabilities and existing over-the-counter (OTC) medicines. It is expected to accelerate growth for
its parent companies and compete for leadership in the consumer healthcare industry. It is expected to start with about $1.3
billion in annual sales with the potential to grow to $4 billion in annual sales towards the end of the decade.
P&G brings consumer understanding, branding, design, and in-store merchandising to Tevas brands, such as ratiopharm.
Teva brings into partnership its pharmacy distribution, including its pharmacy sales force and pharmacy relationships,
regulatory capabilities and new technologies to P&Gs brands, which include Vicks, Metamucil and Pepto-Bismol. The JV will
be led by a management team comprised of senior leaders from both companies, including CEO Briain de Buitleir from P&G,
and COO Eli Shani from Teva Pharmaceutical Industries. It will be governed by a supervisory board representing both parent
companies. Tom Finn, president of Global Health Care of P&G, will be chairman of this supervisory board.
In connection with the transaction, P&G transferred its over-the-counter (OTC) plants in Greensboro, North Carolina and
Phoenix, Arizona, and the employees of both plants to Teva. The plant at Greensboro produces Vicks brand, while Phoenix
plant produces Metamucil brand.
Shlomo Yanai, president and chief executive officer of Teva, said, This unique and transformational partnership creates one of
the broadest and deepest OTC product portfolios and geographic footprints in the industry. Each companys leading brands will
experience tremendous growth by combining our strengths. We will be better together.
Jones Day acted as a legal advisor to Procter & Gamble for the transaction. This agreement enables Teva to strengthen its
business with pharmacies by expanding its offerings. It allows Procter & Gamble to expand the market for its consumer-health
brands.
Deal history
Completed: On November 3, 2011, Teva Pharmaceutical Industries formed a joint venture with The Procter & Gamble
Company (P&G), to create a new company PGT Healthcare, for their consumer-health businesses outside North America.
Update: On October 3, 2011, Teva Pharmaceutical Industries received approval from European Union (EU) to form a joint
venture with The Procter & Gamble Company (P&G), for their consumer-health businesses outside North America.
Announced: On March 24, 2011, Teva Pharmaceutical Industries agreed to form a joint venture with The Procter & Gamble
Company (P&G), to combine their consumer-health businesses outside North America.
Deal Rationale
This agreement enables Teva to strengthen its business with pharmacies by expanding its offerings. It allows Procter & Gamble
to expand the market for its consumer-health brands.
Deal Information
Deal Status
Completed
Announced Date
24-Mar-2011
Completed Date
03-Nov-2011
Company Name
The Procter
Company
&
Gamble

Page 109
Company Name
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
The Procter
Company
Jones Day
&
Gamble
Executive
Peter Izanec
Levine
and
Andy
GlobalData


Page 110
Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery

Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery
Deal Type
Deal Sub Type
Partnerships
Co-Development
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, entered into an agreement with Cocrystal Discovery, Inc.
(CDI), a biotechnology company, for the development of novel antiviral therapeutics drugs that target viral replication
enzymes.Under the terms of the agreement, Teva Pharmaceutical will initially invest $7.5m in Cocrystal Discovery, and the
company will develop for Teva an antiviral drug targeting the polymerase enzyme of the Hepatitis C virus. Upon the completion
of the initial development plan, Teva will have the option to make additional investments under certain milestones. Teva will
have the right to exclusively license the drug for further development and commercialization. Teva also retains the option to
invest further in Cocrystal Discovery for the development of two additional antiviral or antibacterial drugs. For all such
investments, Teva will receive up to approximately 23% holdings in Cocrystal Discovery.Nobel Laureate Roger Kornberg, chief
scientist at Cocrystal Discovery and member of the board of directors of Teva, said, We are delighted with this investment from
Teva, a leading global company that develops important new medicines bringing value to patients. Through this agreement,
CDI is now ideally placed to accelerate the development of our novel platform, which combines high resolution X-ray
crystallography with unique and advanced computational methods. It is our hope we can yield new and better drugs for the
treatment and prevention of many viral diseases."Dr. Aharon Schwartz, head of Teva's Innovative Ventures, said, This new
partnership further illustrates Tevas commitment to develop innovative therapies. If successful, these novel technologies could
revolutionize the drug discovery process for antivirals, an area of a high unmet need. We believe this innovative technology
offers significant promise for pharmaceutical discovery in areas of strategic importance for Teva. The agreement enables
Cocrystal Discovery to accelerate the development of its novel platform, combining high resolution X-ray crystallography with
unique and advanced computational methods.
Deal Rationale
The agreement enables Cocrystal Discovery to accelerate the development of its novel platform, combining high resolution Xray crystallography with unique and advanced computational methods.
Deal Information
Deal Status
Completed
Completed Date
15-Sep-2011
Deal Financials
Deal Value (US$ m)
7.50
Deal Product
Product Description
Small Molecules to Inhibit

NS5B
Polymerase
for
Hepatitis C Virus Infection
<div><p>Small Molecules are under development for the treatment of hepatitis C virus
infections. The program comprises broad-spectrum antiviral therapeutics that are administered
orally once daily. The drug candidates are the small molecule inhibitor of NS5B
Polymerase.</p></div>
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Cocrystal Pharma, Inc.

Page 111
Cocrystal Pharma, Inc. (Cocrystal Pharma) is a clinical stage biopharmaceutical company. The company discovers and
develops new antiviral drugs. It develops and markets new therapeutic drugs for use in the treatment of acute and chronic viral
diseases. The company also develops new programs targeting hepatitis C virus (HCV), influenza, the human rhinovirus (HRV),
dengue, and norovirus disorder. Cocrystal Pharma is headquartered in Bothell, Washington, the US.
GlobalData


Page 112
ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa
ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa
Deal Type
Partnerships
Deal Sub Type
Co-Marketing
Deal in Brief
ERYtech Pharma, a specialty pharma company, entered into an exclusive distribution agreement with Teva Pharmaceutical
Industries, Ltd., a pharmaceutical company, for the registration, marketing, distribution and sale of Graspa in Israel.
Under the terms of the agreement, Teva will submit the drug for approval in Israel, market and distribute it in the territory for a
long term period. Teva will pay milestone payments in addition to sharing profit on the basis of purchase price agreed with
Teva.
Pierre-Olivier Goineau, chief executive officer of ERYTECH Pharma, said, This collaboration represents a significant milestone
as first distribution agreement and a major step in the worldwide product expansion. Thanks to its good efficacy and safety
profile, Graspa, will bring major therapeutic value for Israeli patients in ALL.
Graspa, a new enzyme formulation of L-asparaginase, is indicated for the treatment of acute lymphocytic leukemia (ALL).
Deal Information
Deal Status
Completed
Completed Date
17-May-2011
Deal Product
Product Description
asparaginase
Asparaginase (ERY-ASP, Graspa) is under development for the treatment of leukemia such as
acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), metastatic pancreatic
cancer, diffuse large B-cell leukemia and other solid tumors. Graspa consists of red blood cellencapsulated L-asparaginase (L-ASP). Graspa is a new enzyme formulation of Lasparaginase with a safer and broader range of clinical uses, compared to existing forms, due
to the entrapment and protection of the enzyme inside the homologous red blood cell. The
drug candidate is based on encapsulation technology. Encapsulation enables L-asparaginase
to destroy asparagine inside the red blood cell, preventing allergic reactions and reducing
other adverse events.
Company Name
Erytech Pharma SA
Erytech Pharma SA (Erytech Pharma) is a bio-pharmaceutical company. The company develops and provides innovative
cancer therapies for the healthcare market. Its ERY-ASP product, which is in phase III development, provides therapeutic
solution to frail patients with acute leukaemia. Erytech Pharma has developed ERY-ASP, an original and effective treatment
that targets leukemia cells through starvation. The company also conducts clinical trials with ERY-ASP in Acute Lymphoblastic
Leukaemia and Acute Myeloid Leukaemia. It markets its product under the brand name GRASPA. The company partners with
the Orphan Europe-Recordati company and the TEVA group. Erytech Pharma is headquartered in Lyon, Rhone Alpes, France.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 113
Champions Biotech Enters Into An Agreement With Cephalon

Champions Biotech Enters Into An Agreement With Cephalon
Deal Type
Deal Sub Type
Partnerships
Co-Development
Deal in Brief
Champions Biotechnology, Inc., a biotechnology company, entered into a technology collaboration with Cephalon, Inc., a
biopharmaceutical company, for low passage Tumorgraft.
Under the agreement, Champions will conduct low passage Tumorgraft studies on two proprietary chemical compounds, CEP32496, an inhibitor of mutant B-Raf, and CEP-37440, a selective dual ALK-FAK inhibitor, provided by Cephalon to determine
the activity or response in potential clinical indications. The results of these studies will be used to inform the future clinical
development path of these compounds. In return, Cephalon is entitled to pay Champions an initiation fee of $1.39m by April 15,
2011, and milestone payments of $27m. Cephalon is also entitled to pay royalties on any commercialized products developed
under the agreement.
Guy Malchi, Champion's head of corporate development, said, This is our largest translational oncology services contract to
date and provides us with a great foundation for strong revenue growth for our next fiscal year. We are very excited to be
partnering with an innovative company like Cephalon that can utilize our technology to improve the process of oncology drug
development. The potential for future milestone and royalty payments in these contracts will allow us to capture a portion of the
financial upside our technology generates for our customers. We hope this is just the beginning of a productive and long term
partnership between our companies.
Jeffry Vaught, Cephalon's executive vice president for R&D, said, Our collaboration with Champions Biotechnology
significantly compliments our oncology discovery capabilities by providing wider access to more clinically relevant and
predictive pre-clinical oncology models. In addition, Champions' technology platform will enable us to more effectively select the
subsets of specific human cancers most likely to respond to our novel targeted therapeutic agents and identify the underlying
cancer genotypes associated with drug sensitivity and resistance to chemotherapeutics.
Deal Rationale
This agreement enables Cephalon to compliment its oncology discovery capabilities by providing wider access to more
clinically relevant and predictive pre-clinical oncology models.
Deal Information
Deal Status
Completed
Completed Date
24-Mar-2011
Deal Financials
Deal Value (US$ m)
28.39
Deal Product
Product Description
RXDX-105
<p>RXDX-105 (CEP-32496) is under development for the treatment of advanced solid tumors
including cutaneous melanoma and relapsed/refractory metastatic colorectal cancer. The drug
candidate is administered orally. It is a small molecule which inhibits the BRAF kinase, EGFR
and RET.</p>
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Champions Oncology, Inc.


Page 114
Champions Oncology, Inc. (Champions), formerly known as Champions Biotechnology, Inc., is a biotechnology company. It
develops advanced technology solutions and services to personalize the development and use of oncology drugs. The
companys TumorGraft Platform is developed on the basis of implantation of primary human tumors in immune-deficient mice.
Champions uses TumorGraft platform for identifying different tumor cancers and their response to drugs to predict clinical
outcomes in cancer patients. . It provides a wide range of personalized oncology solutions (POS) to oncologists,
pharmaceutical and biotechnology companies. The company offers personalized TumorGraft development, drug studies and
genome sequencing as part of POS. It also offers translational oncology solutions for faster drug approval, helping the
technology to evaluate tumor sensitivity/resistance. Champions is headquartered in Hackensack, New Jersey, the US.
GlobalData


Page 115
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra

Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra
Deal Type
Partnerships
Deal Sub Type
Co-Development
Deal in Brief
Teva Pharmaceutical Industries Ltd., entered into an agreement with Alcobra Ltd., a pharmaceutical company, for the
development of a treatment for attention deficit disorder (ADD) based on an existing drug.
Under the agreement, Teva will provide the finance for the full development of Alcobra's product and will have the right to
acquire the company for at least several tens of millions of dollars. Teva will make an initial investment of a few million dollars
into the company.
The transaction is subject to approvals that Teva and Alcobra must obtain.
Deal Information
Deal Status
Completed
Completed Date
23-Feb-2011
Deal Product
Product Description
Metadoxine ER
<div><p>Metadoxine (MG01CI) extended release formulation is under development for the

treatment of pediatrics and the adults with attention deficit hyperactive disorder and Fragile X
Syndrome. The drug candidate is administered orally. Metadoxine(MG01CI) is a pyrrolidone
carboxylate of pyridoxine. It acts as 5-HT2B Antagonist. It was also under development for the
treatment of alcoholic addiction.</p></div>
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Alcobra Ltd
GlobalData


Page 116
Celator Pharma Extends Research Agreement With Cephalon

Celator Pharma Extends Research Agreement With Cephalon
Deal Type
Partnerships
Deal Sub Type
Co-Development
Deal in Brief
Celator Pharmaceuticals, Inc., extended its research agreement with Cephalon, Inc., a global biopharmaceutical company, for
focusing on the next phase of development.
Under the agreement, Cephalon will utilize Celator's proprietary technology in an ongoing drug development and life-cycle
management program.
Scott Jackson, chief executive officer, Celator Pharmaceuticals, said: It is rewarding to have a company of Cephalons stature
demonstrate the potential of our technology in its portfolio and make the ongoing financial commitment to continue this
research. We are pleased that our progress to date allows Cephalon and Celator to advance this promising work. It is
rewarding to have a company of Cephalons stature demonstrate the potential of our technology in its portfolio and make the
ongoing financial commitment to continue this research."
Earlier on May 21, 2009, Celator Pharmaceuticals entered into a research agreement with Cephalon, for exploration of the
application of Celator's proprietary technology to an ongoing drug development and life-cycle management program at
Cephalon.
CPX-351 is an investigational cancer therapy developed using Celator's CombiPlex drug-ratio technology.
This agreement will enable Cephalon to demonstrate the technology of Celator in its portfolio.
Deal Rationale
This agreement will enable Cephalon to demonstrate the technology of Celator in its portfolio.
Deal Information
Deal Status
Completed
Completed Date
10-Jan-2011
Deal Product
Product Description
(cytarabine hydrochloride +
daunorubicin hydrochloride)
<div>
<p>CPX-351 (cytarabine hydrochloride and daunorubicin hydrochloride) is under development
for the treatment of relapsed or refractory acute myeloid leukemia, acute lymphoblastic
leukemia, myelodysplastic syndrome and (ALL) and aggressive lymphoma. It is administered
intravenously. It is a liposomal formulation of a fixed combination of the antineoplastic drugs
cytarabine and daunorubicin in a 5:1 molar ratio. It is developed using combiPlex
technology.</p>
</div>
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Celator
Inc.
Pharmaceuticals,

Page 117
GlobalData


Page 118
Auspex Pharma Enters Into Co-Development Agreement With Teva Pharma Industries
Auspex Pharma Enters Into Co-Development Agreement With Teva Pharma Industries
Deal Type
Partnerships
Deal Sub Type
Co-Development
Deal in Brief
Auspex Pharmaceuticals, Inc., entered into an agreement with Teva Pharmaceutical Industries, Ltd., for the discovery and initial
development of a deuterium-containing drug.Dr. Pratik Shah, acting CEO of Auspex Pharmaceuticals and partner at Thomas
McNerney & Partners, said: It is a reflection of our efforts to provide access to novel deuterated drugs that address significant
market opportunities.Dr. Andreas Sommer, COO of Auspex Pharmaceuticals, said: Deuterium is a non-radioactive isotope of
hydrogen that has been demonstrated to generate new chemical entities with unique and beneficial properties. This agreement
demonstrates Auspexs ability to build on its strong intellectual property position across multiple therapeutic areas.This
agreement enables Auspex to provide access to novel deuterated drugs that address significant market opportunities.
Deal Rationale
This agreement enables Auspex to provide access to novel deuterated drugs that address significant market opportunities.
Deal Information
Deal Status
Completed
Completed Date
20-Dec-2010
Deal Product
Product Description
SD-254
SD-254 is under development for the treatment of neuropathic pain and was also under
development for major depressive disorder. SD-254 is a deuterium-substituted version of
venlafaxine. The drug candidate is developed based on deuteration technology. This
technology replaces metabolically-sensitive hydrogen atoms with its non-radioactive isotope
deuterium. SD-254 acts as a selective inhibitor of serotonin- norepinephrine reuptake (SNRI).
Company Name
Auspex
Inc.
Pharmaceuticals,
Parent
Teva
Pharmaceutical
Industries Limited
California, the US.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 119
Teva Pharma Enters Into Co-Development Agreement With MediWound And Polyheal
Teva Pharma Enters Into Co-Development Agreement With MediWound And Polyheal
Deal Type
Deal Sub Type
Partnerships
Co-Development
Deal in Brief
Teva Pharmaceutical Industries Ltd., entered into co-development agreement with MediWound Ltd., a specialty biotechnology
company, and Polyheal Ltd., a provider of wound healing products, to develop products for the treatment of burns and chronic
wounds.
Under the agreement, the partners will together develop, manufacture and market wound healing products. Polyheals wound
treatment technological capability and MediWound's technology, production, and managerial capabilities will be integrated with
Teva's global marketing platform for the development of products.
As part of agreement, Teva will invest $7 million in MediWound, and has a right to invest an additional $65 million, subject to
milestones related to progress in the development of Polyheal's products. Teva will acquire from MediWound shareholders $22
million of shares, upon receipt of authorization to market MediWound products in Europe and will gradually increase its stake in
MediWound to 51% upon achievement of certain milestones. Teva will also acquire from MediWound shareholders $64 million
of share upon receipt of authorization to market MediWound products in the US. Teva is liable to pay MediWound $145 million,
depending on sales and royalties for Polyheal products.
MediWound will use the investment to acquire Polyheal in stages and will initially buy $7 million of Polyheal shares. MediWound
will acquire all the remaining shares of Polyheal for $193 million upon achievement of certain milestones, and will make
additional payments based on the sale of Polyheal products.
Clal Biotechnology Industries Ltd. currently owns 55% and 41% stake in MediWound and Polyheal respectively. Upon
achievement of all the above milestones, Clal Biotechnology will hold 29% stake in MediWound, while Teva, which currently
hold 12% stake, will own 51% of MediWound share capital. Polyheal will operate as a subsidiary of MediWound.
Herzog, Fox & Neeman acted as legal advisor to Mediwound and Polyheal on this transaction.
Deal Information
Deal Status
Completed
Announced Date
24-Jun-2010
Completed Date
09-Nov-2010
Deal Financials
Deal Value (US$ m)
303
Company Name
MediWound Ltd.
MediWound Ltd. (MediWound) is a biotechnology niche specialty company. It develops, manufactures and commercializes
products in the unmet areas of burn and chronic wound management. The key product of the company is Nexobrid. The
companys product, NexoBrid is used for the removal of eschar in adults with deep partial and full-thickness thermal burns. .
The product is in the Phase III clinical study in the US. MediWounds other wound care pipeline products in development stages
are EscharEx and MWPC003. Its products have been investigated in phase 2 and phase 3 clinical studies, by more than 100
burn specialists, in over 550 patients from 15 countries around the world. MediWound is headquartered in Yavne, Israel.
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Polyheal Ltd.


Page 120
Polyheal Ltd. (Polyheal) is a medical device company. The company develops medical devices for the wound care
management. Its product Polyheal is a sterile liquid suspension used for the treatment of skin ulcers, burns, trauma and post
surgery wounds. Polyheals wound healing technology in the wound care market meets the need for therapeutic approaches in
the chronic wound management market. The company provides treatment for ulcus cruris (venous, arterial and mix), postoperative hard to heal and chronic wounds, post-traumatic hard to heal & chronic wounds, diabetic foot ulcers and pressureinduced ulcers. Polyheal is headquartered in Yavne, Israel.
Advisor Information
Legal Advisor
MediWound Ltd.
Herzog, Fox & Neeman
Polyheal Ltd.
Herzog, Fox & Neeman
GlobalData


Page 121
MicroDose Therapeutx Enters Into Co-Marketing Agreement With Nexus6

MicroDose Therapeutx Enters Into Co-Marketing Agreement With Nexus6
Deal Type
Partnerships
Deal Sub Type
Co-Marketing
Deal in Brief
MicroDose Therapeutx, Inc., entered into a non-exclusive worldwide agreement with Nexus6 Limited, a privately held developer
and manufacturer of solutions, to commercialize the SmartinhalerLive Technology with MicroDose's electronic dry powder
inhalers.
Under the agreement, MicroDose will be able to provide its next generation electronic dry powder inhaler (DPI) with Nexus6s
SmartinhalerLive technology built in. MicroDoses inhaler is able to wirelessly upload dosing and compliance information from
the inhaler to a web-based server for data management and reporting. The data collection and global roaming wireless
capability of SmartinhalerLiveTM complements MicroDoses electronic inhaler features thus facilitating better communication
between the physician, patient and pharmaceutical company to improve all aspects of care.
The combined system will have benefits in both the clinical trials setting and with in-market products, by improving compliance
through reminder features, and through real-time tracking of compliance, patient safety and clinical trial data management are
improved.
Michael J. Martin, MicroDoses VP of Business Development and Licensing, said: The combination of Nexus6 Technology and
MicroDoses dry powder inhaler will insure a continuous flow of 'real time' clinical information which will benefit physicians,
patients and pharmaceutical companies.
David Evans, CEO of Nexus6, said: This partnership between Nexus6 and MicroDose will enable the drug delivery
marketplace to access leading edge data collection and transmission capabilities, thereby increasing pharmaceutical
adherence, improving patient well-being and reducing overall health care costs.
This agreement enables Nexus6 to strengthen its drug delivery market by providing improved patient well-being services with
reduced costs.
Deal Rationale
This agreement enables Nexus6 to strengthen its drug delivery market by providing improved patient well-being services with
reduced costs.
Deal Information
Deal Status
Completed
Completed Date
09-Nov-2010
Company Name
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Nexus6 Limited
GlobalData


Page 122
Celator Pharma Expands Research Agreement With Cephalon

Celator Pharma Expands Research Agreement With Cephalon
Deal Type
Partnerships
Deal Sub Type
Co-Development
Deal in Brief
Celator Pharmaceuticals, Inc., a biopharmaceutical company, has expanded its research agreement with Cephalon, Inc., a
pharmaceutical company, for an ongoing drug development and life-cycle management program.
Under the expanded agreement, the partners will utilize Celator's proprietary technology in an ongoing drug development and
life-cycle management program at Cephalon.
Scott Jackson, chief executive officer of Celator Pharmaceuticals, said: "We are pleased that work with this research program
has led to its expansion and excited that a global biopharmaceutical company of Cephalon's stature is increasingly interested in
the potential of our technologies. Because our nano-scale delivery platforms have already been shown to improve the
pharmacokinetics and antitumor activity of several cancer therapies, we are eager to collaborate with companies like Cephalon
with growing oncology portfolios and an established commitment to improving treatment outcomes."
Earlier on May 21, 2009, Celator Pharmaceuticals has entered into a research agreement with Cephalon, Inc., for exploration of
the application of Celator's proprietary technology.
This agreement enables Cephlon to expand its pipeline compounds.
Deal Rationale
This agreement enables Cephlon to expand its pipeline compounds.
Deal Information
Deal Status
Completed
Completed Date
21-Jun-2010
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Celator
Inc.
Pharmaceuticals,
GlobalData


Page 123
Cancer Research Technology Enters Into Co-Development Agreement With Cephalon

Cancer Research Technology Enters Into Co-Development Agreement With Cephalon
Deal Type
Partnerships
Deal Sub Type
Co-Development
Deal in Brief
Cancer Research Technology Limited (CRT), a pharmaceutical company, entered into an exclusive agreement with Cephalon,
Inc., a biopharmaceutical company, for the development of small molecule inhibitors. Under the agreement, CRT is entitled to
receive significant upfront and milestone payments, and a double-digit royalty rate upon achievement of specific product sales
targets. These developed molecules will target specific members of the Protein Kinase C superfamily of cell signalling proteins which have been shown to be associated with the development of cancer. The partners focus on generating pre-clinical
candidate molecules for development by Cephalon into new drug therapies for cancer patients. Cephalon will contribute
substantial resources which will boost existing investment by Cancer Research UK, and allow quicker translation of potential
drugs that may benefit cancer patients. The research will take place at CRT's Discovery Laboratories in London and Cephalon's
research and development facility in West Chester, Pennsylvania. This collaboration enables CRT to progress its promising
lead compounds through to the selection of pre-clinical candidate molecules, to drive forward the development of potential
innovative cancer medicines.
Deal Rationale
This collaboration enables CRT to progress its promising lead compounds through to the selection of pre-clinical candidate
molecules, to drive forward the development of potential innovative cancer medicines.
Deal Information
Deal Status
Completed
Completed Date
19-Mar-2010
Deal Product
Product Description
RXDX-108
<p>RXDX-108 (TEV-44229) is under development for the treatment of cancer. The drug
candidate acts by targeting Protein Kinase (PKC iota).</p>
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Cancer
Research
Technology Limited
Parent
Cancer Research UK
Cancer Research Technology Limited (CRT), a subsidiary of Cancer Research UK is a cancer research organization that
develops and commercializes new discoveries for treatment in the areas of cancer. The organization offers services which
include project development, commercialization, drug discovery, clinical development, imaging and funding. It provides
commercialization services to Cancer Research UK and oncology institutes worldwide, and also operates drug discovery
laboratories. The organization collaborates with clinical and academic institutions, pharmaceutical companies and
biotechnology companies in the UK and worldwide. It operates in the US and the UK. CRT is headquartered in London, the UK.
GlobalData


Page 124
H. Lundbeck Expands Marketing Agreement With Teva Pharma Industries

H. Lundbeck Expands Marketing Agreement With Teva Pharma Industries
Deal Type
Partnerships
Deal Sub Type
Co-Marketing
Deal in Brief
H. Lundbeck A/S, a pharmaceutical company, has expanded its marketing agreement with Teva Pharmaceutical Industries Ltd.,
an international pharmaceutical company, for Parkinson's disease drug Azilect.
Under the agreement, Teva will market Azilect (rasagiline) in six Asian markets comprising China, South Korea, Hong Kong,
Malaysia, Thailand and the Philippines. Lundbeck will conduct clinical trials and prepare application filings required to gain a
marketing authorization in the individual countries. Teva is entitled to receive a share of net sales in the markets.
This agreement will enable Lundbeck to explore market potential of its lead product Azilect in six Asian countries.
Azilect (rasagiline) is a monoamine oxidase-B (MAO-B) inhibitor, used to treat the symptoms of Parkinson's disease.
Deal Rationale
This agreement will enable Lundbeck to explore market potential of its lead product Azilect in six Asian countries.
Deal Information
Deal Status
Completed
Completed Date
24-Feb-2010
Deal Product
Product Description
rasagiline mesylate
<div>
<p>Rasagiline mesylate (Azilect, TVP-1012) is an indanes derivative drug belongs to antiparkinson and central nervous system agent. It is formulated as tablets for oral route of
administration. It is indicated for the treatment of idiopathic Parkinson's disease (PD) as
monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of
dose fluctuations. The drug candidate is under development for the treatment of
Parkinson's disease in Japan and for amyotrophic lateral sclerosis.</p>
</div>
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
H. Lundbeck A/S
Parent
The Lundbeck Foundation
H. Lundbeck A/S (Lundbeck) is a pharmaceutical company, which is committed to enhance the quality of life of people suffering
from brain diseases. It carries out the research, development, manufacturing and marketing of pharmaceuticals for the
treatment of to the central nervous system (CNS) related diseases. Its products are targeted at diseases such as depression,
anxiety, psychotic diseases, alcohol dependence, epilepsy and Huntingtons disease, Alzheimers disease and Parkinsons
disease. Operating through subsidiaries, the company sells its products across the world. The company has production and
research facilities in China, Denmark, France, Italy and the US. Lundbeck is headquartered in Valby, Denmark.
GlobalData


Page 125
UCB Terminates Co-Marketing Agreement With Teva Pharma

UCB Terminates Co-Marketing Agreement With Teva Pharma
Deal Type
Partnerships
Deal Sub Type
Co-Marketing
Deal in Brief
UCB S.A., a biopharmaceutical company, terminated its co-marketing agreement with Teva Pharmaceutical Industries Limited,
a pharmaceutical company, for quitting the primary care market in the US. The termination will be effective from March 1, 2010.
Following the termination, UCB will no longer market Teva's ProAir HFA and will focus on accelerating its US transition to a
biopharmaceutical company related to immunology and neurology, while Teva will take over the control of its products.
Earlier on January 16, 2008, both the companies entered into partnership agreement for the co-commercialization and copromotion of Tevas respiratory medicines, ProAir HFA (albuterol sulfate) Inhalation Aerosol in US.
Deal Rationale
This agreement will enable UCB to accelerate its US transition to a biopharmaceutical company.
Deal Information
Deal Status
Terminated
Terminated Date
Jan 29, 2010
Company Name
UCB S.A.
UCB S.A. (UCB) is a leading global biopharmaceutical company that discovers and develops medicines and solutions to help
treat various diseases. It focuses mainly on products for the treatment of central nervous system and immunology related
conditions. The core products of the company include Vimpat (lacosamide), Neupro (rotigotine), Metadate CD (methylphenidate
HCl), Cimzia (certolizumab pegol), Xyzal (levocetirizine), Zyrtec (cetirizine, including Zyrtec-D/Cirrus), and Tussionex
(hydrocodone polistirex and chlorpheniramine polistirex). UCB operates in about 40 countries through a network of subsidiaries.
It has several research and development partnerships with companies such as AstraZeneca, Otsuka, Astellas, Biogen Idec and
Wilex, among others. UCB is headquartered in Brussels, Belgium.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 126
Celator Pharma Enters Into Research Agreement With Cephalon

Celator Pharma Enters Into Research Agreement With Cephalon
Deal Type
Partnerships
Deal Sub Type
Co-Development
Deal in Brief
Celator Pharmaceuticals, Inc., a biopharmaceutical company, entered into a research agreement with Cephalon, Inc., a
biopharmaceutical company. The agreement provides for exploration of the application of Celator's proprietary technology to an
ongoing drug development and life-cycle management program at Cephalon.
The agreement will enable Cephlon to expand its pipeline compounds.
Deal Rationale
The agreement will enable Cephlon to expand its pipeline compounds.
Deal Information
Deal Status
Completed
Completed Date
21-May-2009
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Celator
Inc.
Pharmaceuticals,
GlobalData


Page 127
Teva Pharma Industries Forms Joint Venture With Lonza Group

Teva Pharma Industries Forms Joint Venture With Lonza Group
Deal Type
Partnerships
Deal Sub Type
Joint Venture
Deal in Brief
Teva Pharmaceutical Industries Ltd., a global pharmaceutical company, has formed joint venture with Lonza Group AG, a
biotechnology company, to develop, manufacture and market a portfolio of biosimilars.
Under the joint venture, Teva and Lonza will cooperate to develop, manufacture and market affordable, efficacious and safe
generic equivalents of a selected portfolio of biologic pharmaceuticals.
Deal Rationale
The joint venture enables both the companies to strengthen its biologic capabilities.
Deal Information
Deal Status
Completed
Announced Date
20-Jan-2009
Completed Date
14-May-2009
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Lonza Group Ltd
Lonza Group Ltd (Lonza) is a biopharmaceutical company. It manufactures and develops chemical and biological active
pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell
therapies, drinking water sanitizers, vitamin B compounds, industrial preservatives, microbial control solutions and organic
personal care ingerdients. It also provides custom development and custom manufacturing services to its clients. Lonzas client
base ranges from professionals in the biotechnology, pharmaceutical, academic, and government research industries to
manufacturers of health and consumer products, distributors, formulators and service companies. The companys key markets
include bioresearch, nutrition, pharma and biotech, microbial control, agriculture, materials science and personal care
industries. It operates several manufacturing and research and development (R&D) facilities across the world. The company
has presence in Asia, Europe, Americas and other countries. Lonza is headquartered in Basel, Switzerland.
GlobalData


Page 128
Debiopharm Enters Into Distribution Agreement With Mepha Pharma

Debiopharm Enters Into Distribution Agreement With Mepha Pharma
Deal Type
Deal Sub Type
Partnerships
Co-Marketing
Deal in Brief
Debiopharm Group, a pharmaceutical company, entered into an exclusive distribution agreement with Mepha Pharma A.G., a
provider of pharmaceutical products, for Pamorelin LA.
Under the agreement, Mepha Pharma is responsible for the commercialization of Pamorelin LA 1-3- and 6-month formulations,
developed by Debiopharm, contains the active substance triptorelin pamoate, used for the treatment of prostate cancer,
endometriosis, and female infertility in Switzerland.
This agreement will enable Mepha Pharma to strengthen its drug-line.
Deal Rationale
This agreement will enable Mepha Pharma to strengthen its drug-line.
Deal Information
Deal Status
Completed
Completed Date
11-May-2009
Deal Product
Product Description
triptorelin pamoate PR
<p>Triptorelin Pamoate (Decapeptyl, Debio 8206) is an antineoplastic agent, formulated as

powder for suspension for intramuscular and subcutaneous administration. It is indicated for
the treatment of patients with locally advanced, non-metastatic prostate cancer, as an
alternative to surgical castration, treatment of metastatic prostate cancer, treatment of
endometriosis, treatment of uterine fibroids prior to surgery or when surgery is not appropriate.
Triptorelin pamoate is under development for the treatment of central precocious puberty and
premenopausal breast cancer.</p>
Company Name
Mepha Pharma AG
Parent
Cephalon, Inc.
Mepha Pharma AG (Mepha Pharma) is a pharmaceutical product manufacturer. The company manufactures and sells generic
pharmaceutical products. Its products include nach namen, nach therapiegebiet, nach wirkstoffen, nach originalnamen and
volltextsuche. Mepha Pharma offers products under various brands such as Aviral, Cet-Mepha, GastroPant, Mepha, Irfen Dolo
L, Lora-allergy Mepha, Mare Mepha, Mepha Tears, Olfen Patch, Pectoral Mepha, Rhagadil, Verrukill, Vitiron and Xylo-Mepha.
The company also provides biosimilars. Its products are used in the therapeutic areas of allergy, malaria, infectious diseases,
diabetes, gynecology, depression and central nervous system. It also sells non-branded generics. Mepha Pharma is
headquartered in Basel, Switzerland.
Company Name
Debiopharm
S.A.
International
Parent
Debiopharm Group
Debiopharm International S.A. (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that operates
as a drug development company. The companys products include Moapar, Eloxatin and Decapeptyl, among others.
Debiopharms pipeline products include Debio8206, Debio 8609, Sanvar, Tremelimumab, Debio 025, Debio 1143, Debio 0826,
and Debio 0932. The company offers services, such as early and preclinical development, clinical development, drug delivery
and formulation and manufacturing and quality assurance. It develops drugs in the therapeutic areas of oncology, immunology,
metabolism, infectious diseases. The company was formerly known as Debiopharm S.A. Debiopharm is headquartered in
Lausanne, Switzerland.
GlobalData


Page 129
Dynamix Pharma Enters Into Co-Development Agreement With Teva Pharma

Dynamix Pharma Enters Into Co-Development Agreement With Teva Pharma
Deal Type
Deal Sub Type
Partnerships
Co-Development
Deal in Brief
Dynamix Pharmaceuticals Ltd., entered into development and licensing agreement with Teva Pharmaceutical Industries
Limited, for the discovery and development of up to two Dynamix's drug candidates.Under the agreement, Dynamix is entitled
to receive milestones based on the achievement of certain discovery, development, regulatory and commercial milestones.
Dynamix will also receive tiered royalties on sales of developed products under collaboration, by Teva.Oren M. Becker,
president and CEO of Dynamix, said, We are very pleased to enter into this collaboration with Teva Pharmaceuticals, one of
the top 15 global pharmaceutical companies. This alliance is a strong vote of confidence by Teva, and will provide us with
access to significant capital to support our rapidly growing drug development pipeline.
Deal Rationale
This agreement enables Dynamix to support the growth of its drug development pipeline.
Deal Information
Deal Status
Completed
Completed Date
16-Feb-2009
Deal Product
Product Description
DNX-2000
DNX-2000 was under development for the treatment of multiple autoimmune disorders. DNX2000 is a type II kinase inhibitor for spleen tyrosine kinase (SYK). It is an intracellular tyrosine
kinase involved in receptor signaling and is activated during the course of inflammatory
autoimmune diseases. The drug candidate is based on company's proprietary DynamixFit
platform technology. DynamixFit is an in silico technology that extracts target-specific,
dynamic, induced fit information from multiple structures of protein-ligand complexes. It
identifies the dynamic parameters and motions that characterize a specific enzyme binding
site, deduces how the shape of the binding site adjusts in response to ligand binding, and
applies this information to drug discovery.
Company Name
Dynamix
Ltd.
Pharmaceuticals
Dynamix Pharmaceuticals (Dynamix Pharma) is a pharmaceutical company. The company discovers and develops small
molecule drugs for treating patients with cancer and autoimmune disorders. Its products under clinical development include
PKM2, SYK, JAK3, FAK/PYK2 and PLK1. Dynamix Pharmas JAK3 is an intracellular tyrosine kinase, which is involved in
cytokine and antibody receptor signaling. The companys FAK/PYK2 is a cytoplasmic protein tyrosine kinase that resides at the
sites of integrin clustering. It also develops type II kinase inhibitor for SYK and DNX-2000. The company partners with Teva
Pharmaceutical Industries Ltd. Dynamix Pharma is headquartered in Rehovot, Israel.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 130
Licensing Agreements
Teva Pharma Enters into Licensing Agreement with Eagle Pharma for EP-3102
Teva Pharma Enters into Licensing Agreement with Eagle Pharma for EP-3102
Deal Type
Licensing Agreement
Deal in Brief
Teva Pharmaceutical Industries Limited, a pharmaceutical company, through its wholly-owned subsidiary Cephalon, Inc., has
entered into a licensing agreement with Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, for EP-3102,
Eagles' bendamustine hydrochloride (HCl) rapid infusion product for the treatment of chronic lymphocytic leukemia (CLL) and
indolent B-cell non-Hodgkin lymphoma (NHL). Under the agreement, Teva will be responsible for all US commercial activities
for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting
post-approval clinical studies, if required, and initially supplying drug product to Teva. The partners will also settle the pending
patent infringement action between them in the US District Court for the District of Delaware involving Teva US Patent No.
8,791,270. Eagle will receive an upfront cash payment of USD30 million and is eligible to receive up to USD90 million in
additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming Food
and Drug Administration (FDA) approval. This agreement enables Teva Pharma to enhance treatment options for cancer
patients.
Deal Rationale
This agreement enables Teva Pharma to enhance treatment options for cancer patients.
Deal Information
Deal Status
Completed
Completed Date
17-Feb-2015
Deal Financials
30
120
30
Cash (US$ m)
Milestone Payment (US$ m)
90
Licensor Company Information
Licensor Name
Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. (Eagle Pharma) is a pharmaceutical company. It focuses on the development and
commercialization of injectable products. The companys product portfolio includes two approved products and six advanced
product candidates. Its pipeline products include Argatroban for
thrombosis; Ryanodex for exertional heatstroke;
Bendamustine RTD for chronic lymphocytic leukemia and non-Hodgkins lymphoma; Bivalirudin for percutaneous transluminal
angioplasty; and Pemetrexed for locally advanced or metastatic non-small cell lung cancer and mesothelioma. The company
filed New Drug Application (NDA) for Ryanodex for use in malignant hyperthermia. It markets its products through partners,
namely, The Medicines Company and Sandoz. The company develops its products especially for critical care and cancer
markets. Eagle Pharmaceuticals is headquartered in New Jersey, the US.
Licensee Company Information
Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 131
Cell Cure Neurosciences Terminates Licensing Option Agreement with Teva Pharma Industries for OpRegen
Cell Cure Neurosciences Terminates Licensing Option Agreement with Teva Pharma Industries for OpRegen
Deal Type
Licensing Agreement
Product Phase
Preclinical
Deal in Brief
Cell Cure Neurosciences Ltd., a biotechnology company and subsidiary of Hadasit Bio-Holdings Ltd., a biotechnology
company, has terminated an exclusive license option agreement with Teva Pharmaceutical Industries Ltd., a pharmaceutical
company, to develop and commercialize Cell Cure's OpRegen product for the treatment of age-related macular degeneration
(AMD). The agreement has terminated due to expiration of option period granted to Teva Pharma. OpRegen is a proprietary
formulation of embryonic stem cell-derived retinal pigment epithelial cells designed by Cell Cure to help save the sight of the
baby boomer generation, it is used for the treatment of age-related macular degeneration (AMD). Earlier, on October 10, 2010,
Cell Cure Neurosciences and Hadasit Bio-Holdings entered into an exclusive license option agreement with Teva Pharma, to
develop and commercialize Cell Cure's OpRegen product for the treatment of age-related macular degeneration (AMD). Under
the agreement, if Teva exercises its option to obtain an exclusive license to OpRegen, Teva will have responsibility for funding
clinical trials from that point on, obtaining regulatory approvals, and marketing the product. Cell Cure will be entitled to receive
milestone payments and royalties if certain development, regulatory, and commercial milestones are achieved. A portion of the
milestone payments and royalties received by Cell Cure would be shared with BioTimes subsidiary ES Cell International Pte
Ltd. (ESI), and with HBLs affiliate Hadasit Medical Research Services and Development Ltd., the technology transfer arm of
the Hadassah Medical Organization (HMO), which have licensed to Cell Cure certain patents and technology used in the
development of OpRegen. Cell Cure will receive an equity investment of USD7.1 million from BioTime, Teva Pharmaceutical
and Hadasit Bio-Holdings. Following BioTime's acquisition of ESI and its additional investment, Cell Cure will become the
neurological arm of BioTimes program for the development of human embryonic stem cell based therapies. As on, January 1,
2015, the option agreement between Cell Cure Neurosciences and Teva Pharma has extended by 30 additional days, such
that the total exercise period is 90 days, as of the date of the approval of the IND by the FDA. As on January 31, 2015, the
option agreement between Cell Cure Neurosciences and Teva Pharma was extended until February 15, 2015.
Deal Information
Deal Status
Terminated
Terminated Date
Feb 16, 2015
Deal Financials
7.10
Upfront Payment (US$ m)
7.10
7.10
Equity (US$ m)
Deal Product
Product Description
OpRegen
<div><p>OpRegen is under development for the treatment of dry age-related macular

degeneration (AMD). The drug candidate is administered as an injection into the sub-retinal
space. It is a suspension of retinal pigment epithelial (RPE) cells which are embryonic stem
cell-derived RPE cells.</p></div>
Licensor Name
Cell Cure Neurosciences,

Ltd.,Hadasit
Bio-Holdings
Ltd.
Parent
BioTime, Inc.
Neurosciences is headquartered in Jerusalem, Israel.$Hadasit Bio-Holdings Ltd. (Hadasit) is a biotechnology company. It
provides biotech financing, research and development, promoting and commercializing the intellectual property services in the
biotechnology field. The company funds the preparation and execution of phase I and preparation for phase II of the portfolio

Page 132
companies. Hadasits preparations include pre-clinical trials, manufacturing, regulatory and business development tasks. The
companys portfolio of companies includes ProtAb, Enlivex Therapeutics, Cell Cure, KAHR Medical, BioMarCare Technologies
and D-Pharm. It provides services in the field of oncology, regenerative medicine and inflammatory disease. Hadasit is a
subsidiary of Hadassah Medical Organization (HMO). Hadasit is headquartered in Jerusalem, Israel.
Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 133
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma

Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma
Deal Type
Licensing Agreement
Deal in Brief
Intellipharmaceutics International Inc., a pharmaceutical company, has entered into a licensing agreement with Teva
Pharmaceuticals USA, Inc., a manufacturer of specialty and generic pharmaceuticals, to market Intellipharmaceutics' extended
release oral drug product candidate in the US.Under the agreement, Teva Pharma obtained an exclusive licensing rights of
extended release oral drug product from Intellipharmaceutics. Intellipharmaceutics will manufacture and distribute the product
exclusively for Teva Pharma and Teva Pharma has agreed that Intellipharmaceutics will be its sole supplier of the product to be
marketed in the US.Intellipharmaceutics' extended release oral drug product candidate is an abbreviated new drug application
(ANDA) pending for US food and drug administration (FDA) approval. There can be no assurance as to when or if the product
will be approved by the FDA or that, if so approved, it will be successfully commercialized and produce significant revenue for
the company.This agreement will enable Teva Pharma and Intellipharmaceutics to commercialize extended release oral drug
product candidate in the US. The agreement is subject to certain closing conditions.
Deal Rationale
This agreement will enable Teva Pharma and Intellipharmaceutics to commercialize extended release oral drug product
candidate in the US.
Deal Information
Deal Status
Completed
Completed Date
02-Feb-2015
Licensor Name
Intellipharmaceutics
International Inc.
Intellipharmaceutics International Inc. (Intellipharmaceutics) is a pharmaceutical company. The company holds expertise in
research, development and manufacture of novel and generic targeted-release and controlled-release oral solid dosage drugs.
Its product portfolio includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix,
Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR and Generic Pristiq.
Intellipharmaceutics offers products in the areas of neurology, gastrointestinal tract, cardiovascular, diabetes and pain. The
companys technology portfolio includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliShuttle,
and IntelliPellets among others. It has partnership with Par Pharmaceutical, Inc. The company was formerly known as
Intellipharmaceutics Ltd. Intellipharmaceutics is headquartered in Toronto, Ontario, Canada.
Licensee Name

Inc.
Parent
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 134
Andromeda Terminates Licensing Agreement With Teva Pharma For DiaPep277 Rights
Andromeda Terminates Licensing Agreement With Teva Pharma For DiaPep277 Rights
Deal Type
Licensing Agreement
Product Phase
Phase III
Deal in Brief
Andromeda Biotech Ltd., a developer of treatment for autoimmune diabetes and subsidiary of Clal Biotechnology Industries
Ltd., terminated its licensing agreement with Teva Pharmaceutical Industries Ltd., a pharmaceutical company, for DiaPep277.
Following the termination, Andromeda receives rights for DiaPep277 and continue the development program of DiaPep277,
currently in a confirmatory Phase III study, according to plan without delays to gain regulatory approval. In conjunction with the
termination, Teva transfers all of its shares in Andromeda to Andromeda. Teva will receive approximately USD72 million for
product rights and shares transfer, payable in installments through future payments based on Andromeda's revenues or on
proceeds payable to its shareholders.Earlier, on November 28, 2007, Andromeda Biotech entered into a co-development
agreement with Teva, to develop and commercialize DiaPep277, a drug targeted for the treatment of type 1 diabetes. Under the
agreement, Teva and other investors agreed to invest in Andromeda and finance the development cost of DiaPep277. In return,
Teva will receive worldwide exclusive rights to manufacture, sell and distribute the drug. Teva and other investors will have the
option to invest USD17.5 million in Andromeda within 60 days of submission of an interim report from the phase III clinical study
of the drug. Subsequently, after the completion of the phase III clinical study, Teva and other investors have an option to invest
additional USD17.5 million in Andromeda. In addition, Andromeda has an option to receive additional USD15 million
investments from Teva and is entitled to receive royalty payment on net sales and additional royalties on accumulated sales of
the product. On February 4, 2008, Teva received an option to invest USD10 million in Andromeda, within two months of an
interim clinical trial results report, expected during the first half of 2008. Institutional investors will invest an additional USD7.5
million in the company. The investments will be made at a company value of USD90 million for Andromeda, before money.
Later, Teva will provide Andromeda with a USD3.5 million owners' loan, which the company will use to repay in full a loan
provided by CBI. After the final report on the Phase III trial, Teva also has an additional option to invest a further USD10 million
in Andromeda and the institutional investors an additional USD7.5 million, at a company value of USD170 million, before
money. Andromeda's shareholders also have two put options to sell their stakes to Teva for USD96 million, provided that
Andromeda's product obtains marketing permits in Europe and the US, at a derived company value of USD480 million for the
first option and USD555 million for the second. On August 25, 2008, Teva Pharmaceutical Industries exercised its option to
invest USD3 million in its development program for Type I diabetes, under an agreement with Andromeda. The remaining
USD7 million was received in the fourth quarter of 2008, after Andromeda provided interim data from the Phase III trial of its
DiaPep277 product candidate for Type I diabetes. A second Phase III trial is scheduled to start in the second half of 2009 and
will be conducted in the US and in Europe.On June 22, 2009, Teva entered into licensing agreement with Andromeda upon
exercise of an option, for Andromedas DiaPep27. Under which, Teva received exclusive worldwide marketing and
commercialization rights to DiaPep277.On June 17, 2010, Teva decided to exercise its option to invest in Andromeda, at a
company per-money valuation of USD170 million. Teva and Clal Biotechnology are making a combined USD17.5 million
investment in Andromeda Biotech. Teva invested USD11.9 million and Clal, which founded Andromeda back in 2007, is putting
another USD5.6 million into its portfolio company. This investment will be utilized by Andromeda to perform DIA-AID 2, a
confirmatory Phase III clinical study using DiaPep277 for the treatment of newly diagnosed Type 1 Diabetes
patients.DiaPep277 is a peptide of 24 amino acids derived from the sequence of the human heat shock protein 60 (Hsp60),
was invented by Prof. Irun Cohen and his team at the Weizmann Institute of Science. The peptide acts by modulating the
immune system, thus preventing the destruction of pancreatic cells that secrete insulin and preserving their natural
function.Deal History:Update: On September 8, 2014, Hyperion Therapeutics agreed to end the development of DiaPep277 for
newly diagnosed type 1 diabetes, following a serious misconduct by the employees of Andromeda Biotech.Update: On June
12, 2014, Hyperion Therapeutics, Inc. has completed the acquisition of Andromeda Biotech.Terminated: On February 24, 2014,
Andromeda Biotech terminated its licensing agreement with Teva Pharmaceutical Industries, for DiaPep277.Licensing
Agreement: On June 22, 2009, Teva entered into licensing agreement with Andromeda upon exercise of an option, for
Andromedas DiaPep27. Under which, Teva received exclusive worldwide marketing and commercialization rights to
DiaPep277.Co-Development Agreement: On November 28, 2007, Andromeda Biotech entered into a co-development
agreement with Teva, to develop and commercialize DiaPep277, a drug targeted for the treatment of type 1 diabetes. In return,
Teva will receive worldwide exclusive rights to manufacture, sell and distribute the drug. Teva and other investors will have the
option to invest USD17.5 million in Andromeda.
Deal Information
Deal Status
Terminated
Terminated Date
Feb 24, 2014


Page 135
Deal Product
Product Description
DiaPep-277
<div><p>DiaPep277 is under development for the treatment of type I diabetes (T1D). The drug
candidate is administered as subcutaneous injection. It is a synthetic peptide of 24 amino
acids derived from the sequence of the human heat shock protein 60 (Hsp60). It targets TollLike Receptor 2 (TLR-2) which plays a fundamental role in pathogen recognition and activation
of innate immunity. It was also under development for the treatment of and latent autoimmune
diabetes of adulthood (LADA)/type 1.5 diabetes</p></div>
Licensor Name
Andromeda Biotech Ltd.
Parent
Hyperion Therapeutics, Inc.
Andromeda Biotech Ltd. (Andromeda Biotech) is a biotechnology company. The company develops therapies for autoimmune
diabetes. Its products include DiaPep277, a synthetic peptide 24 amino acids. The companys DiaPep277 is derived from
Hsp60 antigens. Andromeda Biotechs product, DiaPep277, used in the treatment of type-one diabetes and has medical
benefits, such as prevention of disease deterioration, improved glycemic control, reduction of daily insulin dose requirements,
and reduction in diabetic complications. The companys product was invented at the Weizmann Institute of Science and is fully
licensed to Andromeda by the Yeda Research & Development Company. It is owned by Clal Biotechnology Industries and Teva
Pharmaceutical Industries. Andromeda Biotech is headquartered in Yavne, Israel.
Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 136
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate
Deal Type
Licensing Agreement
Product Phase
Marketed
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, entered into a licensing agreement with Takeda
Pharmaceutical Company Limited, a manufacturer of ethical drugs and consumer healthcare, for glatiramer acetate formulation
for the treatment of multiple sclerosis.
Under the agreement, Takeda will receive commercialization rights for glatiramer acetate in Japan, and will submit a new drug
application (NDA) for registration of the drug in Japan. The two companies are currently working on further agreements in
connection with the implementation of this license. Takeda will submit a New Drug Application (NDA) for registration of
glatiramer acetate in Japan.
This agreement enables Teva and Takeda to provide a new treatment option to patients with multiple sclerosis in Japan.
Glatiramer acetate for injection is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple
sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple
sclerosis. It is considered standard treatment for relapsing-remitting multiple sclerosis, and is now approved in 55 countries
worldwide, including the US, Russia, Canada, Mexico, Australia, Israel, and all European countries, and is marketed under the
brand name COPAXONE. Tevas glatiramer acetate is designated as an orphan drug in Japan, and currently is under
development as an Unapproved New Drug by Teva Pharmaceutical K.K., a subsidiary of Teva, at the request of the Japanese
Ministry of Health, Labour and Welfare.
Deal Rationale
This agreement enables Teva and Takeda to provide a new treatment option to patients with multiple sclerosis in Japan.
Deal Information
Deal Status
Completed
Completed Date
04-Dec-2013
Deal Product
Product Description
glatiramer acetate
<div><p>Glatiramer acetate (Copaxone) is a combination of four amino acids (proteins) with

acetate salts of synthetic polypeptides, acts as immunostimulant agent. It is formulated as
injection, solution or powder for solution for subcutaneous route of administration. It is
indicated for the treatment to reduce the frequency of relapses in patients with RelapsingRemitting Multiple Sclerosis (RRMS). Copaxone is under development for relapse prevention
of multiple sclerosis and Rett syndrome. It was also under development for the treatment of
amyotrophic lateral sclerosis (ALS), Crohn's disease and acute optic neuritis.</p></div>
Licensor Name
Teva
Pharmaceutical
Industries Limited
Licensee Name
Takeda
Pharmaceutical
Company Limited


Page 137
Takeda Pharmaceutical Company Limited (Takeda) is a research-based global pharmaceutical company. It focuses on the
research & development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and
consumer health care products. The company manufactures and markets photographic chemicals, inorganic chemicals, vitamin
bulks, test reagents and clinical diagnostics. Takeda markets its ethical drugs worldwide through its subsidiaries in North
America, Europe and Asia. It operates production facilities in Osaka, Hikari, Italy, Ireland, China and Indonesia. The company
also manages research and development facilities in Palo Alto, San Diego, San Francisco, Deerfield, Osaka, Tsukuba, London,
Cambridge and Singapore. Takeda is the largest pharmaceutical company in Japan and is headquartered in Chuo-ku, Osaka,
Japan.
GlobalData


Page 138
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo
Deal Type
Licensing Agreement
Product Phase
Marketed
Deal in Brief
QRxPharma Limited, a specialty pharmaceutical company, entered into a licensing agreement with Abic Marketing Limited,
Israeli domestic subsidiary of Teva Pharmaceutical Industries Limited, a global pharmaceutical company, for the
commercialization rights to immediate release Moxduo in Israel.
Under the agreement, Teva Pharma will receive the exclusive rights to commercialize immediate release Moxduo in Israel.
Teva Pharma will assume responsibility for all regulatory and product launch costs as well as ongoing marketing and sales
efforts. QRxPharma will receive an undisclosed upfront payment, regulatory and sales milestones, and double-digit royalties on
the sales of immediate release Moxduo in Israel. QRxPharma retains all rights to the intravenous and controlled release
formulations of Moxduo in the territory. QRxPharma will work with Teva Pharma to submit a marketing authorization application
to the Israeli health authority following approval of immediate release Moxduo in the US or Europe.
This agreement enables QrxPharma and Abic Marketing to provide immediate release Moxduo in Israel.
John Holaday, managing director and CEO of QrxPharma, said, We are pleased to announce our strategic collaboration with
Teva, the leading pharmaceutical marketing company in Israel and one of the largest in the world. The company's reputation,
dedicated pain sales team and long-standing relationships with Israeli key opinion leaders will be an asset to the launch of
Moxduo in this market. Teva's interest in Moxduo, together with that of Actavis, Paladin and Aspen, validate the need for safer
opioids in the treatment of moderate to severe pain, and further endorse the commercial value of Moxduo. We are delighted to
be working with such successful companies for the global commercialization of immediate release Moxduo."
Deal Rationale
This agreement enables QrxPharma and Abic Marketing to provide immediate release Moxduo in Israel.
Deal Information
Deal Status
Completed
Completed Date
27-Nov-2013
Deal Product
Product Description
(morphine
oxycodone
CR
sulphate
+
hydrochloride)
<p>MoxDuo CR (Q8011 CR) was under development for the treatment of moderate to severe
chronic pain, including cancer pain, lower back pain, osteoarthritis pain and neuropathic pain.
The drug candidate is administered orally. MoxDuo CR comprises of 3:2 ratio of morphine and
oxycodone. It reduces the number of opioid doses necessary per day for pain control and
minimise the side effects. Oxycodone is a weak agonist of mu, kappa, and delta opioid
receptors and morphine modulates the opioid mu-receptor. Morphine binds to and activates
specific opiate receptors (delta, mu and kappa), each of which are involved in controlling
different brain functions. It is developed utilizing the Dual-Opioid technology. MoxDuo CR
formulation also encompasses both sustained delivery technology as well as abuse deterrent
and tamper resistant features and is designed to provide at least 12 hours of analgesia in
patients.</p>
Licensor Name
QRxPharma Limited
QRxPharma Limited (QRxPharma) is a pharmaceutical company. It develops and commercializes treatments for pain
management and abuse prevention products. The companys product portfolio includes late and early stage clinical drug
candidates. It utilizes Dual Opioid platform technology that reduces opioid related side effects, to develop its drug candidates.
QRxPharmas dual opioid product portfolio includes Moxduo IR (Q8003), an immediate release oral capsule for the treatment of
acute management of moderate to severe pain; Moxduo IV (Q8012), an intravenous formulation for moderate to severe
hospital-based pain; and Moxduo CR (Q8011), a controlled release oral tablet being developed in Phase II clinical trial for the
treatment of chronic pain. Its Moxduo CR has completed Phase I clinical trial while Moxduo IR New Drug Application has been
filed. The company has developed an abuse deterrent technology called Stealth Beadlets that is developed for controlled
release Moxduo formulation. It has operations in the US and Australia. QRxPharma is headquartered in North Sydney, New

Page 139
South Wales, Australia.

Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 140
Rexahn Pharma Terminates Licensing Agreement With Teva Pharma For RX-3117
Rexahn Pharma Terminates Licensing Agreement With Teva Pharma For RX-3117
Deal Type
Licensing Agreement
Product Phase
Phase I
Deal in Brief
Rexahn Pharmaceuticals, Inc. terminated its licensing agreement with Teva Pharmaceutical Industries Ltd. As a result, Rexahn
will retain all the global development and commercialization rights to RX-3117.
Earlier on November 28, 2012, Rexahn entered into an option agreement Teva Pharmaceutical for the development of RX3117.
Under the terms of the amended agreement, Teva Pharmaceutical intended to pay additional US$0.93m research funding for
the development of RX-3117. Teva Pharmaceutical will receive the right to file IND for RX-3117 with the FDA. RX-3117 is a
nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis. It is useful for
treatment of solid tumors.
Earlier in 2009, Rexahn Pharmaceuticals entered into a licensing agreement with Teva Pharmaceutical Industries, for the
development and commercialization of RX-3117.
Peter D. Suzdak, CEO of Rexahn, said, Rexahn looks forward to advancing the clinical development of RX-3117. RX-3117 has
already demonstrated safety and oral bioavailability in cancer patients, and has the potential to treat a wide variety of solid
cancer tumors. We will explore potential partnering opportunities with oncology focused pharmaceutical companies for this
compound, as we continue to make progress in the clinical development of RX-3117."
Deal Rationale
This agreement enables Rexahn Pharmaceuticals to continue the development of RX-3117.
Deal Information
Deal Status
Terminated
Terminated Date
Aug 28, 2013
Deal Financials
Deal Value (US$ m)
0.93
Deal Product
Product Description
RX-3117
<p>RX-3117 is under development for the treatment of solid tumors including colorectal
cancer, non-small cell lung cancer, small cell lung cancer, colon cancer, pancreatic cancer,
renal cell carcinoma, ovarian cancer and cervical cancer. The drug candidate is administered
orally. RX-3117 is a small molecule, nucleoside compound that inhibits DNA methyltransferase
1.</p>
Licensor Name
Rexahn
Inc.
Pharmaceuticals,
Rexahn Pharmaceuticals, Inc. (Rexahn Pharmaceuticals) is a clinical stage biopharmaceutical company. The company
develops, manufactures and supplies therapeutics for the treatment of cancer. Its pipeline product portfolio spans indications
such as small molecule that blocks tumor progression and metastasis for melanoma; cancer cell specific nucleoside that
inhibits DNA and RNA synthesis and induces apoptotic cell death; and an anti-cancer drug candidate that inhibits the activated
form of the cancer cell signaling protein phosphorylated-Akt1. Rexahn Pharmaceuticals products are used in the treatment of
cancers of the ovary, kidney and pancreas. The company markets products under brand names, such as Archexin and
Supinoxin. Rexahn Pharmaceuticals is headquartered in Rockville, Maryland, the US..
Licensee Name
Teva
Pharmaceutical
Industries Limited

Page 141
GlobalData


Page 142
Labrys Biologics Enters Into Licensing Agreement With Pfizer For RN-307
Labrys Biologics Enters Into Licensing Agreement With Pfizer For RN-307
Deal Type
Licensing Agreement
Product Phase
Phase II
Deal in Brief
Labrys Biologics, Inc., a development stage biotechnology company, entered into a licensing agreement with Pfizer Inc. for RN307, a Phase II ready anti-calcitonin gene-related peptide (CGRP) humanized monoclonal antibody for the treatment of chronic
migraine. Under the agreement, Pfizer granted worldwide rights of RN-307 to Labrys. Pfizer received an upfront payment and
will be eligible to receive milestone payments, royalties on any sales, and a liquidity payment if Labrys is acquired. As part of
the agreement, Labrys expects to initiate Phase II clinical trials on RN-307 in 2013.
RN-307 is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a validated target in migraines. RN-307
has successfully completed phase I trials in more than 74 patients. RN-307 was originally discovered and developed by Rinat
Pharmaceuticals, which was acquired by Pfizer in 2006.
Corey Goodman, chairman of Labrys, said, RN-307 is an ideal candidate for a prophylactic drug for chronic migraine that is
capable of reducing both frequency and severity of migraines without debilitating side effects. There is significant interest in
new treatments that can improve upon the limited efficacy of current pharmaceuticals.
Jaume Pons, chief scientific officer of Pfizer's Rinat Research Unit, said, RN-307 is an example of Pfizer's leading expertise in
designing optimized biologics, and we are pleased that the capable team at Labrys will continue to pursue the development of
this potential candidate for patients with migraines.
Steven P. James, CEO of Labrys, said, Labrys is off to a terrific start with a promising drug candidate and a strong financial
position. We have a defined regulatory path in chronic migraine, a broad market opportunity with significant demand for better
treatments, and a top syndicate of venture investors that will bring tremendous strategic value to the company.
Deal Rationale
This agreement enables Labrys Biologics to conduct Phase II clinical trials on RN-307, used for treating chronic migraine.
Deal Information
Deal Status
Completed
Completed Date
03-Jan-2013
Deal Product
Product Description
TEV-48125
Licensor Name
Pfizer Inc.
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. It focuses on the discovery, development,
manufacture and marketing of healthcare products such as medicines, vaccines and consumer health care products. The
companys product offerings are targeted against a wide range of therapeutic areas including respiratory, cardiovascular,
metabolic, infection, inflammation, oncology, ophthalmology, neuroscience, pain, tissue repair, gastrointestinal, womens health,
orphan diseases and genitourinary among others. The companys research and development activities focus on developing
small molecules, biologics and vaccines. The company operates through a network of subsidiaries and affiliates located across
the world. Pfizer is headquartered in New York, the US.
Licensee Name
Parent
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 143
Teva Pharma Terminates Licensing Agreement With Proteologics

Teva Pharma Terminates Licensing Agreement With Proteologics
Deal Type
Licensing Agreement
Deal in Brief
Teva Pharmaceutical Industries Ltd. terminated its licensing agreement with Proteologics, Ltd., a drug discovery company, to
develop several molecules for cancer treatment. The termination is part of Teva's new strategic plan. Following the termination,
Proteologics will have the right to continue development and commercialization of the molecules as part of its research plans
independently. Proteologics focuses primarily on discovering inhibitors for specific E3 ubiquitin ligases for targeted therapies for
cancer and inflammatory diseases.
Earlier in March 2005, Teva and Proteologics entered into an agreement to develop two of the three licensed discovery
programs based on the ubiquitin system components. In September 2008, Teva granted licenses for three drug discovery
programs to Proteologics, to discover and conduct early development of cancer treatments.
Joshua Levine, CEO of Proteologics, said, We thank Teva for its early-stage investment in Proteologics, and for its contribution
over the years to the development and progress of our innovative molecules for the treatment of cancer and inflammatory
diseases. In view of Teva's strategic change, we concluded with its management to terminate our collaboration in these
projects. We believe that we can use our know-how to continue development of these products for the relevant indications, and
that we will find new partners to continue the development of promising molecules by signing agreements with leading
international pharmaceutical companies. We believe that any agreement that we sign for the further development of the
molecules will create value for the company's shareholders.
Deal Information
Deal Status
Terminated
Terminated Date
Dec 27, 2012
Licensor Name
Teva
Pharmaceutical
Industries Limited
Licensee Name
Proteologics Ltd.
Parent
Proteologics, Inc.
Proteologics Ltd. (Proteologics) is a biopharmaceutical company. The company exploits the UBIQUITIN system for the
discovery and development of novel therapeutics. It also discovers inhibitors for specific E3 ubiquitin ligases (E3). Proteologics
enzymes regulate protein breakdown and a variety of cellular processes. The company offers novel drug targets for many types
of cancer, metabolic disease, viral infections and CNS related disorders. Its technologies include the ubiquitin system, target
discovery and validation, assay development, drug discovery and drug development. The company partners with Glaxo Smith
Kline (GSK) and Teva Pharmaceutical Industries Ltd. Proteologics are headquartered in Rehovot, Israel.
GlobalData


Page 144
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402
Deal Type
Licensing Agreement
Product Phase
Phase II
Deal in Brief
Teva Pharmaceutical Industries, Ltd. entered into a development and exclusive worldwide licensing agreement with Xenon
Pharmaceuticals Inc., a clinical genetics based drug discovery and development company, for Xenon's pain drug XEN402.
Under the terms of the agreement, Teva Pharmaceuticals received an exclusive license for XEN402. Xenon is entitled to
receive an upfront fee of $41m, along with royalties payable on sales and an option to participate in commercialization in the
US. Xenon is also eligible to receive development, regulatory, and sales-based milestones totaling up to $335m.
XEN402 is currently in clinical development for a variety of painful disorders. This product specifically targets sodium channels
which are abundantly found in sensory nerve endings that can increase in chronic painful conditions. XEN402 was studied in a
Phase II trial to evaluate for effectiveness in alleviating the pain of post herpetic neuralgia.
Jeremy Levin, CEO of Teva Pharmaceutical, said, "Teva is building a focused pipeline of novel medicines in select areas of
medical need. XEN402 fits this strategy. It holds the potential to address the significant unmet medical need for the many
patients who suffer from chronic pain. In addition, XEN402 has the potential for broader therapeutic use across other pain
conditions."
Simon Pimstone, CEO of Xenon, said, We are delighted to be collaborating with Teva. Teva is among the world's leading
pharmaceutical companies and is building a significant global presence in innovative drug development and commercialization.
This partnership with Teva is Xenon's seventh major pharmaceutical alliance, once again highlighting the value of Xenon's
unique genetics approach and translational R&D capabilities."
Deal Rationale
This agreement enables Teva Pharma to address the unmet medical needs of patients suffering from chronic pain.
Deal Information
Deal Status
Completed
Completed Date
11-Dec-2012
Deal Financials
Deal Value (US$ m)
376
41
41
Cash (US$ m)
335
Deal Product
Product Description
TV-45070
<p>TV-45070 (XEN-402) is under development for the treatment of post herpetic neuralgia
(PHN), pain associated with primary/inherited erythromelalgia, osteoarthritis of the knee and
dental pain. The drug candidate is administered by oral and topical routes. The drug candidate
targets the Nav1.7 and Nav1.8 sodium channels. This target is highly expressed in sensory
nerve endings and its expression has been shown to be up-regulated in chronic painful
conditions such as PHN.</p>
Licensor Name
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company. The company discovers and develops a pipeline of
differentiated therapeutics for orphan indications. Its pipeline products include Glybera, TV-45070, TV-45070, Na 1.7 inhibitor,
sodium channel inhibitor, SCD1 inhibitor and others. Xenon through its core platform, Extreme Genetic, discovers various
validated drug targets through the study of rare human diseases with extreme traits, including channelopathies , diseases
caused by mutations in ion channels. Its platform comprises full complement of in-house capabilities for human genetics, small
molecule drug discovery, and for pre-clinical and clinical development. It has partnered with Genentech, TEVA, MERCK and


Page 145
uniQure, to offer a broader and more diverse pipeline. Xenon is headquartered in Burnaby, Canada.
Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 146
Teva Pharma Terminates Licensing Agreement With MediWound For NexoBrid

Teva Pharma Terminates Licensing Agreement With MediWound For NexoBrid
Deal Type
Licensing Agreement
Product Phase
Marketed
Deal in Brief
Teva Pharmaceutical Industries Ltd. terminated its licensing agreement with MediWound Ltd., a manufacturer of gel for the
treatment of burns and subsidiary of Clal Biotechnology Industries Ltd., related to commercialization of NexoBrid (formerly
Debrase), following Teva's decision to focus on certain areas of development. The termination will be effective from December
31, 2012.
Following the termination, Teva will ensure the transition of operations currently pursued by the company to MediWound's care.
Earlier in June 2007, Teva entered into a licensing agreement with MediWound to commercialize Debrase. Under the
agreement, MediWound granted exclusive rights to Teva to commercialize Debrase in certain countries. Teva and MediWound
were jointly developed the product. In September 2012, MediWound obtained marketing approval from the European Medicines
Agency (EMA) for NexoBrid for the treatment of third degree burns. NexoBrid, a gel made of enzymes extracted from the stem
of pineapple plants to remove eshar (necrotic burned tissue), is smeared on the burn area four hours after it occurred.
Ruben Krupick, CEO of Clal Biotech, said, MedWound thanks Teva for its contribution in developing its innovative products
NexoBrid and PolyHeal.
Deal Information
Deal Status
Terminated
Terminated Date
Dec 10, 2012
Deal Product
Product Description
Debrase
Debrase/ Nexobrid (proteolytic enzymes enriched in bromelain) belong to the class of

proteolytic enzymes. These proteolytic enzymes are a mixture of enzymes from the stem of
Ananas comosus (pineapple plant) which is indicated for removal of eschar in adults with
deep partial- and full-thickness thermal burns which is formulated in the form of powder and
gel, applied topically. Concentrate of proteolytic enzymes enriched in bromelain is a debriding
agent. The major constituent is stem bromelain and the mixture of enzymes in NexoBrid
dissolves burn wound eschar. The specific components responsible for this effect have not
been identified. The usual availbale doses are 2 g and 5 g. Debrase was under investigationin
phase III trails for the treatment of burns in U.S
Licensor Name
MediWound Ltd.
MediWound Ltd. (MediWound) is a biotechnology niche specialty company. It develops, manufactures and commercializes
products in the unmet areas of burn and chronic wound management. The key product of the company is Nexobrid. The
companys product, NexoBrid is used for the removal of eschar in adults with deep partial and full-thickness thermal burns. .
The product is in the Phase III clinical study in the US. MediWounds other wound care pipeline products in development stages
are EscharEx and MWPC003. Its products have been investigated in phase 2 and phase 3 clinical studies, by more than 100
burn specialists, in over 550 patients from 15 countries around the world. MediWound is headquartered in Yavne, Israel.
Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 147
Hospira Terminates Licensing Agreement With Ivax International For Omacetaxine Mepesuccinate
Hospira Terminates Licensing Agreement With Ivax International For Omacetaxine Mepesuccinate
Deal Type
Licensing Agreement
Product Phase
Phase III
Deal in Brief
Hospira, Inc., a specialty pharmaceutical and medication delivery company, terminated its licensing agreement with Ivax
International GmbH (formerly ChemGenex Pharmaceuticals Limited), a pharmaceutical company, for Ivax International s
omacetaxine mepesuccinate, a novel targeted cytotoxic pharmaceutical product.
Earlier, on December 14, 2009, Ivax International entered into licensing agreement with Hospira for the development and
commercialization of Ivax International's omacetaxine mepesuccinate in Europe and Middle East and Africa.
Deal Information
Deal Status
Terminated
Terminated Date
Jun 30, 2012
Deal Product
Product Description
omacetaxine mepesuccinate
<p>Omacetaxine mepesuccinate (Homoharringtonine,Omapro, Synribo,Tekinex,CGX635) is

an antineoplastic agent. The drug candidate is formulated as injection, administered by
subcutaneous route. It is indicated for the treatment of chronic myelocytic Leukemia. The drug
candidate is under development for the treatment of myelodysplastic syndrome and acute
myelocytic leukemia (AML), Philadelphia chromosome-positive (Ph+), acute promyelocytic
leukemia (APL), solid tumors including breast cancer, lung cancer, head and neck cancer,
colorectal cancer, melanoma and sarcoma.</p>
Licensor Name
ChemGenex
Pharmaceuticals Limited
Parent
Teva
Pharmaceutical
Industries Limited
ChemGenex Pharmaceuticals Limited (ChemGenex Pharmaceuticals) is an Australia based genomics-driven pharmaceutical
development company dedicated to improving the lives of patients by developing novel protein, antibody and small molecule
therapeutics in the areas of oncology, obesity, diabetes and central nervous system disorders. It offers a broad product portfolio
ranging from newly discovered novel gene targets to compounds to Phase 2 clinical trials. The company has two compounds in
Phase 2 clinical trials, Ceflatonin for leukemia and Quinamed for solid tumors, and has a significant portfolio of anti-cancer,
diabetes, obesity and depression programs. ChemGenex Pharmaceuticals Limited is headquartered in Melbourne, Australia.
Licensee Name
Hospira, Inc.
Parent
Pfizer Inc.
Hospira, Inc. (Hospira) is a global specialty pharmaceutical and medication delivery company. The company undertakes the
development, manufacturing, and marketing of products that help improve the safety and effectiveness and reduce the cost of
patient care. It is a provider of injectable pharmaceutical drugs and infusion technologies. Hospiras major products include
generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management
products. The company offers its products in three major product lines: Specialty Injectable Pharmaceuticals, Medication
Management, and Other Pharmaceuticals. Its major manufacturing facilities are in Rocky Mount, North Carolina; Austin, Texas;
LaAurora, Costa Rica; McPherson, Kansas; Irungattukottai, India; and Mulgrave, Australia. Its operations are spread across the
Amricas, Europe, the Middle East, Africa and Asia Pacific. Hospira is headquartered in Illinois, the US.
GlobalData


Page 148
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig
Deal Type
Licensing Agreement
Product Phase
Phase III
Deal in Brief
BioAlliance Pharma SA, a biopharmaceutical company, entered into an exclusive license agreement with Abic Marketing
Limited, a group subsidiary of Teva Pharmaceutical Industries Limited, for the commercialization of Sitavig in Israel. Under the
agreement, Teva is consented to pay upfront and milestone payments as well as royalties on sales in Israel, to BioAlliance
Pharma.
BioAlliance Pharma conceived and developed Sitavig (Sitavir in Europe) for the treatment of recurrent labial herpes in
immunocompetent patients presenting more than four episodes a year. Sitavig is based on the innovative mucoadhesive buccal
technology Lauriad, delivering very high concentrations of acyclovir at the site of herpes infection. The Phase III trial (775
patients) has shown a strong efficacy and safety profile, basis for the registration submission.
Judith Greciet, CEO of BioAlliance Pharma, said, This license agreement with Teva is a major step for Sitavig as it
acknowledges the interest and the commercial potential of this innovative product. Teva as the leading player on Israeli market
is a key partner for BioAlliance and for the commercialization of Sitavig, and we look forward to build a constructive and close
partnership.
Deal Information
Deal Status
Completed
Completed Date
13-Jun-2012
Deal Product
Product Description
acyclovir
Acyclovir (Sitavig) a synthetic deoxyguanosine analog, acts as potent anti-viral agent. It is

formulated as tablets for buccal administration. Sitavig is indicated for the treatment of
recurrent herpes labialis (cold sores) in immunocompetent adults. acyclovir is under
development for oral herpes. The drug candidate is developed by using Lauriad technology.
The drug candidate is under development for the treatment of oral herpes (herpes labialis).
Licensor Name
BioAlliance
(Inactive)
Pharma
SA
BioAlliance Pharma SA (BioAlliance) is a biopharmaceutical company. The company focuses on developing drugs for the
treatment of cancer and its related pathologies. The company offers products in two product catagories namely orphan
oncology and speciality. Products. Its product pipeline under orphan oncology category include Livatag, in phase 3 of clinical
trials, Validive, in phase 2 of clinical trials, AMEP in phase 1 of clinical trials, and Irinotecan Transdrug in preclinical stage of
trials. Its specialty product portfolio consists of Loramyc/ Oravig which has already been commercialized in Europe and the US,
Sitavig which has been approved and registered in certain parts of Europe and the US, Fentanyl Lauriad which is in phase 1 of
clinical trials, and Fluriad which is in preclinical stage of trials. BioAlliance is headquartered in Paris, France.
Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 149
Teva Animal Health Exercises Option For Licensing Agreement With Eden Research
Teva Animal Health Exercises Option For Licensing Agreement With Eden Research
Deal Type
Licensing Agreement
Deal in Brief
Teva Animal Health, Inc., an animal health company, exercised its option for an agreement with Eden Research plc, an
agrochemical development company, to obtain rights to Eden's encapsulation technology and terpene formulations for
veterinary health applications. This option follows two years of product development and trial work under the option agreement.
Under the terms of the agreement, Teva obtained an exclusive license to develop, manufacture and market products for the
treatment of common bacterial, fungal, and/or parasitic pathogens in the veterinary health sector in the North American Free
Trade Agreement (NAFTA) region. In return for the license, Eden Research received license fee of $0.1m and entitled to
receive further milestone payments totaling $0.8m, plus royalty on sales of the products. Teva also has a first right to negotiate
for an exclusive license on the same basis to develop, manufacture and market products in the rest of the world.
Clive Newitt, managing director of Eden, said, We have been working closely with TAH since January 2010 to help develop
products which meet their needs for treating various issues in veterinary health. I'm delighted that the result of this work is a
formal, exclusive licensing agreement with a subsidiary of one of the largest pharmaceutical companies in the world. The fact
that we have reached this commercial agreement with such a major, global company as Teva Animal Health Inc. underpins the
efficacy and commercial potential of our products.
Earlier in January 2010, Teva Animal Health entered into a development option and licensing agreement with Eden Research
for all veterinary health applications using Eden's encapsulation technology and terpene formulations in the North American
Free Trade Agreement region.
Deal Information
Deal Status
Completed
Completed Date
06-Jan-2012
Deal Financials
Deal Value (US$ m)
0.90
0.10
0.10
Cash (US$ m)
0.80
Licensor Name
Eden Research plc
Eden Research PLC (Eden Research) is a chemical company. The company develops and markets terpenes based
encapsulation technology and environmentally friendly technologies for agricultural and non-agricultural uses. It offers 3AEY, a
terpene-based fungicide and products for nematodes and whiteflies control. Eden Research offers products for botrytis,
nematodes, spider mites, esca, and eutypa. The company develops natural solutions to agricultural, medical and industrial
problems. It offers products in the areas of foliar disease control, soil pest, protected glass house crop, post harvest
applications and vascular disease control. Eden Research is headquartered in Witney, Oxfordshire, the UK.
Licensee Name
Teva Animal Health, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 150
Immupharma Regains Lupuzor Rights From Cephalon

Immupharma Regains Lupuzor Rights From Cephalon
Deal Type
Licensing Agreement
Product Phase
Phase III
Deal in Brief
Immupharma Plc, a drug discovery and development company, has regained rights to Lupuzor from Cephalon, Inc., a
biopharmaceutical company, due to the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd. The future of the
current clinical trials that Cephalon initiated in Lupus patients in the US and Europe will be decided by Cephalon and
ImmuPharma.
Earlier on November 25, 2008, Cephalon entered into an option agreement with ImmuPharma for the worldwide license to
Lupuzor. On February 2, 2009, Cephalon exercised its option to receive worldwide rights to Lupuzor from ImmuPharma based
on the promising interim results of the ImmuPharma Phase IIb study. As part of the agreement, ImmuPharma received an
upfront option payment of $15m and a one-time license fee of $30m following the exercise of option agreement. ImmuPharma
is entitled to receive future milestone payments totaling up to $455m based on the achievement of certain regulatory and sales
milestones. ImmuPharma will also receive royalties on commercial sales of Lupuzor.
Dimitri Dimitriou, chief executive of ImmuPharma, said, We are delighted to have Lupuzor back. This paves the way for new
options for the future of the company. We appreciate the support of Cephalon in the development of Lupuzor during our
collaboration.
Deal history
Update: On October 21, 2011, Immupharma has regained rights to Lupuzor from Cephalon, due to the acquisition of Cephalon
by Teva Pharmaceutical Industries.
Completed: On February 2, 2009, Cephalon exercised its option to receive worldwide rights to Lupuzor from ImmuPharma
based on the promising interim results of the ImmuPharma Phase IIb study.
Announced: On November 25, 2008, Cephalon entered into an option agreement with ImmuPharma for the worldwide license
to Lupuzor. Under the agreement, Cephalon received an option to obtain an exclusive worldwide license based on the
successful interim results of the Phase IIb study. ImmuPharma received an upfront option payment of $15m.
Deal Information
Deal Status
Terminated
Terminated Date
Oct 21, 2011
Deal Product
Product Description
forigerimod acetate
<p>Forigerimod (lupuzor, IPP-201101, rigerimod or P140) is under development for the

treatment of systemic lupus erythematosus (SLE). The drug candidate is administered
subcutaneously. The drug candidate acts by modulating CD4 T cell.</p>
Licensor Name
Immupharma Plc
ImmuPharma plc (ImmuPharma) develops novel drugs for the treatment of serious medical conditions with unmet medical
need. ImmuPharma has five drugs in development stage towards the treatment of lupus, cancer, moderate to severe pain,
highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection and inflammatory
disorders including rheumatoid arthritis and asthma. The companys product pipeline comprises Lupuzor, for the treatment of
Lupus; IPP-204106, for the treatment of cancer; IPP-102199, for the treatment of moderate and severe pain, IPP-203101, for
the treatment of highly resistant, hospital-acquired infections, such as MRSA; and IPP-201007, for the treatment of
inflammatory and allergic disorders. It has operations in France and Switzerland. ImmuPharma is headquartered in London, the
UK.
Licensee Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries
Limited,Teva
Pharmaceuticals USA, Inc.

Page 151
Frazer (Pennsylvania), the US.$Cephalon, Inc. (Cephalon) is a biopharmaceutical company recently acquired by Teva
Pharmaceutical Industries Ltd. focuses on the research, development and marketing of innovative therapeutic products. The
company through its product portfolio focuses on the treatment of oncology, pain, central nervous system (CNS) disorders and
inflammatory diseases which include NUVIGIL, TREANDA, AMRIX, FENTORA, TRISENOX, GABITRIL, PROVIGIL and
ACTIQ. Cephalon's various products in the pipeline include small molecules, protein peptides and biologics in various stages of
discovery and development. The company markets its products in Europe, the Middle East and Africa through its sales and
marketing organization. The company operates through its subsidiaries and affiliates in France, Germany, Spain, Italy, UK,
Poland and Benelux. Cephalon is headquartered in Frazer (Pennsylvania), the US.
GlobalData


Page 152
Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil
Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil
Deal Type
Licensing Agreement
Product Phase
Marketed
Deal in Brief
Sinclair IS Pharma plc, a specialty pharmaceutical company, entered into a licensing agreement with Teva Pharmaceutical
Industries Limited, a pharmaceutical company, a for Sinclair IS Pharmas oncology supportive care product, episil. episil is a
patented oral spray indicated for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy
and radiotherapy during cancer treatment.
Under the terms of the agreement, Teva Pharmaceutical will have the exclusive commercialization rights for episil in Germany,
Spain, Poland, Switzerland and the Czech Republic. Sinclair IS retains an option to co-promote episil in Germany and Spain.
Teva Pharmaceutical expects to launch episil in the final quarter of 2011.
Chris Spooner, CEO of Sinclair IS Pharma, said, A key part of the rationale behind the merger with IS Pharma was to broaden
the sales reach of the IS portfolio through Sinclairs direct country and regional operations. This is the first in what we expect to
be a number of marketing and co-marketing partnerships. episil is a cornerstone of our supportive oncology portfolio and we
look forward to working with Teva as we drive sales of this product.
The agreement enables Sinclair IS Pharma to expand its supportive oncology portfolio.
Deal Rationale
The agreement enables Sinclair IS Pharma to expand its supportive oncology portfolio.
Deal Information
Deal Status
Completed
Completed Date
31-Aug-2011
Licensor Name
Sinclair IS Pharma Plc

Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 153
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine

CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine
Deal Type
Licensing Agreement
Product Phase
Phase III
Deal in Brief
CEL-SCI Corporation, a biopharmaceutical company, expanded its licensing agreement with Teva Pharmaceutical Industries
Limited, a pharmaceutical company, to distribute Multikine, in Croatia and Serbia. Multikine is a immunotherapeutic agent used
for the treatment of head and neck cancer and is currently in Phase III development.Under the expanded agreement, Teva
obtained the rights to market and distribute Multikine in Croatia and Serbia. Teva will be responsible for the costs of registering
and selling the product in Serbia and Croatia and is also entitled to pay milestone payments to CEL-SCI, upon approval of
Multikine. The partners will share revenue generated from all four countries. Geert Kersten, chief executive officer of CEL-SCI,
said, We are pleased to expand our relationship with Teva. Strengthening this relationship will help in maximizing Multikines
potential in developing markets while retaining rights to market Multikine in North America and most of Europe.Earlier on
August 19, 2008, CEL-SCI entered into an exclusive licensing agreement with Teva Pharmaceutical Industries, to
commercialize Multikine, in Israel and Turkey.This agreement enables CEL-SCI to expand its market presence in Croatia and
Serbia.
Deal Rationale
This agreement enables CEL-SCI to expand its market presence in Croatia and Serbia.
Deal Information
Deal Status
Completed
Completed Date
19-Jul-2011
Deal Product
Product Description
Leukocyte Interleukin
<p>Multikine (Leukocyte Interleukin, Injection) is under development for the treatment of

squamous cell carcinoma (cancer) of the head and neck, peri-anal warts (condyloma ) in
HIV/HPV co-infected patients and cervical dysplasia in HIV/HPV co-infected women. The
therapeutic candidate is a defined mixture of biologically active, natural cytokines that simulate
the body’s immune response. It is a multitargeted agent, injected around the tumor and
in the vicinity of the local lymph nodes as these areas are more prone to metastases and
cancer re-occurrence. It was also under development for the treatment of cervical cancer,
chemotherapy effects, and radiation toxicity.</p>
Licensor Name
CEL-SCI Corporation
CEL-SCI Corporation (CEL-SCI) is a biotechnology company. It focuses on the discovery of techniques to activate the immune
system to fight cancer and infectious diseases. The company carries out the research and development of immunotherapy
products for the treatment of cancer and other diseases. The companys lead investigational therapy is Multikine (Leukocyte
Interleukin, Injection), an investigational immunotherapy against cancer and Human Papilloma Virus (HPV). CEL-SCI is also
investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine
(CEL-2000) for rheumatoid arthritis using its LEAPS technology platform. The company has operations in Vienna, Virginia; and
Baltimore, Maryland. CEL-SCI is headquartered in Vienna, Virginia, the US.
Licensee Name
Teva
Pharmaceutical
Industries Limited

Page 154
GlobalData


Page 155
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637
Deal Type
Licensing Agreement
Product Phase
Phase I
Deal in Brief
Gilead Sciences, Inc., a research-based biopharmaceutical company, entered into an exclusive worldwide license and
collaboration agreement with MicroDose Therapeutx, Inc., a biopharmaceutical company, for the development and
commercialization of MDT-637.
Under the terms of the agreement, Gilead will pay MicroDose an upfront payment and provide research funding to support
MicroDose's continued development of MDT-637 through Phase IIa clinical trials. Gilead can assume full responsibility for
clinical development following Phase IIa. MicroDose could also receive additional payments based upon the achievement of
certain development, regulatory and commercial milestones, as well as development fees and royalties on future potential net
sales. MicroDose intends to file the Investigational New Drug (IND) reactivation with the U.S. Food and Drug Administration
(FDA) and to initiate a Phase I study this year with MDT-637.
Anand Gumaste, president and CEO of MicroDose, said, "This strategic collaboration is a significant milestone in MicroDose's
vision to develop first-in-class therapies for major unmet medical needs. Given Gilead's scientific and clinical expertise in
virology, this partnership provides a strong validation of the potential for MDT-637 to become an important therapeutic advance
for those affected by RSV infection."
Norbert W. Bischofberger, Gilead's executive vice president, research and development and chief scientific officer, said, "There
is an urgent need to improve upon RSV treatment and care. We believe this program aligns well with our expertise in both
antiviral and respiratory drug development and we look forward to working with the MicroDose team to advance MDT-637 into
clinical testing."
MDT-637 is a fusion inhibitor that has been shown to block RSV infection in preclinical testing. It is MicroDose's inhalable small
molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).
Deal Information
Deal Status
Completed
Completed Date
20-Apr-2011
Deal Product
Product Description
MDT-637
MDT-637 was under development for the treatment of respiratory syncytial virus (RSV)
infections and asthma. The drug candidate is an inhalable small molecule anti-viral fusion
inhibitor. It is based on MicroDose dry powder inhaler platform.
Licensor Name
Parent
Teva
Pharmaceutical
Industries Limited
Licensee Name
Gilead Sciences, Inc.
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and
commercialization of innovative medicines for diseases with unmet medical need. The company offers products in various
therapeutic areas including cardiovascular, respiratory, inflammation, liver diseases and cancer. It develops pharmaceutical

Page 156
products for HIV. Gilead undertakes the US and international operations, with more than 40 marketing subsidiaries in the Czech
Republic, Denmark, Finland, France, Australia, Austria, Belgium and Canada, among others. It operates in Europe, North
America and South America and Asia-Pacific. The company continues to add to its existing portfolio of products through its
internal discovery and clinical development programs and through a product acquisition and in-licensing strategy. Gilead is
headquartered in Foster City, California, the US.
GlobalData


Page 157
Lundbeck Enters Into Licensing Agreement With Cephalon

Lundbeck Enters Into Licensing Agreement With Cephalon
Deal Type
Licensing Agreement
Product Phase
Marketed
Deal in Brief
H. Lundbeck A/S, a pharmaceutical company, entered into a licensing agreement with Cephalon, Inc., a biopharmaceutical
company, for several key products.
Under the agreement, Lundbeck obtained registration and commercial rights to a number of Cephalon key products in Canada
and Latin America which are currently available in the US and/or Europe on behalf of Cephalon. The products include Fentora
(fentanyl buccal tablet) [C-II], Provigil, Treanda, Trisenox (arsenic trioxide) injection, Myocet (liposomal- doxorubicin) and
Nuvigil. In return, Lundbeck is entitled to pay a double-digit royalties on sales to Cephalon.
Ulf Wiinberg, Lundbeck's chief executive, said: The Cephalon brands will significantly strengthen our position in these markets
while leveraging on existing sales and marketing capabilities adding significant sales in Canada and Latin America from 2012. It
is our belief that the clinical and regulatory risk is minimal as these products are already approved in the US and some of the
products also in Europe.
Frank Andersen, Jyske Bank analyst, said: The new products are expected to generate peak turnover of $100 million, of which
Lundbeck will be paying royalties to Cephalon. We estimate those (royalties) to be at a level of 20-40 percent.
Deal Rationale
This agreement enables Lundbeck to reinforce its position in Canada and Latin America and to add significant sales in these
markets from 2012.
Deal Information
Deal Status
Completed
Completed Date
08-Feb-2011
Deal Product
Product Description
modafinil
Modafinil (Provigil, Modiodal, Vigil and Alertec) is an anti-narcoleptic agent. It is formulated as

tablet for oral administration. It is indicated in the treatment of narcolepsy. It is approved for the
improvement of wakefulness in adults with a disorder of excessive sleeping due to narcolepsy,
obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. It is also used as
an adjunct for the treatment of underlying obstruction along with or after continuous positive
airway pressure (CPAP) treatment.
Licensor Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries
Limited,Teva

Page 158

Licensee Name
H. Lundbeck A/S
Parent
The Lundbeck Foundation
H. Lundbeck A/S (Lundbeck) is a pharmaceutical company, which is committed to enhance the quality of life of people suffering
from brain diseases. It carries out the research, development, manufacturing and marketing of pharmaceuticals for the
treatment of to the central nervous system (CNS) related diseases. Its products are targeted at diseases such as depression,
anxiety, psychotic diseases, alcohol dependence, epilepsy and Huntingtons disease, Alzheimers disease and Parkinsons
disease. Operating through subsidiaries, the company sells its products across the world. The company has production and
research facilities in China, Denmark, France, Italy and the US. Lundbeck is headquartered in Valby, Denmark.
GlobalData


Page 159
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI
Deal Type
Licensing Agreement
Product Phase
Marketed
Deal in Brief
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., entered into a licensing
agreement with Teva Pharmaceutical USA, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., to
manufacture and market Gemcitabine HCI for injection.
Under the agreement, APP obtained a license to commercialize, manufacture, supply and market gemcitabine HCI for injection
in 200 mg and 1 g single dose vials during the 180 day hatch waxman exclusivity period. APP plans to launch gemcitabine
immediately.
Gemcitabine HCI for injection is therapeutically equivalent to the reference-listed drug Gemzar, which is currently marketed in
these dose forms.
John Ducker, president and CEO of APP Pharmaceuticals, said: The agreement between our two companies demonstrates
APPs willingness and versatility to enter into collaborative agreements to ensure patient access to affordable cancer
treatments. The addition of these two presentations of Gemcitabine HCI for Injection broadens APPs rapidly growing oncology
portfolio, and confirms our reputation as a reliable partner in this important segment.
Tim Crew, senior vice president, Commercial Operations Generics, said: "We are pleased to enter into this agreement with
APP, which allows us to accelerate the availability of this important generic product. This agreement is another example of
Teva's commitment to providing consumers with access to high-quality, affordable medicines."
This agreement enables APP to strengthen its product portfolio to ensure patient access for the affordable cancer treatments.
Deal Rationale
This agreement enables APP to strengthen its product portfolio to ensure patient access for the affordable cancer treatments.
Deal Information
Deal Status
Completed
Completed Date
26-Jan-2011
Licensor Name

Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Licensee Name
Fresenius Kabi USA, LLC
Parent
Fresenius Kabi AG
Fresenius Kabi USA, LLC (Fresenius Kabi) formerly APP Pharmaceuticals, Inc. is a pharmaceutical and medical devices
company. It specializes in developing, manufacturing and marketing generic medicines, transfusion technologies, infusion
therapies and related medical devices. It also offers broad range of ready to use tube feeds, oral nutritional supplements and
powder products in the field of enteral and parenteral nutrition. The company offers its products in three divisions: Infusion,
Transfusion, and Clinical Nutrition. The company offers its products to hospitals, long-term care facilities, alternate care sites
and clinics. Fresenius Kabi is a part of Fresenius Kabi Group, a subsidiary of Fresenius SE & Co. KGaA. The company is
headquartered in Lake Zurich, Illinois, the US.
GlobalData


Page 160
ImmunGene Enters Into Licensing Agreement With Cephalon

ImmunGene Enters Into Licensing Agreement With Cephalon
Deal Type
Licensing Agreement
Deal in Brief
ImmunGene, Inc., a privately-held drug discovery and development company, entered into a licensing agreement with
Cephalon Australia Pty Ltd., a wholly owned subsidiary of Cephalon, Inc., to apply ImmunGene's interferon payload technology
to up to six of its new drug targets for cancers.
Under the agreement, Cephalon Australia is responsible for research, clinical development, manufacturing and
commercialization of products that result from the ImmunGene collaboration. It will pay upfront payment to ImmunGene for a
four-year option to leverage ImmunGene's novel drug development technology in preclinical research on up to six of Cephalon
Australia's drug candidates.
Cephalon has the option to pay ImmunGene license fees for exclusivity on each of these candidates that it decides to move
into clinical trials. ImmunGene is also eligible to receive considerable payments for research, clinical and regulatory milestones
for each drug candidate in the collaboration that is commercialized, in addition to royalties on worldwide net sales of any
resulting products.
Dr. Sanjay Khare, CEO of ImmunGene, said: "This collaboration is a validation of ImmunGene's novel antibody function
enhancement technology that adds the power of cytokines to antibodies while reducing the systemic toxicity of the cytokines."
Dr. Raj Sachdev, ImmunGene's chief operating officer, said: "We are pleased to have Cephalon Australia as a partner with its
strong commitment to advancing this new class of protein therapeutics."
This agreement enables ImmunGene to enhance its technology to reduce the systemic toxicity of the cytokines.
Deal Rationale
This agreement enables ImmunGene to enhance its technology to reduce the systemic toxicity of the cytokines.
Deal Information
Deal Status
Completed
Completed Date
05-Jan-2011
Licensor Name
ImmunGene, Inc.
ImmunGene, Inc. (ImmunGene) is a drug discovery and development company. The company discovers and develops
monoclonal antibody-based therapeutics to treat medical conditions including cancer, autoimmune and inflammatory diseases.
Its products include IGN001 comprising anti-Her2 monoclonal antibody against breast cancer; IGN002 comprising anti-CD20
monoclonal antibody for tumors; IGN003 for multiple myeloma; IGN004 against melanoma/solid tumors; IGN005 for AML
target; and IGN006 against solid tumors. ImmunGene also develops CmAbs technology which concentrates on monoclonal
antibodies to treat cancer, inflammation and other autoimmune diseases. The company partners with pharmaceutical and
biotechnology companies, and academic institutions to develop next generation monoclonal antibody- based therapeutics.
ImmunGene is headquartered in Thousand Oaks, California, the US.
Licensee Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries
Limited,Teva

Page 161
GlobalData


Page 162
Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine
Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine
Deal Type
Licensing Agreement
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, entered into a licensing agreement with Mesoblast Limited, an Australian
regenerative medicine company, for the commercialization of novel adult Mesenchymal Precursor Stem Cell (MPC)
therapeutics for degenerative conditions of the cardiovascular and central nervous systems.<br />Under the agreement,
Cephalon obtains exclusive worldwide rights to commercialize specific products based on Mesoblast's proprietary adult stem
cell technology platform for degenerative conditions of the cardiovascular and central nervous systems. The conditions include
congestive heart failure, acute myocardial infarction, parkinson's disease, and alzheimer's disease. The agreement also
extends to products for augmenting hematopoietic stem cell transplantation in cancer patients. <br />Cephalon will make an
upfront payment to Mesoblast totaling $130 million ($30 million upon Mesoblast shareholder approval) and regulatory milestone
payments of up to $1,700 million. In addition, Cephalon will be responsible for conducting and expenses of all phase IIb and III
clinical trials and subsequent commercialization of the products, while Mesoblast will be responsible for conducting and
expenses of certain phase IIa clinical trials and commercial supply of the products. Mesoblast will retain all manufacturing rights
and will share significantly in the net product sales.<br />J. Kevin Buchi, chief operating officer of Cephalon, said: "This global
licensing agreement positions Cephalon as a leader in regenerative medicine while further strengthening our late stage pipeline
with another innovative biologic platform. Mesoblast has done an outstanding job of developing Phase II clinical data in
congestive heart failure and hematopoietic stem cell transplants, plus preclinical data in acute myocardial infarction. We are
excited to have the opportunity to develop potentially the world's first stem cell therapy for indications that could serve millions
of patients globally."<br />Professor Silviu Itescu, chief executive officer of Mesoblast, said: "Cephalon's demonstrated strength
in late-stage product development and commercialization, and proven expertise in developing products for neurological
diseases make Cephalon an ideal strategic partner for Mesoblast. We are therefore very pleased to partner with Cephalon in
one of the largest biotechnology transactions of the past 12 months, and the largest ever in the regenerative medicine sector.
We look forward to working with the Cephalon team to commercialize and deliver these products to physicians and the patients
who will ultimately benefit from an arsenal of new innovative approaches for degenerative diseases." <br />Deutsche Bank
Securities, Inc. acted as financial advisor, while Johnson Winter & Slattery acted as legal advisor to Cephalon. <br />This
agreement enables Cephalon to strengthen its late stage pipeline with another innovative biologic platform. It enables
Mesoblast to commercialize and deliver regenerative medicine to the patients.
Deal Rationale
This agreement enables Cephalon to strengthen its late stage pipeline with another innovative biologic platform. It enables
Mesoblast to commercialize and deliver regenerative medicine to the patients.
Deal Information
Deal Status
Completed
Completed Date
07-Dec-2010
Deal Financials
Deal Value (US$ m)
1,830
130
130
Cash (US$ m)
1,700
Deal Product
Product Description
MPC-CBE
<p>MPC-CBE (allogeneic mesenchymal precursor cell) is under development for the

treatment of patients with hematologic malignancies undergoing transplantation. Bone marrowderived allogeneic mesenchymal precursor cells (MPCs) expand hematopoietic stem and
progenitor cell numbers. The therapeutic candidate is based on Mesenchymal Precursor Cell
(MPC) technology platform.</p>
Licensor Name
Mesoblast Limited


Page 163
Mesoblast Limited (Mesoblast) is a biotechnology company. The company focuses on developing novel biotherapeutics using
its cell-based technologies for the treatment of a wide range of diseases. Its technology platforms include Mesenchymal
Precursor Cells (MPCs), Mesenchymal Stem Cells (MSCs), Dental Pulp Stem Cells (DPSCs) and Hematopoietic Stem Cells
(HSCs). Mesoblast serves various therapeutic areas such as immunologic/ inflammatory, cardiac vascular, spine disease,
ophthalmolog, neurologic and oncology. The company has partnership with Teva Pharmaceutical Industries Ltd., JCR
Pharmaceuticals Co. Ltd. and Lonza Group. It has operational presence in the US and Singapore. Mesoblast is headquartered
in Melbourne, Victoria, Australia.
Licensee Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries
Limited,Teva
Advisor Information
Legal Advisor
Cephalon, Inc.
Johnson Winter & Slattery
Financial Advisor
Cephalon, Inc.
Deutsche Bank Securities,

Inc.
GlobalData


Page 164
SymBio Pharma Enters Into Licensing Agreement With Cephalon

SymBio Pharma Enters Into Licensing Agreement With Cephalon
Deal Type
Licensing Agreement
Product Phase
Phase I
Deal in Brief
SymBio Pharmaceuticals Limited, a biotechnology company, entered into a licensing agreement with Cephalon, Inc., a
biopharmaceutical company, for the development of Rigerimod (also known as Lupuzor) in Japan.
Under the agreement, SymBio granted exclusive development rights to study the drug in a Japan Phase I trial of Systemic
Lupus Erythematosus (SLE) patients, with the option to negotiate further product development in Japan for clinical outcomes.
Rigerimod is a product candidate used for the treatment of Systemic Lupus Erythematosus (SLE), a chronic and potentially lifethreatening auto-immune disease.
Deal Information
Deal Status
Completed
Completed Date
14-Jun-2010
Deal Product
Product Description
forigerimod acetate

Licensor Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries
Limited,Teva
Licensee Name
SymBio
Limited
Pharmaceuticals
in Tokyo, Japan.
GlobalData


Page 165
AstraZeneca Enters Into Licensing Agreement With Teva Pharma For Entocort EC
AstraZeneca Enters Into Licensing Agreement With Teva Pharma For Entocort EC
Deal Type
Licensing Agreement
Product Phase
Marketed
Deal in Brief
AstraZeneca PLC, a pharmaceuticals company, entered into licensing agreement with Teva Pharmaceutical Industries Ltd., a
pharmaceutical company, for the commercialization of Entocort EC (budesonide) capsules in US. Under the agreement, Teva
obtained US marketing rights for Entocort EC (budesonide) capsules from AstraZeneca, which is expected to be market from
February 15, 2012.
Entocort EC is used to treat used to treat Crohn's disease, a chronic intestinal inflammation that causes sustained diarrhea and
abdominal pain.
Deal Information
Deal Status
Completed
Completed Date
18-May-2010
Licensor Name
Teva
Pharmaceutical
Industries Limited
Licensee Name
AstraZeneca PLC
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. It carries out design, development, production and
commercialization of wide range of primary care and specialty care medicines. The companys product portfolio includes
biologics, prescription pharmaceuticals and vaccines. AstraZenecas prescription medicines focus on three key areas of
healthcare, namely, cardiovascular and metabolic disease (CVMD); cancer; and respiratory, inflammation and autoimmunity
(RIA). The company also focuses in the infection, neuroscience and gastrointestinal (ING) disease areas. Its novel medicines
are used by millions of patients worldwide. The company operates in Europe, the Americas, Asia, Africa and Australasia.
AstraZeneca is headquartered in London, the UK.
GlobalData


Page 166
Watson Pharma Enters Into Licensing Agreement With Teva Pharma

Watson Pharma Enters Into Licensing Agreement With Teva Pharma
Deal Type
Licensing Agreement
Product Phase
Marketed
Deal in Brief
Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, entered into a licensing agreement with Teva Women's
Health, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., an international pharmaceutical company, for Teva's
Seasonale.
Under the agreement, Watson Pharmaceuticals obtained rights for the US patents to market Seasonale. Watson
Pharmaceuticals will also market its generic equivalent product Quasense. Teva Women's Health is entitled to receive licensing
fees from Watson Pharmaceuticals.
Seasonale is used as contraception to prevent pregnancy. Seasonale contains two female hormones that prevent ovulation
(the release of an egg from an ovary). It also causes changes in cervical mucus and uterine lining, making it harder for sperm to
reach the uterus and harder for a fertilized egg to attach.
Quasense is a levonorgestrel and ethinyl estradiol tablets used as contraception to prevent pregnancy.
Deal Information
Deal Status
Completed
Completed Date
07-May-2010
Licensor Name
Teva
Pharmaceutical
Industries Limited
Licensee Name
Actavis plc
Actavis plc (Actavis) is a specialty pharmaceutical company. It focuses on the development, manufacturing, marketing and
distribution of specialized branded, generic, bio-similar and over-the-counter (OTC) products. The company offers products in
the areas of central nervous system, urology, women's health, hormones and synthetic substitutes, cancer, cardiovascular,
nephrology and gastrointestinal, among others. It markets over 250 generic pharmaceuticals and approximately 80 branded
pharmaceuticals. The company develops and out-licenses generic pharmaceutical products through its Medis third-party
business. It has operations in over 60 countries across North America and rest of the world. The company company distributes
approximately 12,650 stock-keeping units (SKUs) through its ANDA Distribution business. It is formed by the merger of Actavis,
Inc. and Warner Chilcott Limited. Actavis is headquartered in Dublin, Ireland.
GlobalData


Page 167
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Barr Labs
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Barr Labs
Deal Type
Licensing Agreement
Product Phase
Marketed
Deal in Brief
Endo Pharmaceuticals Holding Inc., a pharmaceutical company and Penwest Pharmaceutical Co., a pharmaceutical company,
entered into a licensing agreement with Barr Laboratories, Inc., a pharmaceuticals company, for the production and sale of
Opana ER (oxymorphone hydrochloride) Extended Release Tablets CII.Under the agreement, both the companies have settled
patent litigation over Opana ER with Barr. In addition, Barr will obtain a license to sell generic formulations of Opana ER on or
after September 15, 2012 or earlier under certain circumstances.Opana ER is indicated for the relief of moderate to severe
acute pain.
Deal Information
Deal Status
Completed
Completed Date
13-Apr-2010
Deal Product
Product Description
oxymorphone ER
Oxymorphone Hydrochloride (Opana ER) is an analgesic agent. It is formulated in the form of

extended release tablets for oral use. It is indicated for the management of pain severe
enough to require daily, around-the-clock, long-term opioid treatment and for which alternative
treatment options are inadequate.
Licensor Name
Endo
International
plc,Penwest
Pharmaceuticals
Co.
(Inactive)
Endo International plc (Endo) formerly Endo Health Solutions Inc. is a specialty healthcare company. It develops and
commercializes various branded pharmaceuticals, medical devices and generic drugs with focus on pain management and
urology. The companys major branded prescription products include Lidoderm, Opana ER, Voltaren gel and Percocet for the
management of pain; Frova and Sumavel DosePro for the treatment of migraine; Aveed, Natesto testosterone nasal gel and
Fortesta gel to treat adult males with hypogonadism; Supprelin LA to treat precocious puberty in male and female children;
Valstar anti-cancer chemotherapy drug; and Vantas hydrogel implant to treat advanced prostate cancer. It offers generic drugs
for pain management and the treatment of urology and CNS disorders, immunosuppression, cancer, womens health disorders
and hypertension. The company also offers medical devices to treat mens and womens pelvic health conditions. The company
sells its products directly to large pharmacy chains and wholesale drug distributors. Endo is headquartered in Dublin,
Ireland.$Penwest Pharmaceuticals Co. (Penwest) is a pharmaceutical company, which is principally engaged in the
development of pharmaceutical products based on proprietary drug delivery technologies, primarily for disorders of the nervous
system. The drug delivery technologies of the company include TIMERx, a controlled-release technology; SyncroDose, a
technology enabling controlled release at the appropriate site in the body; Geminex, a technology enabling drug release at two
different rates; and GastroDose system, a technology enabling drug delivery to the upper gastrointestinal tract. The company's
products under development include Nalbuphine ER, a Phase IIa clinical trial completed product for the treatment of pain, and
A0001, a Phase IIa clinical trial product for the treatment of diseases related to the inherited mitochondrial respiratory chain
diseases. The product pipeline of the company includes Opana ER, an oral extended release opioid analgesic for patients with
moderate to severe pain requiring continuous opioid treatment; Nalbuphine ER for the treatment of moderate chronic pain; and
Nifedipine XL for the treatment of hypertension and angina. In addition, to formulate product candidates the company is also
applying its drug delivery technologies and drug formulation expertise under licensing collaborations. Penwest is headquartered
in New York, the US.
Licensee Name
Barr Laboratories, Inc.
Parent
Barr Pharmaceuticals, Inc.

(Inactive)

Page 168
Barr Laboratories, Inc. is a pharmaceuticals company engaged in the development, manufacturing and marketing of generic
and innovative pharmaceuticals in different therapeutic categories. It is currently into therapeutics areas like anti-infectives,
oncology, cardiology, psychotherapeutics, and women's health to treat cancer, heart disease, hormonal imbalance, infection,
pain, anxiety, and depression. It is a wholly owned subsidiary of Teva Pharmaceutical Industries Limited.
GlobalData


Page 169
Mersana Therapeutics Enters Into Licensing Agreement With Teva Pharma Industries
Mersana Therapeutics Enters Into Licensing Agreement With Teva Pharma Industries
Deal Type
Licensing Agreement
Product Phase
Preclinical
Deal in Brief
Mersana Therapeutics, Inc. (formerly known as Nanopharma Corp.), a clinical-stage biopharmaceuticals company, entered into
a research and license agreement with Teva Pharmaceutical Industries Limited, to develop and commercialize XMT-1107 for
the treatment of all indications, including cancer. XMT-1107 is a natural anti-angiogenic fumagillin, currently in pre-clinical
studies used as an anti-cancer agent.
Under the agreement, Teva received worldwide rights for XMT-1107 except Japan, from Mersana. Teva will be responsible for
all the development costs except those specific to Japan. Mersana is entitled to receive upfront and milestone payments of
$334 million, and is also eligible to receive royalties on product sales. In addition, Teva has contracted with Mersana, to run a
Phase I solid tumor trial, which will begin in this quarter, and the Phase II trials are expected to begin next year.
Julie Olson, president and CEO of Mersana, said "We are very pleased to enter into this partnership with Teva as it not only
provides the necessary resources for XMT-1107 to achieve broad therapeutic potential but also validates our Fleximer platform
as a means to generate novel products. We have now produced two clinical-stage oncology products and look forward to
progress our lead program, XMT-1001, beyond Phase 1 study and to further expanding our Fleximer-based siRNA delivery
program."
Wilmer Cutler Pickering Hale and Dorr LLP acted as legal counsel to Mersana Therapeutics on the transaction.
This agreement will enable Mersana to fund its other two programs, and will enable Teva to enhance its innovative pipeline.
Deal Rationale
This agreement will enable Mersana to fund its other two programs, and will enable Teva to enhance its innovative pipeline.
Deal Information
Deal Status
Completed
Announced Date
12-Apr-2010
Completed Date
13-Apr-2010
Deal Financials
Deal Value (US$ m)
334
Deal Product
Product Description
XMT-1107
<p>XMT-1107 is under development for the treatment of refractory advanced solid tumors. It is
administered as an intravenous infusion. XMT-1107 is a conjugate of a proprietary fumagillin
analog, Fleximer polymer backbone and a customized linker that prevents delivery of the
active moiety to the brain to avoid CNS-related side effects. The drug candidate acts on the
methionine aminopeptidase 2 (MetAP2). It is based on Fleximer polymer and linker chemistry
technology. Conjugating a drug to Fleximer improves its bioavailability, extends drug exposure,
enhances biodistribution and improves solubility. Fleximer's structure is also conducive to
covalent attachment of multiple, diverse therapeutic payloads.</p>
Licensor Name
Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. (Mersana) is a pharmaceutical company. The company develops novel oncology agents based on
its nanotechnology platform (Fleximer). Its products include antibody-drug conjugates, XMT-1001, and XMT-1107. The
companys XMT-1001 is a cytotoxic drug conjugate for solid tumors. XMT-1107 is an anti-angiogenic, which is designed to
maximize the dramatic anti-angiogenic activity of the fumagillin class. The company has collaboration with Adimab, Endo
Pharmaceuticals and Teva Pharmaceuticals. It was formerly known as Nanopharma Corp. Mersana is headquartered in
Cambridge, Massachusetts, the US.


Page 170
Licensee Name
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
Mersana Therapeutics, Inc.
Wilmer Cutler Pickering Hale

and Dorr LLP
GlobalData


Page 171
Sanofi, Debiopharm Enters Into Licensing Agreement With Sandoz, Fresenius & Teva
Sanofi, Debiopharm Enters Into Licensing Agreement With Sandoz, Fresenius & Teva
Deal Type
Licensing Agreement
Product Phase
Marketed
Deal in Brief
Sanofi-Aventis, a diversified pharmaceutical and healthcare company, and Debiopharm Group, a biopharmaceutical company,
entered into a licensing agreement with Sandoz Inc., a provider of generic pharmaceuticals, Fresenius Kabi Oncology Limited,
a drug development and manufacturing company, and Teva Pharmaceuticals USA, Inc., a drug research, development and
marketing company and a subsidiary of Teva Pharmaceutical Industries Limited.
Under the terms of the agreement, Sandoz, Fresenius and Teva are granted the license to distribute generic Eloxatin
(oxaliplatin) products after August 9, 2012.
ELOXATIN (oxaliplatin) is approved by the Food and Drug Administration (FDA) for adjuvant treatment of people with stage III
colon cancer who have had their primary (original) tumors surgically removed.
Deal Information
Deal Status
Completed
Completed Date
01-Apr-2010
Licensor Name
Debiopharm
S.A.,Sanofi
International
Parent
Debiopharm Group
Debiopharm International S.A. (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that operates
as a drug development company. The companys products include Moapar, Eloxatin and Decapeptyl, among others.
Debiopharms pipeline products include Debio8206, Debio 8609, Sanvar, Tremelimumab, Debio 025, Debio 1143, Debio 0826,
and Debio 0932. The company offers services, such as early and preclinical development, clinical development, drug delivery
and formulation and manufacturing and quality assurance. It develops drugs in the therapeutic areas of oncology, immunology,
metabolism, infectious diseases. The company was formerly known as Debiopharm S.A. Debiopharm is headquartered in
Lausanne, Switzerland.$Sanofi is a diversified global healthcare company. It undertakes the discovery, development and
marketing of therapeutic solutions. The company offers a broad range of prescription medicines, and consumer healthcare and
generic products worldwide..The company offers Pharmaceutical products in the areas of cancer, cardiovascular diseases,
thrombosis, diabetes, central nervous system (CNS) disorders, general diseases such as benign prostatic hyperplasia,
osteoporosis and rheumatoid arthritis. Sanofi offers vaccines such as pediatric combinations and poliomyelitis vaccines,
influenza, adult and adolescent booster, meningitis, travel and endemic, and measles, mumps and rubella (MMR). It also
provides an array of medicines and vaccines for a wide range of animal species. Sanofi is headquartered in Paris, France.
Licensee Name
Fresenius Kabi Oncology

Limited,Sandoz
Inc.,Teva
Parent
Fresenius
SE
&
Co.
KGaA,Sandoz International
GmbH,Teva Pharmaceutical
Industries Limited
Fresenius Kabi Oncology Limited (Fresenius Kabi) is a pharmaceutical company. The company develops and manufactures
oncology drugs. It provides oral cytotoxics, cytostatics, injectables, intermediates and active pharmaceutical ingredients. The
companys products include decitabine, carboplatin, decitabine, irinotecan HCl, letrozole, temsirolimus, bupivacaine,
levobupivacaine, ropivacaine, azacitidine, cabazitaxel, cladiribine, capecitabine, fludarabine, gefitinib, erlotinib, lapatinib,
premetrexed, pralatrexate, anastrazole, bicalutamide, busulfan, bendamustine, and imatinib mesylat. Fresenius Kabis
therapeutic areas include breast cancer, lung cancer, ovarian cancer, head and neck cancer, prostate cancer, hematological
malignancies, gastrointestinal malignancies, brain tumors, and supportive care. It has manufacturing facilities at Baddi,
Himachal Pradesh, West Bengal, India. The company was formerly known as Dabur Pharma Limited. Fresenius Kabi is
headquartered in Gurgaon, Haryana, India.$Sandoz Inc. (Sandoz), is a specialty generic pharmaceutical company. It
undertakes the development, manufacturing and distribution of high-quality pharmaceuticals, delivery systems and follow-on
biologics. The company offers a wide range of products in the therapeutic areas of cardiovascular system, central nervous
system (CNS), alimentary tract and metabolism, respiratory system, blood and blood forming organs, and anti-infectives,

Page 172
among others. Some of the companys key products include Altavera and Loryna, Lovenox , amoxicillin-clavulanic acid,
gemcitabine, Flomax, Cozaar and others. It markets more than 200 generic medicines in the US. Sandoz distributes its
products to retailers, wholesalers, hospitals, prescription benefit managers and public agencies. It operates two manufacturing
facilities located in Broomfiled, Colorado and Wilson, North Carolina; and product development facilities located in East
Hanover, New Jersey and Durham, North Carolina. It is a subsidiary of Sandoz International GmbH. Sandoz is headquartered
in Princeton, New Jersey, the US.
GlobalData


Page 173
Antisense Therapeutics Terminates Licensing Agreement With Teva Pharma

Antisense Therapeutics Terminates Licensing Agreement With Teva Pharma
Deal Type
Licensing Agreement
Deal in Brief
Antisense Therapeutics Limited, a biopharmaceutical drug discovery company, has terminated its worldwide licensing
agreement with Teva Pharmaceutical Industries Ltd., a pharmaceutical company, for ATL1102.
Following the termination, Teva decided to discontinue further clinical development of ATL1102. Antisense will continue the
development of its pipeline projects including ATL1103 for abnormal growth and sight disorders, and ATL1101 for prostate
cancer.
Earlier on February 11, 2008, Antisense Therapeutics entered into a worldwide licensing agreement with Teva Pharmaceutical,
for the development and commercialization of ATL1102.
Deal Information
Deal Status
Terminated
Terminated Date
Mar 24, 2010
Deal Product
Product Description
ATL-1102
ATL-1102, (TV-1102, ISIS 107248) is under development for the treatment of relapsing
remitting multiple sclerosis, asthma. It is administered through subcutaneous, inhalation route
of administration. ATL1102 is a second generation antisense inhibitor of CD49d, a subunit of
VLA-4 (very late antigen-4). The therapeutic candidate is developed based on antisense
technology. It was also under development for the treatment of hematopoietic stem cell
transplantation.
Licensor Name
Antisense
Limited
Therapeutics
Antisense Therapeutics Limited (ANP) is a biopharmaceutical company with focus on the discovery, development and
commercialization of second generation antisense pharmaceuticals for large unmet medical needs. It focuses on the
development of antisense drugs in the fields of oncology, respiratory disease, immunology disorders and opthalmology. The
development pipeline of ANP comprises four products, namely, ATL1102 (injection), is used for reducing brain lesions in
patients with multiple sclerosis and completed a Phase II efficacy and safety trial; ATL1103 is used for blocking GHr production
and lower blood IGF-I levels and is a potential treatment for growth and other GH-IGF-I disorders; ATL1102 (inhaled) is in preclinical development stage for the treatment of asthma and ATL1101 is also in preclinical stage and being investigated for the
potential treatment for prostate cancer. ANP is headquartered in Victoria, Australia.
Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 174
Innate Immune Enters Into Licensing Agreement With Cephalon Australia

Innate Immune Enters Into Licensing Agreement With Cephalon Australia
Deal Type
Licensing Agreement
Deal in Brief
Innate Immune, Inc., a biotechnology company, entered into licensing agreement with Cephalon Australia Pty Ltd,
biopharmaceutical company and a wholly owned subsidiary of Cephalon, Inc., for the patents of its antibodies.
Under the agreement, Cephalon Australia received an exclusive license to patents to develop Innate Immune's antibodies for
the treatment of asthma and systemic lupus erythematosis (SLE). Cephalon Australia will humanize the antibodies using their
proprietary technology and will carryout all development and clinical activities related to the product candidate.
Deal Information
Deal Status
Completed
Completed Date
15-Mar-2010
Licensor Name
Innate Immune, Inc.
Innate Immune, Inc. is a privately held biotechnology company engaged in the discovery and development of drugs that
modulate the activity of natural killer T cells for the treatment of immune disorders.
Licensee Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries
Limited,Teva
GlobalData


Page 175
MediGene Enters Into Licensing Agreement With Teva Pharma

MediGene Enters Into Licensing Agreement With Teva Pharma
Deal Type
Licensing Agreement
Deal in Brief
MediGene AG, a biotechnology company, entered into a license and supply agreement with Teva Pharmaceutical Industries
Ltd., an international pharmaceutical company, for the supply and commercialization of Veregen in Israel.
Under the terms of the agreement, Teva will also be responsible for registering the product in Israel. MediGene is entitled to
receive a milestone payment, upon successful completion of the regulatory procedures. In addition, MediGene is also eligible to
receive royalties on future sales of the product.
Veregen is indicated for the treatment of genital warts and contains a concentrate of catechins with a defined composition
extracted from green tea leaves.
Deal Information
Deal Status
Completed
Completed Date
22-Feb-2010
Deal Product
Product Description
sinecatechins
Sinecatechins (Veregen) is a extract of green tea leaves from Camellia sinensis. It is

formulated in the form of ointment for topical application. It is indicated for the topical treatment
of external genital and perianal warts (condylomata acuminata) in immunocompetent patients
18 years and older. It is also under development for the treatment of Kraurosis vulvae, basal
cell carcinoma and genital warts.
Licensor Name
MediGene AG
MediGene AG (MediGene) is a biotechnology company. It carries out clinical research, development and marketing of novel
drugs for the treatment of cancer and autoimmune diseases. The company's lead product, Veregen, is an ointment used to
treat external genital warts. Its products in the developmental stage are EndoTag-1, being developed for the treatment of
pancreatic cancer and triple-negative breast cancer (TNBC), completed its Phase II clinical trial stage; RhuDex, being
developed for the treatment for autoimmune diseases, in Phase II clinical trial stage; and DC vaccine, being developed for
prostate cancer is in phase II clinical trial. The vaccine is also being developed for acute myeloid lukaemia (AML) and is in
phase I clinical trial. Its products in pre-clinical phase are TCR, TABS and AAVLP, which are being tested for cancer, leukaemia
and autoimmune, and vaccine technology respectively. The company also develops innovative platform technologies for drug
development. It distributes its products through partner companies, which include SynCore, Falk Pharma, Astellas, Abbott,
Pierre Fabre Medicament, Meditrina Pharmaceuticals Ltd., Laboratoiries Expanscience and others. MediGene is headquartered
in Martinsried, Germany.
Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 176
ChemGenex Pharma Enters Into Licensing Agreement With Hospira

ChemGenex Pharma Enters Into Licensing Agreement With Hospira
Deal Type
Licensing Agreement
Deal in Brief
ChemGenex Pharmaceuticals Limited, a pharmaceutical company, has entered into an agreement with Hospira, Inc., a
pharmaceutical and medication delivery company, for licensing, developing and commercialization of ChemGenexs
omacetaxine mepesuccinate in Europe, the Middle East and parts of Africa.
Under the agreement, ChemGenex is responsible to complete registration of omacetaxine in its initial indication with the
European Medicines Agency (EMEA). Hospira and ChemGenex will explore future applications of omacetaxine in a variety of
hematological malignancies. Hospira will be responsible for commercializing omacetaxine in the territory.
ChemGenex is entitled to receive an initial payment of EUR11.1 million ($16.23 million), and additional milestone payments of
up to EUR74.1 million ($108.36 million), upon successful development and commercialization of omacetaxine. ChemGenex is
also eligible to receive royalties on the product sales in the given territory.
Omacetaxine is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological
malignancies.
This agreement enables Hospira in building a strong portfolio of oncology and hematology products and helps ChemGenex to
introduce omacetaxine in Europe.
Deal Rationale
This agreement enables Hospira in building a strong portfolio of oncology and hematology products and helps ChemGenex to
introduce omacetaxine in Europe.
Deal Information
Deal Status
Completed
Completed Date
14-Dec-2009
Deal Financials
Deal Value (EUR million)
85.20
16.23
Deal Value (US$ m)
124.59
108.36
Deal Product
Product Description
omacetaxine mepesuccinate
<p>Omacetaxine mepesuccinate (Homoharringtonine,Omapro, Synribo,Tekinex,CGX635) is

an antineoplastic agent. The drug candidate is formulated as injection, administered by
subcutaneous route. It is indicated for the treatment of chronic myelocytic Leukemia. The drug
candidate is under development for the treatment of myelodysplastic syndrome and acute
myelocytic leukemia (AML), Philadelphia chromosome-positive (Ph+), acute promyelocytic
leukemia (APL), solid tumors including breast cancer, lung cancer, head and neck cancer,
colorectal cancer, melanoma and sarcoma.</p>
Licensor Name
ChemGenex
Parent
Teva
Pharmaceutical
Industries Limited

Page 177
Licensee Name
Hospira, Inc.
Parent
Pfizer Inc.
GlobalData


Page 178
Codexis Extends Collaboration Agreement With Teva Pharma Industries

Codexis Extends Collaboration Agreement With Teva Pharma Industries
Deal Type
Licensing Agreement
Deal in Brief
Codexis, Inc., a clean technology company, entered into a new agreement and extended its collaboration with Teva
Pharmaceutical Industries Limited, a generic drug manufacturer, for three pharmaceutical products.
Under the agreement, Teva will use Codexis biocatalysis technology for key process steps in the manufacture of the covered
generic products. Codexis develops proprietary custom biocatalysts which contribute to lower pharmaceutical process
development and manufacturing costs.
Earlier on January 7, 2009, the companies have entered into a licensing agreement to produce generic products, using a
proprietary Codexis biocatalyst.
Deal Information
Deal Status
Completed
Completed Date
01-Dec-2009
Licensor Name
Codexis, Inc.
Codexis, Inc. (Codexis) is a biotechnology company. It undertakes the development of biocatalysts for fine chemical and
pharmaceutical production. The company discovers, identifies, optimizes, produces and offers enzyme optimization services by
utilizing its technology platforms such as CodeXporter enzyme production platform and CodeEvolver evolution technology
platforms. Its product portfolio includes pharmaceutical enzymes and intermediates, active pharmaceutical ingredients, Codex
screening panels and kits, and enzyme platforms. Codexis offers a wide range of biocatalysis solutions ranging from screening
and optimization to commercial supply of biocatalysts. The company caters its product and services to generic and
pharmaceutical markets. Codexis is headquartered in Redwood, California, the US.
Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 179
Ambrilia Terminates License, Distribution And Supply Agreements With Teva

Ambrilia Terminates License, Distribution And Supply Agreements With Teva
Deal Type
Licensing Agreement
Deal in Brief
Ambrilia Biopharma Inc., a biotechnology company, through its subsidiary Cellpep Pharma Inc., has terminated the license,
distribution and supply agreements with Teva Pharmaceuticals Europe BV, for commercialization of Ambrilia's products.Earlier
on April 24, 2002, Ambrilia Biopharma France S.A. (formerly known as Cellpep S.A.), a subsidiary of Ambrilia, has entered into
licensing and distribution agreement with Teva, and later on the partners entered into supply agreement on May 6, 2002.
Deal Information
Deal Status
Terminated
Terminated Date
Oct 19, 2009
Licensor Name
Ambrilia Biopharma Inc.
Ambrilia Biopharma Inc. (Ambrilia) is a biotechnology company engaged in the discovery, development and commercialization
of small molecules and peptides for the treatment of infectious diseases and cancer. The product pipeline of Ambrilia include:
C2L Octreotide to treat acromegaly;Goserelin to treat hormone-sensitive prostate cancer; NGR-Delivery technology for cancer;
Protease Inhibitors; Integrase Inhibitors; and Influenza M2 Proton Channel Inhibitors. Ambrilia was a public company but the
Toronto Stock Exchange has delisted the common shares of Ambrilia as at the close of market on March 4, 2011 for failure to
meet the continued listing requirements of the Toronto Stock Exchange. Ambrilia is headquartered at Verdun in Quebec,
Canada.
Licensee Name
Teva
Pharmaceuticals
Europe B.V.
Parent
Teva
Pharmaceutical
Industries Limited
Teva Pharmaceuticals Europe B.V. (Teva Pharmaceuticals) is a pharmaceutical company, based in the Netherlands. It
provides generic and branded medicines. The company develops and produces drugs that are used to address patients' needs.
Teva Pharmaceuticals key products include CNS, Respiratory products, womans health, pain and oncology products. Its CNS
products include Copaxone, Azilect, Provigil, Nuvigil and Gabitril. Its oncology products include Treanda, Trisenox, Tevagrastim
and Eporatio. The company markets its products in domestic and international markets. Teva Pharmaceuticals operates as a
subsidiary of Teva Pharmaceutical Industries Ltd. Teva Pharmaceuticals is headquartered in Utrecht, the Netherlands.
GlobalData


Page 180
Rexahn Pharma Enters Into Licensing Agreement With Teva Pharma

Rexahn Pharma Enters Into Licensing Agreement With Teva Pharma
Deal Type
Licensing Agreement
Product Phase
Preclinical
Deal in Brief
Rexahn Pharmaceuticals, Inc., a biopharmaceutical company, entered into a licensing agreement with Teva Pharmaceutical
Industries Ltd., for the development and commercialization of its novel anti-cancer compound RX 3117.
Under the terms of the agreement, Teva paid upfront payments in the form of equity investment of $3.5 million in Rexahn, and
is also eligible to pay development, regulatory and sales milestone payments. Additionally, Rexahn will receive royalties on
worldwide net sales of RX 3117. Teva also has an option to make an additional equity investment in Rexahn within the next 12
months.
RX 3117 is a nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase and DNA synthesis, useful
for broad variety of cancers including colon, lung, and pancreatic cancer.
Deal Rationale
This collaboration will enable Rexahn to bring its three promising phase II compounds, Archexin, Serdaxin and Zoraxel, to
market.
Deal Information
Deal Status
Completed
Announced Date
29-Jun-2009
Completed Date
21-Sep-2009
Deal Financials
3.50
3.50
3.50
Equity (US$ m)
Deal Product
Product Description
RX-3117
<p>RX-3117 is under development for the treatment of solid tumors including colorectal
cancer, non-small cell lung cancer, small cell lung cancer, colon cancer, pancreatic cancer,
renal cell carcinoma, ovarian cancer and cervical cancer. The drug candidate is administered
orally. RX-3117 is a small molecule, nucleoside compound that inhibits DNA methyltransferase
1.</p>
Licensor Name
Rexahn
Inc.
Pharmaceuticals,
Rexahn Pharmaceuticals, Inc. (Rexahn Pharmaceuticals) is a clinical stage biopharmaceutical company. The company
develops, manufactures and supplies therapeutics for the treatment of cancer. Its pipeline product portfolio spans indications
such as small molecule that blocks tumor progression and metastasis for melanoma; cancer cell specific nucleoside that
inhibits DNA and RNA synthesis and induces apoptotic cell death; and an anti-cancer drug candidate that inhibits the activated
form of the cancer cell signaling protein phosphorylated-Akt1. Rexahn Pharmaceuticals products are used in the treatment of
cancers of the ovary, kidney and pancreas. The company markets products under brand names, such as Archexin and
Supinoxin. Rexahn Pharmaceuticals is headquartered in Rockville, Maryland, the US..
Licensee Name
Teva
Pharmaceutical
Industries Limited

Page 181
GlobalData


Page 182
Barr Labs Enters Into Licensing Agreement With Bayer

Barr Labs Enters Into Licensing Agreement With Bayer
Deal Type
Licensing Agreement
Deal in Brief
Barr Laboratories, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries, entered into licensing agreement with
Bayer AG, a healthcare company, for distribution of a generic version of Yasmin.
Under the agreement, Barr Laboratories recieved an exclusive license to distribute generic version of Yasmin in US under the
Barr Laboratories label Ocella.
OCELLA medicine is progesterone and estrogen combination contraceptive pill used to prevent pregnancy.
Deal Information
Deal Status
Completed
Completed Date
05-Aug-2009
Deal Product
Product Description
Yaz
YAZ (SH T00186, BAY86-5300) generically called as drospirenone and ethinyl estradiol is a
combined oral contraceptive (COC) which contains an estrogen and a progestogen hormones.
Drospirenone is a synthetic progestin that is an analog to spironolactone. It is found in a
number of birth control formulations. Drospirenone differs from other synthetic progestins in
that its pharmacological profile in preclinical studies shows it to be closer to the natural
progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogenstimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic. Ethinyl
estradiol is a semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex
and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular
responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers
testosterone levels and may delay progression of prostatic cancer. In addition to its
antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, shortterm therapy with this agent has been shown to provide long-term protection against breast
cancer, mimicking the antitumor effects of pregnancy.YAZ generically called as drospirenone
and ethinyl estradiol is a combined oral contraceptive (COC) which contains an estrogen and a
progestogen hormones. It is a type of hormonal contraception which is a particularly effective
method of family planning. It is fully reversible and a birth control pill.
YAZ is used for the prevention of pregnancy in women, treatment of Premenstrual Dysphric
Disorder (PMDD), treatment of moderate acne vulgaris.
Yaz is under phase III clinical development for the treatment of Premenstrual Dysphric
Disorder (PMDD).
Yasmin is a Combination oral contraceptive containing drospirenone, a synthetic
progestational compound and ethinyl estradiol, a synthetic estrogenic compound. This
formulation is approved as an oral contraceptive as well as the treatment of symptoms of
premenstrual dysphoric disorder (PMDD). It is also used for the treatment of moderate acne
vulgaris in women desiring oral contraception. In Japan Yaz is approved for the treatment of
dysmenorrhea. Yasmin is available as a 21 day therapy drug consisting of 21 active tablets
each containing 3 mg of drospirenone and 0.03 mg of ethinyl estradiol and 7 inert film coated
tablets. The dosage of the drug is one active tablet daily for 21 consecutive days followed by 7
inert tablets per menstrual cycle. Yasmin is the first birth control pill available that contains
drospirenone, the only progestin hormone not derived from testosterone. Yaz is the first FDA
approved drug for the treatment of premenstrual dysphoric disorder.
Licensor Name
Bayer AG

Page 183
Bayer AG (Bayer) is a global healthcare company. It is an investment holding company for its group companies, namely, Bayer
HealthCare, Bayer CropScience, Bayer MaterialScience, Bayer Business Services, Bayer Technology Services and Currenta. It
focuses on the development, production and commercialization of healthcare products, nutritional supplements and specialty
materials. The product portfolio of the company comprises animal health products, consumer care products, medical care
products, pharmaceuticals, fungicides, insecticides, herbicides, polyurethanes, polycarbonates, coatings, adhesives and
specialties. It caters to pharmaceutical, agricultural and polymer industries. The company also offers information technology (IT)
and business services such as IT infrastructure and application, procurement and logistics, process development, plant
engineering and construction, utility supply and waste management infrastructure services. It operates through a network of
subsidiaries in Asia-Pacific, Europe, the US, and other markets such as Latin America, Africa and the Middle East. Bayer is
headquartered in Leverkusen, Germany.
Licensee Name
Barr Laboratories, Inc.
Parent

(Inactive)
Barr Laboratories, Inc. is a pharmaceuticals company engaged in the development, manufacturing and marketing of generic
and innovative pharmaceuticals in different therapeutic categories. It is currently into therapeutics areas like anti-infectives,
oncology, cardiology, psychotherapeutics, and women's health to treat cancer, heart disease, hormonal imbalance, infection,
pain, anxiety, and depression. It is a wholly owned subsidiary of Teva Pharmaceutical Industries Limited.
GlobalData


Page 184
Vical Enters Into Licensing Agreement With Teva Pharma

Vical Enters Into Licensing Agreement With Teva Pharma
Deal Type
Licensing Agreement
Product Phase
Phase III
Deal in Brief
Vical Incorporated, a biopharmaceutical company, entered into an exclusive licensing agreement with Abic Marketing Limited, a
subsidiary of Teva Pharmaceutical Industries Limited, for Allovectin-7 immunotherapeutic product candidate.
Under the agreement, Abic received right to market Vical's Allovectin-7 immunotherapeutic product candidate in Israel. Vical is
entitled to receive upfront and milestone payments.
Allovectin-7 is a plasmid complex containing DNA sequences encoding HLA-B7 and beta-2 microglobulin that together form a
class I major histocompatibility complex (MHC-I antigen). Vical is conducting a phase 3 pivotal trial of Allovectin-7 cancer
immunotherapeutic as first-line therapy in chemotherapy-naive patients with stage III or IV metastatic melanoma.
Deal Information
Deal Status
Completed
Completed Date
03-Aug-2009
Deal Product
Product Description
velimogene aliplasmid
<p>Allovectin-7 (velimogene aliplasmid) was under development for the treatment of

metastatic melanoma, primary, resectable squamous cell carcinoma of the oral cavity or
oropharynx. Allovectin-7 is a plasmid/lipid complex containing the DNA sequences
encoding HLA-B7 and beta2 microglobulin, which together form a major histocompatibility
complex, or MHC, class I. The drug candidate is administered intratumorally. The drug
candidate is developed by plasmid DNA (pDNA) technology.</p>
Licensor Name
Vical Incorporated
Vical Incorporated (Vical) is a biopharmaceutical company. It undertakes the research and development of biopharmaceutical
products based on its patented DNA delivery technologies for the prevention and treatment of life-threatening diseases.
Potential applications of the DNA delivery technology include DNA vaccines for infectious diseases, in which the expressed
protein is an immunogen; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. It is
developing certain infectious disease vaccines internally. Besides, the company collaborates with major pharmaceutical
companies and biotechnology companies that give it access to complementary technologies or greater resources. These
strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address
significant unmet medical needs. Vical is headquartered in California, the US.
Licensee Name
Abic Marketing Limited
Parent
Teva
Pharmaceutical
Industries Limited
Abic Marketing Limited is a subsidiary of Teva Pharmaceutical Industries Limited, a global pharmaceutical company. It is
engagaed in supporting the parent company's business operations.
GlobalData


Page 185
Merck Extends Collaboration Agreement With MicroDose Therapeutx

Merck Extends Collaboration Agreement With MicroDose Therapeutx
Deal Type
Licensing Agreement
Deal in Brief
Merck & Co., Inc., a global pharmaceutical company, through an affiliate, extended its collaboration agreement with MicroDose
Therapeutx Inc. (formerly MicroDose Technologies, Inc.), a biopharmaceutical company. Under the terms of the agreement,
Merck has exercised the option to extend its license to the MicroDose Dry Powder Inhaler (DPI) technology to an additional
investigational compound. Merck will make a payment of an undisclosed exercise fee to MicroDose.
Earlier in March 2008, both the partners entered into a licensing agreement, where in Merck received the right to use
MicroDose's proprietary dry powder inhaler (DPI) with Merck compounds. Under this agreement, MicroDose will receive an
upfront payment and will be eligible for milestone payments totaling $32 million for successful development of the first product
as well as royalties on product revenues. Additional products will also be eligible for milestones and royalties.
Deal Information
Deal Status
Completed
Completed Date
22-Jul-2009
Deal Financials
32
Licensor Name
Parent
Teva
Pharmaceutical
Industries Limited
Licensee Name
Merck & Co., Inc.
Merck & Co., Inc. (Merck), also known as MSD outside the US and Canada, is a research-driven global healthcare company. It
conducts the discovery, development, manufacture and commercialization of branded pharmaceuticals, biologic therapies,
prescription and over-the-counter (OTC) pharmaceuticals, vaccines, consumer care products and animal healthcare products.
The major clients of the company include wholesalers and retailers, hospitals, government agencies, managed health care
providers, and veterinarians. Merck sells its products through direct sales force and a network of subsidiaries and joint ventures
across the US, Europe, the Middle East and Africa, Asia Pacific and Other countries. Merck is headquartered in Whitehouse
Station, New Jersey, the US.
GlobalData


Page 186
Acusphere Amends Licensing Agreement With Cephalon

Acusphere Amends Licensing Agreement With Cephalon
Deal Type
Licensing Agreement
Product Phase
Preclinical
Deal in Brief
Acusphere, Inc., a pharmaceutical company, amended its licensing agreement with Cephalon, Inc., a biopharmaceutical
company, for AI-525, a preclinical-stage injectable formulation of celecoxib.Under the terms of the amended agreement,
Cephalon paid $1 million payment to Acusphere. Cephalon will assume primary responsibility for patent prosecution of licensed
technology. As a result of the transaction, Cephalon will no longer have any rights related to equity ownership in Acusphere or
any product rights to Imagify (Perflubutane Polymer Microspheres) for Injectable Suspension. Earlier on October 24, 2008, the
partners have entered into licensing agreement, under which Cephalon received worldwide license to AI-525, a preclinicalstage injectable formulation of celecoxib using Acuspheres Hydrophobic Drug Delivery System technology. In return,
Acusphere received an upfront payment of $5 million from Cephalon and was to receive $15 million as milestone payment,
upon FDA approval of the initial indication and a royalty on global net sales.AI-525 is an injectable formulation of the
hydrophobic drug, celecoxib, used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and
menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis.
Deal Information
Deal Status
Completed
Completed Date
24-Jun-2009
Deal Financials
1
1
Cash (US$ m)
Deal Product
Product Description
celecoxib
AI-525 is under development as an analgesic and anti inflammatory agent the treatment of
pain. The drug candidate is a formulation of the hydrophobic drug, celecoxib. It is administered
parentrally. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) with a diarylsubstituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and
metastasis. The drug candidate is being developed using the proprietary Hydrophobic Drug
Delivery System (HDDS) technology
Licensor Name
Acusphere, Inc.
Acusphere, Inc. (Acusphere) is a specialty pharmaceutical company. It focuses on the development of its lead product
candidate, Imagify (perflubutane polymer microspheres) for injectible suspension, a cardiovascular drug for the diagnosis of
coronary artery diseases (CAD). The company develops its products based on microsphere technology that enables to create a
wide range of new drugs by reformulating hydrophobic drugs and creating sustained release formulations of existing drugs.
Acusphere submitted the Marketing Authorisation Application (MAA) for Imagify with the European Medicines Agency (EMA) for
regulatory review in the European Union (EU). It also reached an agreement with the US FDA under a Special Protocol
Assessment (SPA) on the design of a new Phase III placebo trial comparing stress ultrasound with Imagify to stress ultrasound
without Imagify for the detection of CAD. Acusphere is headquartered in Lexington, Massachusetts, the US.
Licensee Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries
Limited,Teva

Page 187
GlobalData


Page 188
Cephalon Enters Into Licensing Agreement With SymBio Pharma

Cephalon Enters Into Licensing Agreement With SymBio Pharma
Deal Type
Licensing Agreement
Product Phase
Phase II
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, has entered into licensing agreement with SymBio Pharmaceuticals Limited, a
biotechnology company, by exercising an option, for SyB L-0501 (bendamustine hydrochloride).
Under the agreement, SymBio granted Cephalon exclusive development and commercialization rights of SyB L-0501
(bendamustine hydrochloride) in China (including Hong Kong) and received an option exercise payment of $0.8 million.
SyB L-0501, the principle ingredient of Bendamustine Hydrochloride is indicated for the treatment of non-Hodgkin's lymphoma,
multiple myeloma and chronic lymphocytic leukemia.
Deal Information
Deal Status
Completed
Completed Date
09-Mar-2009
Deal Financials
0.80
0.80
0.80
Cash (US$ m)
Deal Product
Product Description
bendamustine hydrochloride
Bendamustine Hydrochloride is a bifunctional mechlorethamine derivative with alkylating and

anti metabolite activities. It is indicated for the treatment of refractory /relapsed
intermediate/high-grade Non-Hodgkin's Lymphoma, multiple myeloma, frontline low-grade
Non-Hodgkin's Lymphoma and frontline mantle cell lymphoma, indolent non-hodgkin's
lymphoma, and chronic lymphocytic leukemia, Indolent B-cell NHL and low grade NHL. It is
administered as intravenous infusion. Bendamustine metabolites alkylates and crosslink
macromolecules in DNA resulting in inhibition of DNA, RNA and protein synthesis. Then it
stops the growth of cancer cells. It activates p53-dependent stress pathways thereby induce
apoptosis in cancer cells. It also induce mitotic catastrophe and DNA repair pathways. It is also
under development for the treatment of non-Hodgkin lymphoma, relapsed or refractory multiple
myeloma, mantle cell lymphoma, and indolent non-Hodgkin's lymphoma.
Licensor Name
SymBio
Limited
Pharmaceuticals
in Tokyo, Japan.
Licensee Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries
Limited,Teva

Page 189
GlobalData


Page 190
Shire Amends Its Agreement With Duramed Pharma

Shire Amends Its Agreement With Duramed Pharma
Deal Type
Licensing Agreement
Deal in Brief
Shire LLC, a subsidiary of Shire plc, a specialty biopharmaceutical company, amended its development and license agreement
with Duramed Pharmaceuticals, Inc., an affiliate of Barr Laboratories, Inc., for the women's health products.
Under the terms of amended agreement, Shire is agreed return to Duramed its rights and interests under agreement effective
February 24, 2009 and the agreement will terminate on December 31, 2009. Shire also agreed to reimburse Duramed the
development expenditure in 2009 up to a maximum of $30 million. Shire agreed to a one-time payment to Duramed of $10
million and to forego royalties receivable from Barr and cost of goods otherwise payable by Barr to Shire in 2009 under the
license agreement between the parties for the supply of authorized generic ADDERALL XR, up to a maximum of $25 million.
Earlier in August 2006, both companies entered into collaboration and license agreement related to Seasonique, a number of
products using Duramed's transvaginal ring technology and other oral products.
Deal Information
Deal Status
Completed
Completed Date
24-Feb-2009
Deal Financials
Deal Value (US$ m)
40
10
10
Cash (US$ m)
30
Licensor Name
Teva Women's Health
Parent

(Inactive)

Licensee Name
Shire Plc
Shire Plc (Shire) is a specialty biopharmaceutical company. It focuses on the research, development and commercialization of
specialty pharmaceutical products. The company offers a wide range of products in the areas of rare diseases, neuroscience,
gastrointestinal (GI) and internal medicine. Some of its key products include Vyvanse for the treatment of attention deficit and
hyperactivity disorder (ADHD), Lialda/ Mezavant for the treatment of ulcerative colitis, Elaprase for Hunter syndrome, Cinryze
for hereditary angioedema (HAE) and Replagal for Fabry disease. Shire is also focused at developing a portfolio of pipeline
products covering the areas of neuroscience, rare diseases, ophthalmology, hematology and GI. The company operates along
with its subsidiaries and representative offices in several countries with major operations in the US, UK and Switzerland. The
company markets its products in various countries worldwide. Shire is headquartered in Dublin, Ireland.
GlobalData


Page 191
Cephalon Enters Into Licensing Agreement With ImmuPharma For Lupuzor

Cephalon Enters Into Licensing Agreement With ImmuPharma For Lupuzor
Deal Type
Licensing Agreement
Product Phase
Phase II
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, entered into a licensing agreement with ImmuPharma PLC, a drug discovery
and development company, for Lupuzor, a first-in-class immune modulating treatment to modulate a specific subset of CD4 T
cells which play a critical role in the physiopathology of Lupus.
Under the agreement, Cephalon received an exclusive worldwide license to Lupuzor from ImmuPharma. ImmuPharma received
an upfront option payment of $15m and a one-time license fee of $30m following the exercise of option agreement.
ImmuPharma is entitled to receive future milestone payments totaling up to $455m based on the achievement of certain
regulatory and sales milestones. ImmuPharma will also receive royalties on commercial sales of Lupuzor. Cephalon agreed to
assume all expenses for Phase III studies and subsequent commercialization of the product.
Frank Baldino, chairman and CEO of Cephalon, said, These study results are encouraging and bring us one step closer to
providing the first specific medication for the treatment of lupus to patients living with this chronic, potentially life-threatening
disease. Lupuzor recently received a notice of allowance for its novel composition of matter patent, which will support our
development of the product. If our efforts are successful, this product and our recent deal with Ception Therapeutics will allow
us to build a business unit focused on inflammatory diseases.
Dimitri Dimitriou, CEO of ImmuPharma, said, We are truly delighted to have this agreement with Cephalon and believe they
would be a great partner to take Lupuzor forward. It represents an important landmark for the company and secures the future
for our most advanced asset. Importantly, we have appreciated the positive chemistry between Cephalon and ourselves and
believe we would work well together.
This agreement enables Cephalon to further diversify its product portfolio and bring the first specific medication for the
treatment of lupus. It also enables ImmuPharma to accelerate the Phase III program and potential commercialization of
Lupuzor thereby allowing lupus patients access to treatment as soon as possible.
Deal history
Completed: On February 2, 2009, Cephalon exercised its option to receive worldwide rights to Lupuzor from ImmuPharma
based on the promising interim results of the ImmuPharma Phase IIb study.
Announced: On November 25, 2008, Cephalon entered into an option agreement with ImmuPharma for the worldwide license
to Lupuzor. Under the agreement, Cephalon received an option to obtain an exclusive worldwide license based on the
successful interim results of the Phase IIb study. ImmuPharma received an upfront option payment of $15m.
Deal Rationale
This agreement enables Cephalon to further diversify its product portfolio and bring the first specific medication for the
treatment of lupus. It also enables ImmuPharma to accelerate the Phase III program and potential commercialization of
Lupuzor thereby allowing lupus patients access to treatment as soon as possible.
Deal Information
Deal Status
Completed
Announced Date
25-Nov-2008
Completed Date
02-Feb-2009
Deal Financials
Deal Value (US$ m)
500
45
45
Cash (US$ m)
455
Deal Product
Product Description
forigerimod acetate


Page 192

Licensor Name
Immupharma Plc
ImmuPharma plc (ImmuPharma) develops novel drugs for the treatment of serious medical conditions with unmet medical
need. ImmuPharma has five drugs in development stage towards the treatment of lupus, cancer, moderate to severe pain,
highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection and inflammatory
disorders including rheumatoid arthritis and asthma. The companys product pipeline comprises Lupuzor, for the treatment of
Lupus; IPP-204106, for the treatment of cancer; IPP-102199, for the treatment of moderate and severe pain, IPP-203101, for
the treatment of highly resistant, hospital-acquired infections, such as MRSA; and IPP-201007, for the treatment of
inflammatory and allergic disorders. It has operations in France and Switzerland. ImmuPharma is headquartered in London, the
UK.
Licensee Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries
Limited,Teva
GlobalData


Page 193
Codexis Enters Into Licensing Agreement With Teva Pharma

Codexis Enters Into Licensing Agreement With Teva Pharma
Deal Type
Licensing Agreement
Deal in Brief
Codexis, Inc., a clean technology company, entered into licensing agreement with Teva Pharmaceutical Industries Ltd, a
pharmaceutical company, to produce a generic product using a proprietary Codexis' biocatalyst.
Under the agreement, Teva Pharmaceutical received an exclusive licensing rights to produce a undisclosed generic product by
using the Codexis' process for key process steps in the manufacture of the product, assuming technical milestones are met.
Codexis' proprietary custom biocatalyst contributes to lower pharmaceutical process development and manufacturing costs.
Alan Shaw, CEO and president of Codexis, said: Our proven technology reduces the cost of pharmaceutical process
development and manufacturing, and provides our partners with a significant competitive advantage as they respond to
increasing market demands for lower cost pharmaceuticals.
This agreement will enable Codexis to increase market demands for lower cost pharmaceuticals.
Deal Rationale
This agreement will enable Codexis to increase market demands for lower cost pharmaceuticals.
Deal Information
Deal Status
Completed
Completed Date
07-Jan-2009
Licensor Name
Codexis, Inc.
Codexis, Inc. (Codexis) is a biotechnology company. It undertakes the development of biocatalysts for fine chemical and
pharmaceutical production. The company discovers, identifies, optimizes, produces and offers enzyme optimization services by
utilizing its technology platforms such as CodeXporter enzyme production platform and CodeEvolver evolution technology
platforms. Its product portfolio includes pharmaceutical enzymes and intermediates, active pharmaceutical ingredients, Codex
screening panels and kits, and enzyme platforms. Codexis offers a wide range of biocatalysis solutions ranging from screening
and optimization to commercial supply of biocatalysts. The company caters its product and services to generic and
pharmaceutical markets. Codexis is headquartered in Redwood, California, the US.
Licensee Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 194
Equity Offering
Ignyta Raises USD42 Million in Private Placement of Shares
Ignyta Raises USD42 Million in Private Placement of Shares
Deal Type
Deal Sub Type
Equity Offering
PIPE
Deal in Brief
Ignyta, Inc., a precision oncology biotechnology company, has completed the private placement of 4,158,750 shares at a price
of USD10 per share, for gross proceeds of approximately USD41.6 million. The offering was subscribed to by Teva
Pharmaceutical Industries Ltd., and selected additional healthcare investors. Teva subscribed up to 1.5 million shares and other
investors subscribed up to 2.7 million shares. Following the offering, Teva holds approximately 12% of Ignyta common shares.
The company received net proceeds of approximately USD41.3 million, after deducting offering expenses.Concurrently, Ignyta
acquired worldwide rights and assets relating to four targeted oncology development programs from Cephalon, an indirect
wholly owned subsidiary of Teva Pharmaceutical Industries Limited, in exchange for 1.5 million shares (6%) of Ignytas
common stock.The company intends to use the proceeds to fund R&D activities for its development programs, and for working
capital and general corporate purposes. Latham & Watkins LLP acted as legal advisor to the company for the offering.Deal
History:Filing: On March 2, 2015, Ignyta filed a registration statement with the US Securities and Exchange Commission (SEC)
for public offering of its securities, to raise gross proceeds of USD150 million. The company, from time to time, may offer
common stock, preferred stock, warrants, debt and units, in one or more offerings.
Deal Rationale
The company intends to use the proceeds to fund R&D activities for its development programs, and for working capital and
general corporate purposes.
Deal Information
Deal Status
Completed
Completed Date
17-Mar-2015
Deal Financials
Deal Value (US$ m)
41.60
Shares Issued
4,158,750
Offer Price (US$)
10
Offer Price (US$)
10
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Ignyta, Inc.
Ignyta, Inc. (Ignyta), formerly NexDx, Inc., is a biotechnology company. It discovers, develops and commercializes new drugs
targeting activated genes in cancer cells for the treatment of cancer patients. The company develops products using integrated
therapeutic (Rx) and companion diagnostic (Dx) platform. The pipeline products of the company include Entrectinib (formerly
RXDX-101; RXDX-102), RXDX-103, RXDX-104 and Spark Programs. Entrectinib is a tyrosine kinase inhibitor of the TrkA,
TrkB, TrkC, ROS1 and ALK proteins and is used for the targeted therapeutic treatment for patients with cancers. RXDX-103 is

Page 195
an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase. RXDX-104 is a program designed to inhibit the RET
tyrosine kinase. The company also develops Trailblaze Diagnostic Programs. Ignytais headquartered in San Diego, California,
the US.
Advisor Information
Legal Advisor
Ignyta, Inc.
Latham & Watkins LLP
GlobalData


Page 196
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares

Deal Type
Deal Sub Type
Equity Offering
Secondary Offering
Deal in Brief
Auspex Pharmaceuticals, Inc., a biopharmaceutical company, has completed an underwritten public offering of 3,600,000
shares of its common stock at a price of USD56.5 per share, for gross proceeds of USD203.4 million, including the underwriters
over-allotment option of 600,000 shares, for additional gross proceeds of USD33.9 million.The company intends to use the
proceeds to fund building the commercial organization for, and commercial launch of, SD-809, if approved, for the potential
treatment of chorea associated with Huntingtons disease; for R&D, including, but not limited to funding future clinical and
regulatory expenses related to SD-809 and related to the NDA filing and preparation for the commercial launch of SD-809, if
approved, for other indications, such as tardive dyskinesia; to support the development of SD-560 and other programs in its
pipeline; and for working capital and other general corporate purposes, including making monthly principal and interest
payments on its credit facility. It may also use a portion of the proceeds to in-license, acquire, or invest in complementary
businesses, technologies, products or assets.J.P. Morgan Securities LLC acted as book-running manager; Stifel, Nicolaus &
Company, Incorporated and BMO Capital Markets Corp acted as co-lead managers; Robert W. Baird & Co. Incorporated and
William Blair & Company, L.L.C acted as co-managers; Maxim Group LLC acted as an advisor; while Cooley LLP acted as
legal advisor to the company for the offering.Deal History:Pricing: On January 22, 2015, Auspex Pharma has priced an
underwritten public offering of 3,000,000 shares of its common stock at a price of USD56.5 per share, to raise gross proceeds
of USD169.5 million. In addition, the company has granted underwriters a 30-day option to purchase up to an additional
600,000 shares of common stock, to cover any over-allotments.Announced: On January 21, 2015, Auspex Pharma has
announced an underwritten public offering of 3,000,000 shares of its common stock. In addition, the company has granted
underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock, to cover any overallotments.Filing: On January 7, 2015, Auspex Pharma has filed a registration statement with the US Securities and Exchange
Commission (SEC) for public offering of shares of its common stock. In addition, the company granted the underwriters a 30day option to purchase additional shares of common stock, to cover any over-allotments.
Deal Rationale
The company intends to use the proceeds to fund building the commercial organization for, and commercial launch of, SD-809,
if approved, for the potential treatment of chorea associated with Huntingtons disease; for R&D, including, but not limited to
funding future clinical and regulatory expenses related to SD-809 and related to the NDA filing and preparation for the
commercial launch of SD-809, if approved, for other indications, such as tardive dyskinesia; to support the development of SD560 and other programs in its pipeline; and for working capital and other general corporate purposes, including making monthly
principal and interest payments on its credit facility. It may also use a portion of the proceeds to in-license, acquire, or invest in
complementary businesses, technologies, products or assets.
Deal Information
Deal Status
Completed
Announced Date
21-Jan-2015
Completed Date
28-Jan-2015
Deal Financials
Deal Value (US$ m)
203.40
Shares Issued
3,000,000
Offer Price (US$)
56.50
Offer Price (US$)
56.50
Deal Product
Product Description
dutetrabenazine ER

technology.

Page 197

Company Name
Auspex
Inc.
Pharmaceuticals,
Parent
Teva
Pharmaceutical
Industries Limited
California, the US.
Advisor Information
Legal Advisor
Auspex
Inc.
Cooley LLP
Pharmaceuticals,
Book Runner
Auspex
Inc.
J.P. Morgan Securities LLC
Pharmaceuticals,
Under Writer
Auspex
Inc.
William Blair & Company,

L.L.C.
Pharmaceuticals,
BMO Capital Markets Corp.

Robert W. Baird
Incorporated
&
Co.
Stifel, Nicolaus & Company,

Incorporated
Share Price Information
Share Price Before 30 Days
(US$)
53.37
Share Price Before 1 Day

(US$)
60.84
Financial Information (Auspex Pharmaceuticals, Inc.)

(Trailing Twelve Months Ended 30-Sep-2014)
Financial Ratios Information
EV/Total Assets
9.63
Cash Value Per Share (US$)
3.26
Net Assets Per Share Ratio

(US$)
5.08
Book Value Per Share (US$)
5.08
GlobalData


Page 198

Deal Type
Deal Sub Type
Equity Offering
Secondary Offering
Deal in Brief
Auspex Pharmaceuticals, Inc., a biopharmaceutical company, has completed an underwritten public offering of shares of its
common stock, for gross proceeds of USD69.73 million. The company issued 3,622,500 shares, including the underwriters
exercise of full over-allotment option of 472,500 shares, at a price of USD19.25 per share.The company intends to use the
proceeds to fund an additional Phase III pivotal clinical trial of SD-809 in patients with tardive dyskinesia; for R&D, including, but
not limited to funding future clinical and regulatory expenses related to SD-809 and related to the new drug application (NDA)
filing and commercial launch of SD-809, if approved, for the treatment of chorea associated with Huntingtons disease; and for
working capital and other general corporate purposes, including making monthly principal and interest payments on its credit
facility. The company may also use the proceeds to in-license, acquire, or invest in complementary businesses, technologies,
products or assets.Stifel, Nicolaus & Company, Incorporated and BMO Capital Markets Corp acted acting as joint book-running
managers; Robert W. Baird & Co. Incorporated, William Blair & Company, L.L.C., Ladenburg Thalmann & Co. Inc. acted as comanagers; while Cooley LLP acted as legal advisor to the company for the offering.Deal History:Pricing: On July 10, 2014,
Auspex Pharma priced an underwritten public offering of 3,150,000 shares, at a price of USD19.25 per share, to raise gross
proceeds of USD60.6 million. In addition, the company granted underwriters a 30-day option to purchase up to an additional
472,500 shares of common stock to cover over-allotments, if any.Announced: On July 7, 2014, Auspex Pharma announced an
underwritten public offering of 3,000,000 shares of its common stock. In addition, the company has granted the underwriters a
30-day option to purchase up to an additional 450,000 shares of its common stock.Filing: On June 25, 2014, Auspex Pharma
filed a registration statement with the US Securities and Exchange Commission (SEC) for a public offering of its common stock,
to raise gross proceeds of up to USD69 million.
Deal Rationale
The company intends to use the proceeds to fund an additional Phase III pivotal clinical trial of SD-809 in patients with tardive
dyskinesia; for R&D, including, but not limited to funding future clinical and regulatory expenses related to SD-809 and related
to the new drug application (NDA) filing and commercial launch of SD-809, if approved, for the treatment of chorea associated
with Huntingtons disease; and for working capital and other general corporate purposes, including making monthly principal
and interest payments on its credit facility. The company may also use the proceeds to in-license, acquire, or invest in
complementary businesses, technologies, products or assets.
Deal Information
Deal Status
Completed
Announced Date
07-Jul-2014
Completed Date
16-Jul-2014
Deal Financials
Deal Value (US$ m)
60.60
Shares Issued
3,622,500
Offer Price (US$)
19.25
Offer Price (US$)
19.25
Deal Product
Product Description
dutetrabenazine ER

technology.
Company Name
Auspex
Inc.
Pharmaceuticals,
Parent

Teva
Pharmaceutical
Industries Limited
Page 199
California, the US.
Advisor Information
Legal Advisor
Auspex
Inc.
Cooley LLP
Pharmaceuticals,
Book Runner
Auspex
Inc.
Pharmaceuticals,

Incorporated
Under Writer
Auspex
Inc.

L.L.C.
Pharmaceuticals,
Robert W. Baird
Incorporated
&
Co.
Ladenburg Thalmann & Co.

Inc.
(US$)
21.67

(US$)
25.22

(Trailing Twelve Months Ended 31-Mar-2014)
Number of Employees
13

EV/Total Assets
4.70
1.13

(US$)
4.30
GlobalData


Page 200
Auspex Pharma Completes IPO For US$96.6 Million

Auspex Pharma Completes IPO For US$96.6 Million
Deal Type
Deal Sub Type
Equity Offering
IPO
Deal in Brief
Auspex Pharmaceuticals, Inc., a biopharmaceutical company, completed initial public offering (IPO) of shares of its common
stock, for gross proceeds of US$96.6m. The company issued 8,050,000 shares, including the underwriters exercise of full
over-allotment option of 1,050,000 shares, at a price of US$12 per share. The company listed its shares on the NASDAQ
Global Market under the symbol ASPX, on February 5, 2014.The company intends to use the net proceeds to fund the clinical
development of SD-809 for the treatment of chorea associated with Huntingtons disease; planned Phase II/III clinical trial of
SD-809 for the treatment of tardive dyskinesia; Phase Ib clinical trial of SD-809 for the treatment of tics associated with Tourette
syndrome; clinical and regulatory expenses related to SD-809 and related to the launch and commercialization of SD-809, if
approved; acquire, or invest in complementary businesses, technologies, products or assets; and for R&D, working capital and
other general corporate purposes, including making monthly principal and interest payments on credit facility and the additional
costs associated with being a public company. The company may also use the net proceeds to invest in short- and
intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed
obligations of the US government. Stifel, Nicolaus & Company, Incorporated and BMO Capital Markets Corp. acted as joint
book-running managers, whereas Robert W. Baird & Co. Incorporated, William Blair & Company, L.L.C. and Ladenburg
Thalmann & Co. Inc. acted as joint underwriters; while Cooley LLP acted as legal advisor to the company for the offering.Deal
historyCompleted: On February 10, 2014, Auspex Pharmaceuticals completed initial public offering (IPO) of 8,050,000 shares,
including the underwriters exercise of full over-allotment option of 1,050,000 shares, at a price of US$12 per share, for gross
proceeds of US$96.6m.Priced: On February 5, 2014, Auspex Pharmaceuticals priced initial public offering (IPO) of 7,000,000
shares, at a price of US$12 per share, to raise gross proceeds of US$84m. The company granted underwriters a 30-day option
to purchase up to an aggregate of 1,050,000 shares to cover over-allotments, if any.Update2: On February 4, 2014, Auspex
Pharmaceuticals increased the size of initial public offering (IPO) from 5,500,000 shares to 6,000,000 shares, at a price range
between US$10 and US$12 per share, to raise minimum gross proceeds of US$60m and maximum of US$72m.Announced:
On January 17, 2014, Auspex Pharmaceuticals announced initial public offering (IPO) of 5,500,000 shares, at a price range
between US$10 and US$12 per share, to raise minimum gross proceeds of US$55m and maximum of US$66m. The company
granted underwriters a 30-day option to purchase up to 825,000 additional shares to cover over-allotments, if any.Update1: On
December 20, 2013, Auspex Pharmaceuticals filed registration statement with the US Securities and Exchange Commission
(SEC) for initial public offering (IPO) of shares of its common stock, to raise gross proceeds of up to US$69m.Filing: On
November 21, 2013, Auspex Pharmaceuticals filed a draft registration statement with the US Securities and Exchange
Commission (SEC) for initial public offering (IPO) of shares of its common stock.
Deal Rationale
The company intends to use the net proceeds to fund the clinical development of SD-809 for the treatment of chorea
associated with Huntingtons disease; planned Phase II/III clinical trial of SD-809 for the treatment of tardive dyskinesia; Phase
Ib clinical trial of SD-809 for the treatment of tics associated with Tourette syndrome; clinical and regulatory expenses related to
SD-809 and related to the launch and commercialization of SD-809, if approved; acquire, or invest in complementary
businesses, technologies, products or assets; and for R&D, working capital and other general corporate purposes.
Deal Information
Deal Status
Completed
Announced Date
17-Jan-2014
Completed Date
10-Feb-2014
Deal Financials
Deal Value (US$ m)
96.60
Shares Issued
8,050,000
Offer Price (US$)
12
Deal Product
Product Description
dutetrabenazine ER



Page 201

technology.
Company Name
Auspex
Inc.
Pharmaceuticals,
Parent
Teva
Pharmaceutical
Industries Limited
California, the US.
Advisor Information
Legal Advisor
Auspex
Inc.
Cooley LLP
Pharmaceuticals,
Book Runner
Auspex
Inc.
Pharmaceuticals,

Incorporated
Under Writer
Auspex
Inc.
Robert W. Baird
Incorporated
Pharmaceuticals,
&
Co.

L.L.C.
Ladenburg Thalmann & Co.
Inc.
GlobalData


Page 202
NuPathe Files Registration Statement For Public Offering Of Securities For US$100 Million
NuPathe Files Registration Statement For Public Offering Of Securities For US$100 Million
Deal Type
Deal Sub Type
Equity Offering
Secondary Offering
Deal in Brief
NuPathe, Inc., a specialty pharmaceutical company, filed registration statement with the US Securities and Exchange
Commission (SEC) for public offering of its securities to raise gross proceeds of up to $100m. Under the offering, the company
from time to time may issue common stock; preferred stock; debt securities comprising senior debt securities or subordinated
debt securities; warrants to purchase debt securities, common stock, preferred stock, depositary shares or securities of third
parties or other rights; representing an interest in preferred stock; purchase contracts to purchase debt or equity securities or
securities of third parties; either individually or in units consisting of any combination of such securities, in one or more
offerings.
The company intends to use the net proceeds the development, manufacture and commercial launch of Zecuity; development
of pipeline product candidates; and for general corporate purposes, including working capital, acquisitions, capital expenditures
and the repayment of indebtedness.
Morgan, Lewis & Bockius LLP is acting as legal advisor to the company for the offering.
Deal Rationale
The company intends to use the net proceeds the development, manufacture and commercial launch of Zecuity; development
of pipeline product candidates; and for general corporate purposes, including working capital, acquisitions, capital expenditures
and the repayment of indebtedness.
Deal Information
Deal Status
Filling
Announced Date
Dec 21, 2012
Deal Financials
Deal Value (US$ m)
100
Company Name
NuPathe Inc.
Parent
Teva
Pharmaceutical
Industries Limited
NuPathe Inc. (NuPathe) is a pharmaceutical company. The company develops and commercializes branded therapeutics for
diseases of the central nervous system. Its products under clinical development include NP201, and NP202. NuPathes NP201
is a long-acting formulation of ropinirole, which is designed to provide continuous delivery of Parkinsons disease medication for
up to two month. The companys NP202 is also a long-acting formulation of risperidone that provides three months of continual
medication with a single dose. It is FDA certified company. The company collaborates with University of Pennsylvania, Evonik
Industries AG, and LTS Lohmann Therapie-Systeme AG. NuPathe is headquartered in Conshohocken, Pennsylvania, the US.
Advisor Information
Legal Advisor
NuPathe Inc.
Morgan, Lewis & Bockius

LLP
GlobalData


Page 203
NuPathe Completes Private Placement Of Units For US$28 Million

NuPathe Completes Private Placement Of Units For US$28 Million
Deal Type
Deal Sub Type
Equity Offering
PIPE
Deal in Brief
NuPathe, Inc., a specialty pharmaceutical company, completed private placement of units for gross proceeds of $28m. Under
the offering, the company issued 14 million units at a price of $2 per unit, to existing and new investors. Each unit consists of
1/1,000th of a share of series A preferred stock and a warrant to purchase one share of common stock.
Each 1/1,000th of a share of series A preferred stock will initially be convertible into one share of common stock, accrue
quarterly dividends at an initial rate of 8% per annum, have a liquidation preference of $2 (plus accrued and unpaid dividends),
and have certain other powers, preferences and rights. The holders of the series A preferred stock shall initially be entitled to
elect three directors to the company's board of directors and certain corporate actions will require the approval of a majority of
the outstanding shares of series A preferred stock. The warrants are exercisable at a price of $2 per share and will expire five
years from the date of issuance. Both the series A preferred stock and warrants include full ratchet antidilution protection. The
series A preferred stock will automatically convert into common stock and the antidilution feature of the warrants will terminate
upon certain specified conditions.
In conjunction with the financing, James A. Datin, executive vice-president and managing director, and Brian J. Sisko, senior
vice-president and general counsel at Safeguard Scientifics, Inc; Richard S. Kollender, partner at Quaker Partners
Management, L.P. joined NuPathe as board of directors, while Jeanne Cunicelli, investment partner at Bay City Capital LLC,
and Gary Kurtzman, senior vice- president and managing director of Safeguard, resigned from the board.
Armando Anido, CEO of NuPathe, said, "We welcome Jim, Brian and Richard to our board, and expect their significant industry
and business expertise to be strong assets for NuPathe as we work to obtain approval for Zecuity, seek a commercial partner,
and conduct pre-launch activities for this valuable new treatment. We also thank Jeanne and Gary for their valuable
contributions to the company."
The company intends to use the proceeds to fund operations for approximately one year; and obtain approval for NP101, a
transdermal patch for the treatment of migraine.
Leerink Swann LLC acted as lead placement agent and MTS Securities, LLC acted as co-placement agent to NuPathe for the
offering.
Deal history
Completed: On October 23, 2012, NuPathe completed private placement of 14 million units at a price of $2 per unit for gross
proceeds of $28m, to existing and new investors
Announced: On September 25, 2012, NuPathe announced private placement of 14 million units at a price of $2 per unit for
gross proceeds of $28m, to existing and new investors.
Deal Rationale
The company intends to use the proceeds to fund operations for approximately one year; and obtain approval for NP101, a
transdermal patch for the treatment of migraine.
Deal Information
Deal Status
Completed
Announced Date
25-Sep-2012
Completed Date
23-Oct-2012
Deal Financials
Deal Value (US$ m)
28
Shares Issued
14,000,000
Offer Price (US$)
Company Name
NuPathe Inc.
Parent
Teva
Pharmaceutical
Industries Limited

Page 204
Advisor Information
Placement Agent
NuPathe Inc.
Leerink Partners LLC

MTS Securities, LLC
GlobalData


Page 205
NuPathe Completes Second Tranche Of Private Placement Of Common Stock For US$0.6 Million
NuPathe Completes Second Tranche Of Private Placement Of Common Stock For US$0.6 Million
Deal Type
Deal Sub Type
Equity Offering
PIPE
Deal in Brief
NuPathe Inc., a specialty pharmaceutical company, completed second tranche of private placement of its common stock, for
gross proceeds of $0.6m, bringing the total proceeds raised to $1.1m. In total, the company issued 155,587 shares of common
stock at a price of $7.07 per share, to Aspire Capital Fund, LLC.
NuPathe has an obligation to raise total gross proceeds of up to $30m and net proceeds of approximately $29.9m, through the
issuance of shares from time to time to Aspire Capital, over the next 24 months. The pricing for the additional shares will be
determined each time the company elects to sell shares to Aspire, based upon a predetermined formula as set forth in the
purchase agreement. Morgan, Lewis & Bockius LLP acted as legal advisor to the company on the offering.
Jane H. Hollingsworth, chief executive officer of NuPathe, said, "We intend to use this facility opportunistically to add to our
balance sheet. Securing this facility furthers our goal of building our financial strength and flexibility as we continue to prepare
for the expected launch of our migraine patch in the first half of 2012. Aspire Capital's decision to make an initial investment at
a premium to the current market price shows confidence in NuPathe and our ability to execute. We look forward to bringing this
innovative product to market for the millions of under-served migraine patients and particularly for those who suffer from
migraine-related nausea."
The company intends to use the proceeds to get marketing approval for the initiation of commercial manufacture and
commercial launch of NP101 (also Zelrix) in the US. It may also use the proceeds for working capital and other general
corporate purposes, including the acquisition or licensing of other products or technologies, or the acquisition of other
businesses in the biotechnology or specialty pharmaceuticals industry.
Deal history
Completed: On August 8, 2011, NuPathe completed second tranche of private placement of 84,866 shares of common stock at
a price of $7.07 per share, to Aspire Capital Fund, for gross proceeds of $0.6m, bringing the total proceeds to $1.1m.
Announced/ First Tranche: On August 2, 2011, NuPathe completed first tranche of private placement of 70,721 shares of its
common stock at a price of $7.07 per share, to Aspire Capital Fund, for gross proceeds of $0.5m.
Deal Rationale
The company intends to use the proceeds to get marketing approval for the initiation of commercial manufacture and
commercial launch of NP101 (also Zelrix) in the US. It may also use the proceeds for working capital and other general
corporate purposes, including the acquisition or licensing of other products or technologies, or the acquisition of other
businesses in the biotechnology or specialty pharmaceuticals industry.
Deal Information
Deal Status
Completed
Announced Date
02-Aug-2011
Completed Date
08-Aug-2011
Deal Financials
Deal Value (US$ m)
1.10
Shares Issued
155,587
Offer Price (US$)
7.07
Company Name
NuPathe Inc.
Parent
Teva
Pharmaceutical
Industries Limited


Page 206
Acquirer Firm Information

Firm Name
Aspire Capital Fund, LLC
Advisor Information
Legal Advisor
NuPathe Inc.

LLP

(US$)
7.46

(US$)
6.86
Financial Information (NuPathe Inc.)

Number of Employees
26

EV/Revenues
111.18
EV/Total Assets
1.84
2.25

(US$)
2.12
2.12
GlobalData


Page 207
NuPathe Completes IPO Of US$50 Million

NuPathe Completes IPO Of US$50 Million
Deal Type
Deal Sub Type
Equity Offering
IPO
Deal in Brief
NuPathe Inc., a specialty pharmaceutical company, completed initial public offering of its common stock, for gross proceeds of
$50 million. The company issued 5,000,000 common shares at a price of $10 per share. The company received net proceeds
of $43 million, after deducting underwriting fees and offering expenses.
The company listed its shares on the NASDAQ Global Market under the ticker symbol PATH.
Leerink Swann LLC and Lazard Capital Markets LLC acted as joint book-running managers, MTS Securities, LLC acted as
financial advisor, Stifel, Nicolaus & Company and Thomas Weisel Partners LLC acted as underwriters and Needham &
Company, LLC acted as co-manager to the company for the offering. Morgan, Lewis & Bockius LLP acted as legal advisor.
The company intends to use the proceeds from the offering for the development and marketing approvals of Zelrix in the US,
for the preclinical and clinical development of NP201 and NP202, as well as for the working capital and general corporate
purposes including the acquisition or licensing of other products or technologies.
Deal history
Completed: On August 11, 2010, NuPathe completed initial public offering of 5,000,000 common shares at a price of $10 per
share, for gross proceeds of $50 million.
Pricing: On August 6, 2010, NuPathe has priced the initial public offering of 5,000,000 common shares at a price of $10 per
share, to raise gross proceeds of $50 million.
Update: On August 5, 2010, NuPathe decreased the price of the initial public offering to $10 per share from a price range of
$14 - $16 per share. The company will issue 5,000,000 common shares to raise gross proceeds of $50 million.
Announced: On July 21, 2010, NuPathe announced initial public offering of 5,000,000 common shares at a price range of $14 $16 per share, to raise minimum gross proceeds of $70 million and maximum proceeds of $80 million.
Filing: On May 14, 2010, NuPathe filed a registration statement with the US Securities and Exchange Commission, for an initial
public offering of common stock, to raise gross proceeds of $86.25 million.
Deal Rationale
NuPathe intends to use the proceeds for the development and marketing approvals of Zelrix in the US, for the preclinical and
clinical development of NP201 and NP202, and also for working capital and general corporate purposes.
Deal Information
Deal Status
Completed
Announced Date
21-Jul-2010
Completed Date
11-Aug-2010
Deal Financials
Deal Value (US$ m)
50
Shares Issued
5,000,000
Offer Price (US$)
10
Net Proceeds (US$ m)
43
Company Name
NuPathe Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Advisor Information

Page 208
Legal Advisor
NuPathe Inc.

LLP
Book Runner
NuPathe Inc.
Leerink Partners LLC

Lazard Capital Markets, LLC
Under Writer
NuPathe Inc.
Thomas
LLC
Weisel
Partners
Needham & Company, LLC

Stifel Nicolaus Weisel
Financial Advisor
NuPathe Inc.
MTS Securities, LLC

(US$)
10

(Trailing Twelve Months Ended 30-Jun-2010)
Number of Employees
22

EV/Total Assets
15.72
0.58
GlobalData


Page 209
ChemGenex Completes Rights Issue Of US$5.76 Million

ChemGenex Completes Rights Issue Of US$5.76 Million
Deal Type
Deal Sub Type
Equity Offering
Secondary Offering
Deal in Brief
ChemGenex Pharmaceuticals Limited, completed non-renounceable rights issue of its common stock, for gross proceeds of
AUD7.4m ($5.76m).
The company issued 17,122,453 shares at a price of AUD0.43 ($0.33) per share to eligible shareholders along with existing
shareholders Alta Partners, GBS Venture Partners Limited and Orbis Investment Management Limited, on the basis of one new
share for every 14 shares held.
The company intends to use the proceeds to complete clinical development and regulatory filings in the US and Europe for
omacetaxine in CML patients, to further progress discussions with pharmaceutical companies to secure marketing and
distribution partners for omacetaxine outside of the US and to prepare for the commercial launch of omacetaxine in the US.
Dr Greg Collier, managing director and chief executive officer of ChemGenex, said: We are delighted that there has been such
a strong interest in this rights issue, and welcome several new institutional investors to the company. Having completed a very
successful capital raising, we now look forward to clinical and pre-clinical data on omacetaxine being presented at oral sessions
of two major international conferences in the coming weeks, and the completion of the first US and European regulatory
submissions for omacetaxine in mid-year.
ABN AMRO Morgans Corporate Limited acted as underwriter for the rights issue.
Deal Rationale
The company intends to use the proceeds to complete clinical development and regulatory filings in the US and Europe for
omacetaxine in CML patients, to further progress discussions with pharmaceutical companies to secure marketing and
distribution partners for omacetaxine outside of the US and to prepare for the commercial launch of omacetaxine in the US.
Deal Information
Deal Status
Completed
Announced Date
09-Apr-2009
Completed Date
27-May-2009
Deal Financials
Deal Value (AUD million)
7.40
Shares Issued
Deal Value (US$ m)
5.76
17,122,453
Offer Price (Local)
0.43
Offer Price (US$)
0.33
Company Name
ChemGenex
Parent
Teva
Pharmaceutical
Industries Limited
Advisor Information
Under Writer
ChemGenex
ABN
AMRO
Corporate Limited
Morgans
Financial Information (ChemGenex Pharmaceuticals Limited)

(Trailing Twelve Months Ended 31-Dec-2008)


Page 210
Number of Employees
Operating Margin(%)
17
10,356.25
9.69
GlobalData


Page 211
Cephalon Completes Public Offering Of US$300 Million

Cephalon Completes Public Offering Of US$300 Million
Deal Type
Deal Sub Type
Equity Offering
Secondary Offering
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, completed its public offering of common shares for gross proceeds of $300
million. The company issued 5 million common shares at a price of $60 per share. The company received net cash proceeds of
$288 million from the offering after deduction of estimated offering expenses and the underwriters' discounts and commissions.
The company intends to use the net proceeds from the offering for general corporate purposes.
Deutsche Bank Securities, Inc. acted as sole book-running manager; while J.P. Morgan Securities, Inc.; Barclays Capital, Inc.;
Credit Suisse Securities (USA) LLC; Morgan Stanley & Co. Incorporated; ABN AMRO Incorporated; Piper Jaffray & Co.; and
Wachovia Capital Markets, LLC acted as co-managers for the offering. Sidley Austin LLP acted as legal advisor to Cephalon
while Cleary Gottlieb Steen & Hamilton LLP acted as legal advisor to underwriters for the offering.
Deal Rationale
Cephalon intends to use the net proceeds from the offering for general corporate purposes.
Deal Information
Deal Status
Completed
Announced Date
20-May-2009
Completed Date
27-May-2009
Deal Financials
Deal Value (US$ m)
300
Shares Issued
5,000,000
Offer Price (US$)
60
288
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
Cephalon, Inc.
Sidley Austin LLP
Book Runner
Cephalon, Inc.

Inc.
Under Writer
Cephalon, Inc.

Piper Jaffray & Co.
ABN AMRO, Inc.
Morgan Stanley


Page 212
Wachovia Capital Markets,

LLC
Barclays Capital Inc.
Credit Suisse
(USA) LLC
Securities

(US$)
66.29

(US$)
62.17
Financial Information (Cephalon, Inc.)

Operating Margin(%)
EV/Revenues
10.32
2.18
EV/Operating Profit
21.08
EV/EBITDA
11.69
EV/Total Assets
1.25
8.93

(US$)
26
3.77
Earnings per share (US$ )
3.43
Price Earnings Ratio
18.13
GlobalData


Page 213
ChemGenex Completes Private Placement Of US$7 Million

ChemGenex Completes Private Placement Of US$7 Million
Deal Type
Deal Sub Type
Equity Offering
PIPE
Deal in Brief
ChemGenex Pharmaceuticals Limited, a pharmaceutical company, completed private placement of its ordinary shares, for
gross proceeds of AUD10 ($7) million. The company issued 23,255,814 shares at a price of AUD0.43 ($0.3) per share, to
sophisticated and institutional investors including GBS Venture Partners, Merck Serono, and Orbis Funds Management.
ABN AMRO Morgans Corporate Limited acted as manager for the placement.
Greg Collier, CEO and MD of ChemGenex commented: We are delighted to have completed this capital raising in a difficult
financial climate, and look forward to further consolidating our financial position through the rights issue, We look forward to
completing the regulatory submissions for omacetaxine in the US and Europe over the coming months, and to preparing for the
commercial launch of omacetaxine.
The company intends to use the proceeds of the offering to complete the clinical development of omacetaxine in T315I positive
CML, complete the regulatory filings in the USA and Europe for omacetaxine in T315I positive CML, pre-commercialization and
partnering discussions concerning omacetaxine and prepare for the commercial launch of omacetaxine in the United States.
Deal Rationale
The company intends to use the proceeds of the offering to complete the clinical development of omacetaxine in T315I positive
CML, complete the regulatory filings in the USA and Europe for omacetaxine in T315I positive CML, pre-commercialization and
partnering discussions concerning omacetaxine and prepare for the commercial launch of omacetaxine in the United States.
Deal Information
Deal Status
Completed
Completed Date
09-Apr-2009
Deal Financials
10
Shares Issued
Deal Value (US$ m)
23,255,814
Offer Price (Local)
0.43
Offer Price (US$)
0.30
Company Name
Merck Serono Australia Pty

Ltd.
Parent
Merck KGaA
ChemGenex
Parent
Teva
Pharmaceutical
Industries Limited

Company Name
Firm Name
GBS
Venture
Limited
Partners
GBS Venture Partners (GBS) is a venture capital group. It invests in seed, start-up and early expansion stage of a company in
the range between $0.15 million to $16 million focusing on human therapeutics and diagnostics, animal therapeutics and
diagnostics, medical devices, health information technology, agribusiness, food and environmental technology.


Page 214
Firm Name
Orbis Funds Management
Orbis Funds Management is a assest management company.
Advisor Information
Under Writer
ChemGenex
ABN
AMRO
Corporate Limited
Morgans

(US$)
0.37

EV/Total Assets
1.71
0.04

(US$)
0.18
0.03
GlobalData


Page 215
Debt Offering
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Teva Pharmaceutical Industries Limited, through its finance subsidiary Teva Pharmaceutical Finance Netherlands II B.V., has
completed public offering of senior notes due 2023, for gross proceeds of EUR1.3 billion (USD1.41 billion). The notes bear an
interest rate of 1.25% per annum and will mature in March 2023. The company issued the notes priced at EUR990.59
(USD1,075.81) per EUR1,000 (USD1,086) principal amount. The notes are guaranteed by Teva Pharma.Concurrently, Teva
Pharma completed public offering of senior notes due 2027, for gross proceeds of EUR700 million (USD760.2 million). The
notes bear an interest rate of 1.875% per annum and will mature in March 2027. The company issued the notes priced at
EUR995.01 (USD1,080.61) per EUR1,000 (USD1,086.03) principal amount. The company intends to use the proceeds for
general corporate purposes. Deal History:Announced/Pricing: March 24, 2015, Teva Pharma through its finance subsidiary
Teva Pharmaceutical Finance Netherlands, priced public offering of 1.25% senior notes due 2023, to raise gross proceeds of
EUR1.3 billion (USD1.41 billion). The company priced the notes at EUR990.59 (USD1,075.81) per EUR1,000 (USD1,086)
principal amount.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
24-Mar-2015
Completed Date
31-Mar-2015
Deal Financials
Securities Type Offered
1,300
Deal Value (US$ m)
1,411.84
Senior Notes
Interest Rate (%)
1.25
Maturity Date
24-Mar-2023
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 216
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Teva Pharmaceutical Industries Limited (Teva Pharma), through its finance subsidiary Teva Pharmaceutical Finance
Netherlands II B.V., has completed public offering of senior notes due 2027, for gross proceeds of EUR700 million (USD760.2
million). The notes bear an interest rate of 1.875% per annum and will mature in March 2027. The company issued the notes
priced at EUR995.01 (USD1,080.61) per EUR1,000 (USD1,086.03) principal amount. The notes are guaranteed by Teva
Pharma.Concurrently, Teva Pharma completed public offering of senior notes due 2023, to raise gross proceeds of EUR1.3
billion (USD1.41 billion). The notes bear an interest rate of 1.25% per annum and will mature in March 2023. The company
issued the notes priced at EUR990.59 (USD1,075.81) per EUR1,000 (USD1,086) principal amount. The company intends to
use the proceeds for general corporate purposes. Deal History:Announced/Pricing: On March 31, 2015, Teva Pharma through
its finance subsidiary Teva Pharmaceutical Finance Netherlands, has priced public offering of 1.875% senior notes due 2027,
to raise gross proceeds of EUR700 million (USD760.2 million). The company priced the notes at EUR995.01 (USD1,080.61)
per EUR1,000 (USD1,086.03) principal amount.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
24-Mar-2015
Completed Date
31-Mar-2015
Deal Financials
700
Deal Value (US$ m)
760.22
Senior Notes
Interest Rate (%)
1.88
Maturity Date
24-Mar-2027
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 217
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Teva Pharmaceutical Industries Ltd. through its indirect, wholly owned finance subsidiary Teva Pharmaceutical Finance IV,
LLC, completed public offering of senior notes due 2020 for gross proceeds of $700m. The notes bear a coupon rate of 2.25%
and will mature on March 18, 2020. The company issued the notes priced at $999.55 per $1,000 principal amount. The
company received net proceeds of $697.2m, after deducting underwriting discounts and commissions of $2.8m equal to 0.40%
of the principal amount of the notes. Interest on the notes is payable semi-annually on March 18 and September 18 of each
year, beginning March 18, 2013. The company issued the notes with a spread of 110 basis points, and yield to maturity of
2.257%. The company may redeem the notes, in whole or in part, at any time or from time to time, on at least 20 days, but not
more than 60 days, prior notice. The notes will be redeemable at a redemption price equal to the greater of: 100% of the
principal amount of the notes to be redeemed, or the sum of the present values of the remaining scheduled payments
discounted on a semi-annual basis, at a rate equal to the sum of the Treasury Rate plus 20 basis points, plus accrued and
unpaid interest, if any, but excluding the redemption date.The company intends to use the net proceeds to repay approximately
$700m remaining outstanding under a term loan credit facility due in 2013 and 2014, and redeem the $1 billion outstanding
principal amount of its 1.70% senior notes due November 2014 through a make-whole call. The company may also use the
proceeds to repay other debt and/or for general corporate purposes. Barclays Capital Inc., Goldman, Sachs & Co., J.P. Morgan
Securities LLC and Morgan Stanley & Co. LLC acted as joint book-running managers; BNP Paribas Securities Corp., Citigroup
Global Markets Inc., Credit Suisse Securities (USA) LLC and HSBC Securities (USA) Inc. acted as passive book-runners; DNB
Markets, Inc., Mitsubishi UFJ Securities (USA), Inc., Mizuho Securities USA Inc., PNC Capital Markets LLC, RBC Capital
Markets, LLC and SMBC Nikko Capital Markets Limited acted as co-managers for the offering. Willkie Farr & Gallagher LLP,
VanEps Kunneman VanDoorne, and Tulchinsky Stern Marciano Cohen Levitski & Co. acted as legal advisors to Teva for the
offering.Deal historyCompleted: On December 18, 2012, Teva through its finance subsidiary Teva Pharmaceutical Finance IV,
LLC, completed public offering of 2.25% senior notes due March 18, 2020, for gross proceeds of $700m. Announced/Pricing:
On December 13, 2012, Teva through its finance subsidiary Teva Pharmaceutical Finance IV, LLC, priced public offering of
2.25% senior notes due 2020 at $999.55 per $1,000 principal amount, to raise gross proceeds of $700m.Filing: On December
9, 2011, Teva filed a registration statement with the US Securities and Exchange Commission (SEC) for public offering of its
securities.
Deal Rationale
The company intends to use the net proceeds to repay approximately $700m remaining outstanding under a term loan credit
facility due in 2013 and 2014, and redeem the $1 billion outstanding principal amount of its 1.70% senior notes due November
2014 through a make-whole call. The company may also use the proceeds to repay other debt and/or for general corporate
purposes.
Deal Information
Deal Status
Completed
Announced Date
13-Dec-2012
Completed Date
18-Dec-2012
Deal Financials
Deal Value (US$ m)
700
Senior Notes
Interest Rate (%)
2.25
Maturity Date
18-Mar-2020
Company Name
Teva
Pharmaceutical
Industries Limited

Page 218
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited
Tulchinsky Stern Marciano

Cohen Levitski & Co.
VanEps
VanDoorne
Kunneman
Willkie Farr & Gallagher LLP

Book Runner
Teva
Pharmaceutical
Industries Limited

Morgan Stanley & Co. LLC
Goldman Sachs & Co.
Under Writer
Teva
Pharmaceutical
Industries Limited
Citigroup
Inc.
Global
Markets,
Mizuho Securities USA Inc.

PNC Capital Markets LLC
HSBC Securities (USA), Inc.
SMBC Nikko Capital Markets
Ltd
Mitsubishi UFJ
(USA), Inc.
Securities
DnB Markets, Inc.

Credit Suisse
(USA) LLC
Securities
BNP
Corp.
Securities
Paribas

GlobalData


Page 219
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Teva Pharmaceutical Industries Ltd. through its finance subsidiary Teva Pharmaceutical Finance Company BV, completed
public offering of senior notes due 2022 for gross proceeds of $1.3 billion. The notes bear a coupon rate of 2.95% and will
mature on December 18, 2022. The company issued the notes priced at $998.02 per $1,000 principal amount. The company
received net proceeds of $ 994.15m, after deducting underwriting discounts and commissions of $5.85m equal to 0.45% of the
principal amount of the notes. Interest on the notes is payable semi-annually on June 18 and December 18 of each year,
beginning June 18, 2013. The company issued the notes with a spread of 125 basis points, and yield to maturity of 2.973%.
The company may redeem the notes, in whole or in part, at any time or from time to time, on at least 20 days, but not more
than 60 days, prior notice. The notes will be redeemable at a redemption price equal to the greater of: 100% of the principal
amount of the notes to be redeemed, or the sum of the present values of the remaining scheduled payments discounted on a
semi-annual basis, at a rate equal to the sum of the Treasury Rate plus 20 basis points, plus accrued and unpaid interest, if
any, but excluding the redemption date.The company intends to use the net proceeds to repay approximately $700m remaining
outstanding under a term loan credit facility due in 2013 and 2014, and redeem the $1 billion outstanding principal amount of its
1.70% senior notes due November 2014 through a make-whole call. The company may also use the proceeds to repay other
debt and/or for general corporate purposes. Barclays Capital Inc., Goldman, Sachs & Co., J.P. Morgan Securities LLC and
Morgan Stanley & Co. LLC acted as joint book-running managers; BNP Paribas Securities Corp., Citigroup Global Markets Inc.,
Credit Suisse Securities (USA) LLC and HSBC Securities (USA) Inc. acted as passive book-runners; DNB Markets, Inc.,
Mitsubishi UFJ Securities (USA), Inc., Mizuho Securities USA Inc., PNC Capital Markets LLC, RBC Capital Markets, LLC and
SMBC Nikko Capital Markets Limited acted as co-managers for the offering. Willkie Farr & Gallagher LLP, VanEps Kunneman
VanDoorne, and Tulchinsky Stern Marciano Cohen Levitski & Co. acted as legal advisors to Teva for the offering.Deal
historyCompleted: On December 18, 2012, Teva through its finance subsidiary Teva Pharmaceutical Finance Company BV,
completed public offering of 2.95% senior notes due December 18, 2022, for gross proceeds of $1.3 billion. Announced/Pricing:
On December 13, 2012, Teva through its finance subsidiary Teva Pharmaceutical Finance Company BV, priced public offering
of 2.95% senior notes due 2022 at $998.02 per $1,000 principal amount, to raise gross proceeds of $1.3 billion.Filing: On
December 9, 2011, Teva filed a registration statement with the US Securities and Exchange Commission (SEC) for public
offering of its securities.
Deal Rationale
The company intends to use the net proceeds to repay approximately $700m remaining outstanding under a term loan credit
facility due in 2013 and 2014, and redeem the $1 billion outstanding principal amount of its 1.70% senior notes due November
2014 through a make-whole call. The company may also use the proceeds to repay other debt and/or for general corporate
purposes.
Deal Information
Deal Status
Completed
Announced Date
13-Dec-2012
Completed Date
18-Dec-2012
Deal Financials
Deal Value (US$ m)
1,300
Senior Notes
Interest Rate (%)
2.95
Maturity Date
18-Dec-2022
Company Name
Teva
Pharmaceutical
Industries Limited

Page 220
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited

VanEps
VanDoorne
Kunneman

Book Runner
Teva
Pharmaceutical
Industries Limited

BNP
Corp.
Paribas
Securities
Credit Suisse
(USA) LLC
Securities

Goldman Sachs & Co.
Citigroup
Inc.
Global
Markets,

Under Writer
Teva
Pharmaceutical
Industries Limited
Mizuho Securities USA Inc.

DnB Markets, Inc.
Mitsubishi UFJ
(USA), Inc.
Securities
SMBC Nikko Capital Markets

Ltd
PNC Capital Markets LLC
GlobalData


Page 221
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, through its finance subsidiaries Teva Pharmaceutical Finance
IV B.V. and Teva Pharmaceutical Finance V B.V., completed public offering of senior notes due 2018 for gross proceeds of
CHF450m ($495.3m). The company received net proceeds of CHF447.6m ($492.66m), after deducting managers discounts
and offering expenses.
The notes bear a coupon rate of 1.50% and will mature in October 2018. The company issued the notes at a price of
CHF998.86 ($1,099.41) per CHF1,000 ($1,100.7) principal amount of notes. The notes carry a spread of 80 basis points over
mid-swaps.
The company intends to use the proceeds to refinance and extend the maturities of certain of its outstanding debt.
Shlomo Yanai, president and CEO of Teva, said, This successful funding is a vote of confidence in Teva and a demonstration
of our diversified and robust business model.
Eyal Desheh, chief financial officer of Teva, said, "We are happy to report the successful outcome of these three debut
financings, which were executed in order to diversify Tevas funding sources and refinance certain of our outstanding debt to
extend its maturity. Our ability to raise capital in three of the most important capital markets in the world, and the success of the
offerings and syndication, demonstrates the strength of Tevas brand name and the confidence investors and financial
institutions have in it. Moreover, our strong business presence in Europe and Japan, and the reputation of Teva as a provider of
quality affordable medicines in these markets, helped to promote our financings.
BNP Paribas SA, HSBC Bank Plc, JPMorgan Chase & Co. and Credit Suisse Group AG acted as joint book-running managers
for the offering. Bank Julius Baer & Co. Ltd. acted as co-lead manager. Bar & Karrer acted as Swiss legal counsel, while Willkie
Farr & Gallagher LLP acted as international counsel to Teva for the offering.
Deal history
Completed: On April 25, 2012, Teva Pharmaceutical Industries completed public offering of 1.500% senior notes due 2018 at
an issue price of CHF998.86 ($1,099.41) per CHF1,000 ($1,100.7) principal amount of notes, for gross proceeds of CHF450m
($495.3m) and net proceeds of CHF447.6m ($492.66m).
Pricing: On April 2, 2012, Teva Pharmaceutical Industries priced public offering of 1.500% senior notes due 2018 at an issue
price of CHF998.86 ($1,099.41) per CHF1,000 ($1,100.7) principal amount of notes, to raise gross proceeds of CHF450m
($495.3m).
Announced: On March 25, 2012, Teva Pharmaceutical Industries, through its finance subsidiaries, announced public offering of
senior notes denominated in Euros and Swiss Francs, to raise gross proceeds of up to $1,500m.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
25-Mar-2012
Completed Date
25-Apr-2012
Deal Financials
Deal Value (CHF million)
450
Deal Value (US$ m)
495.30
Senior Notes
Interest Rate (%)
1.50
Offer Price (Local)
998.86
Offer Price (US$)
1,099.41
492.66
Maturity Date
25-Oct-2018
Company Name
Teva
Pharmaceutical


Page 222
Industries Limited
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited

Bar & Karrer AG
Book Runner
Teva
Pharmaceutical
Industries Limited
BNP Paribas SA
JPMorgan Chase & Co.
Credit Suisse Group AG
HSBC Bank plc
Under Writer
Teva
Pharmaceutical
Industries Limited
Bank Julius Baer & Co. Ltd.
GlobalData


Page 223
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, through its finance subsidiaries Teva Pharmaceutical Finance
IV B.V. and Teva Pharmaceutical Finance V B.V., completed public offering of senior notes due 2019 for gross proceeds of
1,000m ($1,327m). The notes bear a coupon rate of 2.875% and will mature on April 15, 2019. The company issued the notes
at a price of 996.48 ($1,322) per 1,000 ($1,326.5) principal amount of notes. The notes carry a spread of 100 basis points
over mid-swaps.
Shlomo Yanai, president and CEO of Teva, said, This successful funding is a vote of confidence in Teva and a demonstration
of our diversified and robust business model.
Eyal Desheh, chief financial officer of Teva, said, "We are happy to report the successful outcome of these three debut
financings, which were executed in order to diversify Tevas funding sources and refinance certain of our outstanding debt to
extend its maturity. Our ability to raise capital in three of the most important capital markets in the world, and the success of the
offerings and syndication, demonstrates the strength of Tevas brand name and the confidence investors and financial
institutions have in it. Moreover, our strong business presence in Europe and Japan, and the reputation of Teva as a provider of
quality affordable medicines in these markets, helped to promote our financings.
BNP Paribas SA, HSBC Holdings Plc, JPMorgan Chase & Co. and Credit Suisse Group AG acted as joint book-running
managers for the offering.
Deal history
Completed: On April 4, 2012, Teva Pharmaceutical Industries completed public offering of 2.875% senior notes due 2019 at an
issue price of 996.48 ($1,322) per 1,000 ($1,326.5) principal amount of notes, for gross proceeds of 1,000m ($1,327m).
Pricing: On April 2, 2012, Teva Pharmaceutical Industries priced public offering of 2.875% senior notes due 2019 at an issue
price of 996.48 ($1,322) per 1,000 ($1,326.5) principal amount of notes, to raise gross proceeds of 1,000m ($1,327m).
Announced: On March 25, 2012, Teva Pharmaceutical Industries, through its finance subsidiaries, announced public offering of
senior notes denominated in Euros and Swiss Francs, to raise gross proceeds of up to $1,500m.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
25-Mar-2012
Completed Date
04-Apr-2012
Deal Financials
1,000
Deal Value (US$ m)
1,327
Senior Notes
Interest Rate (%)
2.88
Offer Price (Local)
996.48
Offer Price (US$)
1,322
Maturity Date
15-Apr-2019
Company Name
Teva
Pharmaceutical
Industries Limited

Page 224
Advisor Information
Book Runner
Teva
Pharmaceutical
Industries Limited
BNP Paribas SA
HSBC Holdings plc
JPMorgan Chase & Co.
Credit Suisse Group AG
GlobalData


Page 225
Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For US$875 Million
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Teva Pharmaceutical Industries Limited (Teva), through its special purpose finance subsidiary Teva Pharmaceutical Finance IV
B.V., completed public offering of its senior notes due 2021, for gross proceeds of $875m. The company issued the notes at a
price of $996.35 per $1,000 principal amount of notes guaranteed by Teva.
The notes bear an interest rate of 3.65% and will mature on November 10, 2021. Interest on the fixed rate notes will be payable
semi-annually in arrears on May 10 and November 10 of each year, beginning on May 10, 2012.
The company may redeem the notes in whole or in part, at any time or from time to time, at a redemption price equal to the
greater of: 100% of the principal amount of the notes to be redeemed, or the sum of the present values of the remaining
scheduled payments discounted, on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months), at a
rate equal to the sum of the treasury rate and 30 basis points, plus accrued and unpaid interest.
Barclays Capital Inc., BNP Paribas Securities Corp., Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC,
Goldman, Sachs & Co. (The Goldman Sachs Group, Inc.), HSBC Securities (USA) Inc., J.P. Morgan Securities LLC and
Morgan Stanley & Co. LLC. acted as joint book-running managers for the offering. Willkie Farr & Gallagher LLP, VanEps
Kunneman VanDoorne and Tulchinsky Stern Marciano Cohen Levitski & Co. acted as legal advisors to the company for the
offering.
The company intends to use the proceeds to repay its unsecured bridge loan, debt outstanding under its unsecured credit
facilities, to finance the anticipated conversion of the outstanding 2% convertible senior subordinated notes due 2015 issued by
Cephalon, and for general corporate purposes.
Deal history
Completed: On November 10, 2011, Teva Pharmaceutical through its special purpose finance subsidiary Teva Pharmaceutical
Finance IV B.V., completed public offering of 3.65% senior notes due November 10, 2021, for gross proceeds of $875m.
Announced/Pricing: On November 7, 2011, Teva Pharmaceutical through its special purpose finance subsidiary Teva
Pharmaceutical Finance IV B.V., priced the public offering of 3.65% senior notes due November 2021, to raise gross proceeds
of $875m.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
07-Nov-2011
Completed Date
10-Nov-2011
Deal Financials
Deal Value (US$ m)
875
Senior Notes
Interest Rate (%)
3.65
Offer Price (US$)
996.35
Maturity Date
10-Nov-2021
Company Name
Teva
Pharmaceutical
Industries Limited

Page 226
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited
VanEps
VanDoorne
Kunneman

Book Runner
Teva
Pharmaceutical
Industries Limited
The Goldman Sachs Group,

Inc.
BNP
Corp.
Paribas
Securities
Credit Suisse
(USA) LLC
Securities

Citigroup
Inc.
Global
Markets,

GlobalData


Page 227
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$200 Million
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$200 Million
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Teva Pharmaceutical Industries Limited (Teva), through its special purpose finance subsidiary Teva Pharmaceutical Finance
IV, LLC, completed public offering of its floating rate senior notes due 2013, for gross proceeds of $200m. The company issued
the notes at a price of $1,000 per $1,000 principal amount of notes guaranteed by Teva.
The notes bear an interest rate of three-month LIBOR plus 0.80% and will mature on May 8, 2013. Interest on floating rate
notes will be payable quarterly in arrears in February, May, August and November each year, beginning on February 2012.
offering.
Deal history
Completed: On November 10, 2011, Teva Pharmaceutical Industries through its special purpose finance subsidiary Teva
Pharmaceutical Finance IV, completed public offering of its floating rate senior notes due May 8, 2013, for gross proceeds of
$200m.
Announced/Pricing: On November 7, 2011, Teva Pharmaceutical Industries through its special purpose finance subsidiary Teva
Pharmaceutical Finance IV, priced the public offering of its floating rate senior notes due May 2013, to raise gross proceeds of
$200m.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
07-Nov-2011
Completed Date
10-Nov-2011
Deal Financials
Deal Value (US$ m)
200
Senior Notes
Offer Price (US$)
1,000
Maturity Date
08-May-2013
Company Name
Teva
Pharmaceutical
Industries Limited

Page 228
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited
VanEps
VanDoorne
Kunneman

Book Runner
Teva
Pharmaceutical
Industries Limited

Inc.
BNP
Corp.
Paribas
Securities

Credit Suisse
(USA) LLC
Citigroup
Inc.
Global
Securities
Markets,
GlobalData


Page 229
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Company B.V., completed public offering of its senior notes due 2021, for gross proceeds of $875m. The company issued the
notes at a price of $996.35 per $1,000 principal amount of notes guaranteed by Teva.
offering.
Deal history
Finance Company B.V., completed public offering of 3.65% senior notes due November 10, 2021, for gross proceeds of
$875m.
Pharmaceutical Finance Company B.V., priced the public offering of its senior notes due November 2021, to raise gross
proceeds of $875m.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
07-Nov-2011
Completed Date
10-Nov-2011
Deal Financials
Deal Value (US$ m)
875
Senior Notes
Interest Rate (%)
3.65
Offer Price (US$)
996.35
Maturity Date
10-Nov-2021
Company Name
Teva
Pharmaceutical
Industries Limited

Page 230
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited
VanEps
VanDoorne
Kunneman

Book Runner
Teva
Pharmaceutical
Industries Limited

Citigroup
Inc.
Global
Markets,

BNP
Corp.
Paribas
Securities

Inc.
Credit Suisse
(USA) LLC
Securities
GlobalData


Page 231
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$1.1 Billion
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$1.1 Billion
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Company B.V., completed public offering of its floating rate senior notes due 2013, for gross proceeds of $1,100m. The
company issued the notes at a price of $1,000 per $1,000 principal amount of guaranteed by Teva.
The notes bear an interest rate of three-month LIBOR plus 0.90% and will mature on November 8, 2013. Interest on floating
rate notes will be payable quarterly in arrears in February, May, August and November each year, beginning on February 2012.
offering.
Deal history
Completed: On November 10, 2011, Teva Pharmaceutical Industries through its special purpose finance subsidiary Teva
Pharmaceutical Finance Company, completed public offering of its floating rate senior notes due November 8, 2013, for gross
proceeds of $1,100m.
Announced/Pricing: On November 7, 2011, Teva Pharmaceutical Industries through its special purpose finance subsidiary Teva
Pharmaceutical Finance Company, priced the public offering of its floating rate senior notes due November 2013, to raise gross
proceeds of $1,100m.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
07-Nov-2011
Completed Date
10-Nov-2011
Deal Financials
Deal Value (US$ m)
1,100
Senior Notes
Offer Price (US$)
1,000
Maturity Date
08-Nov-2013
Company Name
Teva
Pharmaceutical
Industries Limited

Page 232
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited

VanEps
VanDoorne
Kunneman
Book Runner
Teva
Pharmaceutical
Industries Limited
Credit Suisse
(USA) LLC
Securities
BNP
Corp.
Securities
Paribas

Citigroup
Inc.
Global
Markets,

Inc.
GlobalData


Page 233
Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For US$1 Billion
Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For US$1 Billion
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
IV, LLC, completed public offering of its senior notes due 2014, for gross proceeds of $1,000m. The company issued the notes
at a price of $998.69 per $1,000 principal amount of notes guaranteed by Teva.
offering.
Deal history
Finance IV, completed public offering of 1.7% senior notes due November 10, 2014, for gross proceeds of $1,000m.
Pharmaceutical Finance IV, priced the public offering of 1.7% senior notes due November 2014, to raise gross proceeds of
$1,000m.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
07-Nov-2011
Completed Date
10-Nov-2011
Deal Financials
Deal Value (US$ m)
1,000
Senior Notes
Interest Rate (%)
1.70
Offer Price (US$)
998.69
Maturity Date
10-Nov-2014
Company Name
Teva
Pharmaceutical
Industries Limited

Page 234
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited

VanEps
VanDoorne
Kunneman

Book Runner
Teva
Pharmaceutical
Industries Limited
Credit Suisse
(USA) LLC
Securities

Citigroup
Inc.
Global
Markets,

Inc.
BNP
Corp.
Paribas
Securities

GlobalData


Page 235
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Company B.V., completed public offering of its senior notes due 2016, for gross proceeds of $950m. The company issued the
notes at a price of $999.16 per $1,000 principal amount of notes guaranteed by Teva.
offering.
Deal history
Finance Company B.V., completed public offering of 2.4% senior notes due November 10, 2016, for gross proceeds of $950m.
Pharmaceutical Finance Company B.V., priced the public offering of 2.4% senior notes due November 2016, to raise gross
proceeds of $950m.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
07-Nov-2011
Completed Date
10-Nov-2011
Deal Financials
Deal Value (US$ m)
950
Senior Notes
Interest Rate (%)
2.40
Offer Price (US$)
999.16
Maturity Date
10-Nov-2016
Company Name
Teva
Pharmaceutical
Industries Limited

Page 236
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited

VanEps
VanDoorne
Kunneman

Book Runner
Teva
Pharmaceutical
Industries Limited

Inc.
Credit Suisse
(USA) LLC
Securities
BNP
Corp.
Securities
Paribas

Citigroup
Inc.
Global
Markets,

GlobalData


Page 237
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Teva Pharmaceutical Industries Limited, through its special purpose finance subsidiary Teva Pharmaceutical Finance III BV,
completed public offering of its senior notes due 2014, for gross proceeds of $250m. The notes bear fixed interest rate of 1.7%
per annum and will mature in March 2014.
The company issued notes at a price of $999.42 per $1,000 principal amount of notes. The notes carry a risk premium of 73
basis points over Treasurys. The notes are guaranteed by Teva.
Barclays Capital Inc., Goldman, Sachs & Co. oHG and Morgan Stanley & Co. Incorporated acted as underwriters for the
offering. Tulchinsky Stern Marciano Cohen Levitsky & Co., Willkie Farr & Gallagher LLP and VanEps Kunneman VanDoorne
acted as legal advisors to the company.
The company intends to use the proceeds to repay a portion of the short-term debt outstanding under its unsecured credit
facilities, and also for general corporate purposes.
Deal History
Completed: On March 21, 2011, Teva Pharmaceutical Industries Limited completed public offering of its senior notes due
March 2014, for gross proceeds of $250m.
Announce/ Pricing: On March 16, 2011, Teva Pharmaceutical Industries Limited announced pricing of public offering of its
senior notes due March 2014, to raise gross proceeds of $250m.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
16-Mar-2011
Completed Date
21-Mar-2011
Deal Financials
Deal Value (US$ m)
250
Senior Notes
Interest Rate (%)
1.70
Maturity Date
21-Mar-2014
Company Name
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited



Page 238

VanEps
VanDoorne
Under Writer
Teva
Pharmaceutical
Industries Limited
Morgan Stanley
Kunneman

Goldman Sachs AG
GlobalData


Page 239
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Teva Pharmaceutical Industries Limited, through its special purpose finance subsidiary Teva Pharmaceutical Finance III BV,
completed public offering of its senior notes due 2014, for gross proceeds of $500m. The notes bear interest of three-month
LIBOR +0.500% floating rate.
The company issued the notes at a price of $1,000 per $1,000 principal amount. The notes carry a risk premium of 50 basis
points over the three-month London interbank offered rate. The notes are guaranteed by Teva.
Barclays Capital Inc., Goldman, Sachs & Co. oHG and Morgan Stanley & Co. Incorporated acted as underwriters for the
offering. Tulchinsky Stern Marciano Cohen Levitsky & Co., Willkie Farr & Gallagher LLP and VanEps Kunneman VanDoorne
acted as legal advisors to the company.
Deal history
Completed: On March 21, 2011, Teva Pharmaceutical Industries Limited completed public offering of its senior notes March
2014, for gross proceeds of $500m.
Announce/ Pricing: On March 16, 2011, Teva Pharmaceutical Industries Limited, announced pricing of public offering of its
senior notes March 2014, to raise gross proceeds of $500m.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
16-Mar-2011
Completed Date
21-Mar-2011
Deal Financials
Deal Value (US$ m)
500
Senior Notes
Maturity Date
21-Mar-2014
Company Name
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited
VanEps
VanDoorne
Kunneman


Page 240

Under Writer
Teva
Pharmaceutical
Industries Limited
Morgan Stanley
Goldman Sachs AG
GlobalData


Page 241
ChemGenex Completes Private Placement Of Convertible Notes For US$15 Million

ChemGenex Completes Private Placement Of Convertible Notes For US$15 Million
Deal Type
Deal Sub Type
Debt Offering
Private Placement
Deal in Brief
ChemGenex Pharmaceuticals Limited, completed private placement of convertible notes, for gross proceeds of AUD15m
($14.71m), to Cephalon, Inc., a biopharmaceutical company. The notes are convertible into shares of company's common
stock, at a price of AUD0.5 ($0.49) per share. Under the agreement, ChemGenex has issued Cephalon, AUD10m ($9.81m),
worth convertible notes in October 2010, and remaining AUD5m ($4.9m) in December 2010.Kevin Buchi, chief operating officer
at Cephalon, said: "Our deal with ChemGenex allows us to provide the necessary resources to support the completion of a
clinical and regulatory pathway for omacetaxine for CML patients facing a critical unmet medical need." The company intends
to use the proceeds to support its operations, including clinical activities to complete a planned New Drug Application
submission to the U.S. Food and Drug Administration for omacetaxine for the treatment of chronic myelogenous leukemia
(CML) patients who have failed two or more tyrosine kinase inhibitor (TKIs).
Deal Rationale
The company intends to use the proceeds to support its operations and for omacetaxine for the treatment of chronic
myelogenous leukemia (CML) patients who have failed two or more tyrosine kinase inhibitor (TKIs).
Deal Information
Deal Status
Completed
Announced Date
21-Oct-2010
Completed Date
31-Dec-2010
Deal Financials
15
Deal Value (US$ m)
14.71
Convertible Debt
Deal Product
Product Description
AGT-901
AGT-901 was under development for the treatment of inflammation. The drug candidate is an
antibody. The exact mechanism of action of the drug candidate is not known.
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
ChemGenex
Parent
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 242
Teva Pharma Completes Private Placement Of 1.5% Senior Notes For US$1,000 Million
Teva Pharma Completes Private Placement Of 1.5% Senior Notes For US$1,000 Million
Deal Type
Deal Sub Type
Debt Offering
Private Placement
Deal in Brief
Teva Pharmaceutical Industries Limited, a pharmaceutical company, through its subsidiary Teva Pharmaceutical Finance III
LLC, completed private placement of its senior notes, for gross proceeds of $1,000 million. The company issued notes at an
offer price of $998.76 per $1,000 principal amount.
The notes bear fixed interest rate of 1.5% and will mature on June 15, 2012. Interest on the notes is payable semi annually,
commencing from December 15, 2010. The company issued the notes at a spread of 80 basis points and yield to maturity of
1.55%. The company intends to use the net proceeds from the offering for the acquisition of Merckle-ratiopharm group, for the
repayment of existing debt of approximately $800 million, and also for general corporate purposes.
Willkie Farr & Gallagher LLP, Tulchinsky Stern Marciano Cohen Levitski & Co. and Zeven & Associates acted as legal advisors
to the company for the offering. Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co., Morgan Stanley & Co.
Incorporated acted as active joint book-running managers, Barclays Capital Inc., Citigroup Global Markets Inc. acted as passive
book-running managers, to the company for the offering.
Eyal Desheh, chief financial officer of Teva Pharmaceutical, said: We are pleased with today's results, having raised the
necessary capital to complete the ratiopharm acquisition through the debt offering and new loan commitments, while
maintaining our current credit ratings. We intend to continue to maintain a strong balance sheet following the completion of the
acquisition, with sufficient resources to support the continued growth of our business and with ample flexibility for potential
future strategic opportunities. We continue to make progress to obtain the necessary regulatory approvals for this acquisition,
which we expect will close before the end of the year.
Deal history
Completed: On June 18, 2010, Teva Pharmaceutical through its subsidiary Teva Pharmaceutical Finance, completed private
placement of its 1.5% senior notes, for gross proceeds of $1,000 million.
Pricing: On June 15, 2010, Teva Pharmaceutical through its subsidiary Teva Pharmaceutical Finance, announced pricing of
private placement of its senior notes, to raise gross proceeds of $1,000 million.
Announced: On June 15, 2010, Teva Pharmaceutical through its subsidiary Teva Pharmaceutical Finance, announced private
placement of its senior notes to raise gross proceeds of $2,500 million.
Deal Rationale
The company intends to use the net proceeds from the offering for the acquisition of Merckle-ratiopharm group, for the
Deal Information
Deal Status
Completed
Announced Date
15-Jun-2010
Completed Date
18-Jun-2010
Deal Financials
Deal Value (US$ m)
1,000
Senior Notes
Interest Rate (%)
1.50
Offer Price (US$)
998.76
Maturity Date
15-Jun-2012
Company Name
Teva
Pharmaceutical
Industries Limited

Page 243
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited
Zeven & Associates

Book Runner
Teva
Pharmaceutical
Industries Limited
Credit Suisse
(USA) LLC
Undisclosed Investor(s)
Securities
Morgan Stanley
Citigroup
Inc.
Global
Markets,
Morgan Stanley
GlobalData


Page 244
Teva Pharma Completes Private Placement Of Senior Notes For US$500 Million
Teva Pharma Completes Private Placement Of Senior Notes For US$500 Million
Deal Type
Deal Sub Type
Debt Offering
Private Placement
Deal in Brief
Teva Pharmaceutical Industries Limited, a pharmaceutical company, through its subsidiary Teva Pharmaceutical Finance III
LLC, completed private placement of its senior notes, for gross proceeds of $500 million. The company issued notes at an offer
price of $1,000 per $1,000 principal amount.
The notes bear floating interest rate of LIBOR+0.40% and will mature on December 19, 2011. Interest on the notes is payable
semi annually, commencing from December 15, 2010. The company intends to use the net proceeds from the offering for the
acquisition of Merckle-ratiopharm group, for the repayment of existing debt of approximately $800 million, and also for general
corporate purposes.
Incorporated acted as active joint book-running managers, Barclays Capital Inc., Citigroup Global Markets Inc. are acting as
passive book-running managers, to the company for the offering.
Deal history
placement of its senior notes, for gross proceeds of $500 million.
private placement of its senior notes, to raise gross proceeds of $500 million.
Deal Rationale
repayment of existing debt of approximately $800 million as well as for general corporate purposes.
Deal Information
Deal Status
Completed
Announced Date
15-Jun-2010
Completed Date
18-Jun-2010
Deal Financials
Deal Value (US$ m)
500
Senior Notes
Offer Price (US$)
1,000
Maturity Date
15-Dec-2011
Company Name
Teva
Pharmaceutical
Industries Limited

Page 245
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited

Zeven & Associates
Book Runner
Teva
Pharmaceutical
Industries Limited

Credit Suisse
(USA) LLC
Citigroup
Inc.
Securities
Global
Markets,
Goldman Sachs AG
Morgan Stanley
GlobalData


Page 246
Teva Pharma Completes Private Placement Of 3% Fixed Rate Senior Notes For US$1,000 Million
Teva Pharma Completes Private Placement Of 3% Fixed Rate Senior Notes For US$1,000 Million
Deal Type
Deal Sub Type
Debt Offering
Private Placement
Deal in Brief
Teva Pharmaceutical Industries Limited, a pharmaceutical company, through its subsidiary Teva Pharmaceutical Finance BV,
completed private placement of its senior notes, for gross proceeds of $1,000 million.
The notes bear fixed interest rate of 3% per annum and will mature on June 15, 2015. Interest on the notes is payable semi
annually, commencing from December 15, 2010. The company issued notes at an offer price of $998.76 per $1,000 principal
amount. The company issued the notes at a spread of 95 basis points and yield to maturity of 3.027%. The company intends to
use the net proceeds from the offering for the acquisition of Merckle-ratiopharm group, for the repayment of existing debt of
approximately $800 million, and also for general corporate purposes.
Incorporated acted as active joint book-running managers, Barclays Capital Inc., Citigroup Global Markets Inc. acted as passive
book-running managers, to the company for the offering.
Deal history
placement of its 3% senior notes, for gross proceeds of $1,000 million.
private placement of its senior notes, to raise gross proceeds of $1,000 million.
Deal Rationale
Deal Information
Deal Status
Completed
Announced Date
15-Jun-2010
Completed Date
18-Jun-2010
Deal Financials
Deal Value (US$ m)
1,000
Senior Notes
Interest Rate (%)
Offer Price (US$)
998.76
Maturity Date
15-Jun-2015
Company Name
Teva
Pharmaceutical
Industries Limited

Page 247
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited
Zeven & Associates

Book Runner
Teva
Pharmaceutical
Industries Limited
Credit Suisse
(USA) LLC
Securities
Morgan Stanley
Goldman Sachs AG
Citigroup
Inc.
Global
Markets,
GlobalData


Page 248
Cephalon Completes Public Offering Of Convertible Senior Subordinated Notes For US$500 Million
Cephalon Completes Public Offering Of Convertible Senior Subordinated Notes For US$500 Million
Deal Type
Deal Sub Type
Debt Offering
Public Offering
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, completed its public offering of convertible senior subordinated notes for gross
proceeds of $500 million. The offering includes an over-allotment option of additional $65 million in aggregate principal amount
of the notes that has been exercised by the underwriters. The company received net proceeds of approximately $485 million
from the offering after deduction of estimated offering expenses and the underwriters' discounts and commissions.
The notes will carry a coupon of 2.5% per annum and will mature on May 1, 2014. Interest on the notes is payable on May 1
and November 1 of each year, commencing on November 1, 2009. The notes are convertible prior to maturity into cash and
shares of company's common stock at an initial conversion price of $69 per share.
The company intends to use the net proceeds from the offering for general corporate purposes, as well as to increase the
number of shares of common stock underlying the convertible note hedge and the warrant transaction.
Deutsche Bank Securities, Inc. acted as sole book-running manager; while J.P. Morgan Securities, Inc.; Barclays Capital, Inc.;
Credit Suisse Securities (USA) LLC; Morgan Stanley & Co. Incorporated; ABN AMRO Incorporated; Piper Jaffray & Co.; and
Wachovia Capital Markets, LLC acted as co-managers for the offering. Sidley Austin LLP acted as legal advisor to Cephalon
while Cleary Gottlieb Steen & Hamilton LLP acted as legal advisor to underwriters for the offering.
Deal Rationale
Cephalon intends to use the net proceeds from the offering for general corporate purposes, as well as to increase the number
of shares of common stock underlying the convertible note hedge and the warrant transaction.
Deal Information
Deal Status
Completed
Announced Date
20-May-2009
Completed Date
27-May-2009
Deal Financials
Deal Value (US$ m)
500
Convertible Debt
Interest Rate (%)
2.50
485
Maturity Date
01-May-2014
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
Cephalon, Inc.
Sidley Austin LLP
Book Runner
Cephalon, Inc.


Page 249
Inc.
Under Writer
Cephalon, Inc.

Morgan Stanley
Wachovia Capital Markets,
LLC
Credit Suisse
(USA) LLC
Securities
Piper Jaffray & Co.

ABN AMRO, Inc.
GlobalData


Page 250
Asset Transactions
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma
Deal Type
Asset Transactions
Deal in Brief
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, has acquired the Approved New Drug Application (ANDA) for
a testosterone gel 1% product, from Teva Pharmaceutical Industries Ltd., a pharmaceutical company. Pursuant to the
transaction, upon commercialization of the product, ANI Pharma will pay Teva Pharma up to USD5 million at a rate of 5% of the
consideration received by ANI Pharma as a result of commercial sale of the product. According to IMS Health, the overall
market for testosterone gel 1% was approximately USD300 million in 2014. In addition, ANI Pharma will begin work
immediately to maximize the value of this product.Testosterone gel is an androgen indicated for replacement therapy in males
for conditions associated with deficiency or absence of endogenous testosterone including primary hypogonadism (congenital
or acquired) and hypogonadotropic hypogonadism (congenital or acquired).This transaction enables ANI Pharma to further
expand its product portfolio.
Deal Rationale
This transaction enables ANI Pharma to further expand its product portfolio.
Deal Information
Deal Status
Completed
Completed Date
13-May-2015
Deal Financials
Company Name
ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (ANI) is a pharmaceutical company. The company develops, manufactures and markets prescription
pharmaceuticals. Its businesses include Rx products and contract manufacturing. ANIs Rx products include cortenema
hydrocortisone retention enema, esterified estrogen and methyltestosterone, methyltestosterone, fluvoxamine maleate,
hydrocortisone rectal suspension USP, metoclopramide oral solution USP, opium tincture, and reglan. The companys Rx
products are sold to the wholesalers and distributors, smaller regional distributors and chains, as well as pharmacy and retail
outlets in the country. It offers products in the form of liquids, syrups, powders, solutions, suspensions, lotions, and ointments,
and OTC products for the stomach category. The company was formerly known as BioSante Pharmaceuticals, Inc. ANI is
headquartered in Baudette, Minnesota, the US.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 251
Teva Pharma Plans to Divest Some Operations

Teva Pharma Plans to Divest Some Operations
Deal Type
Asset Transactions
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, intends to divest some operations. The company intends to
divest the operations to obtain regulatory clearance for the proposed acquisition of Mylan NV for USD40 million.Teva plans to
work with antitrust authorities and expects that the proposed transaction with Mylan can be completed by the end of 2015.
Deal Information
Deal Status
Planned
Announced Date
Apr 22, 2015
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 252
Ignyta Acquires Four Oncology R&D Assets from Cephalon

Ignyta Acquires Four Oncology R&D Assets from Cephalon
Deal Type
Asset Transactions
Deal in Brief
Ignyta, Inc., a precision oncology biotechnology company, has acquired worldwide rights and assets relating to four targeted
oncology development programs, from Cephalon, Inc., a biopharmaceutical company and an indirect wholly owned subsidiary
of Teva Pharmaceutical Industries Limited, in exchange for 1.5 million shares (6%) of Ignytas common stock.Pursuant to the
transaction, the company has acquired Cephalons right, title and interest in and to certain intellectual property, compounds,
products, contracts, books and records, data and inventory related to these programs (purchased assets), and assumed related
liabilities. Upon the terms and subject to the conditions of the agreement, as consideration for the purchased assets, the
company issued to Cephalon 1,500,000 unregistered shares of its common stock; paid Cephalon USD0.85 million in cash for
product inventory; and assumed the related liabilities. The company has also acquired next generation PKCiota inhibitors in
addition to the lead compound.In connection to the transaction, Cephalon will not, without the companys prior written consent,
offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, lend or otherwise transfer or dispose of any of the shares, until the earlier of; March 17,
2016 and; a change of control of the company. The agreement also includes customary representations, warranties and
covenants. Subject to certain exceptions and limitations, each of the company and Cephalon has agreed to indemnify the other
for breaches of representations, warranties and covenants and other specified matters. The transaction contains covenants by
Cephalon and its affiliates, including an agreement not to sue the company with respect to certain intellectual property relating
to the assets and not to compete with the company on a worldwide basis with respect to the assets for four years following the
closing, subject to certain exceptions. In addition, the company granted Cephalon an exclusive right and option to negotiate
with the company to manufacture, supply and market authorized generics of any products developed and commercialized from
the assets, subject to the terms and conditions specified in the asset purchase agreement. The agreement also contains a
covenant by the company to use commercially reasonable efforts to develop and commercialize compounds and products
included in the assets. The four targeted oncology development programs include, RXDX-105 (formerly called CEP-32496), a
small molecule inhibitor of the BRAF, EGFR and RET kinases that is currently in a Phase I/II dose escalation clinical trial;
RXDX-106 (formerly called CEP-40783), a pseudo-irreversible, small molecule inhibitor of the AXL and cMET kinases that is in
late preclinical development; RXDX-107 (formerly called CEP-40125), a small molecule nanoformulation of a modified
bendamustine with potential activity in solid tumors that is in late preclinical development; and RXDX-108 (formerly called TEV44229), a small molecule inhibitor of the atypical kinase PKCiota that is in preclinical studies. Ignyta also assumed all of Tevas
ongoing obligations under certain contracts relating to the purchased programs, including the agreements under which Teva inlicensed rights to the assets.Concurrently, Ignyta completed the private placement of 4,158,750 shares at a price of USD10 per
share, for gross proceeds of approximately USD41.6 million. The offering was subscribed to by Teva, and selected additional
healthcare investors. Teva purchased up to 1.5 million shares and other investors purchased up to 2.7 million shares. Upon
closing, Teva holds approximately 12% of Ignyta common shares.This transaction enables Ignyta to add critical mass to its
pipeline and to leverage its precision oncology platform, including its proprietary multiplex diagnostic assays and its CLIA
certified, QSR compliant diagnostic laboratory. The assets also complement entrectinib development program and extend its
ability to target the majority of known oncogenic drivers across multiple solid tumor indications.
Deal Rationale
This transaction enables Ignyta to add critical mass to its pipeline and to leverage its precision oncology platform, including its
proprietary multiplex diagnostic assays and its CLIA certified, QSR compliant diagnostic laboratory. The assets also
complement entrectinib development program and extend its ability to target the majority of known oncogenic drivers across
multiple solid tumor indications.
Deal Information
Deal Status
Completed
Completed Date
17-Mar-2015
Deal Financials
Deal Payment
Cash (US$ m)
0.80
Others
6%
Company Name
Ignyta, Inc.


Page 253
Ignyta, Inc. (Ignyta), formerly NexDx, Inc., is a biotechnology company. It discovers, develops and commercializes new drugs
targeting activated genes in cancer cells for the treatment of cancer patients. The company develops products using integrated
therapeutic (Rx) and companion diagnostic (Dx) platform. The pipeline products of the company include Entrectinib (formerly
RXDX-101; RXDX-102), RXDX-103, RXDX-104 and Spark Programs. Entrectinib is a tyrosine kinase inhibitor of the TrkA,
TrkB, TrkC, ROS1 and ALK proteins and is used for the targeted therapeutic treatment for patients with cancers. RXDX-103 is
an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase. RXDX-104 is a program designed to inhibit the RET
tyrosine kinase. The company also develops Trailblaze Diagnostic Programs. Ignytais headquartered in San Diego, California,
the US.
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 254
ANI Pharma Acquires ANDA from Teva Pharma

ANI Pharma Acquires ANDA from Teva Pharma
Deal Type
Asset Transactions
Deal in Brief
ANI Pharmaceuticals, Inc., a generic pharmaceutical company, has acquired the approved abbreviated new drug application
(ANDA) for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, from Teva Pharmaceuticals USA, Inc., a manufacturer of
specialty and generic pharmaceuticals. ANDA for flecainide acetate tablets was previously marketed by Teva Pharma.The
transaction enables ANI Pharma to further expand its near-term generic pipeline; and to re-launch the product within the next
12 months.
Deal Rationale
The transaction enables ANI Pharma to further expand its near-term generic pipeline; and to re-launch the product within the
next 12 months.
Deal Information
Deal Status
Completed
Completed Date
05-Mar-2015
Company Name
Company Name

Inc.
Parent
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 255
ANI Pharma Acquires 31 Generic Drug Products from Teva Pharma

ANI Pharma Acquires 31 Generic Drug Products from Teva Pharma
Deal Type
Asset Transactions
Deal in Brief
ANI Pharmaceuticals, Inc., a generic pharmaceutical company, acquired 31 previously marketed generic drug products from
Teva Pharmaceuticals Industries Limited, for a purchase consideration of US$12.5m in cash. Under the transaction, the cash
consideration will paid by ANI Pharma in two installments (upfront payments). Teva Pharma will receive an initial nonrefundable payment of US$8m following the execution of a bill of sale relating to and delivery to ANI of all of the initial
purchased assets. A second non-refundable payment of US$4.5m will be made by ANI Pharma in 90 days from execution of a
second bill of sale relating to and delivery of all of the purchased assets. In addition, Teva Pharma will also receive a royalty on
future gross profits from product sales. The company assumed all liabilities and obligations for the purchased assets from
Teva.The acquired assets include 20 solid-oral immediate release products, four extended release products and seven liquid
products. Following the acquisition, ANI Pharma will begin work immediately on transferring these products into its
manufacturing facilities and expects to launch these products beginning in the fourth quarter of 2014.This acquisition enables
ANI Pharma to expand its generic product portfolio.Arthur S Przybyl, president and CEO of ANI Pharma, said, This acquisition
is a significant opportunity for ANI to expand our generic product portfolio beyond our current seven marketed products. When
launched, these products will strengthen our business by growing our revenue base and leveraging our manufacturing
capabilities. We are excited that this transaction extends the ANI-Teva relationship beyond the existing generic testosterone gel
partnership.Robert W Schrepfer, vice president of new business development, said, This transaction demonstrates ANIs
commitment to diversify our marketed product portfolio and supplement our internal product development efforts through a
business development plan that includes partnerships, acquisitions and in-licensing.
Deal Rationale
This acquisition enables ANI Pharma to expand its generic product portfolio.
Deal Information
Deal Status
Completed
Completed Date
26-Dec-2013
Deal Financials
12.50
Deal Payment
Cash (US$ m)
12.50
Company Name
Company Name
Teva
Pharmaceutical
Industries Limited

Page 256
GlobalData


Page 257
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California

Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California
Deal Type
Asset Transactions
Deal in Brief
Teva Pharmaceutical Industries Ltd. planned to sell its injectable products manufacturing facility located in Irvine, California.
The potential buyer will continue to manufacture products for Teva until the company moves its production to other facilities.
In January 2004, Teva acquired the facility through its acquisition of generics and active pharmaceutical ingredients maker
Sicor Inc. The company spent $375m to upgrade the facility but full production never resumed. In 2012, Teva intended to cut
annual costs by $2 billion through changes to its manufacturing network and sourcing strategy.
Deal Information
Deal Status
Planned
Announced Date
Feb 07, 2013
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 258
CleveXel Pharma Acquires Development Center From Teva Pharma

CleveXel Pharma Acquires Development Center From Teva Pharma
Deal Type
Asset Transactions
Deal in Brief
CleveXel Pharma SAS, a developer of anti-inflammatory agents for ulcerative colitis and Crohns disease, acquired a
development center based at Maisons-Alfort, France, from Teva Pharmaceutical Industries Limited, a pharmaceutical company.
The development center is part of the assets acquired by Teva Pharma from Cephalon Inc. in 2011.
Deal Information
Deal Status
Completed
Completed Date
04-Feb-2013
Company Name
Clevexel Pharma SAS
CleveXel Pharma SAS (CleveXel Pharma) is a pharmaceutical company. The company invests in the development of
molecules between proof-of-concept in animals, and proof-of-concept in humans. CleveXel Pharmas products include CVXL0060, CVXL-0069, CVXL-0074, CVXL-0056 and CVXL-0105. The companys products are used in drug characterization,
development, validation and transfer of analytical methods, stability studies, batch release, ADME, toxicology and
pharmacology studies. It partners with Medicen, Lyonbiopole, Grand Lyon, Leem, Ansm, Oseo, Val de Marne and
Biotechnologie France, among others. CleveXel Pharma is headquartered in Maisons-Alfort, France.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 259
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma
Deal Type
Asset Transactions
Deal in Brief
The Procter & Gamble Company (P&G), a provider of consumer products in the areas of pharmaceuticals, cleaning supplies,
personal care, and pet supplies, received The European Commission approval to acquire the over-the-counter (OTC) business
of Teva Pharmaceutical Industries Ltd., a developer, manufacturer and marketer of pharmaceutical products.
Deal Information
Deal Status
Announced
Announced Date
09-Nov-2012
Company Name
The Procter
Company
&
Gamble
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 260
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada
Deal Type
Asset Transactions
Deal in Brief
Halo Pharmaceutical, Inc., a provider of drug development and commercial manufacturing services, completed the acquisition
of a manufacturing facility in Mirabel, Canada, from Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries
Ltd.The acquisition enables Halo Pharmaceutical to provide new dosage forms and specialized R&D services to clients and
export its production outside of Canada. As part of the agreement, Teva Canada and Halo established manufacturing
agreements and Halo will continue to manufacture all products currently produced at the Mirabel site until the end of 2012,
during which time certain of these products will be transferred to Teva's Stouffville facility. In the long term, production of
selected Teva Canada products will remain at the site. In addition, the five year manufacturing agreements also assure the
employment of at least 152 employees. Securing supplemental production capacity through the Mirabel site enables Teva
Canada to continue to strengthen its drug supply to the Canadian market, ensuring maximum production capacity at other Teva
manufacturing sites. Barry Fishman, president & CEO, Teva Canada Limited, said, "Successfully concluding this sale and
securing the right partner in Halo is a positive outcome for the dedicated employees at Mirabel. The new contract
manufacturing relationship will assist us in maintaining a consistent supply of pharmaceuticals to patients that rely on our
products." Clive Bennett, president and CEO, Halo Pharmaceutical, said, "Completing this acquisition is a strategically
important event for Halo. We look forward to building our pharmaceutical development business in Mirabel, and to expanding
the amount of commercial manufacturing conducted at the site." Mohd Asif, CFO, Halo Pharmaceutical, said, "This platform in
Mirabel gives us immediate export potential into the European Union, and provides new dosage forms and specialized R&D
services for our clients."Deal historyCompleted: On July 31, 2012, Halo Pharmaceutical completed the acquisition of a
manufacturing facility in Mirabel, Canada, from Teva Canada.Announced: On March 28, 2012, Halo Pharmaceutical agreed to
acquire a manufacturing facility in Quebec, Canada, from Teva Canada.
Deal Rationale
The acquisition enables Halo Pharmaceutical to provide new dosage forms and specialized R&D services to clients and export
its production outside of Canada.
Deal Information
Deal Status
Completed
Announced Date
28-Mar-2012
Completed Date
31-Jul-2012
Company Name
Halo Pharmaceutical, Inc.
Halo Pharmaceutical, Inc. (Halo) is a pharmaceutical company. The company develops and manufactures a range of
pharmaceutical products in various dosage forms. Its dosage forms include compressed tablets, micro tablets, aqueous film
coated tablets, capsules, sustained release beads, powders, liquids, ointments and suppositories. Halo provides services such
as project management, formulation development and analytical development. The company provides dry blending, direct
compression tablets, high shear granulation, fluid bed drying, tablet film coating, tablet compression, wurster column based
beads and bead coating, encapsulation, controlled substances handling services. It offers solids, liquids and sterile ointment;
and packaging services. Halo is headquartered in Whippany, New Jersey, the US.
Company Name
Teva Canada Limited
Parent
Teva
Pharmaceutical
Industries Limited
Teva Canada Limited (Teva Canada) is a pharmaceutical company. The company develops, produces and markets generic
and branded pharmaceuticals. It offers various products for diabetes, ear infections, heart disease, multiple sclerosis and
cancer products in the form of tablets and capsules. Teva Canada also produces animal health products. The companys vet
products include NV-clindamycin, NV-ketoprofen and others. Its three leading proprietary drugs include Copaxone (glatiramer
acetate), Azilect (rasagiline) and Frova (frovatriptan succinate). The company operates through its manufacturing facilities
including Teva Canada Centre of Excellence for Solid Dose Products, Teva Canada Centre of Excellence for Penicillin
Products, and Teva Canada Centre of Excellence for Packaging. The company was formerly known as Novopharm Limited.
Teva Canada is headquartered in Ontario, Canada.
GlobalData


Page 261
Acino Pharma Completes Acquisition Of Asia, Latin America, Middle East And Africa Businesses From
Mepha For US$123 Million
Acino Pharma Completes Acquisition Of Asia, Latin America, Middle East And Africa Businesses From Mepha For
US$123 Million
Deal Type
Asset Transactions
Deal in Brief
Acino Pharma Ltd., a pharmaceutical company and subsidiary of Acino Holding AG, completed the acquisition of international
business and a site in Aescha (Switzerland) from Mepha, for a purchase consideration of 94m ($122.6m). The acquisition
includes Asia, Latin America, Middle East and African businesses, along with the production and R&D facilities in Aesch,
Switzerland. Acino financed the acquisition through the issuance of shares from authorized capital in the amount of 20m, cash
and cash equivalents, and a bank loan.The Aesch facility comprises an FDA-compliant manufacturing facility, office space and
an R&D unit focused on the development of oral formulations. Teva will market and develop the Mepha brand in Switzerland.
As part of the agreement, Mepha will transfer a number of its existing generic R&D development projects to Acino, and will
continue to source products from the former Mepha site in Aesch. The Middle East and African business includes Cephalon
and Mepha brands. It also comprises of analgesic Olfen (diclofenac), the anti-spasmotic Spasfon
(phloroglucinol/trimethylphloroglucinol), the gastrointestinal drug Gasec (omeprazole) and the antibiotic Mesporin
(ceftriaxone).This acquisition enables Acino to strengthen its product portfolio and establish its own market presence under the
Acino Switzerland brand.Peter Burema, CEO of Acino, said, This is a truly perfect fit in every respect. Mepha's expertise and
competence in R&D and manufacturing will boost our own capabilities and capacities, and we share the same commitment to
highest quality standards for products and services. We thank Mepha for their vote of confidence by retaining us as a preferred
supplier. Personally, I would like to extend a warm welcome to all employees joining our Group. Through this acquisition, we
have secured a foothold in important growth economies around the globe where we also intend to establish our own presence
under the "Acino Switzerland" brand.Andreas Bosshard, general manager of Mepha, said, This agreement is a win-win
situation for all parties. Following the acquisition of Mepha by Teva, we now have access to world-class global resources with a
broad portfolio and a very promising product pipeline and at the same time continue to source an important part of our product
range made in Switzerland from the plant in Aesch. Mepha clients will continue to benefit from the same product quality and
range, made to the highest standards that customers across Switzerland have a right to expect.Deal history:Completed: On
February 17, 2012, Acino completed the acquisition of international business and a site in Aescha (Switzerland) from Mepha,
for a purchase consideration of 94m ($122.6m).Update: On December 19, 2011, Acino also agreed to acquire Asia and Latin
America businesses, along with Middle East and African businesses from Mepha, for a purchase consideration of 94m
($122.6m).Announced: On October 17, 2011, Acino agreed to acquire Middle East and Africa business from Mepha, for a
purchase consideration of 80m ($110.9m). The total consideration includes 60m ($83.25m) in cash and 20m ($27.75m)
through the issuance of shares from authorized capital (calculated at the average share price on the day prior to the closing of
the transaction).
Deal Rationale
This acquisition enables Acino to strengthen its product portfolio and establish its own market presence under the Acino
Switzerland brand.
Deal Information
Deal Status
Completed
Announced Date
17-Oct-2011
Completed Date
17-Feb-2012
Deal Financials
94
Deal Value (US$ m)
122.60
Deal Payment
Company Name
Acino Holding AG
Parent
Pharma
GmbH
Strategy
Partners
Acino Holding AG (Acino) manufactures and commercializes generic and prescription pharmaceuticals in novel drug delivery
forms. It offers products for the treatment of cancer, pain, cardiovascular disorders, cold and cough, urological disorders,
diabetes, osteoporosis, and disorders of the central nervous system, among others. It also offers business-to-business services

Page 262
such as product development, registration and contract manufacturing. The company's drug delivery technologies focus on
modified release oral forms, extended release parenterals, transdermal systems and oral dispersible forms. It has
manufacturing facilities in Germany and Switzerland. The company markets its products in more than 80 countries in the Middle
East, Latin America, Africa and Asia. Acino is headquartered in Basle, Switzerland.
Company Name
Mepha Pharma AG
Parent
Cephalon, Inc.
GlobalData


Page 263
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma
Deal Type
Asset Transactions
Deal in Brief
Par Pharmaceutical Companies, Inc., a drug developing and manufacturing company, completed the acquisition of rights and
assets related to generic versions of Actiq (fentanyl), Amrix and Provigil, from Teva Pharmaceutical Industries Ltd.
Under the transaction, Par will own the ANDAs (Abbreviated New Drug Applications) of fentanyl citrate lozenges, a generic
version of Actiq, and cyclobenzaprine ER capsules, the generic version of Amrix, as well as the US rights to market modafinil
tablets, the generic version of Provigil. In addition, Teva and Par will enter into an agreement to supply Provigil in the US for a
period of one year and this collaboration includes an option to extend the supply agreement for an additional year.
AMRIX (Cyclobenzaprine Hydrochloride extended-release capsules) is a skeletal muscle relaxant used to relieve muscle
spasm of local origin without interfering with muscle function. Actiq is used to treat cancer pain. Provigil (modafinil) is a
prescription medicine used in the treatment of diagnosed sleep disorders such as: obstructive sleep apnea (OSA) and shift
work sleep disorder (also shift work disorder or narcolepsy).
Deal history
Completed: On October 18, 2011, Par Pharmaceutical Companies completed the acquisition of rights to three products
comprising Actiq, Amrix and Provigil, from Teva Pharmaceuticals.
Announced: On October 7, 2011, Teva Pharmaceutical Industries entered into an agreement to divest the rights and assets
related to its generic versions of Actiq (fentanyl) and Amrix, to Par Pharmaceutical Companies.
Deal Information
Deal Status
Completed
Announced Date
07-Oct-2011
Completed Date
18-Oct-2011
Company Name
Par
Pharmaceutical
Holdings, Inc.
Parent
Endo International plc
Par Pharmaceutical Companies, Inc. (Par Pharmaceutical Companies) carries out the research, development, manufacture,
commercialization and distribution of generic and branded drugs in the US. Its generic products include oral solids, oral
suspensions, gels, nasal sprays, and injectables. It also markets authorized in-licensed generic drugs. Some of its branded
products include Nascobal, a nasal spray; and Megace ES, which is indicated for the treatment of anorexia, cachexia or for
weight loss in patients diagnosed with AIDS. The company also offers branded and generic aseptic injectables. It manufactures
all the products in its manufacturing facilities in India and the US. It markets generic products through wholesalers, drug store
chains, super market chains, mass merchandisers, distributors, and government and mail order accounts. Par Pharmaceutical
Companies is headquartered in Woodcliff Lake, New Jersey, the US.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 264
Partners In Life Sciences Completes Acquisition Of Manufacturing Facility In Mitry-Mory From Cephalon
Partners In Life Sciences Completes Acquisition Of Manufacturing Facility In Mitry-Mory From Cephalon
Deal Type
Asset Transactions
Deal in Brief
Partners in Life Sciences (PILS), a private investment group, completed the acquisition of a manufacturing facility in Mitry-Mory,
France, from Cephalon, Inc., a biopharmaceutical company, for a purchase consideration of $6.1m.As per the terms of the
agreement, the manufacturing facility will continue with the production of active pharmaceutical ingredients (API) and generics.
PILS retained the 50 employees of the site. Alain Aragues, executive vice president and president, Cephalon Europe, said,
"Cephalon is satisfied in a difficult economic and social circumstances, be able to maintain the industrial site of Mitry-Mory
operational, and have found a buyer whose projects are promising future development of the site."Deal historyCompleted: On
October 3, 2011, Partners in Life Sciences completed the acquisition of a manufacturing facility located in Mitry-Mory, France,
from Cephalon, Inc., a biopharmaceutical company, for a purchase consideration of $6.1m.Update2: On September 30, 2011,
Partners in Life Sciences and Cephalon formalized the purchase agreement for Cephalon's manufacturing facility located in
Mitry-Mory, France.Update1: In April 2011, Cephalon entered into an agreement to divest its manufacturing facility located in
Mitry-Mory, France for a consideration of $6.1m.Announced: On March 17, 2011, Cephalon intends to divest its manufacturing
facility located in Mitry-Mory, France.
Deal Information
Deal Status
Completed
Announced Date
17-Mar-2011
Completed Date
03-Oct-2011
Deal Financials
Deal Value (US$ m)
6.10
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Firm Name
Partners in Life Sciences
Partners in Life Sciences (PiLS) is a private equity firm.
GlobalData


Page 265
Perrigo Acquires Rights For Allegra From Teva Pharma

Perrigo Acquires Rights For Allegra From Teva Pharma
Deal Type
Asset Transactions
Deal in Brief
Perrigo Company, a global healthcare supplier, acquired the exclusive US store brand rights to sell and distribute OTC versions
of Fexofenadine HCl 180 mg and 60 mg tabs, plus Fexofenadine HCl 60 mg and Pseudoephedrine 120 mg tabs, the generic
versions of Sanofi-Aventis Allegra and Allegra D-12 products, from Teva Pharmaceutical Industries Ltd, a pharmaceutical
company.
Allegra is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. ALLEGRA-D 12 (fexofenadine
hydrochloride and pseudoephedrine hydrochloride) extended-release tablets for oral administration contain 60 mg fexofenadine
hydrochloride for immediate release and 120 mg pseudoephedrine hydrochloride for extended release.
Allegra 180 mg, 60 mg, and Allegra D-12 are indicated for the relief of symptoms associated with seasonal allergies. SanofiAventis has applied to the FDA for the Rx-to-OTC switch of these drugs.
Joseph C. Papa, chairman and CEO of Perrigo, said, This is another example of Perrigos strategic focus on making quality
healthcare more affordable to American consumers by introducing new Rx-to-OTC switch products.
Deal Information
Deal Status
Completed
Completed Date
29-Jun-2010
Company Name
Perrigo Company plc
Perrigo Company plc (Perrigo) is one of the leading pharmaceutical companies. It develops, manufactures and distributes overthe-counter products, generic and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (APIs),
infant formulas, and consumer products. The company operates its business through six reportable segments, namely,
Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, APIs, Specialty Sciences and Others. It also provides consumer
products such as cosmetics, toiletries, bar soaps, and detergents. Perrigo operates in the US, the UK, Mexico, Israel, Australia,
Canada and China, besides Latin America. Perrigo is headquartered in Dublin, Ireland.
Company Name
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 266
Hospira Acquires Worldwide Rights To Filgrastim From PLIVA

Hospira Acquires Worldwide Rights To Filgrastim From PLIVA
Deal Type
Asset Transactions
Deal in Brief
Hospira, Inc., a pharmaceutical and medication delivery company, has acquired worldwide rights to a biogeneric version of
filgrastim, from PLIVA Hrvatska d.o.o., a subsidiary of PLIVA d.d., a global generic pharmaceutical company.
As part of the agreement, Hospira has also acquired process development capabilities and a manufacturing plant in Croatia,
which has capacity sufficient to meet Hospira's worldwide filgrastim and pegfilgrastim requirements, along with expansion
possibility for additional biogenerics manufacturing.
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) used to treat neutropenia, a condition in which the body makes too
few infection-fighting white blood cells. Blank Rome LLP advised Hospira on the transaction.
Deal Rationale
The transaction will enable the company to extend its reach to new markets and vertical integration in biogenerics.
Deal Information
Deal Status
Completed
Completed Date
30-Sep-2009
Company Name
Hospira, Inc.
Parent
Pfizer Inc.
Company Name
Pliva Hrvatska doo
Parent
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
Hospira, Inc.
Blank Rome LLP
GlobalData


Page 267
Acquisition
Teva Pharma Acquires Auspex Pharma
Teva Pharma Acquires Auspex Pharma
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, has acquired Auspex Pharmaceuticals, Inc., a
biopharmaceutical company, for a purchase consideration of USD101 per share in cash, representing total consideration of
approximately USD3.2 billion in enterprise value and approximately USD3.5 billion in equity value. The offer price represents a
premium of 42.4% to Auspex Pharma's closing price on March 27, 2015. The transaction was funded with cash on hand and is
not subject to any financing contingencies.In the transaction, as of the expiration of the tender offer, a total of 24,889,292
shares were validly tendered into and not validly withdrawn (not including 613,455 shares tendered pursuant to notices of
guaranteed delivery), representing approximately 77.7% of Auspex's outstanding shares. The condition to the tender offer that
at least a majority of the outstanding shares of Auspex's common stock be validly tendered and not validly withdrawn prior to
the expiration of the tender offer was thus satisfied and, accordingly, all such validly tendered shares were accepted for
payment. Teva will promptly pay for all such shares in accordance with the terms of the tender offer. As a result of the
acquisition, each share of Auspex that was not validly tendered in the tender offer (other than shares held by any stockholder of
Auspex who properly demanded appraisal of such shares under the applicable provisions of Delaware law) was cancelled and
converted into the right to receive the same USD101.00 per share in cash that will be paid in the tender offer.Following the
completion of the transaction, Auspex became a wholly owned subsidiary of Teva pharma, and shares of Auspex will cease to
be traded on the NASDAQ Global Market, effective later on May 5, 2015. This transaction enables Teva Pharma to strengthen
its position within central nervous system (CNS) and expand presence into underserved movement disorder markets.Goldman,
Sachs & Co. acted as financial advisor; while Goodwin Procter LLP acted as legal advisor to Teva Pharma and J.P. Morgan
Securities LLC acted as financial advisor; while Cooley LLP acted as legal advisor to Auspex Pharma for the transaction. Deal
History:Announced: On March 29, 2015, Teva Pharma agreed to acquire Auspex Pharma, for a purchase consideration of
USD101 per share in cash, representing total consideration of approximately USD3.2 billion in enterprise value and
approximately USD3.5 billion in equity value. The transaction has been unanimously approved by the boards of directors of
both Teva Pharma and Auspex Pharma, and key shareholders of Auspex Pharma have entered into agreements indicating
their support for the transaction.
Deal Rationale
This transaction enables Teva Pharma to strengthen its position within central nervous system (CNS) and expand presence
into underserved movement disorder markets.
Deal Information
Deal Status
Completed
Announced Date
29-Mar-2015
Completed Date
05-May-2015
% Acquired
100
Deal Financials
3,200
Bid Premium (%)
42.40
3,500
Deal Payment
Cash (US$ m)
3,500
Company Name
Teva
Pharmaceutical
Industries Limited

Page 268
Company Name
Auspex
Inc.
Pharmaceuticals,
Parent
Teva
Pharmaceutical
Industries Limited
California, the US.
Advisor Information
Legal Advisor
Auspex
Inc.
Cooley LLP
Pharmaceuticals,
Teva
Pharmaceutical
Industries Limited
Goodwin Procter LLP
Financial Advisor
Auspex
Inc.
Pharmaceuticals,
Teva
Pharmaceutical
Industries Limited
Goldman Sachs & Co.

(US$)
67.24

(US$)
70.91

Number of Employees
35

EV/Total Assets
14.73
0.94

(US$)
3.81
GlobalData


Page 269
Teva Pharma May Increase Bid to Acquire Mylan

Teva Pharma May Increase Bid to Acquire Mylan
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, intends to increase the bid to acquire Mylan N.V., a
pharmaceutical company, reported by Reuters, citing people familiar with the matter. According to the sources, Teva Pharma
would increase the size of the cash component of its rejected bid for Mylan. The offer is now worth USD43 billion.Earlier, on
April 21, 2015, Teva Pharma agreed to acquire Mylan for a purchase consideration of USD40.1 billion or USD82 per share of
Mylan. The transaction was unanimously approved by the board of directors of Teva Pharma. On April 22, 2015, Teva Pharma
filed a notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the US Department of Justice
Antitrust Division and the Federal Trade Commission regarding the transaction.Pursuant to the transaction, Mylan stockholders
will be provided with consideration representing a 37.7% premium to the stock price of Mylan on April 7, 2015, and a 48.3%
premium to the unaffected stock price of Mylan on March 10, 2015. Following the transaction, the combined company would
leverage its significantly more efficient and advanced infrastructure, with enhanced scale, production network, end-to-end
product portfolio, commercialization capabilities and geographic reach. With this platform, the combined company would focus
on complex technologies and more durable and sustainable products, in combination with robust capabilities in specialty drug
development and commercialization. As a result, the combined company would have a business model addressing significant
trends and discontinuities prevailing today among patients and healthcare systems around the world. The combined company
would also have an enhanced financial profile, creating the opportunity for rapid deleveraging and the funding of future growth
in generics, specialty and the intersection of the two. This transaction will enable Teva Pharma to further strengthen its position
in the pharmaceutical industry.Barclays and Greenhill & Co., Inc. are acting as financial advisors, while Kirkland & Ellis LLP and
Tulchinsky Stern Marciano Cohen Levitski & Co. are acting as legal advisors to Teva Pharma, and De Brauw Blackstone
Westbroek N.V. and Loyens & Loeff N.V. are acting as legal advisors in the Netherlands. The transaction is subject to
customary conditions and is expected to be completed by year-end 2015. The transaction would not be subject to a financing
condition or require a Teva stockholder vote. The transaction is contingent on Mylan not completing its proposed acquisition of
Perrigo or any alternative transactions. There can be no assurance that a transaction between Teva and Mylan will be
consummated. Deal History:Rejected: On April 27, 2015, Mylan rejected the acquisition offer from Teva Pharma, for a
consideration of USD40.1 billion or USD82 per share.Announced: On April 21, 2015, Teva Pharma agreed to acquire Mylan for
a purchase consideration of USD40.1 billion or USD82 per share of Mylan. The transaction was unanimously approved by the
board of directors of Teva Pharma. Dead Rumor: On April 18, 2015, Mylan has denied rumors that it is selling the company to
Teva Pharma. Reportedly, the proposed transaction would have enabled Teva to re-establish as the dominant market
leader.Rumor: On April 17, 2015, Teva Pharma intends to acquire Mylan, according to the Wall Street Journal citing people
familiar with the matter.
Deal Rationale
This transaction will enable Teva Pharma to further strengthen its position in the pharmaceutical industry.
Deal Information
Deal Status
Rumor
RumorDate
Apr 17, 2015
% Acquired
100
Deal Financials
40,100
Bid Premium (%)
43,000
43.06
Company Name
Teva
Pharmaceutical
Industries Limited

Page 270
Company Name
Mylan N.V.
Mylan Inc. (Mylan) is one of the leading generic drug and specialty drug manufacturing companies in the world. The company
focuses on the development, licensing, production, commercialization and distribution of generics, branded generics, specialty
pharmaceuticals and active pharmaceutical ingredients (API). The company manufactures specialty pharmaceuticals with
special focus on respiratory and allergic conditions. The company markets more than 1,400 products comprising vast array of
therapeutic categories to consumers in more than 140 countries and territories across the world. Mylan sells its products to
proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains,
independent pharmacies, drug manufacturers, institutions, and public and governmental agencies primarily in the US and
Canada, Europe, the Middle East and Africa, and India, Australia, Japan,New Zealand and Brazil. Mylan is headquartered in
Canonsburg, Pennsylvania, the US.
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited
De
Brauw
Westbroek N.V.
Blackstone
Kirkland & Ellis LLP

Loyens & Loeff NV
Financial Advisor
Teva
Pharmaceutical
Industries Limited
Greenhill & Co., Inc.

Barclays
Financial Information (Mylan N.V.)

Number of Employees
25,000

Operating Margin(%)
17.38
EV/Revenues
0.80
EV/Operating Profit
4.58
EV/EBITDA
2.73
EV/Total Assets
0.39
0.46

(US$)
6.66
1.90
GlobalData


Page 271
Ind-Swift Lab May Sell Stake in Company

Ind-Swift Lab May Sell Stake in Company
Deal Type
Deal Sub Type
Acquisition
Minority Acquisition
Deal in Brief
Ind-Swift Laboratories Ltd., a manufacturer and exporter of active pharmaceutical ingredients, has intends to sell up to a 30%
stake for a consideration of INR2 billion (USD3.33 million), reported Times of India, citing sources familiar with the matter.
Reportedly, Ind-Swift Lab is in talks with Teva Pharmaceuticals USA, Inc. and Perrigo International Holdings Inc. for this
transaction.According to the sources, the company uses the proceeds to expand its existing manufacturing capacities.
Deal Rationale
The company intends to uses the proceeds to expand its existing manufacturing capacities.
Deal Information
Deal Status
Rumor
RumorDate
Jul 30, 2014
Deal Financials
Deal Value (INR million)
2,000
Deal Value (US$ m)
33.28
Company Name

Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Perrigo
Holdings Inc.
International
Ind-Swift
Limited
Laboratories
Parent
Perrigo Company plc

Company Name
Ind-Swift Laboratories Limited. (ISLL) is a contract research and manufacturing services (CRAMS) company. It undertakes the
manufacturing of active pharmaceutical ingredients (API), allied menthol and mint derivatives and custom chemical products.
The companys product portfolio includes APIs such as Roxithromycin, Azithromycin, Bexarotene, Deferasirox, and others;
allied menthol and mint derivatives such as Mentho Oil Rectified, Mint Terpenes, and Dihydro Myrcenol, among others; and
custom chemical products including 5-Hexynoic acid, 2-Flouro-5-bromobenzonitrile, 5-Hexyne-1-ol, and others. Its products find
application in the therapeutic area of cardiovascular, antidiabetic, bone resorption inhibitor, Parkinsons disease, and analgesic,
among others. ISLL offers services such as drug development, process research and development, contract manufacturing,
API manufacturing, custom chemical synthesis, analytical services and others. It operates manufacturing plants, which are
certified by international agencies such as TGA, UK-MHRA, US-FDA, UAE and others. ISLL is headquartered in Chandigarh,
India.
GlobalData


Page 272
Teva Pharma Completes Acquisition of Labrys Biologics

Teva Pharma Completes Acquisition of Labrys Biologics
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Teva Pharmaceutical Industries Ltd., a developer of generic drugs, specialty pharmaceuticals and active pharmaceutical
ingredients, has completed the acquisition of Labrys Biologics, Inc., a provider of treatments for chronic migraine and episodic
migraine. As consideration, Teva Pharmaceutical Industries paid USD200 million in cash upon closing and will pay additional
USD625 million in contingent payments upon achievement of certain pre-launch milestones.This acquisition enables Teva
Pharmaceutical Industries to broaden its array of biotechnology assets and capabilities. The acquisition of LBR101complements the Teva Pharmaceutical Industriess recent addition of Zecuity, a novel iontophoretic patch that delivers
sumatriptan via the skin for the acute treatment of migraine, and positions Teva to compete for leadership in the treatment and
prevention of migraine, obtained through the acquisition of NuPathe.LBR-101 developed by Labrys, is a fully humanized
monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) currently in Phase IIb clinical trials for prevention of
chronic and episodic migraine.Deal History:Announced: On June 3, 2014, Teva Pharmaceutical Industries agreed to acquire
Labrys Biologics. As consideration, Teva Pharmaceutical Industries agreed to pay USD200 million in cash at closing and up to
USD625 million in contingent payments upon achievement of certain pre-launch milestones.
Deal Rationale
This acquisition enables Teva Pharmaceutical Industries to broaden its array of biotechnology assets and capabilities.
Deal Information
Deal Status
Completed
Announced Date
03-Jun-2014
Completed Date
21-Jul-2014
% Acquired
100
Deal Financials
200
825
Deal Payment
Cash (US$ m)
200
Deal Product
Product Description
TEV-48125
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Parent
Teva
Pharmaceutical
Industries Limited
GlobalData


Page 273
Novartis Terminates Planned Acquisition Of Gamida Cell For US$600 Million

Novartis Terminates Planned Acquisition Of Gamida Cell For US$600 Million
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Novartis AG terminated its planned acquisition of Gamida Cell Ltd., a healthcare company. The transaction was valued at
approximately US$600m. Novartis intended to fund up to US$300m in upfront cash payment and the remaining US$300m in
milestone payments and royalties.As reported by Globes, Novartis had signed a memorandum of understanding including the
exact financial conditions of the transactions with the shareholders of Gamida Cell for the acquisition.Earlier on March 7, 2014,
Clal Biotechnology Industries Ltd. Ltd and Elbit Medical Technologies Ltd. received non-binding proposal from a global
pharmaceutical company for acquisition of their stake in Gamida Cell. The consideration included significant immediate
payment and future milestone-based payments (development/regulatory/sales related to the drugs developed by Gamida
Cell).Currently, Elbit Medical Technologies holds 30.8% stake, Clal Biotechnology holds 22% stake, and Israel Healthcare
Venture, Teva Pharmaceutical Industries Limited, Amgen Inc., Denali Ventures and Auriga Ventures (Auriga Partners) holds
the remaining 47.2% stake in Gamida Cell.
Deal Information
Deal Status
Terminated
Terminated Date
May 01, 2014
% Acquired
100
Deal Financials
600
Company Name
Novartis AG
Novartis AG (Novartis) is a global healthcare company, which focuses on the discovery and development of novel healthcare
solutions. It provides a wide range of prescription and generic products for the treatment of various diseases and disorders in
humans and animals. The company provides drugs for treatment of cancer, cardiovascular diseases, dermatological conditions,
neurological disorders, ophthalmic diseases, respiratory diseases, immune disorders and infections, among others. Novartis
also offers preventive vaccines and over-the-counter (OTC) products. The company sells its products in the US, Europe and
Rest of the World. Novartis is headquartered in Basel, Switzerland.
Company Name
Elbit Medical Technologies

Ltd.
Company Name
Amgen Inc.
Parent
Elbit Imaging Ltd.
Amgen Inc. (Amgen) is a biotechnology company. It undertakes the discovery, development, manufacture and
commercialization of innovative human therapeutics. The company pioneered the development of new products based on
advances in recombinant DNA and molecular biology. It offers medicines for the treatment of cancer, rheumatoid arthritis,
kidney disease, bone disease and many other serious illnesses. Amgens R&D organization has expertise in multiple treatment
modalities, antibodies, large-molecule proteins and small molecules. The companys key products include Neulasta
(pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis;
Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidney disease
and in cancer; and Prolia (denosumab) used in the treatment of osteoporosis in postmenopausal women among others. Its
product pipeline focuses on treating conditions such as ovarian cancer, heart disease, migraine and schizophrenia. The
company has research and development (R&D) facilities in the US, Canada, the UK, Germany and Iceland. Amgen is
headquartered in Thousand Oaks, California, the US.
Company Name
Teva
Pharmaceutical
Industries Limited

Page 274
Company Name

Ltd.
Parent
Clal
Industries
Investments Ltd.
and
Company Name
Gamida Cell Ltd.
Gamida Cell Ltd. (Gamida) is a health care company. The company is into development of therapeutic products. It offers
products such as StemEx, NiCord, CordBridge, and NK Cell product. Gamidas product StemEx is used for the treatment of
leukemia, lymphoma, krabbe disease, metachromatic leukodystrophy and hurler syndrome. The companys cell therapy
products provide the treatment for blood cancer, peripheral vascular diseases and neurological disorders. It markets its
products through brands such as NiCord, and StemEx. Gamida operates with copper Chelator based technology and NAM
based technology towards developing an impressive pipeline of cell therapy products for a wide range of clinical applications.
Gamida is headquartered in Jerusalem, Israel.
Vendor Firm Information
Firm Name
Auriga Partners
Auriga Partners is a venture capital firm that invests in life sciences and information technology companies. The firm manages
funds focusing mainly in startups, early and growth companies. The firms AURIGA IV Bioseeds, is a seed fund focusing on
projects in the areas of infectiology and microbiology. It also invests in businesses such as digital economy that are in the
commercial expansion phases, especially on an international basis. Since its incorporation, the firm has accumulated around
EUR350 M through several investment vehicles such as AURIGA Ventures I, AURIGA Ventures II, AURIGA Ventures III,
AURIGA IV Bioseeds and European Medical Ventures. Auriga Partners is headquartered in Paris, France.
Firm Name
Israel HealthCare Ventures
Israel HealthCare Ventures is a venture capital fund that offers investment to Israeli and Israeli related companies functioning in
the areas of medical devices, biotechnology, pharmaceuticals, nanotechnology and medical-related IT.
Firm Name
Denali Ventures
Denali Ventures is a venture capital fund.
GlobalData


Page 275
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer
Deal Type
Acquisition
Deal Sub Type
100% Acquisition
Deal in Brief
Teva Pharmaceutical Industries Ltd., a developer of generic drugs, specialty pharmaceuticals and APIs, through its whollyowned subsidiary Train Merger Sub, Inc. completed the acquisition of NuPathe, Inc., a specialty pharmaceutical company, for a
purchase consideration of approximately US$144m or US$3.65 per share, in a cash tender offer. In addition to the upfront cash
payment, NuPathe shareholders will receive rights to receive additional cash payments of up to US$3.15 per share if specified
net sales of NuPathes migraine treatment, Zecuity, are achieved over time. The board of directors of NuPathe unanimously
approved the transaction. Under the transaction, Teva Pharma through its subsidiary acquired all of the issued and outstanding
shares of the common stock of NuPathe at a price of US$3.65 per share in cash. In the offering, a total of 28,178,652 shares
were validly tendered into and not validly withdrawn from the offer (not including 1,229,499 shares tendered pursuant to notices
of guaranteed delivery), representing approximately 80.01255% of NuPathes outstanding shares. The condition to the offer
that at least a majority of the outstanding shares of NuPathes common stock on a fully diluted basis be validly tendered and not
validly withdrawn prior to the expiration of the offer was satisfied, and, accordingly, all such validly tendered shares were
accepted for payment and Teva Pharma will promptly pay for all such shares in accordance with the terms of the offer. The
contingent cash consideration payments will not be publicly traded. The contingent cash consideration payments can be
summarized as follows: US$2.15 per share if net sales of Zecuity exceed US$100m during any four-quarter period prior to the
ninth anniversary of the first commercial sale of Zecuity; and an additional US$1 per share if net sales of Zecuity exceed
US$300m during any four-quarter period prior to the ninth anniversary of the first commercial sale of Zecuity. The affiliate of
Teva Pharma that consummates the tender offer entered into a separate contingent cash consideration agreement with
American Stock Transfer & Trust Company as paying agent to provide for the payment of the contingent cash consideration
payments. The stockholders of NuPathe will be third party beneficiaries under this agreement. Pursuant to the terms of the
contingent cash consideration agreement, Teva Pharma will guarantee the obligations of its affiliate to make the contingent
cash consideration payments.Following the completion of the tender offer, NuPathe became a wholly-owned subsidiary of Teva
Pharma. In the offer, each share of NuPathe that was not validly tendered in the offer (other than shares held directly or
indirectly by Teva Pharma, Merger Sub or NuPathe, or by any stockholder of NuPathe who is entitled to and properly demands
appraisal of such shares under the applicable provisions of Delaware law) will be cancelled and converted into the right to
receive US$3.65 per share in cash and the right to receive contingent cash consideration payments of up to US$3.15 per
share, without interest, that was paid in the offer. Following the acquisition, the common stock of NuPathe will cease trading on
the NASDAQ market.Zecuity, which was approved by the US Food and Drug Administration (FDA) in January 2013 for the
acute treatment of migraine with or without aura in adults, is the first and only FDA-approved prescription migraine patch.
Zecuity is a disposable, single-use, battery-powered transdermal patch that actively delivers sumatriptan, the most widely
prescribed migraine medication, through the skin. This transaction enables Teva Pharma to strengthen and expand its CNS
specialty business. MTS Securities, LLC acted as financial advisor and rendered a fairness opinion to NuPathe, and Morgan,
Lewis & Bockius LLP acted as legal advisor to NuPathe for the transaction.Mike Derkacz, vice president and general manager
of Teva CNS, said, We believe that Zecuity is a great fit within our existing US CNS business unit, with near-term sales and
significant commercial potential. Zecuity enables rapid transdermal delivery of sumatriptan and bypasses the GI tract to avoid
issues with oral intake, addressing an important, unmet patient need, especially for those with migraine-related nausea. At
Teva, we will leverage our unique shared solutions infrastructure to support patient utilization of this important new medicine for
migraine sufferers. Armando Anido, chief executive officer of NuPathe, said, Teva's offer represents a premium of US$0.8 per
share (28%) over the upfront cash consideration offered by Endo, with equal contingent cash consideration. As a recognized
leader in the field of diseases of the central nervous system, we believe that Teva is well-positioned to maximize Zecuity's
potential.Deal historyCompleted: On February 20, 2014, Teva Pharma through its wholly-owned subsidiary Train Merger Sub
completed the acquisition of NuPathe for a purchase consideration of approximately US$144m or US$3.65 per share, in a cash
tender offer. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash
payments of up to US$3.15 per share if specified net sales of NuPathes migraine treatment, Zecuity, are achieved over time.
Announced: On January 17, 2014, Teva Pharma through its wholly-owned subsidiary Train Merger Sub, agreed to acquire
NuPathe for a purchase consideration of approximately US$144m or US$3.65 per share, in a cash tender offer. In addition to
the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to US$3.15 per
share if specified net sales of NuPathes migraine treatment, Zecuity, are achieved over time.
Deal Rationale
This transaction enables Teva Pharmaceutical to strengthen and expand its CNS specialty business.
Deal Information
Deal Status
Completed
Announced Date
17-Jan-2014


Page 276
Completed Date
20-Feb-2014
% Acquired
100
Deal Financials
144
Bid Premium (%)
28
Deal Payment
Cash (US$ m)
144
Deal Product
Product Description
sumatriptan succinate
Sumatriptan Succinate (Zecuity) is antimigraine drug a selective agonist of vascular serotonin.

Zecuity is an extended release transdermal patch. Zecuity is indicated for the treatment of
acute migraine with or without aura in adults. Zelrix, is a single-use patch applied to the upper
arm or thigh for the treatment of migraine. Zelrix actively delivers sumatriptan through the skin
using iontophoresis in a controlled manner using proprietary SmartRelief technology.
Sumatriptan is serotonin (5HT) 1b/1d receptor agonist.
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
NuPathe Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
NuPathe Inc.

LLP
Financial Advisor
NuPathe Inc.
MTS Securities, LLC

(US$)
3.24
4.38


Page 277
(US$)
Number of Employees
14

EV/Total Assets
6.33
0.33

(US$)
0.23
0.23
GlobalData


Page 278
NuPathe Terminates Its Acquisition By Endo Health Solutions For US$105 Million In Tender Offer
NuPathe Terminates Its Acquisition By Endo Health Solutions For US$105 Million In Tender Offer
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
NuPathe, Inc., a specialty pharmaceutical company, terminated its acquisition by Endo Health Solutions Inc., a specialty
healthcare company, for a consideration of approximately US$105m or US$2.85 per share, in a cash tender offer. Pursuant to
the termination of the agreement, Endo Health Solutions received US$5m termination fee from NuPathe. NuPathe entered into
an agreement with Teva Pharmaceutical Industries Ltd., under which Teva Pharma will acquire NuPathe for US$3.65 per share
in cash.
Earlier, on December 15, 2013, Endo Health Solutions, through its indirect subsidiary DM Merger Sub Inc., intended to acquire
all of the issued and outstanding shares of the common stock of NuPathe, par value US$0.001 per share, at a price of US$2.85
per share, in a cash tender offer. In addition to the upfront cash payment, NuPathe shareholders would receive rights to receive
additional cash payments of up to US$3.15 per share if specified net sales of NuPathe's migraine treatment Zecuity are
achieved over time. The contingent cash consideration payments would not be publicly traded. The contingent cash
consideration payments was summarized as follows: US$2.15 per share if net sales of Zecuity exceed US$100m during any
four-quarter period prior to the ninth anniversary of the first commercial sale of Zecuity; and an additional US$1 per share if net
sales of Zecuity exceed US$300m during any four-quarter period prior to the ninth anniversary of the first commercial sale of
Zecuity.
The affiliate of Endo Health Solutions that consummates the tender offer would enter into a separate contingent cash
consideration agreement with American Stock Transfer & Trust Company as paying agent to provide for the payment of the
contingent cash consideration payments. The stockholders of NuPathe would be third party beneficiaries under this agreement.
Pursuant to the terms of the contingent cash consideration agreement, Endo Health would guarantee the obligations of its
affiliate to make the contingent cash consideration payments. Endo Health would acquire all remaining shares not tendered in
the tender offer through a second-step transaction at the same price and the obligation to make the same contingent cash
consideration payments as was deliverable to those stockholders tendering their shares in the tender offer, following the
completion of the tender offer.
Under the terms, the offer, if successful, would be followed by a transaction of DM Merger Sub with and into NuPathe, with
NuPathe as the surviving corporation and an indirect subsidiary of Endo Health Solutions, unless Endo Health elects in its
discretion to reconstitute the transaction as a merger of NuPathe with and into DM Merger Sub, with DM Merger Sub continuing
as the surviving corporation and an indirect subsidiary of Endo.
Zecuity, which was approved by the US Food and Drug Administration (FDA) in January 2013 for the acute treatment of
migraine with or without aura in adults, is the first and only FDA-approved prescription migraine patch. Zecuity is a disposable,
single-use, battery-powered transdermal patch that actively delivers sumatriptan, the most widely prescribed migraine
medication, through the skin.
This transaction would enable Endo Health Solutions to strengthen its pharmaceutical portfolio.
Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates was suppose to act as legal advisor to Endo Health Solutions; MTS
Securities, LLC was suppose to act as financial advisor and rendered a fairness opinion to NuPathe, and Morgan, Lewis &
Bockius LLP was suppose to act as legal advisor to NuPathe for the transaction.
Deal history
Terminated: On January 21, 2014, NuPathe terminated its acquisition by Endo Health Solutions, for a consideration of
approximately US$105m or US$2.85 per share, in a cash tender offer.
Announced: On December 15, 2013, Endo Health Solutions through its indirect subsidiary DM Merger Sub Inc., agreed to
acquire NuPathe for a purchase consideration of approximately US$105m or US$2.85 per share, in a cash tender offer.
Deal Rationale
This transaction would enable Endo Health Solutions to strengthen its pharmaceutical portfolio.
Deal Information
Deal Status
Terminated
Terminated Date
Jan 21, 2014
% Acquired
100
Deal Financials
105


Page 279
Deal Payment
Cash (US$ m)
105
Company Name
Endo International plc (Endo) formerly Endo Health Solutions Inc. is a specialty healthcare company. It develops and
commercializes various branded pharmaceuticals, medical devices and generic drugs with focus on pain management and
urology. The companys major branded prescription products include Lidoderm, Opana ER, Voltaren gel and Percocet for the
management of pain; Frova and Sumavel DosePro for the treatment of migraine; Aveed, Natesto testosterone nasal gel and
Fortesta gel to treat adult males with hypogonadism; Supprelin LA to treat precocious puberty in male and female children;
Valstar anti-cancer chemotherapy drug; and Vantas hydrogel implant to treat advanced prostate cancer. It offers generic drugs
for pain management and the treatment of urology and CNS disorders, immunosuppression, cancer, womens health disorders
and hypertension. The company also offers medical devices to treat mens and womens pelvic health conditions. The company
sells its products directly to large pharmacy chains and wholesale drug distributors. Endo is headquartered in Dublin, Ireland.
Company Name
NuPathe Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
Skadden,
Arps,
Slate,
Meagher & Flom LLP &
Affiliates
NuPathe Inc.

LLP
Financial Advisor
NuPathe Inc.
MTS Securities, LLC

(US$)
2.02

(US$)
2.30

EV/Total Assets
3.29
0.33

(US$)
0.23
0.23
GlobalData


Page 280
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million

Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Actelion Ltd, a pharmaceutical company, through its subsidiary Actelion US Holding Company, completed the acquisition of
Ceptaris Therapeutics Inc. (formerly Yaupon Therapeutics, Inc), a specialty pharmaceutical company, for a purchase
consideration of US$250m. Ceptaris is backed by Vivo Ventures, LLC, Palo Alto Investors, LLC, Burrill & Company, Aperture
Venture Partners, LLC, Osage Partners, BioAdvance Ventures LP, Third Point LLC, Silicon Valley Bank and Oxford Finance
Corporation.Of the total consideration, the company paid US$25m upon signing and US$225m to Ceptaris Therapeutics'
shareholders on closing of the transaction. Ceptaris Therapeutics' shareholders are also eligible to receive additional payments
based on net sales of its product, Valchlor (chlormethine), and/or the achievement of certain commercial milestones. Valchlor is
a topical formulation of mechlorethamine for the treatment of early-stage mycosis fungoides-type cutaneous T-cell
lymphoma.This transaction compliments Actelion's product portfolio by adding Valchlor drug. Jean-Paul Clozel, CEO of
Actelion, said, " Prior to the approval of Valchlor, there were no approved topical mechlorethamine products available for
prescription. As a result, patients were dependent on formulations prepared locally by compounding pharmacies in a nonstandardized environment. Information about pharmacy-compounded preparations is not required to be submitted to, or
reviewed by, the FDA prior to their use by patients. Therefore, such preparations do not undergo the same rigorous FDA review
as Valchlor has. This new standardized product represents a clinically relevant improvement for patients suffering from mycosis
fungoides."Nicholas Franco, chief business development officer at Actelion, said, "If this transaction is consummated, we can
build a product portfolio beyond our PAH franchise. We expect the transaction to become cash-accretive before the end of
2014."Stephen Tullman, president and CEO of Ceptaris Therapeutics, said, We believe that Actelion's expertise in rare
diseases make it an ideal partner to deliver Valchlor to patients globally. We look forward to advancing Valchlor together to
meet the needs of patients. We appreciate the ongoing support of our investors, led by Vivo Ventures (represented by Albert
Cha), who have enabled us to develop Valchlor."The transaction was approved by US Food and Drug Administration (FDA) for
its Valchlor gel. Aquilo Partners, L.P. acted as financial advisor to Ceptaris Therapeutics, while Covington & Burling LLP acted
as legal advisor to Actelion for the transaction.Deal historyCompleted: On September 19, 2013, Actelion through its subsidiary
Actelion US Holding Company completed the acquisition of Ceptaris for a purchase consideration of US$250m.Update: On
August 26, 2013, Actelion through its subsidiary Actelion US Holding Company, finalized the acquisition of Ceptaris for a
purchase consideration of US$250m, following Ceptaris receiving the approval of US Food and Drug Administration (FDA) for
its Valchlor gel.Announced: On July 31, 2013, Actelion through its subsidiary Actelion US Holding Company, agreed to acquire
Ceptaris for a purchase consideration of US$250m.
Deal Rationale
This transaction compliments Actelion's product portfolio by adding Valchlor drug.
Deal Information
Deal Status
Completed
Announced Date
31-Jul-2013
Completed Date
19-Sep-2013
% Acquired
100
Deal Financials
Deal Value (US$ m)
250
Deal Product
Product Description
lobeline
Lobeline was under development for the treatment of methamphetamine addiction and
inhibits
attention deficit hyperactivity disorder. Lobeline is a non-stimulant alkaloid
hyperactivity induced by nicotine and amphetamine. The drug candidate is a natural alkaloid
found in Indian tobacco (Lobelia inflata). In its pure form it is a white amorphous powder which
is freely soluble in water. Lobeline is used as a smoking cessation aid, and may have
application in the treatment of other drug addictions such as addiction to amphetamines,
cocaine or alcohol. Lobeline act as a potent antagonist at both alpha3beta2 and alpha4beta2
neuronal nicotinic receptor subtypes.

Page 281
Company Name
Actelion Ltd
Parent
Actelion Ltd
Actelion Ltd. (Actelion) is a biopharmaceutical company. It discovers, develops and commercializes innovative treatments,
which serve considerable unmet medical needs. Actelion Ltd. (Actelion) is a biopharmaceutical company. It discovers, develops
and commercializes innovative treatments, which serve considerable unmet medical needs. Actelion pioneered the
development of endothelin receptor antagonists (ERA). The companys major products include Tracleer (bosentan) for the
treatment of pulmonary arterial hypertension; Ventavis (iloprost), an inhaled synthetic analog of prostacyclin; Veletri
(epoprostenol for injection, an intravenous prostacyclin; Opsumit (macitentan), endothelin receptor antagonist, Zavesca
(miglustat), low-molecular-weight inhibitor and Valchlor (mechlorethamine). The company operates across Switzerland, United
States, Europe and Other. Actelion is headquartered in Allschwil, Switzerland.
Company Name
Parent
Cephalon, Inc.

Firm Name
Vivo Ventures, LLC
Firm Name
BioAdvance
Firm Name
Burrill & Company
California, the US.
Firm Name
Third Point LLC
Third Point LLC is an employee owned hedge fund sponsor. The firm provides its services to pooled investment vehicles.
Firm Name
Firm Name
Silicon Valley Bank
Parent
SVB Financial Group
Silicon Valley Bank (SVB), a subsidiary of SVB Financial Group, is a bank. The companys product portfolio includes business
checking, in-country accounts, multi-currency accounts, money market accounts, and sweep accounts. Its services comprise
treasury management, digital solutions, credit solutions, and strategic advisory services. SVB also provides investments
solutions, asset management, finance management, conventional construction financing, and wealth management services.
The company caters to software and internet, hardware and infrastructure, life science and healthcare, energy and resource
innovation, venture capital and private equity, community development finance, and premium wine bank industries, among

Page 282
others. It operates across the US, the UK, Israel, China, and India. SVB is headquartered in Santa Clara, California, the US.
Firm Name
Osage Partners LLC
Firm Name

LLC
Firm Name
Oxford Finance LLC
Oxford Finance LLC (Oxford Finance) is a financial service provider. The company provides financial services to public and
private life science and health care services companies. It offers financial services such as senior secured term loans, cash
flow loans, revolving lines of credit, real estate term loans and equipment loans. Oxford Finance offers its services to life
sciences sectors such as pharmaceuticals and biopharmaceuticals, and healthcare services, among others. The company
provides its services to acute care and specialty hospitals sectors such as LTACH, psychiatric, rehabilitation and sub-acute
facilities, medical laboratories and large physician groups, among others. Oxford Finance is headquartered in Alexandria,
Virginia, the US.
Advisor Information
Legal Advisor
Actelion Ltd
Covington & Burling LLP
Financial Advisor
Aquilo Partners, L.P.
GlobalData


Page 283
Teva Pharma Completes Acquisition of MicroDose Therapeutx

Teva Pharma Completes Acquisition of MicroDose Therapeutx
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, has completed the acquisition of MicroDose Therapeutx Inc.,
a pharmaceutical and drug delivery company.Under the terms, Teva Pharmaceutical acquired all the outstanding shares of
MicroDose Therapeutx for a cash consideration of USD40 million at closing. In addition, Teva Pharmaceutical will pay
additional payments of approximately USD206 million upon achievement of regulatory and development milestones, plus salesbased milestones and tiered royalty payments upon commercialization of MDT-637 and an earlier stage Asthma/COPD
medicine.Following the acquisition, Teva Pharmaceutical ceased access to MicroDose Therapeutxs proprietary technology
including its multi-dose dry powder nebulizer device, which requires no preparation and can be administered in less than 30
seconds. MicroDose Therapeutxs current pipeline is anchored by MDT-637 for respiratory syncytial virus (RSV) - an inhaled,
low dose, small molecule, fusion inhibitor which prevents viral replication, delivered via MicroDose Therapeutxs
technology.This acquisition enables Teva to expand its respiratory pipeline products. Stifel Financial Corp. acted as financial
advisor to MicroDose Therapeutx in the transaction.Deal History:Announced: On June 17, 2013, Teva Pharmaceutical entered
into a definitive agreement to acquire MicroDose Therapeutx for a consideration of USD40 million in cash at closing and
additional payments of USD125 million upon achievement of certain milestones.
Deal Rationale
This acquisition enables Teva Pharmaceutical to expand its respiratory pipeline products.
Deal Information
Deal Status
Completed
Announced Date
17-Jun-2013
Completed Date
08-Jul-2013
% Acquired
100
Deal Financials
40
246
Deal Payment
Cash (US$ m)
40
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Parent
Teva
Pharmaceutical
Industries Limited

Page 284
Advisor Information
Financial Advisor
Stifel Financial Corp.
GlobalData


Page 285
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company
Deal Type
Acquisition
Deal Sub Type
Majority Acquisition
Deal in Brief
Chairman and CEO of Celltrion Inc., Jung Jin Seo, intends to divest a controlling stake in the company to an interested party or
parties. Additionally, Celltrion received EMA approval for its first biosimilar product Remsima, a treatment for rheumatism.
Chairman Jung Jin Seo currently holds a stake of 97.28% in Celltrion Holdings Co., Ltd., 50.31% in Celltrion Healthcare Co.
Ltd., 68.42% in Celltrion GSC Co., Ltd., while Celltrion Holdings, Celltrion GSC and Celltrion Healthcare, hold 20.69%, 9.2%
and 0.2% respectively, in Celltrion. Celltrion Holdings also has a 31.6% stake in Celltrion Pharma, worth US$50.2m.
According to sources, Roche Holding AG (F. Hoffmann-La Roche Ltd.), Teva Pharmaceutical Industries Limited and
AstraZeneca Plc were among parties in negotiation to acquire Celltrion.
Seo Jung-jin, said, I decided to sell my company to a multinational pharmaceutical company to make it a strong one that can
guard off continuous suspicions and attacks by speculative investors."
J.P. Morgan Securities (Far East) Ltd. is advising Jung Jin Seo for the transaction.
Deal history
Update2: On January 8, 2014, According to sources, Roche Holding, Teva Pharmaceutical Industries and AstraZeneca were
among parties in negotiation to acquire Celltrion.
Update1: On January 2, 2014, Chairman and CEO of Celltrion, Jung Jin Seo, intends to divest a controlling stake in the
company to an interested party or parties. Additionally, Celltrion received EMA approval for its first biosimilar product Remsima.
Planned: On April 16, 2013, Chairman and CEO of Celltrion, Jung Jin Seo, intends to divest his entire direct and indirect stake
in the company to a multinational pharmaceutical company after obtaining EMA approval for the companys first biosimilar
product Remsima, a treatment for rheumatism. The divestment is expected to be valued at US$894m based on its closing price
on April 17, 2013 in the junior Kosdaq market.
Deal Information
Deal Status
Planned
Announced Date
Apr 16, 2013
Company Name
AstraZeneca PLC
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. It carries out design, development, production and
commercialization of wide range of primary care and specialty care medicines. The companys product portfolio includes
biologics, prescription pharmaceuticals and vaccines. AstraZenecas prescription medicines focus on three key areas of
healthcare, namely, cardiovascular and metabolic disease (CVMD); cancer; and respiratory, inflammation and autoimmunity
(RIA). The company also focuses in the infection, neuroscience and gastrointestinal (ING) disease areas. Its novel medicines
are used by millions of patients worldwide. The company operates in Europe, the Americas, Asia, Africa and Australasia.
AstraZeneca is headquartered in London, the UK.
Company Name
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. (Roche) is a research-focused healthcare company. It is one of the leading providers of
biopharmaceuticals, cancer medicines and in vitro diagnostics (IVD) systems. Its major products include medicines to treat
cancers, brain diseases, viral and bacterial infections, debilitating diseases, cardiovascular and metabolism diseases; point-ofcare testing devices; analyzers; blood glucose meters; laboratory information, workflow and data management software; and
instruments and reagents for life science research. Roche offers its products and services to hospitals, commercial diagnostic
laboratories, healthcare professionals, researchers and pharmacists. The company has operations in more than 150 countries
in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Roche is headquartered in Basel, Switzerland.
Company Name
Teva
Pharmaceutical
Industries Limited

Page 286
Company Name
Seo Jung-jin

Company Name
Celltrion, Inc.
Celltrion, Inc. (Celltrion) is a biopharmaceutical company that focuses on research, development and manufacture of biosimilars
and novel biopharmaceuticals. Through Biosimilars category, the company develops monoclonal antibodies (mAb) and under
novel biopharmaceuticals category, it develops antibodies and vaccines for infectious diseases such as influenza, rabies and
hepatitis. Its major products include Remsima for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis,
adult Crohns disease, psoriasis and psoriatic arthritis; Herzuma for the treatment of breast cancer; CT-P10, for the treatment of
Non-Hodgkins lymphoma and rheumatoid arthritis; and CT-P27 for the treatment of influenza. It offers antibody drug
conjugates (ADC) and antibody for breast/lung cancer. The company also undertakes contract manufacturing of pharmaceutical
products. Celltrion is headquartered in Incheon city, South Korea.
Advisor Information
Financial Advisor
Seo Jung-jin
J.P. Morgan Securities (Far

East) Ltd.
GlobalData


Page 287
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million
Deal Type
Deal Sub Type
Acquisition
Deal in Brief
BioTime, Inc., a biotechnology company, has completed the acquisition of 62.6% stake in Cell Cure Neurosciences Ltd., a
pharmaceutical company developing cell therapies for the treatment of neural degenerative diseases, for a purchase
consideration of approximately USD3.5 million in an all-stock transaction. Earlier, Cell Cure Neurosciences raised funds
through venture financing from ES Cell International, Hadasit Bio-Holdings Ltd. and Teva Pharmaceutical Industries
Limited.Under the transaction, BioTime acquired 87,456 shares of Cell Cure Neurosciences in exchange for 906,735 BioTime
common shares at an average market price of USD3.86 per BioTime's common share determined on the basis of the ten actual
trading days prior to November 1, 2012. Following the transaction, BioTime owns, directly and through its wholly-owned
subsidiary ES Cell International Pte. Ltd. (ESI), holds approximately 62.6% of the outstanding ordinary shares of Cell Cure
Neurosciences. In addition, BioTime may issue additional shares to Cell Cure, or Cell Cure may be required to issue additional
Cell Cure shares to BioTime, depending upon whether the market value of BioTime common shares increases or decreases by
more than 15%, based upon the average closing price for the ten trading days commencing on May 1, 2013. If the market value
of BioTime common shares declines by more than 15%, then BioTime will issue an additional number of shares required to
make the value of the total number of shares issued equal to USD3.5 million, less the initial USD3.86 market price multiplied by
any BioTime common shares sold by Cell Cure prior to that date, and subject to a maximum 33% increase in the number of
BioTime shares issued. Conversely, if the value of BioTime shares increases by more than 15% as of such date, Cell Cure will
be required to issue to BioTime a number of additional Cell Cure ordinary shares sufficient to bring the value of the Cell Cure
shares issued to BioTime under the share purchase agreement to the value of the BioTime common shares issued determined
on the basis of a ten-day trading period commencing on May 1, 2013, subject to a 33% maximum increase in the number of
Cell Cure shares issued.Deal History: Announced: On November 7, 2012, BioTime agreed to acquire 62.6% stake in Cell Cure
Neurosciences, for a purchase consideration of approximately USD3.5 million in an all-stock transaction.
Deal Information
Deal Status
Completed
Announced Date
07-Nov-2012
Completed Date
31-Jan-2013
% Acquired
62.60
Deal Financials
3.50
Deal Payment
Share (US$ m)
3.50
Company Name
BioTime, Inc.
BioTime, Inc. (BioTime) is a biotechnology company. It is focused on research and development in the field of regenerative
medicine. The companys products can be used in various fields of medicine such as oncology, neuroscience, orthopedics and
blood and vascular diseases. It is developing medicines using pluripotent stem technology that is based on induced pluripotent
stem (iPS) cells and human embryonic stem (hES) cells. The company is developing PureStem cell lines and associated
ESpan culture media, HyStem hydrogels and human embryonic stem cell lines. Its potential near term therapeutic and
diagnostic product opportunities include Renevia as a cell delivery device and PanC-Dx as a novel blood-based cancer screen.
It operates in two areas of biomedical research and product development, namely, plasma volume expander products and
regenerative medicine. The companys lead blood plasma expander product, Hextend, is used in the treatment of hypovolemia.
It operates in the US and Asia. BioTime is headquartered in California, the US.
Company Name
Hadasit Bio-Holdings Ltd.

Page 288
Hadasit Bio-Holdings Ltd. (Hadasit) is a biotechnology company. It provides biotech financing, research and development,
promoting and commercializing the intellectual property services in the biotechnology field. The company funds the preparation
and execution of phase I and preparation for phase II of the portfolio companies. Hadasits preparations include pre-clinical
trials, manufacturing, regulatory and business development tasks. The companys portfolio of companies includes ProtAb,
Enlivex Therapeutics, Cell Cure, KAHR Medical, BioMarCare Technologies and D-Pharm. It provides services in the field of
oncology, regenerative medicine and inflammatory disease. Hadasit is a subsidiary of Hadassah Medical Organization (HMO).
Hadasit is headquartered in Jerusalem, Israel.
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Cell
Ltd.
Cure
Neurosciences,
Parent
BioTime, Inc.
Neurosciences is headquartered in Jerusalem, Israel.
GlobalData


Page 289
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million
Deal Type
Deal Sub Type
Acquisition
Deal in Brief
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, acquired 31.35% stake in Proteologics Ltd., a biopharmaceutical
company, from Teva Pharmaceutical Industries Limited, a pharmaceutical company, for a purchase consideration of ILS6.5m
($1.66m).
Under the transaction, XTL acquired 4,620,356 shares at a price of ILS1.045 ($0.26) per share from Teva. The shares
represent Tevas stake in Proteologics and represent approximately 31.35% of Proteologics issued and outstanding share
capital.
Deal Information
Deal Status
Completed
Completed Date
21-Nov-2012
% Acquired
31.35
Deal Financials
Deal Value (ILS million)
6.50
Deal Value (US$ m)
1.66
Deal Payment
Cash
1.66
Deal Product
Drug to Inhibit
Ligase for Cancer
Product Description
Ubiquitin
Anticancer program was under development. Anticancer program prevents the cancer by
targeting the ubiquitin-proteasome pathway. It inhibits the ubiquitin ligase E3 enzyme.
Company Name
XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company. It carries out the acquisition and development of
proprietary products. It focuses on the development of late stage pharmaceutical products in the areas of unmet clinical needs.
The company has three product candidates such as hCDR1, Erythropoietin (EPO) and SAM-101. Its product hCDR1 peptide is
used for the treatment of Systemic Lupus Erythematosus; EPO can prolongate multiple myeloma advanced-stage patients'
survival and can improve their quality of life; and SAM-101 can treat psychotic diseases. XLTs product pipeline is in their
clinical development stages. It is headquartered in Herzliya Pituach, Tel Asviv, Israel.
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Proteologics Ltd.
Parent
Proteologics, Inc.
Proteologics Ltd. (Proteologics) is a biopharmaceutical company. The company exploits the UBIQUITIN system for the

Page 290
discovery and development of novel therapeutics. It also discovers inhibitors for specific E3 ubiquitin ligases (E3). Proteologics
enzymes regulate protein breakdown and a variety of cellular processes. The company offers novel drug targets for many types
of cancer, metabolic disease, viral infections and CNS related disorders. Its technologies include the ubiquitin system, target
discovery and validation, assay development, drug discovery and drug development. The company partners with Glaxo Smith
Kline (GSK) and Teva Pharmaceutical Industries Ltd. Proteologics are headquartered in Rehovot, Israel.
GlobalData


Page 291
Teva Pharma Rumored To Acquire Amarin

Teva Pharma Rumored To Acquire Amarin
Deal Type
Acquisition
Deal Sub Type
Deal in Brief
Teva Pharmaceutical Industries Ltd., a developer, manufacturer and marketer of pharmaceutical products, intends to acquire
Amarin Corporation plc, a biopharmaceutical company, reported Calcalist financial daily citing sources familiar with the matter.
According to the sources, AstraZeneca PLC, a global biopharmaceutical company, is among the possible bidder to acquire
Amarin. On January 10, 2011, Bloomberg reported that Pfizer Inc and Merck & Co., Inc were among possible bidders to acquire
Amarin.
J.P. Morgan Securities Ltd. is reportedly acting as financial advisor to Amarin for the transaction.
Deal history
Rumor: On November 15, 2012, Calcalist financial daily reported that Teva Pharmaceutical intends to acquire Amarin.
Planned: On January 10, 2011, Amarin planned to put itself for sale.
Deal Information
Deal Status
Rumor
RumorDate
Nov 15, 2012
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Amarin Corporation plc
Amarin Corporation plc (Amarin), formerly Ethical Holdings plc, is a biopharmaceutical company. It develops and
commercializes products in cardiovascular therapeutic area. The company's lead product Vascepa consists of Vascepa
(formerly known as AMR101), an adjunct to diet, for the reduction of triglyceride levels in adult patients with severe
hypertriglyceridemia. Amarin markets the product in the US through wholesalers. The company's pipeline candidates include,
Vascepa, indicated for the treatment of patients with mixed dyslipidemia; and Vascepa, evaluated to reduce major
cardiovascular events in patients on statin therapy. It operates along with its subsidiaries in Ireland, the US, Scotland and
Israel. Amarin is headquartered at Dublin, Ireland.
Advisor Information
Financial Advisor
Amarin Corporation plc
J.P. Morgan Securities Plc

(US$)
5.58

(US$)
8.81
Financial Information (Amarin Corporation plc)


Page 292
Number of Employees
26

EV/Total Assets
14.72
0.52

(US$)
0.49
0.49
GlobalData


Page 293
Teva Completes Acquisition Of Cephalon For US$6,800 Million

Teva Completes Acquisition Of Cephalon For US$6,800 Million
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Teva Pharmaceutical Industries Limited, completed the acquisition of all the outstanding shares of Cephalon, Inc., a
biopharmaceutical company, for $81.50 per share in cash or a total enterprise value of approximately $6,800m. Following the
closing of the transaction, Cephalon became a wholly-owned subsidiary of Teva and ceased to be traded on NASDAQ. The
purchase price of $81.50 per share represents 39% premium to Cephalons stock price on March 29, 2011, the last closing
price before Valeant Pharmaceuticals' unsolicited proposal was announced; a premium of 44% to Cephalons average closing
stock price over the last 30 trading days prior to the unsolicited proposal; a 12% premium to Valeants proposal of $73 per
share and a premium of 6% to Cephalons closing stock price on April 29, 2011. Teva funded the transaction through cash on
hand, lines of credit and the public debt market.Following the acquisition, the combined company will utilize its complementary
commercial, R&D and operational capabilities. The combined company is expected to have a portfolio of branded drugs with $7
billion in annual sales and more than 30 potential products in late-stage development. The transaction reinforces Tevas long
term strategy of building out its branded and specialty pharmaceuticals business through diversification and expansion of the
companys product portfolio and pipeline. The transaction is expected to be immediately accretive to Tevas non-GAAP
earnings per share and accretive to Tevas GAAP earnings within the fourth quarter of closing.As part of the transaction, Teva
is required to divest Cephalon's marketing authorization of generic modafinil in France and grant certain additional rights with
respect to the entire European Economic Area, including a covenant not to sue effective as of October 2012. Teva has to divest
some (abbreviated new drug applications) applications for generic drugs Actiq and Amrix. Teva will also grant non-exclusive US
rights to Par Pharmaceutical to market a generic version of Cephalon's Provigil (modafinil), for which the patent will expire in
2012.Shlomo Yanai, president and CEO of Teva, said, "This important transaction reinforces Teva's long term strategy of
building out our branded and specialty pharmaceuticals business through diversification and expansion of our product portfolio
and pipeline, while enhancing our position as the worldwide leader in generics. Our newly-expanded portfolio in CNS,
Oncology, Respiratory and Women's Health along with our robust pipeline of more than 30 late-stage products truly cements
our position as a leader in specialty pharma. We are welcoming many of Cephalon's talented employees into the Teva family.
The combination of our two winning teams will position Teva to create maximum value for our patients and customers." Credit
Suisse Securities (USA) LLC acted as financial advisor, while Kirkland & Ellis LLP acted as legal advisor to Teva. Deutsche
Bank Securities, Inc. and BofA Merrill Lynch acted as financial advisors, and Skadden, Arps, Slate, Meagher & Flom LLP acted
as legal advisor to Cephalon for this transaction.The acquisition enables Teva to expand and diversify its marketed products in
CNS and will add commercial presence in oncology and pain management.Deal historyCompleted: On October 14, 2011, Teva
Pharmaceutical Industries completed the acquisition of all the outstanding shares of Cephalon, for a total enterprise value of
approximately $6,800m or $81.50 per share in cash.Update3: On October 13, 2011, Cephalon received European Commission
approval for its acquisition by Teva Pharmaceutical Industries, for $81.50 per share in cash or a total enterprise value of
approximately $6,800m.Update2: On October 7, 2011, Cephalon received US Federal Trade Commission approval for its
acquisition by Teva Pharmaceutical Industries, for $81.50 per share in cash or a total enterprise value of approximately
$6,800m.Update1: On July 14, 2011, Cephalon received shareholders approval for its acquisition by Teva Pharmaceutical
Industries, for $81.50 per share in cash or a total enterprise value of approximately $6,800m.Announced: On May 2, 2011,
Teva Pharmaceutical Industries entered into a definitive agreement to acquire all of the outstanding shares of Cephalon, for a
total enterprise value of approximately $6,800m or $81.50 per share in cash.
Deal Rationale
The acquisition enables Teva to expand and diversify its marketed products in CNS and will add commercial presence in
oncology and pain management.
Deal Information
Deal Status
Completed
Announced Date
02-May-2011
Completed Date
14-Oct-2011
% Acquired
100
Deal Financials
Deal Value (US$ m)
6,800
Bid Premium (%)
Deal Payment
Cash (US$ m)
6,800


Page 294
Deal Product
Product Description
Small
Molecule-1
to
Antagonize 5-HT6 Receptor
for CNS Disorders
<p>5-HT6 inverse agonist is under development for the treatment of central nervous system
disorders. It is a non-sulfonamide/non-sulfone derivative which targets 5-HT6 receptor. 5hydroxytryptamine-6 receptor is a serotonin receptor which stimulates the adenylyl
cyclase.</p>
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Parent
Cephalon, Inc.
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
Cephalon, Inc.
Skadden,
Arps,
Slate,
Affiliates
Teva
Pharmaceutical
Industries Limited
Financial Advisor
Cephalon, Inc.

Inc.
Teva
Pharmaceutical
Industries Limited
Bank of
Lynch
America
Credit Suisse
(USA) LLC
Merrill
Securities

(US$)
76.04

(US$)
77.02


Page 295

Number of Employees
3,726
Operating Margin(%)
25.99
EV/Revenues
2.07
EV/Operating Profit
7.97
EV/EBITDA
6.14
EV/Total Assets
1.17
15.32

(US$)
34.77
7.91
5.52
13.95
GlobalData


Page 296
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For US$150 Million
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For US$150 Million
Deal Type
Deal Sub Type
Acquisition
Deal in Brief
Teva Pharmaceutical Industries Limited, acquired the remaining 50% stake in Teva-Kowa Pharma Co., Ltd., a provider of
generic pharmaceutical products, from Kowa Company, Ltd., a diversified company, for a purchase consideration of $150m.
Teva-Kowa Pharma is a joint venture between Kowa and Teva. Following the acquisition, Teva holds 100% stake in the joint
venture, which is doing business as wholly-owned member of the Teva Group.
This acquisition enables Teva Pharmaceutical to strengthen its position in the Japanese generics market.
Shlomo Yanai, president and CEO of Teva, said, We are happy to have reached this agreement to bring all our Japanese
operations under Teva's full control and ownership. Full ownership of all our activities including Taiyo will allow us to better
grow our business in Japan. With this stronger platform, Teva will be in a better position to further drive penetration of high
quality generic pharmaceuticals in Japan and make better healthcare accessible to the Japanese people.
Deal Rationale
This acquisition enables Teva Pharmaceutical to strengthen its position in the Japanese generics market.
Deal Information
Deal Status
Completed
Completed Date
26-Sep-2011
% Acquired
50
Deal Financials
Deal Value (US$ m)
150
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Kowa Company, Ltd.
Kowa Company, Ltd. (Kowa) develops, manufactures and commercializes textiles; machinery and construction materials;
medicines and medical equipment; eco-friendly products; and energy-saving products. These products are offered to both
households and business consumers. The company operates through eight business segments, namely, Pharmaceutical, Life
Science, Environmental & Energy Saving Products, Industrials & Infrastructures, Chemicals & Foods, Lifestyle Business,
Information System Solution and Hospitality. Its products and services include fashion and accessories, consumer healthcare
products, LEDs and optical technology, education services, textile and fashion products, prescription medicines and equipment,
LED lighting fixtures, precision equipment, educational solutions, machinery, building materials, chemical goods and foods. It
operates along with its subsidiaries in Japan, North America, Latin America, Europe, Asia and Oceania. Kowa is headquartered
in Tokyo, Japan.
Company Name
Teva-Kowa Pharma Co., Ltd.

Page 297
Teva-Kowa Pharma Co., Ltd. (Teva-Kowa) is a generic pharmaceutical company and a joint venture of Teva Pharmaceutical
Industries Ltd. and Kowa Company, Ltd. The company engaged in research and development of pharmaceutical and
manufacturing, distributing of pharmaceutical raw materials. Besides it provides prescription drugs , OTC drug, and generic
pharmaceutical products with high quality and safety. The company is the worlds leading generic maker and has ranked in the
top 15 pharmaceutical companies of Teva Pharmaceutical Industries Ltd. The company is headquartered in Tokyo, Japan.
GlobalData


Page 298
Teva Pharma Invests Additional US$19 Million In CureTech

Teva Pharma Invests Additional US$19 Million In CureTech
Deal Type
Deal Sub Type
Acquisition
Deal in Brief
Teva Pharmaceutical Industries Limited, a pharmaceutical company, invested an additional $19m in CureTech Ltd., a
biotechnology company. Following the transaction, Tevas holding in CureTech increased to 75%. Teva intends to finance up to
$50m for CureTechs research and development program and has an option to acquire the remaining 25% stake in CureTech.
Dr. Aharon Schwartz, head of Teva's Innovative Ventures, said, We are excited at this opportunity to continue working with
CureTech on the development of CT-011. We believe CT-011 has great potential to help many currently unserved cancer
patients. This investment is part of Teva's strategy to expand our branded activities into specialty therapeutic areas, such as
oncology.
This transaction enables Teva Pharmaceutical to expand its branded activities into specialty therapeutic areas.
Deal Rationale
This transaction enables Teva Pharmaceutical to expand its branded activities into specialty therapeutic areas.
Deal Information
Deal Status
Completed
Completed Date
13-Sep-2011
Deal Financials
Deal Value (US$ m)
19
Deal Product
Product Description
pidilizumab
<div><p>Pidilizumab (CT-011) is under development for the treatment of relapsed

glioblastoma multiforme, acute myelocytic leukemia (AML), colorectal cancer, follicular
lymphoma, relapsed and refractory multiple myeloma, renal cell carcinoma, metastatic
melanoma, pancreatic cancer, diffuse intrinsic pontine glioma and hormone refractory prostate
cancer. CT-011 is an intravenously administered humanized monoclonal antibody (mAb) that
modulates the immune response and inhibits tumor growth and the spread of metastases. CT011 interacts with PD-1 (Programmed Death-1). It was also under development for
hepatocellular carcinoma, hepatitis C and diffuse large B-cell lymphoma.</p></div>
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
CureTech Ltd.
CureTech Ltd. (CureTech) is a pharmaceutical company that conducts research, develops and commercializes immune
modulating products used in the treatment and control of cancer. The company develops products which include antibodies and
peptide based vaccines. Its product pidilizumab (CT-011) is a humanized monoclonal antibody that interacts with PD-1, a B7
receptor family associated protein, and exhibits anti cancer immune response against tumors. The company undertakes
research studies and clinical trials in other cancer diseases including renal cell carcinoma, multiple myeloma, pancreatic
cancer, and glioblastoma. CureTech is headquartered in Yavne, Israel.
GlobalData


Page 299
Teva Pharma Industries Acquires Taiyo Pharma Industry

Teva Pharma Industries Acquires Taiyo Pharma Industry
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Teva Pharmaceutical Industries, Ltd., a pharmaceutical company, completed the acquisition of 100% of the outstanding shares
of Taiyo Pharmaceutical Industry Co. Ltd., a developer and manufacturer of pharmaceutical products, for a purchase
consideration of $934m in cash. The transaction was funded through a combination of cash on hand and bank debt, and
represents a revenue multiple of 1.76x.
Following the acquisition, Teva gains a portfolio of over 550 products and a strong presence in all major channels in the
Japanese pharmaceutical market, from Taiyo. Teva also obtains access to Taiyo's strong R&D team, local regulatory expertise
and a state of the art production facility. Teva expects to reach $1 billion in sales in Japan, ahead of its original 2015 target.
Shlomo Yanai, president and chief executive officer of Teva, said, This is an important milestone in executing Teva's long term
strategic plan. The acquisition of Taiyo, along with Teva's existing Japanese business, assures that Teva will deliver on our
strategic objective of becoming a leading player in Japan."
This acquisition enables Teva Pharmaceutical to expand and diversify its drug portfolio in Japanese market.
Deal history
Completed: On July 14, 2011, Teva Pharmaceutical Industries completed the acquisition of 100% of the outstanding shares of
Taiyo Pharmaceutical Industry, for a purchase consideration of $934m in cash.
Announced: On May 16, 2011, Teva Pharmaceutical Industries entered into an agreement to acquire 57% stake in Taiyo
Pharmaceutical Industry., for a purchase consideration of $460m in cash. Alongside, the company was extending its offer to
purchase all the remaining outstanding shares of Taiyo.
Rumor: On May 2, 2011, Teva Pharmaceutical Industries decided to acquire majority stake in Taiyo Pharmaceutical Industry,
for a purchase consideration of JPY40,000m ($491.79m), reported by Nikkei newspaper.
Deal Rationale
This acquisition enables Teva Pharmaceutical to expand and diversify its drug portfolio in Japanese market.
Deal Information
Deal Status
Completed
Announced Date
16-May-2011
Completed Date
14-Jul-2011
% Acquired
100
Deal Financials
Deal Value (US$ m)
934
Deal Payment
Cash (US$ m)
934
Deal Product
Product Description
chlorpheniramine maleate
Neomallermin (Dexchlorpheniramine maleate) is an orally administered antihistamine agent. It

is indicated for the treatment of perennial and seasonal allergic rhinitis, Measles, renal
vasomotor edema, hay fever, caused by skin diseases, So Itching (eczema, dermatitis, skin So
Itching disease, drug eruption).vasomotor rhinitis, sneezing, nasal discharge cough due to
colds and other upper respiratory tract inflammation. It works by blocking the action of
histamine which is released in response to allergens present in the body. This leads to
temporary relief of the negative symptoms (allergic reaction) that are brought on by histamine.
The usual adult oral dosage is one to four times a day 1-2 tablets once.
Company Name
Teva
Pharmaceutical
Industries Limited

Page 300
Company Name
Taiyo
Pharmaceutical
Industry Co., Ltd.
Parent
Teva
Pharmaceutical
Industries Limited
Taiyo Pharmaceutical Industry Co., Ltd. (Taiyo) is a bio-pharmaceutical company. The company manufactures generic
pharmaceutical products. Its products include generic medicines. Taiyo provides services such as research and development
and contract manufacturing. The company utilizes technology and equipment. It develops products for cancer and ophthalmic
solutions. The company also manufactures glass syringes and pre-filled syringes. It also offers contract manufacturing service
to domestic and international innovators. The company research and development department provides generic drugs in the
form of tablets, injectables and formulations for external use. It is a subsidiary of Teva Pharmaceutical Industries Limited and is
headquartered in Nagoya-city, Japan.
GlobalData


Page 301
Cephalon Acquires 91.73% Stake In ChemGenex

Cephalon Acquires 91.73% Stake In ChemGenex
Deal Type
Deal Sub Type
Acquisition
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, through its wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd.,
completed the acquisition of 287,640,175 shares, representing 91.73% stake in ChemGenex Pharmaceuticals Limited.
Cephalon funded the transaction from its available cash on hand. Under the transaction, Cephalon acquired the shares at an
offer of AUD0.70 ($0.71) cash for each ChemGenex share, dividends and other rights, and paid AUD0.02 ($0.02) cash for each
ASX-listed ChemGenex option. In total, the bid values ChemGenex shares and options at approximately AUD225m ($231m).
The offer price of AUD0.70 ($0.71) per ChemGenex share represented a 59% premium to the last traded price of ChemGenex
shares, a 58% premium to the one month VWAP of ChemGenex shares up to the date of this announcement, a 31% premium
to the mid point of the valuation range of each ChemGenex share of AUD0.46 ($0.47) to AUD0.61($0.62) on a controlling
interest basis assessed by BDO Corporate Finance in its Independent Expert's Report (IER) of November 15, 2010. The total
offer value for ChemGenex shares and listed ChemGenex options that Cephalon does not own is approximately AUD159m
($163m). Following the acquisition, Dan Janney, George Morstyn, Geoff Brooke, Jean-Luc Tetard and Elmar Schnee have
resigned as non-executive directors; and Kevin Buchi, wilco Groenhuysen and ron Kal have been nominated by Cephalon and
appointed as directors of the company. Brett Heading and Greg Collier intend to continue to act as chairman and managing
director until the conclusion of the compulsory acquisition process.Earlier on April 13, 2011, Cephalon through its wholly-owned
subsidiary, Cephalon International Holdings, Inc. (Cephalon International), acquired a pre-bid shareholding of 27.57% by
purchasing shares pursuant to call option agreements with two of ChemGenex's major shareholders, Merck Sante S.A.S. and
Stragen International N.V., and converted AUD15m ($15.38m) of convertible notes issued by ChemGenex to Cephalon
International in October 2010.Kevin Buchi, chief executive officer of Cephalon, said, The proposed transaction allows
ChemGenex shareholders to realize cash proceeds at a significant premium to recent trading levels and adds an interesting
late-stage opportunity to our portfolio.Brett Heading, chairman of ChemGenex, said, The ChemGenex Board welcomes
Cephalon's bid which represents an attractive premium to the current and recent trading prices of ChemGenex Shares. In the
absence of a superior offer, the Board will unanimously recommend that ChemGenex shareholders accept the offer and realize
value for their shares.Merrill Lynch & Co., Inc. acted as financial advisor, while Johnson Winter & Slattery acted as legal
advisor to Cephalon. Canaccord Genuity Corp. acted as financial advisor, while McCullough Robertson acted as legal advisor
to ChemGenex in the transaction.Deal historyCompleted: On June 7, 2011, Cephalon through its wholly-owned subsidiary,
Cephalon CXS Holdings, completed the acquisition of 91.73% stake in ChemGenex Pharmaceuticals, for a purchase
consideration of approximately AUD225m ($231m). Update: On April 13, 2011, Cephalon through its wholly-owned subsidiary,
Cephalon CXS Holdings, submitted an offer document to acquire ChemGenex Pharmaceuticals, for a purchase consideration
of approximately AUD225m ($231m) or at an offer price of AUD0.70 ($0.71) cash for each ChemGenex share, dividends and
other rights, and AUD0.02 ($0.02) cash for each ASX-listed ChemGenex option.Announced: On March 28, 2011, Cephalon
through its wholly-owned subsidiary, Cephalon CXS Holdings, intends to make a takeover bid to acquire ChemGenex
Pharmaceuticals, for a purchase consideration of approximately AUD225m ($231m).
Deal Rationale
This acquisition enables Cephalon to add an interesting late-stage opportunity to its portfolio.
Deal Information
Deal Status
Completed
Announced Date
28-Mar-2011
Completed Date
07-Jun-2011
% Acquired
91.73
Deal Financials
225
Bid Premium (%)
Deal Value (US$ m)
231
59
Deal Product
Product Description
CXS-299
CXS-299 was under development for the treatment of cancer. The drug candidate was
administered intravenously. CXS299 is active against cancer cells resistant to approved
platinum-based therapies. CXS299 is a platinum (IV) drug, which has an enhanced level of
activity against cancer cells that have the wild type p53 gene. CXS-299 plays a major role in
the defense against the cancer cells with wild type p53 gene found in various types of cancer.
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited

Page 302
Company Name
ChemGenex
Parent
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
Cephalon, Inc.
ChemGenex
McCullough Robertson
Financial Advisor
Cephalon, Inc.
Bank of
Lynch
ChemGenex
Canaccord Genuity Corp.
America
Merrill

(US$)
0.43

(US$)
0.44

Number of Employees
19

EV/Revenues
651.33
EV/Total Assets
1.49
0.07

(US$)
0.23
0.02
GlobalData


Page 303
Cephalon Acquires Gemin X Pharma

Cephalon Acquires Gemin X Pharma
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, completed the acquisition of all the outstanding capital stock of Gemin X
Pharmaceuticals, Inc., for a cash consideration of $225m. Following the acquisition, Gemin X operates as a wholly-owned
subsidiary of Cephalon. Gemin X stockholders will also receive up to $300m in cash payments upon the achievement of certain
regulatory and sales milestones.
Gemin X Pharmaceuticals is a portfolio company of Caxton Advantage Life Sciences Fund, L.P, Sanderling Ventures,
GrowthWorks Capital Ltd., Vantage Point Partners, SB Life Science Equity Management, LLC, ProQuest Investments,
Business Development Bank of Canada, Solidarity Fund QFL, Merlin Nexus, Pinnacle Ventures, L.L.C., HBM Partners AG,
H.I.G. Ventures LLC and Ontario Teachers' Pension Plan.
Deutsche Bank Securities, Inc. acted as financial advisor, while Ballard Spahr Andrews & Ingersoll, LLP acted as legal counsel
to Cephalon. Citigroup Inc. acted as financial advisor, and Cooley LLP acted as legal counsel to Gemin X.
Deal history
Completed: In April 2011, Cephalon, Inc., completed the acquisition of all the outstanding capital stock of Gemin X
Pharmaceuticals, Inc., for a consideration of $225m cash on a cash-free, debt-free basis.
Announced: On March 21, 2011, Cephalon, Inc., entered into a definitive merger agreement to acquire all the outstanding
capital stock of Gemin X Pharmaceuticals, Inc., for a consideration of $225m on a cash-free, debt-free basis.
Deal Rationale
This acquisition enables Gemin X to return value to its shareholders and advance an innovative program in a cancer indication.
Deal Information
Deal Status
Completed
Announced Date
21-Mar-2011
Completed Date
30-Apr-2011
% Acquired
100
Deal Financials
225
525
Deal Payment
Cash (US$ m)
525
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Ontario Teachers' Pension

Plan


Page 304
The Ontario Teachers Pension Plan Board is responsible for investing the funds assets and administering the pensions of
Ontarios 163,000 elementary and secondary school teachers and 101,000 retired teachers.
Company Name
Parent
Cephalon, Inc.
Firm Name
Caxton
Advantage
Sciences Fund, L.P
Life
Firm Name
SB Life Science
Management, LLC
Equity
SB Life Science Ventures is a venture capital firm with committed life sciences venture capital fund backed by institutional
investors from Japan. The firm mainly focuses in the life sciences and biomedical sectors.
Firm Name
Vantage Point Partners
Firm Name
Merlin Nexus
Merlin Nexus is a private equity firm focused on crossover investing in the life sciences industry. Merlin Nexus invests globally
in private and public healthcare companies.
Firm Name
Pinnacle Ventures, L.L.C.
Pinnacle Ventures is a venture capital and private equity fund focused on providing debt and equity financing to early-stage
companies across technology and healthcare. The firm provides venture debt, growth capital loans, equipment loans, accounts
receivable financing, convertible debt and M&A financing. The investment size ranges between $0.5million - $15 million.
Firm Name
Solidarity Fund QFL
Solidarity Fund QFL is a labor-backed development capital fund that helps to create and maintain jobs in Quebec by investing
in small and medium-sized businesses in Quebec province, Canada.
Firm Name
Sanderling Ventures
Firm Name
GrowthWorks Capital Ltd.
GrowthWorks Capital Ltd. is a venture capital firm with more than CAD685 million ($560.05 million) capital under management.
The firm invests in growth-oriented companies within the range of CAD0.1 million ($0.8 million) to CAD5 million ($4.08 million)
across information technology, life sciences, advanced manufacturing, clean technology and alternative energy sectors.


Page 305
Firm Name
Business Development Bank

of Canada
Business Development Bank of Canada (BDC) is a financial services company. The company provides financing, consulting,
and venture capital services to small and medium-sized businesses. It provides financing solutions for the purchase of land and
buildings, construction of new premises, and expansion or improvement of existing or rented premises. BDC also provides debt
and equity financing. In addition, the company offers consulting services to manage, develop, enhance efficiency and sale
businesses. Further, it provides venture capital services to various sectors including energy or cleantech, health, information
technology, and communications. It operates through a network of branches in Canada. BDC is owned by the Government of
Canada. The company is headquartered in Montreal, Canada.
Firm Name
H.I.G. Ventures LLC
H.I.G. Ventures LLC is a private investment firm with over $7,500 million of capital under management. It invests in early and
growth stage companies across media & internet, semiconductor, wireless & communication, enterprise software & services,
life sciences & healthcare, alternative energy and clean technology sectors.
Firm Name
HBM Partners AG
HBM Partners AG (HBM Partners) is a healthcare investment firm that focuses on buyout, seed stage, growth and replacement
capital financings in both private and public companies. It invests in pharma, medical devices, diagnostics and biotech
industries. The firm also offers advice to HBM Healthcare Investments AG, HBM BioCapital and to specialized private-equity
and public-equity funds. HBM Partners Healthcare Investment products include Healthcare Investments, Public Equity
Investment Funds and Private Equity Investment Funds. Its investment portfolio include Barofold, Basilea Pharmaceutica,
BioControl Medical, Delenex Therapeutics, Ellipse, Interventional Spine and Kolltan Pharmaceuticals, Inc. among others. The
firm has gained FINMA Authorization to protect and ensure the functioning of financial markets. HBM Partners is headquartered
in Zug, Switzerland.
Firm Name
ProQuest Investments
ProQuest Investments is a healthcare venture capital company. The company offers financing for biotech and pharmaceutical
companies. It provides scientific, clinical, operational and financial investment services. ProQuest Investments provides
financial support for product development, launch and revenue building. The company has investment in therapeutic categories
such as oncology, pain and infectious diseases. It offers advisory services for converting basic research into clinical practice.
The companys investment portfolio includes Achillion Pharmaceuticals, Acurian, Aerovance, Agile Therapeutics, Aires
Pharmaceuticals, Clarus Therapeutics, Eagle Pharmaceutical, Tragara Pharmaceuticals, Mast Therapeutics, Sopherion
Therapeutics, Ziopharm Oncology, Zosano Pharma and US Bioscience. ProQuest Investments is headquartered in Naples,
Florida, the US.
Advisor Information
Legal Advisor
Cephalon, Inc.
Ballard Spahr LLP
Cooley LLP
Financial Advisor
Cephalon, Inc.

Inc.
Citigroup Inc.
GlobalData


Page 306
Cephalon Rejects Unsolicited Bid For Its Acquisition By Valeant Pharma

Cephalon Rejects Unsolicited Bid For Its Acquisition By Valeant Pharma
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, rejected the unsolicited bid for the acquisition of all of its outstanding shares by
Valeant Pharmaceuticals International, Inc., for a consideration of $5,700m or $73 per share in cash, because the offer is
opportunistic, inadequate, undervalues the companys marketed and experimental medicines and not in the best interests of
Cephalon shareholders.
The offer price represented a premium of 24% to Cephalon's closing price of $58.75 before the offer.
Goldman Sachs & Co. was acting as debt provider for the transaction. Deutsche Bank Securities Inc. and Merrill Lynch & Co.,
Inc. were acting as financial advisors, while Skadden, Arps, Slate, Meagher & Flom LLP was acting as legal counsel for
Cephalon in the transaction. Cleary Gottlieb Steen & Hamilton LLP was acting as counsel to Goldman Sachs.
J. Michael Pearson, Valeant's chairman and CEO, said, In the three weeks since our initial offer, Valeant has recruited seven
experienced candidates to serve as director-nominees of Cephalon. We have arranged financing for our proposed acquisition
of Cephalon. We have received positive feedback from many of the largest stockholders of Cephalon. We stand ready to
quickly commence and close our transaction as proposed, unless Cephalon stockholders do not support our offer, in which
case we will focus our attention on other opportunities to invest our capital. While we are disappointed with the response from
Cephalon's board, we remain committed to our process, which includes trying to find a modest amount of additional value if
Cephalon engages with us and allows us to conduct due diligence, which we believe would take only 2-3 weeks. We continue
to strongly believe that it is in the best interests of both Valeant's and Cephalon's stockholders to resolve this matter quickly,
one way or the other. Valeant will move fast. We had hoped that Cephalon would do the same. Now, it will be in the
stockholders' hands. This is all about shareholder value and we take this responsibility very seriously. The Cephalon board
believes that your proposed price significantly undervalues Cephalon, its key assets and its prospects.
Kevin Buchi, Cephalon's chief executive officer, said, This is all about shareholder value. The Cephalon board believes that
your proposed price significantly undervalues Cephalon, its key assets and its prospects.
Deal history
Terminated: On April 5, 2011, Cephalon, Inc., rejected the unsolicited bid for the acquisition of all of its outstanding shares by
Valeant Pharmaceuticals International, Inc., as the offer is opportunistic, inadequate, undervalues the companys marketed and
experimental medicines and not in the best interests of Cephalon shareholders.
Update2: On March 29, 2011, Cephalon, Inc., received an unsolicited proposal from Valeant Pharmaceuticals International,
Inc., to acquire all the outstanding shares of Cephalon, for a purchase consideration of $73 per share or $5,700m in cash.
Update1: On March 25, 2011, Cephalon, Inc., received proposal from Valeant Pharmaceuticals International, Inc., to acquire
non-oncology related assets of Cephalon, for a purchase consideration of $73 per share or $2,200m.
Announced: On March 18, 2011, Cephalon, Inc., received proposal from Valeant Pharmaceuticals International, Inc., to acquire
Cephalon, for a purchase consideration of $73 per share.
Deal Information
Deal Status
Terminated
Terminated Date
Apr 05, 2011
% Acquired
100
Deal Financials
Deal Value (US$ m)
5,700
Bid Premium (%)
24
Deal Payment
Cash (US$ m)
5,700
Debt Provider
Provider Name

Inc.
Provider Type
Lead
Debt Type
Bank Facilities


Page 307

Company Name
Valeant
Pharmaceuticals
International, Inc.
Valeant Pharmaceuticals International, Inc. (Valeant) is a specialty pharmaceutical company. It carries out the development,
manufacture and marketing of a wide range of specialty, over-the-counter (OTC) and generic drugs. The company also offers
medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in
the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions
across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has
manufacturing facilities in Canada and the US. Valeant is headquartered in Laval, Quebec, Canada.
Company Name
Parent
Cephalon, Inc.
Teva
Pharmaceutical
Industries Limited
Advisor Information
Legal Advisor
Cephalon, Inc.
Skadden,
Arps,
Slate,
Affiliates
Financial Advisor
Cephalon, Inc.

Inc.
Bank of
Lynch
America
Merrill

(US$)
56.31

(US$)
57.57

Number of Employees
3,726
Operating Margin(%)
25.99
EV/Revenues
1.54
EV/Operating Profit
5.91
EV/EBITDA
4.56
EV/Total Assets
0.87
15.32

(US$)
34.77


Page 308
7.91
5.52
10.43
GlobalData


Page 309
Clal Biotech Acquires Stake In TransPharma Medical From Teva

Clal Biotech Acquires Stake In TransPharma Medical From Teva
Deal Type
Deal Sub Type
Acquisition
Deal in Brief
Clal Biotechnology Industries Ltd., a biotechnology investment company, acquired stake in TransPharma Medical Ltd., a
specialty pharmaceutical company, from Teva Pharmaceutical Industries Ltd., for a purchase consideration of $2.5m.
Following the acquisition, Clal Biotech holds 12% stake in Transpharma Medical.
Reuven Krupick, CEO of Clal Biotech, said, "These acquisitions are required under Clal Biotech's policy of active involvement in
its portfolio companies. Our interest in Transpharma is based on its challenge technologically and business-wiseunder its highly
qualified management. We believe that the increased holding will allow us to expand our contribution to the company's
progress."
This acquisition enables Clal to enhance its operations.
Deal Rationale
This acquisition enables Clal to enhance its operations.
Deal Information
Deal Status
Completed
Completed Date
22-Feb-2011
Deal Financials
Deal Value (US$ m)
2.50
Deal Product
Product Description
somatropin
ViaDor-hGH (somatropin) was under development in adult patients with growth hormone
deficiency syndrome. hGH refers to human growth hormone. Somatropin made by the pituitary
gland or a synthetic version of that hormone. Naturally occurring somatropin is a polypeptide
containing 191 amino acids. hGH is a protein secreted by the pituitary gland that is critical to
normal growth in children and is involved in regulating metabolism in both children and adults.
Growth hormone is normally secreted throughout a persons lifetime. The drug candidate is
developed based on transdermal drug delivery system, ViaDerm.
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
TransPharma Medical Ltd.
TransPharma Medical Ltd. (TransPharma) is a pharmaceutical company, based in Israel. The company develops and markets
drug products by using proprietary active transdermal drug delivery technology. It develops multiple drug-products through its
strategic partnerships with pharmaceutical companies. TransPharmas drug product portfolio includes ViaDor-hPTH (1-34),
ViaDor-GLP1 agonist and ViaDor-Calcitonin. The company drug product development activities utilize RF-MicroChannel
Technology. Its ViaDor-hPTH product is used for the treatment of osteoporosis and ViaDor-GLP1 agonist for the treatment
diabetes. The company RF-MicroChannel Technology is the ViaDor delivery system offers painless and safe solution for

Page 310
immunization programs. TransPharma is headquartered in Lod, Tel Aviv, Israel.

Firm Name

Ltd.
Parent
Clal
Industries
Investments Ltd.
and
GlobalData


Page 311
Cephalon Completes Acquisition Of 20% Stake In Mesoblast

Cephalon Completes Acquisition Of 20% Stake In Mesoblast
Deal Type
Deal Sub Type
Acquisition
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, completed the acquisition of 19.99% stake in Mesoblast Limited, an Australian
regenerative medicine company, for a purchase consideration of $220 million. Following the acquisition, J. Kevin Buchi, the
chief operating officer of Cephalon joined the Mesoblast's board of directors.
Under the transaction, Cephalon made an equity investment to purchase 19.99% stake of Mesoblasts 279 million issued
shares at AUD4.35 ($4.31) per share, totaling approximately AUD222.48 million ($220 million). This price represents a 45%
premium to the last 30 days' volume weighted average price for Mesoblast shares. Mesoblast also issued an additional
24,702,056 ordinary shares to Cephalon and received an additional cash of AUD139 million ($139.32 million).
The transaction was approved overwhelmingly by Mesoblast shareholders at an extraordinary general meeting on February 9,
2011.
According to the Australian Securities Exchange rules, Cephalon has entered into a standstill agreement to limit its investment
to 19.99% of Mesoblast common stock for the next 12 months, with a right to maintain its equity stake on a top up basis.
Professor Silviu Itescu, Mesoblast chief executive and managing director, said: Furthermore, our financial independence
enables us to significantly broaden our range of product offerings for the treatment of major diseases. The alliance with
Cephalon brings strength and proven execution capability in late phase clinical development, as well as product sales and
marketing. Cephalon will fund and oversee phase 3 trials for both Revascor, our product for cardiovascular diseases, and our
bone marrow regeneration product. Additionally, the alliance brings in Cephalon's considerable expertise in neurological
disorders, facilitating development of new products for diseases such as stroke and Parkinson's disease. In parallel,
Mesoblast's financial strength will enable the company to simultaneously drive to market products for new and large clinical
indications. We have sufficient financial resources now to complete clinical development and product registration for a suite of
new and existing products, thereby maximizing full shareholder value from product sales. Coupled with our corporate strategy
for commercial product manufacture and rollout, we believe that Mesoblast is poised to become the global leader in
commercializing therapeutic products for regenerative medicine.
Deutsche Bank Securities Inc. acted as financial advisor, while Johnson Winter & Slattery acted as legal advisor to Cephalon.
Deal History:
Completed: On February 14, 2011, Cephalon, Inc., completed acquisition of 19.99% stake in Mesoblast Limited, for a total
purchase consideration of $359.32 million.
Announced: On December 7, 2010, Cephalon, Inc., entered into a stock purchase agreement to acquire 19.99% stake in
Mesoblast Limited, for a purchase consideration of $220 million.
Deal Rationale
This acquisition enables Mesoblast to strengthen and prove execution capability in late phase clinical development, along with
product sales and marketing.
Deal Information
Deal Status
Completed
Announced Date
07-Dec-2010
Completed Date
14-Feb-2011
% Acquired
19.99
Deal Financials
Deal Value (US$ m)
359.32
Bid Premium (%)
45
Deal Product
Product Description
Chondrogen
<p>Chondrogen was under development for the prevention of osteoarthritis in the knee and
cartilage protection. The drug candidate is administered as an intraarticular injection. It is a
formulation of adult mesenchymal stem cells (MSCs). The drug repairs the damaged meniscus
tissue and prevent the progression of arthritis. Cartilage is a protein substance that serves as a
"cushion" between the bones of the joints. The drug candidate may produce
therapeutic effect by limiting the underlying cause of the disease.</p>


Page 312
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Mesoblast Limited
Mesoblast Limited (Mesoblast) is a biotechnology company. The company focuses on developing novel biotherapeutics using
its cell-based technologies for the treatment of a wide range of diseases. Its technology platforms include Mesenchymal
Precursor Cells (MPCs), Mesenchymal Stem Cells (MSCs), Dental Pulp Stem Cells (DPSCs) and Hematopoietic Stem Cells
(HSCs). Mesoblast serves various therapeutic areas such as immunologic/ inflammatory, cardiac vascular, spine disease,
ophthalmolog, neurologic and oncology. The company has partnership with Teva Pharmaceutical Industries Ltd., JCR
Pharmaceuticals Co. Ltd. and Lonza Group. It has operational presence in the US and Singapore. Mesoblast is headquartered
in Melbourne, Victoria, Australia.
Advisor Information
Legal Advisor
Cephalon, Inc.
Financial Advisor
Cephalon, Inc.

Inc.

(US$)
2.75

(US$)
3.29
Financial Information (Mesoblast Limited)

(Trailing Twelve Months Ended 30-Jun-2010)
EV/Revenues
EV/Total Assets
590.70
11.04
0.23

(US$)
0.27
0.26
GlobalData


Page 313
Teva Pharma Industries Acquires Corporacion Infarmasa

Teva Pharma Industries Acquires Corporacion Infarmasa
Deal Type
Acquisition
Deal Sub Type
100% Acquisition
Deal in Brief
Teva Pharmaceutical Industries Ltd., acquired Corporacion Infarmasa S.A., a pharmaceutical company, from The Rohatyn
Group, LLC (TRG), an asset management firm, and Altra Investments Inc., a private equity firm.
Shlomo Yanai, president and chief executive officer of Teva, said, "The acquisition of Infarmasa in Peru expands our activity in
Latin America, and highlights our growth strategy for the coming years. Infarmasa complements Teva's activity in Peru and will
advance our position as a market leader in this region."
Mauricio Camargo, a board member of Altra, said, "We congratulate Infarmasa and its management for positioning the
company to take advantage of this outstanding opportunity."
Roberto Chute, board member of TRG, said, "Becoming part of the Teva Group, should enable Infarmasa to expand its leading
position in Peru and throughout the region."
Credit Suisse (USA), Inc. acted as financial advisor to Altra Investments and The Rohatyn Group. This acquisition enables
Teva to strengthen its portfolio and expand Latin American presence.
Deal Rationale
This acquisition enables Teva to strengthen its portfolio and expand Latin American presence.
Deal Information
Deal Status
Completed
Completed Date
26-Jan-2011
% Acquired
100
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
Corporacion Infarmasa S.A.
Parent
Teva
Pharmaceutical
Industries Limited
Corporacion Infarmasa S.A. (Corporacion Infarmasa) is a pharmaceutical company that develops, manufactures and markets
quality pharmaceutical products. It was formed with the merger of two pharmaceutical companies, namely, Laboratorios Magma
and Instituto Sanitas SPSA. There are two plants of the company namely, the district of Miraflores, for the development of
penicillinic products and the other in the district of Ate, for the development of non-penicillinic products. The company markets
its products with two major distributors, namely, Qumica Suiza and Representaciones Deco. The new division, the Linea
Commercial LCG (LGG Business Line) was created to offer generic medications to the market. Corporacion Infarmasa is
headquartered in Peru.
Firm Name
The Rohatyn Group, LLC
The Rohatyn Group, LLC is a financial services firm and a privately owned hedge fund sponsor. The firm offers services to

Page 314
pooled investment vehicles including public equity and fixed income markets while focusing on emerging markets of Latin
America, Asia, Africa and Central and Eastern Europe.
Firm Name
Altra Investments Inc.
Altra Investments Inc. is a private equity firm. It is engaged in offering private equity investment solutions in the Andean region
to a local investor base. The company is based in Colombia.
Advisor Information
Financial Advisor
Altra Investments Inc.
Credit Suisse (USA), Inc.
The Rohatyn Group, LLC
Credit Suisse (USA), Inc.
GlobalData


Page 315
Teva Pharma Industries Acquires THERAMEX From Merck Serono

Teva Pharma Industries Acquires THERAMEX From Merck Serono
Deal Type
Acquisition
Deal Sub Type
100% Acquisition
Deal in Brief
Teva Pharmaceutical Industries Ltd., completed the acquisition of THERAMEX SpA, a women's health business from Merck
Serono S.A., a division of Merck KgaA, a pharmaceutical and chemical company, for a purchase consideration of EUR265
million ($365.54 million).
Under the transaction, Merck Serono will also be entitled to receive certain performance-based milestone payments. Teva
financed the acquisition from its internal resources.
Following the acquisition, Theramex brings to Teva a wide variety of women's health and gynecology products sold in 50
countries primarily France and Italy. Theramex's pipeline includes NOMAC/E2, a new oral contraceptive based on natural
estrogens, which has completed phase III studies and was submitted for approval in Europe. As part of the acquisition, Teva
will also have distribution rights for Theramex's products in certain countries including Spain and Brazil.
Willkie Farr & Gallagher LLP acted as legal advisor to Teva Pharmaceutical in this transaction.
Shlomo Yanai, Teva's president and chief executive officer, said: "This is an important acquisition for Teva's women's health
franchise. Theramex's diversified product portfolio, its seasoned sales force and promising pipeline will be combined with the
strong R&D capabilities and product portfolio of our U.S. women's health business. Together the global team will accelerate the
expansion of our women's health franchise into key growth markets in Europe and around the world and provide an excellent
springboard for future sales. We very much look forward to working together with Theramex's experienced management team
and having its work force join the Teva family."
Elmar Schnee, member of the executive board of Merck KGaA and president of the Merck Serono division, said: "Theramex
has built a solid reputation in France and Italy as a company dedicated to women's health and gynecology. As Theramex is
entering the contraceptive market, we firmly believe that a combination with Teva will not only contribute to growing its position
in the gynecological market but also to building a major player in the area of contraceptives."
This acquisition enables Teva to strengthen its product portfolio of women's health business.
Deal history
Completed: On January 5, 2011, Teva Pharmaceutical Industries Ltd. completed the acquisition of THERAMEX SpA, from
Merck Serono S.A., for a purchase consideration of EUR265 million ($365.54 million).
Announced: On October 28, 2010, Teva Pharmaceutical Industries Ltd. entered into a definitive agreement to acquire
Theramex SpA and related companies, from Merck Serono S.A., a division of Merck KgaA.
Deal Rationale
This acquisition enables Teva to strengthen its product portfolio of women's health business.
Deal Information
Deal Status
Completed
Announced Date
28-Oct-2010
Completed Date
05-Jan-2011
% Acquired
100
Deal Financials
265
Deal Product
Product Description
(nomegestrol
estradiol)
acetate
Deal Value (US$ m)
365.54
Nomegestrol acetate and estradiol (Zoely , Nomac/E2, EMM 310066, SCH 900121, MK8175A) is a fixed combination acts as oral contraceptive.Nomegestrol acetate is a highly
selective progestogen derived from the naturally occurring steroid hormone, progesterone and
estradiol is a natural estrogen. Zoely is formulated as film coated tablets for oral route of
administration. It is used for contraception.
Company Name
Teva
Pharmaceutical
Industries Limited


Page 316
Company Name
Merck Serono S.A.
Parent
Merck KGaA
Merck Serono S.A., (Merck Serono) is the biopharmaceutical division of Merck KGaA. It discovers, develops, manufactures and
commercializes prescription medicines of both chemical and biological origin in specialist indications with focus on the
neurology, cancer, immuno-oncology and immunology. Merck Serono has a broad product portfolio, which is distributed across
the world through a network of distributors. The division manages four research and development centers in the US, Germany,
China and Japan. It has a global presence with operations in more than 150 countries and production facilities in four countries.
Merck Serono markets its products to wholesale distributors or directly to hospitals, medical centers, and pharmacies. Merck
Serono is headquartered in Geneva, Switzerland.
Company Name
THERAMEX SpA
Parent
Teva
Pharmaceutical
Industries Limited
THERAMEX SpA is a pharmaceutical company engaged in drug manufacturing in Gynaecology and for the woman's health.
Advisor Information
Legal Advisor
Teva
Pharmaceutical
Industries Limited
Wilkie Farr & Gallagher LLP
GlobalData


Page 317
Cephalon Acquires BioAssets Development

Cephalon Acquires BioAssets Development
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, acquired all the outstanding shares of BioAssets Development Corporation
(BDC), a developer of biological drugs, for a total consideration of $46.3 million. Following the transaction, BDC became a
wholly-owned subsidiary of Cephalon.
Of the consideration, Cephalon made an upfront payment of $30 million, paid $12.5 million to purchase all of the outstanding
capital stock of BDC and paid an additional net working capital adjustment of $3.8 million. BDC stockholders will also receive
additional future payments upon regulatory and sales milestones.
As part of the transaction, Cephalon obtained rights to the BDC intellectual property estate that covers the use of cytokine
inhibitors, including TNF inhibitors, for sciatic pain in patients with intervertebral disk herniation, as well as other spinal
disorders.
Extera Partners advised BDC on the transaction. This transaction will enable Cephalon to develop and commercialize tumor
necrosis factor inhibitor, CEP-37247, used in the treatment of sciatica.
Dr. Lesley Russell, chief medical officer for Cephalon, said: "With this acquisition, Cephalon combines BDC's intellectual
property and scientific expertise regarding TNF inhibitors with our own pipeline. The BDC data provide a path forward to
evaluate a potential non-surgical approach for the treatment of patients suffering from the debilitating effects of sciatica."
Dr. James Gorman, CEO and chief medical officer for BDC, said: "The Cephalon commitment to develop CEP 37247 for nonoperative treatment of sciatic pain is encouraging news for the patients, physicians and payors urgently seeking a more
effective non-operative treatment for this prevalent, debilitating condition. We believe that the combination of BDC's assets with
the Cephalon expertise and pipeline greatly increases the potential to provide in the foreseeable future an FDA-approved TNFinhibitor therapeutic for sciatica."
Deal history
Completed: On November 19, 2010, Cephalon completed acquisition of BioAssets Development Corporation.
Update: On October 21, 2010, Cephalon has exercised its option to acquire all the outstanding shares of BDC, for a minimum
consideration of $30 million and a maximum consideration of $42.5 million, subject to net working capital and debt adjustments.
Announced: On October 26, 2009, Cephalon entered into an option agreement to acquire BDC. Under the agreement,
Cephalon is entitled to pay an upfront payment of $30 million and an additional payment up on completion of the acquisition.
BDC stockholders will also receive additional future payments upon regulatory and sales milestones.
Deal Rationale
This transaction will enable Cephalon to develop and commercialize tumor necrosis factor inhibitor, CEP-37247, used in the
treatment of sciatica.
Deal Information
Deal Status
Completed
Announced Date
26-Oct-2009
Completed Date
19-Nov-2010
% Acquired
100
Deal Financials
Deal Value (US$ m)
46.30
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited

Page 318
Company Name
BioAssets
Corporation
Development
BioAssets Development Corporation (BDC) is involved in the research and development of tumor necrosis factor alpha (TNF)
inhibitors to treat the underlying causes of pain in spinal disorders. BDC is developing new novel indications for marketed and
emerging biologic drugs and focuses on the development of cytokine inhibitors. BDC has designed a series of strategies to
develop the design and conduct of radiculopathy trials. The company uses drugs already proven safe and effective for other
indications. BDCs lead indication targets on patients with pain that radiates along a nerve caused due to inflammation of the
spinal nerve root at its connection to the spinal column. In October 2009, Cephalon, Inc., a biopharmaceutical company,
acquired BDC. The company is headquartered at Wellesley in Massachusetts, the US.
GlobalData


Page 319
Teva Pharma Industries Completes Acquisition Of ratiopharm For Approximately US$4.9 Billion
Teva Pharma Industries Completes Acquisition Of ratiopharm For Approximately US$4.9 Billion
Deal Type
Acquisition
Deal Sub Type
100% Acquisition
Deal in Brief
Teva Pharmaceutical Industries Ltd., a pharmaceutical company, completed the acquisition of ratiopharm GmbH, a generic
drug maker, from VEM Vermoegensverwaltung GmbH, an investment company, for a purchase consideration of approximately
$4,950 million.
Following the acquisition, the combined entity will have a strong European footprint, holding the market position in ten
European markets, including key markets such as the UK, Hungary, Italy, Spain, Portugal and the Netherlands as well as a top
three ranking in 17 countries, including Germany, Poland, France and the Czech Republic. In addition, the transaction
significantly increases Tevas sales in Canada.
Under the transaction, Teva paid EUR3,625 million ($4,804.65 million) for the ratiopharm shares, which reflects the agreed
enterprise value (on a cash free/debt free basis), plus accrued interest from January 1, 2010 to the closing date, which totaled
EUR186 million ($246.53 million). Teva funded the transaction through a combination of cash on hand and lines of credit.
Commerzbank AG and Royal Bank of Scotland Group Plc acted as the financial advisors, while Stikeman Elliott LLP acted as
Canadian counsel to ratiopharm. GOERG Rechtsanwaelte and Noerr Stiefenhofer Lutz acted as its legal advisors.
Commerzbank AG and BNP Paribas SA acted as financial advisors, and Freshfields Bruckhaus Deringer LLP acted as legal
counsel to VEM. Goldman Sachs & Co. (now The Goldman Sachs Group, Inc.) acted as financial advisor and Kirkland & Ellis
LLP acted as legal counsel to Teva on this transaction. Willkie Farr & Gallagher LLP represented Teva before the European
Commission.
Shlomo Yanai, Tevas president and CEO, said: "This is an exciting day for Teva and ratiopharm. Teva, the worlds leading
generic pharmaceutical company, will now become the number one generics company in Europe as well. Increasing Tevas
market share in Europe geography with tremendous potential for generics penetratio is an important pillar of our long-term
growth strategy. With the acquisition of ratiopharm we will become the leader in key European markets and we are wellpositioned to become the leader in many other European markets in the near future. We have great respect for ratiopharms
tradition of leadership, and their dedication to excellence and quality. We are thrilled to welcome ratiopharm's outstanding team
into the Teva family, and we are confident that the combined experience of the Teva and ratiopharm teams will ensure a quick,
smooth, and successful integration process. Together we will continue to make affordable, high-quality medicine accessible to
more and more patients across Europe".
Oliver Windholz, chief executive officer of ratiopharm, said: "We are proud to join the Teva family. We have long viewed Teva
as the right match for our company, thanks to its clearly defined strategic vision and commitment to generic medicines and its
highly reputable management. We look forward to making this acquisition a success story both for our employees and for Teva,
and will do our utmost to leverage ratiopharm's activities into a truly advantageous business for Teva."
This acquisition enables Teva to strengthen its market position and double its sales in Canada. The transaction allows VEM to
repay debt from the proceeds of the sale.
Deal history
Completed: On August 10, 2010, Teva Pharmaceutical Industries completed the acquisition of ratiopharm, from VEM
Vermoegensverwaltung GmbH, for a purchase consideration of EUR3,811 million ($4,950 million).
Update 4: On August 3, 2010, Teva Pharmaceutical Industries received an approval from the European Commission to acquire
ratiopharm, from VEM Vermoegensverwaltung GmbH, for a purchase consideration of EUR3,625 million ($5,353.91 million).
Update 3: On 18 March, 2010, Teva Pharmaceutical Industries Ltd. entered into a definitive agreement to acquire ratiopharm,
from from VEM Vermoegensverwaltung GmbH, for a purchase consideration of EUR3,625 million ($5,353.91 million).
Update 2: On March 2, 2010, VEM Vermoegensverwaltung GmbH announced the final round of the auction of ratiopharm
GmbH, a generic drug maker, for an estimated consideration of EUR2,800 million ($4,135.43 million) to EUR3,000 million
($4,430.82 million).
Update 1: On November 11, 2010, Reuters reported that Ratiopharm has attracted at least 10 first-round bids in amounts
between EUR2,000 million ($3,000 million) and EUR2,500 million ($3,692.35 million). The bidders include Teva Pharmaceutical
Industries Ltd., Mylan Inc., sanofi-aventis, SINOPHARM HOLDING CO., LIMITED and Actavis of Iceland. Buyout firms
participating in the round of bids, include TPG, Advent in collaboration with Goldman Sachs, Permira, KKR and EQT.
Announced: On November 5, 2009, VEM Vermoegensverwaltung GmbH completed two rounds of bids for the sale of
ratiopharm, which were quoted at around EUR2,500 million ($3,692.35 million).
Deal Rationale
This acquisition will enable Teva to strengthen its market position and to increase its sales in Canada. The transaction allows
VEM Vermoegensverwaltung to repay debt from the proceeds of the sale.


Page 320
Deal Information
Deal Status
Completed
Announced Date
05-Nov-2009
Completed Date
10-Aug-2010
% Acquired
100
Deal Financials
Deal Value (US$ m)
4,950
Deal Product
Product Description
Amiodarone Ratiopharm
Amiodarone Hydrochloride, is an antiarrhythmic agent, formulated as oral administration. It is

an antianginal drug with predominant Class III (Vaughan Williams' classification) effects. It is
indicated only for the treatment of documented, life-threatening recurrent ventricular
arrhythmias. It is used in the treatment of recurrent ventricular fibrillation, and recurrent
hemodynamically unstable ventricular tachycardia. Amiodarone stabilizes the heart rhythm and
acts by slowing nerve impulses in the heart and acting directly on the heart tissues.
Company Name
Teva
Pharmaceutical
Industries Limited
Company Name
VEM Vermoegensverwaltung
GmbH
VEM Vermoegensverwaltung GmbH (VEM VV GmbH) is an investment company, owned by Ludwig Merckle.
Company Name
ratiopharm GmbH
Parent
Teva
Pharmaceutical
Industries Limited
ratiopharm GmbH (ratiopharm) is a pharmaceutical company. It develops, manufactures and sells generic medicines and
biosimilars. The company's product portfolio comprises prescription (ethical) and non-prescription preparations (OTC) products
which include creams, tablets, suppositories, ampoules, ointment and liquids. It produces medicines in the therapeutic areas of
skin diseases, asthma, arthritis, bronchitis, cardiovascular diseases, diabetes and cancer with tumor blockers and immune
modifiers. Some of its brands include AZ Complex, Acarbose, Ace inhibitor, Aciclovir, Allopurinol and Amantidine. ratiopharm is
headquartered in Ulm, Germany.
Advisor Information
Legal Advisor
ratiopharm GmbH
Noerr Stiefenhofer Lutz
Teva
Pharmaceutical
Industries Limited
Stikeman Elliott LLP


Page 321
GmbH
Freshfields
Deringer LLP
Bruckhaus
Financial Advisor
ratiopharm GmbH
Commerzbank AG
Teva
Pharmaceutical
Industries Limited
The Royal Bank of Scotland

Group PLC
GmbH

Inc.
BNP Paribas SA
Commerzbank AG
Financial Information (ratiopharm GmbH)

Number of Employees
4,716
GlobalData


Page 322
Cephalon Acquires Mepha Pharma For US$616 Million

Cephalon Acquires Mepha Pharma For US$616 Million
Deal Type
Acquisition
Deal Sub Type
100% Acquisition
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, completed the acquisition of Mepha Pharma AG, a pharmaceutical company
and its subsidiaries, from Mepha Holding AG, for a purchase consideration of CHF662.4m (US$616.3m).
Following the acquisition, Mepha Pharma has become wholly-owned subsidiary of Cephalon. In addition, Cephalon will serve
three types of pharmaceutical markets including proprietary branded, generic and branded generic and expands its operations
to serve global markets in Western and Central Europe, African and Middle East territories.
In August 2009, Mepha, owned by Germanys Merckle family, announced it had hired investment bank Rothschild to examine
all options for the firm, including a sale. Subsequently, on October 23, 2009, Mepha Pharma is expected to receive first round
bids for the company, two sources familiar with the situation told Pharmawire.
Frank Baldino, chairman and CEO of Cephalon, said, We are proud to include Mepha as part of the Cephalon family. Mepha
has a strong reputation for high quality products and services that deliver value to patients and healthcare professionals. This
acquisition expands our presence in Europe, and we believe Mepha will contribute to our long-term growth.
Alain Aragues, executive vice president and president of Cephalon Europe, said, We are pleased to add Mepha's experience
and expertise, which are critical to our successful development of a balanced business mix in Europe, Middle East and Africa.
Cephalon intends to leverage Mepha's brand recognition as the number one generics company in Switzerland and a prominent
generic pharmaceutical company in many other markets.
Deutsche Bank Securities Inc. acted as the financial advisor and Sidley Austin LLP acted as legal advisor to Cephalon, while
Rothschilds acted as financial advisor and Lenz & Staehelin acted as legal advisor to Mepha Pharma.
This acquisition enables Cephalon to diversify and expand its business operations in Europe.
Deal Rationale
This acquisition enables Cephalon to diversify and expand its business operations in Europe.
Deal Information
Deal Status
Completed
Announced Date
01-Feb-2010
Completed Date
09-Apr-2010
% Acquired
100
Deal Financials
Deal Value (CHF million)
662.40
Deal Value (US$ m)
616.30
Deal Product
Product Description
clopidogrel bisulfate
Clopidogrel is an thienopyridine anti-platelet agent. It is formulated in the form of film coated

tablet for oral administration. It is indicated for prevention of atherothrombotic events : patients
suffering from myocardial infarction, ischaemic stroke andperipheral arterial disease and
patients suffering from patients suffering from acute coronary syndrome and prevention of
atherothrombotic and thromboembolic events in atrial fibrillation.
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited

Page 323

Company Name
Mepha Holding AG
Mepha Holding AG engaged in developing and manufacturing pharmaceuticals. The company provides products in various
therapeutic areas, including anti-infective, anti-malarial, cardiovascular-endocrinological, central nervous system,
gastrointestinal-urogenital, musco sceletal-pain, respiratory-ENT, and vitamins-mineral. The company is headquartered at
Switzerland.
Company Name
Mepha Pharma AG
Parent
Cephalon, Inc.
Advisor Information
Legal Advisor
Cephalon, Inc.
Sidley Austin LLP
Mepha Pharma AG
Lenz & Staehelin
Financial Advisor
Cephalon, Inc.

Inc.
Mepha Pharma AG
N M Rothschild & Sons

Limited
GlobalData


Page 324
Cephalon Acquires Ception Therapeutics

Cephalon Acquires Ception Therapeutics
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Cephalon, Inc., a biopharmaceutical company, completed the acquisition of all the outstanding capital stock of Ception
Therapeutics, Inc., a biopharmaceutical company, for a purchase consideration of $250 million, subject to adjustment for any
third party debt held by Ception. Following the acquisition, Ception operates as a wholly-owned subsidiary of Cephalon.Ception
Therapeutics is a portfolio company of Essex Woodlands Health Ventures, Investor Growth Capital, Inc., Lumira Capital Corp,
New Science Ventures, Aperture Venture Partners, LLC, Third Point LLC, MDS Capital Corp, Astellas Venture Management
LLC and Greenlight Capital, Inc. Dr. Frank Baldino Jr., chairman and CEO of Cephalon, said: we are fortunate to have the
opportunity to advance CINQUIL (reslizumab) into phase III studies for patients with eosinophilic asthma. This acquisition
enables Cephalon to strengthen its position as a biotechnology company, and also to advance its CINQUIL (reslizumab) into
phase III studies for the treatment of eosinophilic asthma and to introduce its first biologic in the market.Deal historyCompleted:
On April 5, 2010, Cephalon completed the acquisition of Ception Therapeutics, for a purchase consideration of $250
million.Update 1: On February 22, 2010, Cephalon exercised its option to acquire all the outstanding capital stock of Ception
Therapeutics. Cephalon exercised the option after receiving positive data from a clinical study report for Ception's ongoing
phase IIb/III clinical trial for reslizumab in pediatric patients with eosinophilic esophagitis (Res-5-0002 EE Study) indicating that
the co-primary endpoints are achieved.Announced: On January 13, 2009, Cephalon entered into a definitive option agreement
to acquire Ception Therapeutics, for a purchase consideration of $350 million. The consideration includes $100 million upfront
and $250 million on the exercise of the option. Ception stockholders were also entitled to receive clinical and regulatory
milestone payments and royalties on net sales of products developed from Ception's program.
Deal Rationale
This acquisition will strengthen Cephalons position as a biotechnology company, and also to advance its CINQUIL (reslizumab)
into phase III studies for the treatment of eosinophilic asthma and to introduce its first biologic in the market.
Deal Information
Deal Status
Completed
Announced Date
13-Jan-2009
Completed Date
05-Apr-2010
% Acquired
100
Deal Financials
250
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Parent
Cephalon, Inc.

Firm Name
New Science Ventures

Page 325
New Science Ventures, LLC (NSV) is a venture capital firm. The company invests in both early and late stage companies using
novel scientific approaches. NSV invests in the Life Sciences sector which include pharma, biotech and medical devices and in
the Information Technology sector such as photonics, semiconductors and advanced materials. It has invested approximately
$300 million companies located in the US, Europe, India and China. The investment portfolio includes Achronix Semiconductor
Corp., Symphogen A/S, BioScale, Inc, Celleration Inc., Juventas Therapeutics, Dali Wireless, Inc., Vaultive, Inc., Silicon Space
Technology Corporation, RF Arrays Systems Pvt. Ltd., and TherOx among others. NSV is headquartered in New York, the US.
Firm Name
MDS Capital Corp.
MDS Capital Corp. is a venture capital firm that invests in healthcare and life sciences companies through its five private funds.
The firm invests between $0.5 million to $5 million, at all stages of development of the companies.
Firm Name
Astellas
Management LLC
Venture
Parent
Astellas Pharma Inc.
Astellas Venture Management LLC. (AVM) is the corporate venture capital arm of Astellas Pharma Inc. The firm mainly invests
in expansion-stage of companies operating in the pharmaceuticals and medical devices sectors.
Firm Name
Greenlight Capital, Inc.
Greenlight Capital, Inc. is a hedge fund firm that invests primarily in publicly traded North American corporate debt offerings and
equities. Founded in 1996, Greenlight Capital also manages a fund of funds and a private equity fund through its affiliates,
Greenlight Masters and Greenlight Private Equity Partners.
Firm Name
Essex Woodlands
Ventures
Health
Essex Woodlands Health Ventures (Essex Woodlands) is a health care venture capital and growth equity firm. It is a lead
investor and offered critical financings to over 140 health care companies in the medical device, biotechnology, pharmaceutical,
services and information technology sectors. Essex Woodlands offers seed, late venture, growth equity, private investment in
public equity, and buyout financings. The company offers growth equity investments in companies whose enterprise value is
between $50 - $250m. It offered growth capital to companies such as Abiomed, ATS Medical, Bioform, Cell Biosciences,
Corium, ikaSystems, MicroPort, and PreCision Dermatology, among others. Essex Woodlands operates five offices in the US,
Europe, Asia and Latin America. The company is headquartered in California, the US.
Firm Name

LLC
Firm Name
Third Point Ventures
Third Point Ventures is a venture capital arm of Third Point LLC. The company invests in early stage companies primarily
across the technology sector. it also invests in the alternative energy and clean technology sectors.
Firm Name
Lumira Capital Corp.
Lumira Capital Corp (Lumira Capital) is a life science venture capital firm. The company invests in later stage
biopharmaceutical and medical device companies. It also invests in biopharmaceutical and medical device companies with
minimum preliminary clinical safety, proof of concept data and high revenue generation. Lumira Capitals investment portfolio
companies include AvidBiologics, Argos Therapeutics, Aurinia Pharmaceuticals, BAROnova, Cardiac Dimensions, DC Devices,
Engene, Lorus, Spinal Kinetics, Thrasos, Vendorlink.ca, Alexza Pharmaceuticals, and NephroGenex. The firm has operations
in Canada and the US. The company was formerly known as MDS Capital Corp. Lumira Capital is headquartered in Toronto,

Page 326
Ontario, Canada.
Firm Name
Investor Growth Capital, Inc.
Parent
Investor AB
Investor Growth Capital is a venture arm of Investor AB with 1,500 million of capital under management. It invests in private and
public companies at expansion stage, focusing on information technology, software, cleantech, semiconductors, internet,
healthcare and media. Its investment size ranges between USD3 million to USD30 million.
GlobalData


Page 327
Cephalon Acquires Arana Therapeutics

Cephalon Acquires Arana Therapeutics
Deal Type
Deal Sub Type
Acquisition
100% Acquisition
Deal in Brief
Cephalon, Inc., a biopharmaceutical company through its subsidiary Cephalon International Holdings, Inc., has completed the
acquisition of all of the outstanding ordinary shares of Arana Therapeutics Limited, a biotechnology company, for a purchase
consideration of AUD318 million ($207 million) or AUD1.4 ($0.91) for each Arana share. The offer price represents a 70%
premium to Aranas 90-day volume weighted average price and 69% premium to the closing price on February 25, 2009.
Cephalon financed the offer price using a portion of its existing cash balance. Following the acquisition, Arana is now a whollyowned subsidiary of Cephalon. Earlier on February 27, 2009, Cephalon acquired 27.4% stake in Arana Therapeutics Limited,
from Start-up Australia Ventures Pty., Ltd., Rockwell Securities Limited and others, for a purchase consideration of AUD1.4
($0.91) for each Arana share. Ferghana Partners Group and Deutsche Bank Ltd. acted as the financial advisors and Johnson
Winter & Slattery acted as the legal advisor to Cephalon for the transaction.
Deal Information
Deal Status
Completed
Announced Date
27-Feb-2009
Completed Date
10-Aug-2009
% Acquired
100
Deal Financials
318
Bid Premium (%)
Deal Value (US$ m)
207
69
Deal Payment
Cash (US$ m)
207
Deal Product
Product Description
LOR-1284
LOR-1284 (formerly known as siRNA-1284) was under development for the treatment of renal
cell carcinoma, melanoma and colon adenocarcinoma. LOR-1284 is a small interfering RNA
(siRNA). The drug candidate acts by targeting the R2 subunit (also known as RRM2) of
ribonucleotide reductase. The drug candidate is based on RNA interference (RNAi)
technology.
Company Name
Cephalon, Inc.
Parent
Teva
Pharmaceutical
Industries Limited
Company Name
Rockwell Securities Limited
Rockwell Securities Limited is an investment company. The company is focused on investing in biotechnology companies.

Page 328
Company Name
Arana Therapeutics Limited

(Inactive)
Arana Therapeutics Limited (Arana), a biopharmaceutical company, is engaged in the research and development of new
generation products for the treatment of inflammatory diseases and cancer. The company also involves in the research,
development, manufacturing and marketing of protein based products for the pharmaceutical industry. The company is
headquartered in Sydney at New South Wales, Australia.
Firm Name
Start-up Australia Ventures

Pty., Ltd.
Start-up Australia Ventures Pty., Ltd. is an Australian specialist venture capital company that invests in innovative life science
companies.
Advisor Information
Legal Advisor
Cephalon, Inc.
Financial Advisor
Cephalon, Inc.
Deutsche Bank Ltd.

Ferghana Partners, Inc.

(US$)
0.57

(US$)
0.57
Financial Information (Arana Therapeutics Limited (Inactive))

Number of Employees
21

EV/Operating Profit
3.86
0.63

(US$)
1.06
0.64
GlobalData


Page 329
Teva Pharmaceutical Industries Limited - Key Competitors

Teva Pharmaceutical Industries Limited, Key Competitors
Name
Headquarters
Revenue (US$ m)
Actavis plc
Ireland
13,062
Amgen Inc.
United States
20,063
Apotex, Inc.
Canada
AstraZeneca PLC
United Kingdom
BiondVax Pharmaceuticals Ltd.
Israel
Bristol-Myers Squibb Company
United States
D-Pharm Ltd.
Israel
Mallinckrodt plc
Ireland
Mapi Pharma Ltd.
Israel
MediciNova, Inc.
United States
0.0
Merck & Co., Inc.
United States
42,237
Mylan Laboratories Limited
India
Pfizer Inc.
United States
Sandoz Inc.
United States
Tesaro, Inc.
United States
26,095
0.0
15,879
0.0
2,540
49,605
0.0
GlobalData


Page 330
Key Employees
Teva Pharmaceutical Industries Limited, Key Employees
Name
Job Title
Board Level
Since
Age
Yitzhak Peterburg
Chairman
Executive Board
2015
Erez Vigodman
Chief Executive Officer
Executive Board
2009
54
Director
President
Chaim Hurvitz
Director
Non Executive Board
2010
53
Dan S. Suesskind
Director
Non Executive Board
2010
70
Joseph Nitzani
Director
Non Executive Board
2008
67
Roger Abravanel
Director
Non Executive Board
2007
67
Dafna Schwartz
Director
Non Executive Board
2011
63
Amir Elstein
Vice Chairman
Non Executive Board
2009
58
Dr. Arie Belldegrun
Director
Non Executive Board
2013
63
M.D., Director
Non Executive Board
2010
85
Galia Maor
Director
Non Executive Board
2012
71
Ory Slonim
Director
Non Executive Board
2008
71
Richard Alan Lerner
Director
Non Executive Board
2012
75
Dan Propper
Director
Non Executive Board
2012
72
Allan Oberman
Senior Management
2012
56
Senior Management
2012
62
Senior Management
2013
61
Senior Management
2012
55
Senior Management
2012
56
2012
46
Moshe
Ph.D.
Many,
Teva
Americas
GenericsPresident
Dr. Michael Hayden
Chief Scientific Officer

President
Research
Development
Eyal Desheh
Global
and
Chief Financial Officer

Group Executive Vice
President
Judith Vardi

Teva EMIA and Asia
Pacific President Teva
EMIA and Asia Pacific
Dr.
Carlo
Notaristefani
Iris Beck Codner
De Chief Executive Officer

Global
OperationsPresident
Chief Communications Senior Management

Officer
Senior Vice President
Erez Israeli
Chief Business Process Senior Management

Officer
Executive
President
Vice
Interim Head of Global

Quality
Guy Hadari
Corporate
Vice Senior Management


Page 331
President
Global
Chief
Information Officer
Itzhak Krinsky
Chairman - Teva Japan
Senior Management
2012
Senior Management
1993
Isaac Abravanel
Group Executive Vice Senior Management

President,
Teva
Corporate in Israel and
Global
Community
Alliances
2013
Kevin Mannix
Head of Global Investor Senior Management

Relations
2011
Chairman
South Korea
61
Teva
Head
Business
Development
Asia
Pacific
Ron Grupel
Chief Internal Auditor

Corporate
President
Vice
59
Vice President
Mark Sabag
Group Executive Vice Senior Management

President,
Human
Resources
2013
Ichiro Kikushige
Chief Executive Officer Senior Management

Teva Japan
2013
Paul J. Sekhri
Chief Strategy Officer
Senior Management
2013
55
Senior Management
2012
51
Senior Management
2013
53
Senior Management
2010
51
Senior Management
2014
Vice Senior Management
2015
43
Group Executive Vice

President
Global
Business Development
Dr. Robert Koremans

Global
Specialty
MedicinesPresident
Dipankar Bhattacharjee

Generics
EuropePresident
Richard S. Egosi
Chief Legal Officer

Company Secretary
Executive
President
Sigurdur Olafsson
Vice

Global
Generic
Medicines
GroupPresident Global
Generic
Medicines
Group
Timothy R. Wright
Executive
President
Head
Business
Development, Strategy
and Innovation
GlobalData


Page 332
Locations And Subsidiaries

Head Office
Teva Pharmaceutical Industries Limited
5 Basel Street
P.O. Box 3190
Petah Tikva
ZIP: 49131
Tel: 972 3 9267267
Fax: 972 3 9234050
Other Locations & Subsidiaries

Teva Pharmaceutical Industries Limited, Other Locations
Teva Brazil
Teva Parenteral Medicines Inc.
Rua James Joule, 92
19 Hughes
15 andar
Irvine
Sao Paulo
California
Zip: 04576-080
Zip: 92618
Brazil
United States
Tel: 55 11 51055750
Tel: 1 949 4554700

Fax: 1 949 4588210
Teva Pharmaceuticals (Pty) Ltd.
Assia Pharmaceuticals Ltd.
Suite 1, Building 4
Funzi Road
Ruimsig Office Park, Hole In One Road
P.O.B. 30620
Ruimsig
Nairobi
Zip: 1732
Kenya
South Africa
Tel: 254 20 537622
Tel: 27 11 9580271
Fax: 254 20 537628
Fax: 27 11 9580550
Regent Drugs Limited
Teva Group Germany
Plot No. 2G, 2H, 2I
Kandelstrasse 10
Udyog Vihar
Kirchzarten
Greater Noida
Zip: D-79199
Zip: 201308
Germany
India
Tel: 49 6105 976760
Tel: 91 120 235134046
Fax: 49 6105 976761
Fax: 91 120 2351357

GlobalData


Page 333
Teva Pharmaceutical Industries Limited, Subsidiaries

Teva Animal Health, Inc.
Teva API, Inc.
3915 South 48th Street Terrace
United States
Saint Joseph
Zip: 64503
United States
Tel: 1 800 7593664
Url: www.tevaanimalhealth.com
Teva Pharmaceuticals Hellas S.A.
Taiyo Pharmaceutical Industry Co., Ltd.
Athens
24-11 Taikou 1-Chome
Greece
Nakamura-ku
Fax:
Nagoya
CHB
Zip: 453-0801
Japan
Tel: 81 52 4595001
Url: www.taiyo-yakuhin.com
Fax: 81 52 4592851
Sicor Biotech UAB
Teva UK Limited
V A Graiciuno Street 8
Ridings Point
Vilnius
Whistler Drive
California
Castleford
Zip: 02241
West Yorkshire
Lithuania
Zip: WF10 5HX
Tel: 370 5 2660203
United Kingdom
Url: www.sicor.lt
Tel: 44 1977 628500
Fax: 370 5 2660206
Url: www.tevauk.com
Teva Parenteral Medicines, Inc
Teva Pharmaceuticals Europe B.V.
17 Hughes
5 Basel Street
Irvine
Petach Tikva
Petah Tikva
United States
Zip: 49131
Tel: 1 949 4554700
Israel
Url: www.lemmon.com
Tel: 972 3 9267267
Fax:
Url: www.tevapharm.com
Fax: 972 3 9234050
Teva Pharma, S.L.U.
Teva Pharmaceutical K.K.
Spain
Level 8, KSK Main Building
Fax:
3-25-7 Hacchobori
Chuo-ku
TKY
Zip: 104-0032
Japan
Tel: 81 3 55428980


Page 334
Url: www.teva.jp
Fax: 81 3 55428981
Pharmachemie B.V
Teva Denmark A/S
Swensweg 5
Parallelvej 12
P.0.B. 552
Lyngby
RN Haarlem
Zip: 2800
Zip: 2003
Denmark
Netherlands
Tel: 45 44 985511
Tel: 31 23 5147147
Url: www.tevapharm.dk
Url: www.pharmachemie.nl
Fax: 45 25 274233
NuPathe Inc.
Teva Czech Industries S.R.O.
227 Washington Street
Czech Republic
Suite 200
Tel: 420 553 641111
Conshohocken
Url: www.tevapharm.cz
CHB
Fax: 420 553 642150
Zip: 19428
United States
Tel: 1 484 5670130
Url: www.nupathe.com
Fax: 1 484 5670136
Pliva Hrvatska doo
Cephalon, Inc.
Russia
41 Moores Road
Tel: 385 1 3720000
P.O. Box 4011
Url: www.pliva.com
Frazer
PA
Zip: 19355
United States
Tel: 1 610 3440200
Url: www.cephalon.com
Teva Pharma Italia Srl
ratiopharm GmbH
Viale G. Richard 7
Graf-Arco-Strasse 3
Milan
Ulm
Petah Tikva
Baden-Wurttemberg
Zip: 20143
Zip: 89079
Italy
Germany
Tel: 39 2 8917981
Tel: 49 731 40202
Fax: 39 2 89179825
Url: www.ratiopharm.com
Fax: 49 731 4027832
Ivax Corporation
Teva Italia S.r.l.
4400 Biscayne Blvd
Via Messina, 38
Miami
Milan
TKY
Lombardia
United States
Zip: 20154
Tel: 1 305 5756000
Italy
Url: www.ivax.com
Tel: 39 2 8917981
Fax:
Url: www.tevaitalia.it


Page 335
Fax: 39 2 70057995
Teva Pharmaceutical Works Ltd.
Teva Belgium
13 Pallagi St.
Belgium
Debrecen
Url: www.tevabelgium.be
Zip: H-4042
Hungary
Tel: 36 52 515100
Fax: 36 52 311633
Teva Pharmaceutical Works Ltd. Hungary
SICOR Pharmaceuticals, Inc.
13 Pallagi St.
United States
Debrecen
Zip: H-4042
Hungary
Tel: 36 52 515100
Fax: 36 52 311633
Merckle GmbH
Germany
TEVA Generics GmbH

Kandelstrasse 10
Kirchzarten
Baden-Wurttemberg
Zip: 79199
Germany
Tel: 49 7661 984504
Fax: 49 7661 984569
Plantex Chemicals B.V.
Plantex USA
Computerweg 10
400 Chestnut Ridge Road
DR Utrecht
Woodcliff Lake
Zip: 3542
New Jersey
Netherlands
Zip: 07677-7604
Tel: 31 346 290222
United States
Fax: 31 346 290296
Tel: 1 201 3076900

Fax: 1 201 3076909
Teva Canada Limited
Teva Neuroscience, Inc.
30 Novopharm Court
901 East 104th Street
Toronto
Suite 900
Lombardia
Kansas City
Zip: M1B 2K9
KS
Canada
Zip: 64131
Url: www.tevanovopharm.com
United States
Fax: 1 416 3354472
Tel: 1 800 2214026

Url: www.tevaneuroscience.com
Fax: 1 816 5085016
Teva Pharmaceuticals (Pty) Ltd
Teva Europe B.V.
Suite 2 Building 4 Ruimsig Office Estate
Industrieweg 23 P.0.B. 206
Hole in One Avenue
Mijdrecht


Page 336
Ruimsig
Zip: 3640
Zip: 1724
Netherlands
South Africa
Tel: 31 346 290200
Tel: 27 11 9582196
Url: www.tevapharm.com
Fax: 31 346 290289
Teva Pharmaceutical Fine Chemicals S.r.l.
Teva Pharmaceuticals USA, Inc.
Strada Statale Briantea 83
1090 Horsham Road
Bulciago
North Wales
Bulciago
PA
Zip: 23892
Zip: 19454
Italy
United States
Tel: 39 31 8721
Tel: 1 215 5913000

Url: www.tevausa.com
Fax: 1 215 5918600
Teva Pharma Belgium NV
4262 US Route 1
Laarstraat 16/A
Monmouth Junction
Antwerp
Baden-Wurttemberg
Zip: B-2610
Zip: 08852
Belgium
United States
Tel: 32 - 38207371
Tel: 1 732 3552100
Url: www.tevabelgium.be
Url: www.mdtx.com
Fax: 1 732 3552101
Laboratoire Ratiopharm S.A.
5, rue Charles Martigny
San Francisco
Alfort Cedex
CA
Maisons
United States
Zip: 94702
France
Tel: 33 1 42079704
Fax: 33 1 42075863
Teva Sante
Teva Pharma GmbH
France
Waldecker Street 7
Url: www.teva-france.fr
Morfelden-Walldorf
Fax:
Frankfurt
Hessen
Zip: 64546
Germany
Tel: 49 6105 976760
Barr Pharmaceuticals, Inc. (Inactive)
Abz-Pharma Gmbh
225 Summit Avenue
Dr.-Georg-Spohn-Str. 7
Montvale
Blaubeuren
Zip: 89143
Zip: 07645
Germany
United States
Tel: 49 73 44921496
Tel: 1 201 930 3300
Url: www.abz-pharma.de


Page 337
Url: www.barrlabs.com
Fax: 49 73 44921497
Fax: 1 201 9303330
CT Arzneimittel GmbH
Teva Pharmaceuticals Mexico, S.A. de C.V.
Lengeder Strabe 42a
Martires De Rio
Berlin
Blanco No. 54
Zip: 13407
Ciudad de Mexico
Germany
Distrito Federal
Tel: 49 30 4090080
Mexico
Url: www1.ct-arzneimittel.de
Url: www.lemery.com.mx
Fax: 49 303 40900821
PLIVA d.d.
Teva Limited Liability Company
Prilaz baruna Filipovica 25
Russia
Zagreb
Zip: 10000
Croatia
Tel: 385 1 3720000
Url: www.pliva.com
Teva Tuteur S.A.
Teva Global Respiratory Research, LLC
Encarnacin Ezcurra 365
425 Privet Rd
Piso 3
Horsham
Buenos Aires
PA
CA
Zip: 19044
Zip: C1107CLA
United States
Argentina
Tel: 54 11 57872222
Url: www.tevatuteur.com.ar
Rimafar S.L.
CoGenesys, Inc.
Spain
9410 Key West Avenue

Rockville
MD
Zip: 20850
United States
Tel: 1 240 8219000
Url: www.cogenesys.com
PLIVA Pharma Iberia S.A.
Dorom S.r.l.
8-2a planta-oficina 203
Via Messina 38
Milano
Zip: 28290
Zip: 20154
Spain
Italy
Tel: 34 91 630 8280
Tel: 39 02 8917981
Fax: 34 91 630 8281
Url: www.dorom.it
Fax: 39 02 91390748
THERAMEX SpA
Corporacion Infarmasa S.A.
Public square of the Pigneto, 9
Av Nicolas Ayllon


Page 338
Rome
No 3130 Ate
Zip: 00176
Lima
Italy
Lima
Tel: 39 6 703841
Peru
Url: www.theramex.it
Tel: 51 1 3483300
Url: www.infarmasa.com
Fax: 51 1 3493722
Med Ilac Sanayi ve Ticaret A.S
Cephalon s.r.l.
Turkey
Piazza Guglielmo Marconi 25

Rome
Lazio
Zip: 00144
Italy
Tel: 39 65 919351
Fax: 39 65 924704
Cephalon Australia Pty Ltd
IVAX Research, Inc.
Level 2
4400 Biscayne Blvd
37 Epping Road
Miami
Macquarie Park
FL
PA
Zip: 331373212
Zip: 2113
United States
Australia
Tel: 1 800 3274114

Fax: 1 305 5756055
Teva Branded Pharmaceutical Products, R&D Inc.
Copley Pharmaceutical, Inc.
Pasadena
25 JOHN ROAD
MD
CANTON
United States
MA
Zip: 02021
United States
Teva Classics S.A.S
Teva Pharma Portugal Ltd.
Immeuble Palatin I
Lagoas Park
1 cours du Triangle de l'Arche
Ed 1, Piso 3
Paris
Salvo
Porto
Zip: 92936
Zip: 2740-264
France
Portugal
Tel: 33 1 55917800
Tel: 351 214 235910
Url: www.tevaclassics.fr
Url:
www.tevapharm.com/enUS/Pages/Country.aspx?Country
Fax: 33 1 55917941
Fax: 351 214 235919

IVAX Laboratories, Inc.
Ivax Pharmaceuticals Incorporated
Canada
Canada
Fax:
Ivax Pharmaceuticals sro
IVAX Pharmaceuticals Ireland
Russia
Russia


Page 339
Fax:
IVAX-CR, a.s.
Teva Pharma AG
Ostravsk 29
St. Alban-Anlage 46
Opava
Basel
Zip: 747 70
Zip: 4052
Czech Republic
Switzerland
Tel: 420 553 641111
Tel: 41 61 7569750
Fax:
Url: www.tevapharma.ch
Fax: 41 61 7569755
Teva EMIA
Teva Respiratory, LLC
Israel
650 Cathill Rd
Sellersville
PA
United States
Tel: 1 888 4829522
Url: www.tevarespiratory.com
Teva API Japan LTD.
Laboratorios Davur, S.L
Toranomon 45MT Bldg
Spain
7F, 5-1-5 Toranomon

Minato-ku
Porto
Zip: 105-0001
Japan
Tel: 81 3 54048441
Url: www.tapi.jp
Fax: 81 3 54048442
Laboratorios Belmac S.A.
Bentley Pharmaceuticals Ireland Ltd
Montearagon, 9-1.a pta
25/28 North Wall Quay
Madrid
Dublin
Dublin
Zip: 28033
Ireland
Spain
Tel: 34 91 3677602
Url: www.belmac.com
ChemGenex Pharmaceuticals Limited
Teva Pharma Japan Inc.
Level 4
1-24-11
199 Moorabool Street
Nakamura-ku
Geelong
Nagoya
Zip: 3220
CHB
Australia
Japan
Tel: 61 3 52239900
Tel: 81 52 4592001
Url: www.chemgenex.com
Url: www.teva-seiyaku.com
Auspex Pharmaceuticals, Inc.
Teva Pharmaceutical Finance Netherlands II B.V.
3333 North Torrey Pines Court
Netherlands


Page 340
Suite 400
La Jolla
Zip: 92037
United States
Tel: 1 858 5582400
Url: www.auspexpharma.com
Fax: 1 858 5582401
Abic Marketing Limited
Abic Ltd.
Kiryat Nordau Ind. Zone Netanya
Kiryat Sapir Industrial Zone
Netanya
PA
P.O.Box 8077
Zip: 8077
Israel
Netanya
Tel: 972 3 9267272
Sharon (Netanya)
Zip: 42504
Israel
Tel: 972 2 9906901
Fax: 972 2 9906900
GlobalData


Page 341

Teva Pharmaceutical Industries Limited (TEVA) - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Teva Pharmaceutical Industries Limited (TEVA) - Pharmaceuticals &amp; Healthcare - Deals and Alliances Profile

Uploaded by

Copyright:

Available Formats

Teva Pharmaceutical Industries Limited (TEVA) - Pharmaceuticals &

Healthcare - Deals and Alliances Profile

Publication Date: MAY 2015

Teva Pharmaceutical Industries Limited (Teva) is a fully integrated global

Teva Pharmaceutical Industries Limited,

Revenue (US$ million)

Financial Deals Landscape

Teva Pharmaceutical Industries Limited, Pharmaceuticals &

Note: Deals include all announced pharmaceuticals & healthcare deals

Teva Pharmaceutical Industries Limited, Pharmaceuticals &

Teva Pharmaceutical Industries Limited, Pharmaceuticals &

Note: Deals include all announced pharmaceuticals & healthcare deals

Note: Deals include all announced pharmaceuticals & healthcare deals

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Reference Code: GDPH33504D

Reference Code: GDPH33504D

Reference Code: GDPH33504D

SymBio Pharma Receives Investment In Second Tranche Of Series C Financing ................................................................... 82

Reference Code: GDPH33504D

Reference Code: GDPH33504D

Reference Code: GDPH33504D

Teva Pharma Rumored To Acquire Amarin ............................................................................................................................ 292

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Reference Code: GDPH33504D

Reference Code: GDPH33504D

Reference Code: GDPH33504D

Reference Code: GDPH33504D

Reference Code: GDPH33504D

Cephalon Completes Acquisition Of 20% Stake In Mesoblast ....................................................................................................... 312

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Reference Code: GDPH33504D

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Reference Code: GDPH33504D

Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Year,

Deal Value (US$ million)

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Reference Code: GDPH33504D

Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare Deals By Type,

Deal Value (US$ million)

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Reference Code: GDPH33504D

Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Region,

Deal Value (US$ million)

Middle East and Africa

South and Central America

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Reference Code: GDPH33504D

Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals By Therapy

Deal Value (US$ million)

Central Nervous System

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Reference Code: GDPH33504D

Mouth And Dental Disorders

Ear Nose Throat Disorders

Pharmaceuticals and Healthcare

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Reference Code: GDPH33504D

Deal Value (US$ million)

Wound Care Management

Drug Delivery Devices

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Reference Code: GDPH33504D

Teva Pharmaceutical Industries Limited, Pharmaceuticals & Healthcare, Deals Summary,

Teva Pharmaceutical Industries Limited - Pharmaceuticals &

Teva Pharmaceutical Industries Limited (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Teva Pharmaceutical Industries Limited (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile